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ABSTRACT 
The, effects of deuteration on the metabolism and 
activity of two widely used drugs, nitroglycerin and 
imipramine, has been investigated in the rat. 
Deuteration of nitroglycerin produced no significant 
isotope effect on biological denitration and the two forms 
were pharmacologically identical. Comparison with a 
sustained-release nitroglycerin preparation indicated that 
this type of formulation was a much better approach to 
extending the duration of activity of this drug. Other ways 
of slowing the metabolism of nitroglycerin, e. g. glutathione 
depletion and use of enzyme inhibitors were attempted, but 
only glutathione depletion resulted in significant slowing 
of nitroglycerin metabolism. 
Deuteration of imipramine produced a significant 
kinetic isotope effect, although this was quite small having 
a magnitude of, -1.33. The isotope effect occurred on the 
N- demethylation step, and no, isotope effect was observed 
for aromatic hydroxylation. Although a significant 
slowing of biological half-life occ urr ed, there were no 
changes in the pharmacological properties of deuteroimipramine 
from imipramine. 
The general pharmacokinetic properties of each drug 
have also been studied and, in the case of nitroglycerin, 
extensive in vitro investigations have been conducted to 
elucidate the tissue site, subcellular site and nature of 
the enzyme(s) responsible for denitration. 
The pharmacokinetic properties of nitroglycerin were 
characterised by: a large "first-pass" effect, low plasma 
levels and a rapid biological half-life, a sex difference in 
biological half-life in the rat but not in the rabbit, and 
species variation in the rate of elimination. Bioavailability 
for the sublingual route approached that for the intravenous 
route, and no major drug interaction effect on elimination 
occurred when nitroglycerin pharmacokinetics were determined 
in the presence of a number of'regularly co-administered 
. 
drugs. 
Nitroglycerin biotransformation occurred primarily 
in rat liver, but also in kidney, heart, intestine and 
plasma. Denitration was catalysed by enzymes of the 
soluble fraction, namely the glutathione-S-transferases, 
the activity of which appeared to parallel the rates of 
tissue denitration. 
The pharmacokinetic properties of imipramine in the 
rat were characterised by an extensive "first-pass" effect, 
rapid elimination and very low plasma levels of the parent 
drug, due to extensive tissue binding. Large quantities 
of metabolites (particularly desmethylimipramine) are 
quickly formed following oral administration; the 
2-hydroxylated metabolites are the major urinary metabolites 
but these are not detected in plasma. 
Although numerous analytical procedures have been 
published for the determination of nitroglycerin in 
biological fluidst these methods are difficult to reproduce. 
It was therefore necessary to modify one of these procedures 
in order to obtain a sensitive, specific and reproducible 
means of determination of nitroglycerin in biological fluids. 
This procedure enabled plasma levels as low as 100pg/ml to 
be quantified. A means of protecting nitroglycerin from 
degradation by isolated plasma was also developed, this 
involved inhibition of the metabolising enzyme with 
iodoacetamide. 
0 
The fascination of what's difficult, 
Has dried the sap out of my veins, and rent 
Spontaneous joy and natural content 
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CHAPTER 1 
GENERAL INTRODUCTION 
Drug Metabolism and Pharmacokinetics - General Aspects 
Following administration of a drug, it is 
absorbed into the body and distributed to many tissues. 
The concentration of drug observed in plasma is determined, 
in part, by its lipid solubility and protein affinity 
characteristics; the greater the lipid solubility and 
higher the protein affinity, then the greater the 
distribution within the body and the lower the plasma 
concentration. The drug is alsolmetabolised, and usually 
deactivated, from its original form responsible for 
therapeutic activity. Invariably, as the drug is metabolised 
its plasma level falls and its therapeutic activity is lost. 
If no metabolism of the drug took place then such a drug 
might be expected to exist and maintain its therapeutic 
activity for the life of its host. Brodie in, 1964 stated 
that if there was no such process as drug metabolism, it 
would take the body about one hundred years to terminate 
the action of a drug such as pentobarbital which is lipid 
soluble and thus cannot be readily excreted without first 
being metabolised to a more polar molecule. However, the 
majority of drugs are metabolised and some like 
nitroglycerin and imipramine are metabolised quite rapidly. 
The rate and pattern of drug metabolism often varies 
in. different animal species and even in different strains 
of the same species; it can also be affected by a number of 
other factors such as sex, nutritional status, disease, 
pregnancy, various environmental factors, and the presence 
of other drugs. The influence of these factors has been 
extensively reviewed (Parke, 1968,1976; Briggs and 
Briggs, 19? 5). 
Therefore, as a result of drug metabolism, the 
lifetime'of a drug in the body is finite. The function of 
drug metabolism, which occurs principally in the liver but 
also in kidney, lung and-intestine, is to render the 
compound more suitable for excretion by the kidneys or in 
bile, that is, to convert the compound from an often 
non-polar form into a more water soluble form which is 
usually pharmacologically inactive. The easiest way of 
achieving this is by conjugation (known as a Phase II 
reaction), which involves attachment of a water soluble 
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moiety (usually an endogenous compound) such as glifcuronic 
acid, sulphate or an amino acid, - to a polar group of the 
drug. For conjugation to occur, a group is necessary in 
the drug molecule (the so called "electronegative handle") 
which can react with the conjugating agent. If not already 
present, this group may be supplied by a Phase I (or 
preconjugation) reaction which involves either the insertion 
of a reactive group, 
e. g. 
2ýC 
-H -ýýC - OH C- hydroxylation . 00, 
or the uncovering of a reactive group, 
e. g. -_ý: C - OCH ---)-ýýC - OH 0- demethylation 101 . 00, 
Phase I reactions are classified according to the 
site of metabolism in the body and the intracellular origin 
of the enzyme involved, into: 
a) transformations catalysed by microsomal drug metabolising 
enzymes - enzymes of the endoplasmic reticulum 
(e. g. cytochrome P-450) 
b) transformations catalysed by non-microsomal mammalian 
enzymes present in mitochondria, lysosomes, cytoplasm and 
plasma 
c) transformations-catalysed by enzymes of gut microflora. 
Phase Il reactions are generally catalysed by enzymes 
involved in intermediary metabolism which attach endogenous 
compounds to the drug molecule or its metabolites. 
Drug metabolism can be divided into two distinct 
aspects: 
a) the pattern of metabolism of a drug - the tissue site of 
metabolism of the drug, the type and relative proportion 
of metabolites formed, 
b) pharmacokinetics of metabolism - the kinetics of a drug 
entering and being eliminated by the body, by excretion 
and metabolism, and the relative rates of these part 
processes. 
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Pha=acokinetics 
The study of pharmacokinetics is very 'important in 
the development of drugs and drug formulations as well as 
in designing dosage regimens and is used to estimate drug 
bioavailability and to correlate the plasma levels of a 
drug with its pharmacological effect. In brief, 
pharmacokinetics is concerned with the fate of adrug after 
it has been introduced into the body. The analysis is 
carried out throughout the entire time course for the drug 
in the body, and by analysing the content of accessible 
fluids (blood and urine), one can obtain information regard- 
ing the amount of drug in non-accessible regions - perhaps 
even at the site of action. The most widely sampled fluids 
are blood and urine, which are often analysed for both drug 
and metabolites; this data*is used to produce a 
compartmental analysis*. The relative volumes of distri- 
bution and rate constants derived from the analysis are 
significant parameters in the comparison of analogues of a 
given drug or a wide variety of dosage forms. The 
applications and uses of pharmacokinetics are manifold and 
a number of examples are given here: 
a) therapeutics - evaluation of drug absorption and design 
of dosage regimens, i. e. assessment of best route of 
administration, best dose level, best drug preparation 
etc.; estimation of drug bioavailability 
b) clinical - assessing the dosage required by an 
individual in cases where distinct population differences 
in drug metabolism are known; why particular patients 
respond to drugs in particular ways. 
c) pharmacological - assessing concentrations at sites of 
action as indications of onset, intensity and duration 
of drug activity; relationship to absorption, metabolism, 
distribution, excretion etc. 
See Appendix 1. 
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d) toxicological - onset, duration and intensity of a 
toxic effect in relation to absorption, elimination, 
plasma levels etc.; individual differences in drug 
toxicity. 
Factors Affecting the'Pharmacokinetics of Drugs 
Thus pharmacokinetics is an invaluable discipline 
in the design of new drugs, the development of optimum 
drug characteristics and for the extrapolation of data 
from animal studies to human therapeutics. The pharmaco- 
kinetic properties-and efficacy of a drug can be 
profoundly affected by a number of factors such as: 
a) purely pharmaceutical factors such as tablet and 
capsule properties, particle size of the drug. 
b) factors associated with disposition and fate such as 
route of administration, rate of elimination etc. 
Comparison of the route of administration of a drug 
is of prime importance in the optimisation of drug 
therapy. Bioavailability studies are conducted to 
. assess 
the most effective routes of administration, 
e. g. to indicate use of the sublingual route in order 
to avoid "first-pass" effects due to the liver. 
C) general physiological factors such as age, body weight, 
sex, genetics, pathological state and tolerance, which 
include a component associated with disposition and 
fate, as well as a purely physiological component. 
Comparison of the pharmacokinetics of a drug in a 
number of species is of great importance in drug 
metabolism for the extrapolation of animal data to 
humans. Obviously, the more species studied then the 
safer is a prediction about what may occur in the 
human; species differencesýare also important to 
further our understanding of drug metabolism in general, 
and for correlation between the distribution and 
elimination of a drug with its pattern and site of 
metabolism, and the activity of various enzyme systems. 
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_There 
is mounting evidence for an increase in body 
weight of the species to show slower elimination of 
a given drug; this is particularly pronounced with 
mono-oxygenase enzymes (Walker, 1979). 
Although sex differences in rate of elimination 
generally occur in'the rat, and the male and female 
rat have been likened to two distinct species, there 
are few reports of sex differences in other species; 
this may in part be because the majority of studies 
have been conducted in the rat, and because many other 
species show genetic inhomogeneities compared with the 
rat which is bred under strict genetic control. 
However7 sex'differences in mice (Nebert and Gielen, - 
1972) and even in humans (Giudicelli and Tillement, 
19? 7) have been reported. Investigations into sex 
differences is of importance in human therapy in order 
to check whether modification to dosage regimens are 
necessary for different sexes. 
d) purely physiological factors such as environment, 
acid-base balance, body water, electrolyte balance 
and individual sensitivity. 
e) drug interactions. - Studies of drug interactions are 
important in the safety evaluation of drug combina- 
tions.. Often, a number of drugs are prescribed rather 
than one; a pharmacokinetic interaction may result in 
increased half-life, increased plasma levels etc. 
leading to toxic side effects. Experimental observ- 
ation of this enables such a drug combination to be 
avoided or modified. This also includes the effects 
of other chemicals in the environment. 
In subsequent chapters, a number of investigations 
into the effects of sex, species, route of administration 
and drug interaction on the pharmacokinetics of 
nitroglycerin have been conducted. 
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Methods Available for Modifying the Pharmacokinetic 
Properties of a Drug 
Since metabolism and excretion of drugs are often 
quite rapid it would sometimes be useful if a means was 
found of slowing the rate of metabolism, as the drug 
would remain longer in the body and so be therapeutically 
more effective. Two approaches are being investigated at 
the present time, one is an indirect approach (the 
sustained-release preparation), the other a more direct 
approach (deuterium labelling). 
Sustained-release Preparations 
In this type of preparation, designed for oral 
administration, the active medicaments are adsorbed onto 
particulate colloidal Mg-Al-silicate (some of these 
particles having an enteric and/or retardant coating). 
Most prolonged-release preparations initially make avail- 
able to the body a quantity of drug comparable to that 
delivered from a single dose of the drug in a conventional 
dosage form, but contain additional quantities of drug 
which are slowly made available to the body so-as to 
prolong the clinical effect beyond that attainable with a 
single dose, and maintain plasma levels within the thera- 
peutic range. Ideally, the additional drug should be 
absorbed constantly at a rate just sufficient to replace 
drug in the body that is lost by metabolism and excretion. 
The most obvious advantage of these dosage forms is the 
reduction in fFequency of administration and the potential 
improvement in patient compliance. The sustained-release 
dosage form could be most useful for drugs that are used 
chronically but that have relatively short half-lives and 
must be administered several times a day. This dosage 
form could also prove useful for administration of certain 
drugs with relatively long half-lives if there is a 
question regarding the safety of giving the entire dose in 
a conventional form and, in theory, for drugs which are 
absorbed by specialised, capacity-limited transport 
mechanisms e. g. iron. 
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The most common types of prolonged-release 
products are the encapsulated or tabletted coated pellets 
and the matrix tablet. The absorption of drugs from 
these products is rate limited by diffusion of drug from 
the dosage form to the gastro-intestinal fluids. Most 
sustained-release formulations appear to release the drug 
in a first-order rather than a zero-order fashion. An 
exception is the elementary osmotic pump (Theeuwes, 1975) 
which consists of an osmotic core containing the drug, 
surrounded by a semipermeable membrane with a delivery 
orifice. Whenthe dosage form is exposed to the gastro- 
intestinal fluids, the core imbibes water osmotically at 
a controlled rate, determined by the permeability of the 
membrane and by the osmotic pressure of the core formula- 
tion. Since the system maintains a constant internal 
volume, a volume of saturated solution equal to the water 
uptake passes through the delivery orifice. 
The sustained-release dosage form is finding wide 
-application at 
the present time for the rapidly 
deactivated drug nitroglycerin, and sustained-release 
preparations such as sustac, nitrocontin and sustachron 
are available. 
Sustained-release-preparations are not restricted 
to the oral route of administration. Drugs which are 
- 
relatively insoluble, 'or can be made so by salt formation 
(e. g. Procaine penicillin, G) are available for intra- 
muscular administration. This "depot" type of preparation 
enables the drug to be slowly absorbed (due to its lack of 
solubility) in a muscle depot as a means of attaining 
prolonged drug action. Other examples of drugs administered 
in this fashion are the poorly water soluble esters of 
prednisolone, testosterone and oestradiol. Administration 
of-this, dosage form may only be required weekly, monthly 
or- even. quarterly. 
Deuteration of Drugs 
A more direct approach is to slow the actual rate 
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metabolism of the drug. This can theoretically be 
achieved by utilising the kinetic isotope effect, 
particularly that of deuterium. Isotope effects have 
been used in organic chemistry for a great many years 
in the study of reaction mechanisms and in biochemistry 
in the study of the mechanisms of enzyme action. 
Deuteration involves the substitution of one or 
more hydrogen atoms in a molecule with its heavy isotope 
2 deuteri= (D, H): deuteri= is a stable isotope of 
hydrogen, it is not radioactive. The effects of deuter- 
ation can be separated into two categories. 
Kinetic isotope effects 
The kinetic isotope effect on the rates of chemical 
reaction resulting from the substitution of deuterium for 
hydrogen has received thorough theoretical treatment 
(Bigeleisen, 1949a; Wiberg, 1955; Bigeleisen, 1958; 
Melander, 1960; Westheimer, 1961). Kinetic and 
equilibrium isotope effects arise from the effect of 
isotopic substitution on the translationall rotational, 
and vibrational motions of a substrate relative to the 
transition state or product of a reaction. Among these 
degrees of freedom characterising a stable molecule (or 
transition state), the effect of isotopic substitution on 
molecular vibrations is by far the most important factor 
determining the magnitude of an isotope effect. Fig. 1.1 
is a pictorial representation of the effect of isotopic 
substitution on molecular vibrations and energies of 
activation for the reaction A-B+C)A+B-C, 
where B is isotopically labelled. The curvature of the 
potential energy wells in Fig. 1.1 is a direct reflection 
of the force constant of the vibrating bond; that is, a 
sharply curved well indicates a large force'constant. It is 
important to distinguish whether the force constant of the 
transition state has been decreased (Fig. 1.1a) or increased 
(Fig. 1.1b) relative to the ground state. A rule of thumb in 
interpeting kinetic isotope effects is that decreased 
force constants in the transition state lead to normal 
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Fig. 1.1 Free Energy for the Reaction 
A-B+CA+B-C 
The molecular vibrations of the isotopically labelled 
substrate (A -B vs. A- BI), product (B -C vs. BI - C), 
and transition state (A--B--C vs. A--B'--C) are super- 
imposed on the electronic potential energy surface for 
the overall reaction. The distinction between Fig. 1-a 
and Fig. 1-b concerns whether the vibrational frequencies 
of the transition state are decreased (1-a) or increased 
(1-b) relative to the ground states. 
E 
L[A-B--C] 
[A--B--C] 
[A--B I -C] 
[A-B I --C] INV 
A-2 -B Tt A-B B-C A-B B-C 
BI -C A-B+C Bl-C 
A-B+C A+B-C A+B-C 
(a) (b) 
k/kl >1 k/k' <1 
isotope effects, kl/k2 > 1, whereas increased force 
constants lead to inverse isotope effects, ki/k2< 1. 
By the same reasoning, the effect of isotopic 
substitution on the overall equilibrium may be either 
normal or inverse, depending on the relative vibrational 
force constants of product and reactant. The lower 
vibrational frequency for A- BI versus A-B is a 
direct reflection of the larger reduced mass of A- BI: 
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tAA - B(A - BI) = 
MAO MB(BI) 
MA + MB(BI) 
F 
/AA - B(A - B') 
where; - reduced mass 
F- force constant 
0- vibrational frequency 
c- speed of light 
M- mass 
Hookes law expression 
In the case of hydrogen isotope effects, the low mass of 
hydrogen relative to other atoms in a polyatomic molecule 
leads to an increase in ýk and a decrease in C,. ) which is 
roughly proportional to. the mass of D or T: 
ý4A -D(T)//AA -H Cý 2(3) and 
rVA 
- D(T)/COA H=YV//2"(3)- 
The small isotope effects observed for carbon, nitrogen, 
and oxygen reflect a greatly reduced sensitivity of/4 
to isotope substitution. (see Table 1.1). 
In simpler terms; the difference in mass between 
1H 
and 
2 H(D) causes the vibrational frequencies of 
carbon, oxygen and nitrogen bonds to deuterium to have 
lower frequencies than corresponding bonds to hydrogen. 
As a result, the chemical bonds involving 
2H 
will 
generally be more stable than those of 
lH. It has been 
calculated that the zero-point energy (lowest ground 
state vibrational level) for many bonds to deuterium is 
, A-, 1.2 - 1.5 kcal/mol smaller than for bonds to hydrogen. 
The zero point energy of a bond undergoing chemical 
reaction reflects the ease with which the molecule is 
activated from a ground state to the transition state 
required for bond scission to occur. The more stable 
deuterium bond requires a greater energy of activation to 
achieve the transition state, and as a consequence, the 
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rate of reaction is generally slower. Thus substitution 
of deuterium for hydrogen in a chemical bond can affect 
significantly the rate of bond cleavage and exert marked 
effects on the-relative rates of chemical reactions. An 
isotope effect will only be apparent, however, when the 
breaking of aC-H or C-D bond occurs in the rate 
determining step of the reaction. 
A deuterium isotope effect is given by the 
quotient kH/kD (or kl/k2) where: 
kH rate of metabolic/chemical reaction for the protium form 
E-- rate of metabolic/chemical reaction for 11 deuterium form D 
There are two types of isotope effect: 
1) Primary isotope effects - occur 
' 
where cleavage involves 
a bond to deuterium at the reaction site, and this type of 
isotope effect can be quite large. Bigeleisen (1949b) 
calculated the maximurn possible ratios in specific rate 
constants for a number of stable and radioactive isotopes: - 
Table 1.1 Maximum Isotope Effects for Some Common 
Elements 
Natural Abundance 
Isotope 
Heavy Isotope Maximum rate ratio 
kl/k2 
1H 2 H(D) 18.00 
lH 3H(T) 60.00 
12C 13C 1.25 
12C 14C 1.50 
14 N' 15N 1.14 
160 180 1.19 
32 S 35S 1.05 
*k I- light isotope 
k21- heavy isotope 
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Obviously the most useful isotope effects are for 
deuterium (kj/k24,18.0) and tritium (kl/k2 60.0) but, 
as tritium is radioactive, only the deuterium isotope 
effect would be any use in drug therapy. In fact, 
experimental values in the range 2- 13, for kH/kDj have 
been observed in biological systems. Many of these 
kinetic isotope effects have been observed with oxidative 
modes of metabolism which involved the microsomal enzyme 
system, cytochrome P-4.50 (Foster et al. 1974; Baillie, 
1978). 
2) Secondary isotope effects - are produced by deuterium 
_atoms 
in non-exchangeable positions located near, but not 
at, the reaction centre. These derive from steric, 
inductive, or resonance factors and, whilst secondary 
deuterium isotope effects are real and measurable they are 
usually very much smaller than primary isotope effects. 
Belleau (1965) indicated that the kH/kD for secondary 
isotope-effects falls in the range 1.05 - 1.25. However, 
secondary isotope effects, although small, may be 
important in biological systems sensitive to kinetic 
effects. 
The majority of reactions are characterised by 
isotope effects less than the calculated maximum. One 
frequent cause is a kinetically complex reaction in which 
hydrogen abstraction is only partially rate-determiningt 
which is often the case in enzyme-catalysed reactions. A 
second major cause is the presence of transitional state 
vibrational frequencies which cancel ground state 
frequencies. In recent years it has become clear that 
many enzymes are so "fine-tuned" that the chemical 
conversion step is no longer rate limiting and this leads 
to smaller isotope effects than expected. 
Miscellaneous effects of deuteration 
There are a number of miscellaneous effects 
resulting from deuteration; these are not well documented, 
but are of prime importance in biological systems. The 
physicochemical effects of a drug may be affected; 0 
physicochemical properties such as lipid solubility, 
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basicity and van der Waals forces, which can lead to 
effects on drug-receptor/bnzyme/protein affinities 
(potency, metabolism, binding and distribution), 
transport and drug absorption. 
Lipid solubility is increased as a result of the 
increased mass of the hydrophobic proton to an even more 
hydrophobic deuteron which is thus more soluble in 
non-polar media such as lipid. Another consequence of 
the increase in mass on deuteration is the expected 
increase in van der Waals forces which may lead to 
increased affinity between drugs and binding proteins 
such as transport proteins, enzymes and receptors. 
Effects of deuteration on basicity are the best 
documented of the miscellaneous effects; this type of 
effect may again lead to increased drug-protein 
affinity. Determination of pka's established that the 
deuterated analogues are significantly stronger bases 
than their protium counterparts. This effect has been 
reported with benzylamine-Cý--d 2 which is 13% more basic 
than benzylamine (Halevi and Nussim, 1957). The pka of 
N-deuteromethylnormorphine was found to be 8.17 as 
compared to 8.05 for morphine (Elison et al., 1963) 
making the deuterium analogue a stronger base by 2456- 
Approximately the same increase (26ý6) was found in 
comparing N-deuteromethylcodeine (pka 8.19) with 
codeine (pka 3.06). There is thus much evidence that 
deuteration will affect the basicity of amine-containing 
drugs. Together with the effect of altered basicity in 
biological systems, an effect of basicity change is 
observed in many types of chromatography. This effect is 
known as isotopic fractionation (Klein, 1966; Van Hook, 
1969; Heck et al., 1977) whereby the deuterated analogue 
interacts more strongly with the chromatographic support 
than does the non-deuterated analogue, leading to an 
increased retention time for the compound, and this is 
believed to be the result of increased basicity (Van der 
Linde and Robertson, 1964; Northcott and Robertson, 1969). 
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Applications of Deuteration in Pharmacology 
Specific labelling of drugs with deuterium can 
have a number of applications in pharmacology: 
a) Design of safer drugs the possibility of decreasing 
the rate of metabolism of a drug to a toxic metabolite. 
For example, deuterated amphetamines are significantýy 
less toxic in mice than protioamphetamines and exhibit 
an isotope effect of., - 1.9 in a rabbit liver homogenate 
system in vitro (Foreman et al, 1969; Benoit and Lu, 
1978); deuterochloroform is less hepatotoxic than 
chloroform and exhibits an isotope effect of. -- 2.1 in vivo 
(Pohl and Krisha, 1978; Pohl et al., 1978) This 
application could be extended to many drugs which generate 
toxic metabolites. 
b) Improvement of drug efficiency - man7, drugs are 
rapidly metabolised and might be therapeutically more 
useful if this metabolism could be slowed. A number of 
barbiturates have been studied in this context; butethal 
was compared with dideuterobutethal containing two 
deuterium atoms on C3 of the butyl side chain (Soborent et 
al., 1965; Tanabe et al., 1969). Sleeping times in mice 
were increased over two fold, the in vivo half-life was 
. e-2.5 times longer and an in vitro isotope effect of 
, 4-11.6 observed. As is described in more detail later, it 
was in this context that the deuteration of nitroglycerin 
was examined. 
c) Modification of the pharmacological properties of drugs 
imipramine is believed to possess tranquillising properties 
which are, not exhibited to any great extent because of its 
rapid demethylation to desipramine, the active metabolite 
responsible for the antidepressant effects associated with 
imipramine. Inhibition of this metabolism could lead to 
more pronounced tranquillising properties. This example 
will be dealt with later-in more detail. Extensive 
deuteration of drugs may also affect other pharmacological/ 
pharmacodyhamic properties such as passage across membranes, 
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tissue distribution and drug-receptor interactions as a 
result of changes in lipid solubility and basicity. 
d) For studying the mechanisms of drug metabolism. 
e) In pharmacokinetics; to study absolute bioavailabilities 
by administering drug and labelled drug via two different 
routes. Comparison of the pharmacokinetics of the routes 
allows absolute bioavailabilities to be determined. 
f) For simplification of drug administration - if a drug 
is more slowly metabolised then fewer doses are required 
to maintain the therapeutic plasma level; this could be 
advantageous in respect of patient compliance. 
Common Metabolic Reactions and Associated Isotope Effects 
An isotope effect of 2 means a 50% reduction in rate 
of reaction, whereas an isotope effect of 10 means that 
metabolism is virtually blocked at this locus. Although 
the factors which control the occurrence and magnitude of 
deuterium isotope effects remain to be fully determined, 
certain trends are now reasonably clear: 
O-De-methylation 
R-0 -CH 3 ). R- OH 
These are usually 
of -2; this may rise to 
contains two-OCH 3 groups 
to ; -OCD 3' An example of 
which exhibits an in vit 
et al., 1974). 
associated with isotope effects 
between 7- 10 if the compound 
and only one of them is converted 
this is p-trideuteromethoxyanisole 
ro isotope effect of , -10.0 (Foster, 
Oxidative dehydrogenation 
R- CHO >R- COOH 
R' CHOH RC0 2 00 2 -0*' 
This type of metabolism is associated with isotope 
effects of between 2-4. 
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C-Hydroxylation 
R -CH 3R- CH2 OH 
R CH R CHOH 2, -- 2 
R CH R COH 5:: - 3 
This type of metabolism may be associated with 
substantial isotope effects. For example, deuteration of 
antipyrine (-CH 3 -4 ' --CH2ýH) produces an isotope effect 
of -13. The occurrence of such a large isotope effect 
can cause a substantial change in the metabolism profile 
on deuteration and has led to the term "metabolic 
switching" whereby a minor route of metabolism for a 
certain drug may now become a primary route. 
A good example of how isotope effects only work 
through the rate determining step of the reaction is that 
of tolbutamide. This drug is rapidly metabolised, 
primarily by C-Hydroxylation (-CH 3 --ý4 -CH20H), and at 
first sight one may think it an ideal choice for deuter- 
ation. However CD3-tolbutamide displayed no isotope 
effect and was pharmacologically similar to tolbutamide 
itself (Kimbrough, 1972). Obviously bonds to deuterium 
are not cleaved during the rate limiting step of this 
reaction. 
N-De-methylation 
RN -CH R N- H 2 -*' 32 ---' 
This type of metabolism is generally associated 
with small isotope effects of <., 2.0. 
Aromatic hydroxylation 
The, occurrence of an isotope effect in this-type 
of metabolism depends on whether an-epoxide (or arene 
oxide) intermediate is initially formed and subsequently 
rea=anges into a phenol: 
(00 lol 
ý OH 
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For mono-substituted benzenes, hydroxylations 
ortho and para are not associated with isotope effects 
whereas hydroxylations meta, as for example in 
chlorobenzene, an arene oxide is probably not the 
intermediate and: an isotope effect is observed. 
At present there is only one commercially 
available deuterated drug, the antibacterial agent 
2-deuterio-3-fluoro-D-alanine (Kollonitsch and Barash, 
1976) of Merck, Sharp and Dohme Ltd. This compound was 
found to be effective both in vivo and in vitro against 
every bacterial strain it was tested against and displayed 
increased metabolic stability over 3-fluoro-D-alanine 
with no impairment of antibacterial activity. The benefit 
of deuteration in this case is to increase metabolic 
stability (i. e. slow metabolic degradation). There are no 
drugs marketed which are enriched in any other stable 
isotope. So far, deuterated drugs have proved useful in 
studying isotope effects, in permitting a better under- 
standing of the mechanism of drug action, and in 
elucidating metabolic and biosynthetic pathways. 
A number of examples of the type of study previously 
undertaken with deuterated drugs in a pharmacological 
context are described below. Many of these studies 
indicate that it is still possible to see significant 
changes in pharmacological activity with isotope effects of 
2.0 or below., 
Barbiturates. As mentioned earlier, the pharmacological 
effect of deuterium substitution in butethal (5-n-butyl-5- 
ethylbarbituric acid) was studied (Soboren 
' 
et al., 1965; 
Tanabe, et al., 1969). 3-Dideuterobutethall which contains 
2D atoms on C-3 of the butyl side chain in the 5-Positions 
was synthesised. The deuterated derivative was compared 
with the, non-deuterated form by intraperitoneal injection 
in mice and measurement of the duration of the induced 
sleeping time. The deuterated barbiturate increased the 
sleeping time over two-fold in comparison with 
non-deuterated controls. The biological half-life for the 
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former was, -4-, 2.5 times longer than the latter. In vitro 
studies were conducted by incubation with mouse liver 
microsomes and an isotope effect of about 1.6 was 
observed for the in vitro rate of hydroxylation. 
Replacement of H by D at the site of oxidation appears 
to decrease the rate of oxidation, increase half-life and 
prolong pharmacological activity. Not excluded in these 
studies was the possibility that. deuterated butethal may 
be less readily metabolised because of a weaker affinity 
for the hepatic microsomal enzymes. 
The effects of deuteration on the activity of 
5- (1-methylbutyl) -5-ethylbarbituric acid were 
investigated (Mark et al., 1971). The 31-dideuter, o- 
derivative was synthesised and its anaesthetic potency 
compared with the non-deuterated drug in mice. While the 
onset of sedation was similar in both compounds, the time 
to peak depression was delayed and total sleeping time 
extended significantly by the deuterated derivative. The 
biological half-life, determined in dogs, was 1.7 - 2.0 
fold greater for the deuterated compound than for the 
non-deuterated drug. , 
Hormones. The androgenic activity of 3 V--deutero-1704- 
methyl-50C-androstane-3 
,, 
S, 17, d-diol was compared with the 
corresponding 1H derivative (Ringold et al., 1961). The 
3-hydroxy form is androgenically inactive as such and must 
be oxidised in vivo to the keto derivative, which is a 
potent androgen. If the oxidation to the 3-ketone with 
loss of 3 V--H(D) is the rate limiting step then the 
3cL-deutero compound should be oxidised more slowly and 
thus be less, active. This was tested in castrated male 
rats and it was found that the 1H compound was 3.36 times 
more active than the deuterated compound on the basis of 
the ventral prostate-response, and 4.65 times more active 
in the response of the seminal vesicles. This was 
interpreted in terms of an in vivo isotope effect on the 
oxidation of the 3-hydroxy group which involves the 
. )O(-deuterium-carbon 
bond. cleavage of the - 
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Amphetamine. Fully deuterated and two other highly 
deuterated amphetamines were synthesised. Their 
toxicities (estimated by the LD 50 test) and in vivo 
spontaneous locomotor activity in mice were compared 
with ptotioamphetamine (Foreman et al., 1969; Benoit 
and Lu, 1978). A significant reduction in toxicities 
and a decrease in spontaneous locomotor activity were 
observed for the deuterated amphetamines compared with 
protioampethamine. An isotope effect of magnitude 
/-1.9 was found for the in vitro metabolism of 
OC-deuterated amphetamine using rabbit liver homogenates. 
In man also, deuterium isotope effects have been reported 
for the metabolism of N-alkyl-deuterated andOC-deuterated 
amphetamines (Vree et al., 1971). 
Morphine. N-deuteromethylnormorphine was synthesised and 
its pharmacological potency and toxicity compared with 
protiomorphine (Ellison et al., 1961). Deuterium 
, labelling produced a significant reduction in the potency 
and lethality of morphine in mice regardless of the route 
of administration. However there was no effect on the 
time of onset, maximal effect, or duration of action. In 
vitro studies using rat liver microsomes indicated that 
N-demethylation of the deutero form was characterised by 
a smaller reaction rate constant, higher energy of 
activation and a larger Michaelis constant (contrary to 
the expected decrease due to increased van der Waals 
forces and increased basicity; an isotope effect of--l-4 
was observed. The observed difference in potency was 
explained by differences in affinities for the receptors 
as a result of a 24/06 increase in basicity. 
Many other studies have been conducted with 
deuterium labelled drugs and endogenous compounds, a large 
proportion of these studies'have revealed a negligible 
isotope effect, or absence of an isotope effect, which can 
readily be explained on the basis that breaking of the 
bond to deuterium is not rate limiting. 
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There is thus much evidence that deuterium 
labelling can produce isotope effects in drug metabolism 
and lead to extension of biological half-lives and changes 
in pharmacological potency. Two drugs, nitroglycerin and 
imipramine, were therefore chosen for study in this 
context. These drugs are well known and widely used and 
are good choices for investigation of the type of effects 
indicated above. 
Nitroglycerin 
-Nitroglycerin 
(glycerol trinitratq, GTN) is an ideal 
choice for deuteration. This is a classic example of a 
very important drug which is rapidly metabolised (Nickerson, 
1975) and which would be therapeutically much more effective 
if its rate of metabolism was decreased. In this context 
the indirect method of extending the duration of action of 
a drug, that is, the sustained-release preparation, has 
been widely studied for nitroglycerin. The use of 
deuteration is explored here (Chapter 4). 
Background and Uses of Nitroglycerin 
William Murrell was the first to introduce 
nitroglycerin as a therapeutic agent (Murrell, 18? 9); since 
that time it has been used for the treatment of angina 
pectoris, and there is little doubt as to its effectiveness 
in the treatment of this affliction (Aronow, 19? 2). The 
action of nitroglycerin in the alleviation. of anginal pain 
is believed to be mediated by reduction of systemic blood 
pressure and cardiac output, so diminishing the work load 
on the heart and reducing myocardial oxygen requirement. 
Although most of the evidence still points to venodilation 
as the predominant mechanism whereby nitroglycerin relieves 
anginal pain, there are two other pharmacological actions 
of 
' 
the drug which may contribute to its efficacy in angina. 
These. are the direct cardiac stimulant action and a unique 
dilator effect on large coronary arteries and collateral 
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vessels. The mechanism of action in angina and uses of 
nitroglycerin have been reviewed recently by Parratt 
(1979). The other uses of nitroglycerin as a therapeutic 
agent are as an anti-arrhythmic drug and, quite recently, 
it has become widely used in the treatment of congestive 
heart failure. 
Mechanism of Action at the Cellular Level 
The mechanism by which nitroglycerin causes 
venodilation and reduction in blood pressure has not been 
fully elucidated. All the major pharmacological properties 
of nitroglycerin are shared qualitatively by the nitrite 
ion and by many organic-nitrate esters, and only compounds 
capable of denitration will relax smooth muscle. The 
organic nitrates act at least as rapidly as administered 
nitrite ion, ýLnd are much more potent; a dose of 
nitroglycerin could release < 1% of the nitrite ion 
required for an equivalent pharmacological effect. Based 
on a great number of studies, it would appear that in 
smooth muscle-containing structures during responses to 
organic nitrates, the active nitrates react with and are 
reduced by sulphhydryl groups involved'in a nitrate 'receptor'; 
in some way, this interaction or the nitrite ion formed 
locally causes relaxation (Goodman and Gilman, 19? 5). The 
link between interaction with sulphhydryl containing a 
receptors and smooth muscle relaxation is unclear but is 
probably the result of locally released nitrite causing 
loss of respiratory control in mitochondria by inhibition 
of electron transport at the phosphorylation level 
(Needleman and Johnson, 1975). 
Metabolism of Nitroglycerin 
The biotransformation of nitroglycerin is initiated 
by a redox reaction and is manifested by the conversion of 
this potent lipid-soluble vasodilator compound into water 
soluble metabolites which have much lower biological 
potency and which are readily excreted in the urine. Studies 
by num erous workers (Needleman, 1975) have indicated that 
deactivation of nitroglycerin is rapidly and specifically 
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catalysed by glutathione-organic nitrate reductase which 
occurs predominantly in the liver. Blood clearance data 
expýicitly demonstrate that the parent nitrate ester 
(after intravenous administration) has a very transient 
lifetime, whereas the metabolites circulate for hours. 
The duration of the vasodilator effectiveness is in direct 
temporal correlation with blood levels of the intact ester 
and is completely out of phase with circulating metabolites 
(Needleman, 1976a). Thus the parent compound appears to be 
the active species. Several definitive experiments 
(Needleman et al., 1971,1972; Needleman, 19? 5,19? 6; 
Johnson et al., 19? 2) on the metabolism of nitroglycerin 
in the rat have indicated the stepwise denitration of the 
parent drug to give glycerol mononitrate as the primary 
urinary metabolite, with glycerol dinitrate, glycerol and 
carbon dioxide (from glycerol via the citric acid cycle) 
being the other principal metabolites. Although glycerol 
mononitrate is the major unconjugated urinary metabolites 
there is evidence that a glucuronide conjugate of glycerol 
dinitrate is the major urinary metabolite (Hodgson and Lee, 
1975). Of the total administered dose, , -10% appears as 
glycerol mononitrate and --1350ol as glycerol dinitrate - 
glucuronic acid. 
H 
H-ý-OH H 
I H H-U-U-NO H-ý-OH 
1121 
fi--C-0-NO H-C-O-NO 2 02 2H 2GSH II H-C-O-NO H ll-ý-OH 2 
,ý 
H-C-OH 
H-ý-O-NO 2GSH HI 2 2GSH H-C-OH 
HH 
I H-ý-OH 
li-C-0-NO HI 12 2GSH IzH ll-C-OH 
I 
ll--C-0-NO H-ý-OH 2 
H-ý-O-NO 
12 
H 
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trinitrate dinitrate mononitrate 
II 
glucuronide glucuronide 
Fig. 1.2 Major Pathways of Nitroglycerin Metabolism 
citric 
acid 
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The biotransformation of organic nitrates, both 
in vivo and in vitro, has been extensively reviewed by 
Needleman (1975). Based on a large number of experiments 
it would appear that nitroglycerin, and other organic 
nitrate esters, are metabolised primarily by the enzyme 
glutathione (GSH) organic-nitrate reductase, the 
stoichiometry for which requires 2 GSH per N02 liberated. 
Regeneration of GSH occurs at the expense of NADPH if 
organic nitrate reductase is coupled with glutathione 
reductase thus, 
+ organic-nitrate GTN + 2GSH GSSG + N02 + GDN +H reductase 
GSSG + 2NADPH. 2GSH + 2NADP glutathione reductase 
The reaction is essentially reduction, the liberation 
of NO- rather than NO-; it is a de-esterification rather than 23 
a denitration, and this activity resides primarily in the 
liver (Lang et al., 1972). There is'little doubt that GSH 
is required for this metabolism; glutathione depletion 
experiments (Needleman and Harkey, 1971) have produced a 
70-90% decrease in the rate of nitroglycerin degradation in 
an isolated-perfused rat liver system. This is supported 
presently in Chapter 4. 
Conflicting evidence exists as to the subcellular 
location of organic nitrate reductase. The balance of 
evidence indicates that this enzyme resides in the cytosolic 
fraction of hepatocytes. Needleman and Krantz (1965) 
performed a differential centrifugation of rat liver 
homogenates and demonstrated that the primary site of the 
nitroglycerin metabolising enzyme was in the 100,000g 
soluble fraction; a low level of mitochondrial activity did 
however exist, which these workers attributed to contamina- 
tion with the 100,000g supernatant fraction. Contrary to 
this, Hunter and Ford (1955) observed a GSH-dependent 
denitration of several organic nitrates, including 
nitroglycerin, in rat 1 iver mitochondria preparations. 
Di Carlo et al., (1967) have demonstrated that rat heart is 
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capable of metabolising penta-erythritol tetranitrate 
in vitro and that each subeellular fraction effected 
extensive degradation, with the highest activity being 
present in mitochondria and microsomes. Also, organic 
nitrate reductase is known to be induced by 
phenobarbital (Needleman and Krantz, 1965; Needleman 
and Harkey, 1971; Lee and Belpaire, 1972), and this 
property is almost exclusively associated with enzymes 
which reside in the microsomal rather than soluble 
fraction of hepatocytes. 
However, in none of these studies have marker 
enzymes been used, and organ ic nitrate reductase*activity 
has been assessed using a system whereby this enzyme is 
coupled to glutathione reductase and the disappearance of 
NADPH is the index of nitroglycerin consumption. 
For many years it has been widely accepted that 
nitroglycerin biotransformation occurs primarily in the 
liver and only to a minor extent in other tissues such as 
kidney and blood. Quite recently, Maier et al. 
-(1980) demonstrated negligible activity for organic nitrate 
reductase in small intestine, skin and heart; the bulk 
of activity occurred in the liver but significant activity 
was also observed in the kidney. These workers used 
100,000g supernatants and followed NADPH disappearance as 
the index of organic nitrate reductase activity. 
However, Posadas del Rio and Hunter (19? 3) demonstrated 
that the 1090OOg supernatant of intestinal mucosa showed 
organic nitrate reductase activity of the same order of 
magnitude as liver supernatants. As described earlier, 
(Di Carlo et al., 1967), heart is capable of metabolising 
organic nitrates and Oberst and Snyder (1948) demonstrated 
metabolism of nitroglycerin by rabbit muscle. Di Carlo 
and Melgar (1969,1970) indicated that rat serum was 
capable of denitrating nitroglycerin with a half-time of 
,, v 20 min. in an isolated buffered serum preparation; 
recently, Armstrong et al. (1980b) have demonstrated a 
quite rapid metabolism of nitroglycerin by whole human 
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blood, with a half-time of -6 min. Coupled with the 
studies of Lang et al., (1972), using totally eviscerated 
rats, which showed a biological half-life of 7-8 min. 
compared with , -l min. in controls, there, is good 
evidence that significant nitroglycerin metabolism occurs 
at sites other than the liver and these may be of great 
importance in the overall elimination of nitroglycerin and 
organic nitrates in general. 
Until recently the natural substrate for 
glutathione-organic nitrate reductase was unknown. The 
work of Keen et al. (1976), however, has suggested that 
organic nitrate reductase is one of the several activities 
possessed by the multifunctional enzymes, GSH-S-transferases; 
this was demonstrated with purified forms of these enzymes. 
However, there are several reports in the literature of 
GSH-independent organic nitrate metabolising enzymes, and 
GSH-S-transferase activity which differs from organic 
nitrate reductase. For example, Tsuruta and Hazegawa (1970) 
described an enzyme isolated from either plasma or liver 
that catalyses the degradation of ethylene glycol dinitrate 
into inorganic nitrate and ethylene glycol mononitrate, and 
which does not require GSH. Johnson (1963) studied an 
enzyme which conjugates GSH with aliphatic halogen compounds 
and observed that this enzyme was inactivated by dialysis 
in contrast to organic nitrate reductase which was enhanced 
by dialysis (Heppel and Hilmoe, 1950; Needleman and Krantz, 
1965). Grover and Sims (1964) studied an enzyme in which 
sulphobromophthalein was a competitive substrate in the 
reaction of 1,2-dichloro-4-nitrobenzene with GSH. The 
activity of this enzyme was diminished by pretreating rats 
with phenobarbital, thereby contrasting with organic 
nitrate reductase which was induced by phenobarbital. 
Organic nitrate reductase appears to differ from the enzymes 
that have been shown to conjugate organic compounds with 
GSH, since organic nitrates and GSH undergo a redox 
reaction and no permanent mercapturic acid conjugation 
product is formed. There is thus the possibility that 
nitroglycerin may be metabolised by multiple forms of the 
enzyme.. 
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The glutathione-S-transferases have been extensively 
reviewed by Jakoby (1978) and Chasseaud (1979). The 
GSH-S-transferases are capable of catalysing a protean 
spectrum of reactions, they are widely distributed and 
are present at high concentrations in the cytosol. The 
GSH-S-transferases serve three functions; they are 
involved in the catalysis of reactions in which glutathione 
acts as a nucleophile, they serve as binding proteins as 
manifested by their storage function for bilirubin in liver, 
and, like proteins in g eneral, they are capable of forming 
covalent linkages with alkylating agents. They are multi- 
functional in detoxification, they bind an enormous number 
of compounds that-appear to have in common only hydrophobic 
topography. If the ligand bears a sufficiently electro- 
philic centre, it will be attacked by the nucleophile GSH$ 
and such compounds would be substrates for the enzyme which 
would generally lead to the production of mercapturic 
acids. - 
In the rat there are six GSH-S-transferases, 
distinguished by their elution from a DEAE-cellulose ion 
exchange colilmn; these six are transferases AAIAIBICID and 
E. Although there is a degree of substrate specifity 
between the six transferases, it is generally not absoluteý 
and does not conform to the suggested groupings. All the 
transferases for example are active towards 1-chloro-2, 
4-dinitrobenzene, a typical aryl-transferase substrate. 
Like GSH, the GSH-S-transferases are located principally 
in the cytosol. Crude differential--centrifugation 
experiments showed that at least Kr/-6 of transferase 
activity-resided in the soluble supernatant fraction of 
rat, liver. The-remaining activity was-equally distributed 
amongýother subcellular fractions, but this may have been 
due to contaminating cytosol. Studies of the enzyme- 
catalysed conjugation of benzo(a)pyrene-4t5-oxide with 
GSH indicated that there may be some transferase activity 
in the hepatic endoplasmic reticulum (microsomes) of mice 
constituting, however, only a minor proportion of total 
hepatic GSH-S-transferase activity. The more recent 
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purification studies of Jakoby et al. (1976a, b) clearly 
suggest that the transferases are mainly present in the 
cytosol as has also been shown for ligandin 
(GSH-S-transferase B in rat liver)(Fleischner and Arias, 
1976). GSH-S-transferase activity appears to reside in 
most tissues but. is generally greater in the liver and 
kidney than in other tissues, and all the animal species 
so far investigated demonstrate hepatic GSH-S-transferase 
activity (Chasseaud, 19? 9). 
An investigation is made presently (Chapter 6) to 
determine the subcellular site(s), tissue site(s) and 
nature of organic nitrate reductase, in order to clarify 
the confusing situation outlined above. 
Pharmacokinetics of Nitroglycerin 
The pharmacokinetic properties of nitroglycerin, 
in man or animals have not been widely investigated due 
to the lack of suitably sensitive analytical methodology. 
The major metabolic studies to date with nitroglycerin 
have either employed radiolabel or used in vitro systems 
and vast quantities of the drug. Some preliminary 
pharmacokinetic studies have been reported. In rats, 
Johnson et al. (19? 2) have demonstrated a half-'life for 
nitroglycerin of the order of one minute following 
intravenous administration, whereas Yap et al. (19? 8) 
demonstrated a half-life of -4 minutes following 
intracardial administration. In man, following 
sublingual administration, Bogaert and Rosseel (19? 2) 
showed that peak plasma levels were obtained at four 
minutes and the rate for which at least half the intact 
drug was cleared from the blood was 1-3 minutes. 
Armstrong et al. (1980a) demonstrated that peak blood 
levels following sublingual administration occurred 
within two minutes, and a half-life of - 1.9 minutes in 
man was demonstrated following termination of an 
intravenous infusion. A number of other studies have been 
conducted and these will be discussed in more detail 
later (Chapter 5). 
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Deuteratibn of Nitroglycerin 
One of the disadvantages of nitroglycerin is its 
short duration of action. Following sublingual 
administration, peak blood levels occur within two 
minutes but are barely detectable after 20 minutes 
(Armstrong, et al , 1980a). Although attempts have been 
made to produce compounds resembling nitroglycerin but 
with a longer duration of action, there is much contro- 
versy regarding the efficacy and sustained effects of 
such "long-acting" nitrates. More recently sustained- 
release nitroglycerin preparations have been examined. 
The micro-encapsulation procedure allows the drug to be 
released progressively throughout the gastro-intestinal 
tract; the release of the active drug thus depends 
predominantly on the mode of pharmaceutical preparation. 
Theefficacy of the oral nitrates has been questioned on 
the grounds of inadequate absorption and rapid hepatic 
breakdown (leading to very low plasma levels) but there is 
considerable evidence supporting the effectiveness of this 
route in the treatment of angina pectoris (Windsor and 
Berger, 19? 5: Abrams, 1980). For acute treatment and 
rapid relief of anginal pain the sublingual route has no 
equal and because of the high lipid solubility of 
nitroglycerin closely resembles the intravenous route 
with respect to pharmacokinetic characteristics. 
There is thus a great deal of scope for the study 
of the effects of deuterium labelling on nitroglycerin 
metabolism and kinetics and for extensive pharmacokinetic 
studies on nitroglycerin itself. 
Imipramine 
Imipramine is another suitable example of a widely 
used drug, the efficacy of which may be improved by the 
application of deuterium labelling. As a consequence of 
its structure and different pathways of metabolism in 
different regions of the molecule, it also permits the 
study of the individual kinetic isotope effects for these 
two pathways of metabolism, by specific deuterium 
labelling. 
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Background and Uses of Imipramine 
The development of imipramine as a therapeutic 
agent was originally based on the observation that 
chlorpromazine exhibited therapeutic activity in 
psychiatric disorders (Delay and Deniker, 1953). This 
observation stimulated interest in structurally similar 
iminodibenzyl derivatives and led to the screening of a 
large number of these compounds in pharmacological tests 
for tranquillising activity (Hafliger, 1959; Hafliger 
and Burchardt, 1960). Observation that imipramine was 
ineffective in the treatment of psychotic patients, but 
was effective in the treatment of some depressive states 
(endogenous depression rather than reactive depression) 
by Kuhn (1957), and subsequent clinical trials, led to 
the introduction of imipramine into therapy in Europe in 
1958 and the U. S. A. in 1959. 
Since the introduction of imipramine, the prototype 
of the tricyclic antidepressant group of drugs, it has 
been shown that the clinical effectiveness of the drug is 
mainly due to its metabolite desmethylimipramine 
(Gillette et al., 1961), and this compound has since been 
introduced for the treatment of depression. Based on the 
early results with imipramine, numerous derivatives of 
iminodibenzyl have been examined for antidepressant 
activity. As a result of these studies with structural 
modifications of iminodibenzyl and imipramine, a large 
number of structurally similar compounds have been 
introduced into therapy (Fig. 1.4). 
Mechanism of Action 
Imipramine is used as a therapeutic agent in the 
treatment of endogenous depression and enuresis in 
children. The biochemistry of depression, is extremely 
complex and is-thought to involve a deficiency in nor- 
adrenaline and/or 5-hydroxytryptamine (serotonin) at 
central neuronal synapses (Byck, 1975; Spencer, 1977; 
Hollister, 1978; Sulser et al., 1978). The activity of 
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Fig. 1.4 Structures ofýImipramine and Related Compounds 
imipramine and the other tricyclic antidepressant drugs 
is thought to be a result of the blockade of the reuptake 
of nor-adrenaline and serotonin in the neurones resulting 
in an increased availability of the transmitter substances 
at their post synaptic receptor sites (Sulser et al., 1973). 
It is thought that the mood elevating action of these drugs 
is due to the blockade of serotonin uptake and that 
activation of motor activity is related to the effect on 
nor-adrenaline (Randrup and Braestrup, 197? ). As a result 
of this activityi the tricyclic drugs have been classified 
as membrane-pump inhibitors (Spencer, 1977). 
The entire picture is confused however with the 
observation that some of the more recently introduced 
compounds have little or no activity on serotonin reuptake 
and variable effects on nor-adrenaline reuptake, and this 
has raised doubts about the amine-uptake hypothesis 
(Randrup and Braestrup, 19? 7; Hollister, 19? 8; Sulser 
et al., 1978). 
As a result of the amine-uptake hypothesis there 
have been numerous studies into the structural requirements 
for the inhibition of nor-adrenaline and serotonin reuptake 
(Lippman, 1971; Horn, 19? 6; Segawa et al., 19? 7; Thomas 
and Jones, 19? 7). Inhibition of serotonin uptake activity 
is greatest in those compounds with a tertiary terminal 
amino group in the side chain and it has been shown that 
clomipramine is the most potent of this class of compounds 
(Horn, 1976; Randrup and Braestrup, 1977). With 
demethylation of the dimethylamino group to give the 
secondary amines, this activity decreases markedly; however 
with didemethylation to the primary amine the potency of 
the compound increases to that of the parent drug (Horn, 
1976). The secondary amines (e. g. desipramine and 
nortriptyline) are potent inhibitors of tor-adrenaline 
reuptake, desmethylimipramine being the most active 
compound (Randrup and Braestrup, 1977; Segawa et al., 19? 7). 
The metabolic conversion tertiary ýsecondary amine thus 
appears to produce a change in activity from serotonin 
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uptake inhibition to nor-adrenaline uptake inhibition 
which mirrors the observed clinical effects of 
azitianxiety and antidepressant respectively. Opipramol, 
which is unable to form a secondary amine, has only weak 
antidepressant properties and its efficacy is due mainly 
to an antianxiety and moderate tranquillising action 
(Kirkhorn, 1962; Theobald, 1964). The rates of metabolism 
of the tertiary amines to the secondary amines and the 
further metabolism of the secondary amines are therefore 
important factors in the effectiveness of these compounds. 
The rates of metabolism of imipramine and desmethylimipramine 
have been shown to be related to the species variation in 
the pharmacological activity of imipramine (Gillette, 
et al., 1961). 1-ý 
Metabolism and Pharmacokinetics 
The present known or postulated pathways of the 
metabolism of imipramine are siimmarised in Fig. 1.5. This 
pattern of metabolism has been established on the basis 
of the demonstration of the metabolic products in vivo and 
_LU. vitro 
in various species. These metabolic processes 
have been reviewed recently by Gram (1974,1977), and 
include: N-demethylation in the side chain by which DMI 
is formed, further demethylation to DDMI has also been 
demonstrated in several species but to a much lesser 
extent, N-oxidation in the side chain, C-hydroxylation both 
aromatic and aliphatic (positions 2 and 10 respectively), 
dealkylation of the side chain, glucuronide formation from, 
the hydroxy metabolites, and other transformations such as 
N-hydroxylation of imipramine. 
In man, data on imipramine metabolism were obtained 
by studies on urinary 'excretion of 
14C-imipramine'metabolites 
(Christiansen and Gram, 1967; Crammer et al., 1969). These 
studies demonstrated that demethylation, 2-hydroxylation, 
N-oxidation and glucuronide formation are all quantitatively 
important processes. In contrast, 10-hydroxylation, 
dealkylation and demethylation toMMI are small or 
insignificant. 
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A metabolite pattern similar to that in man has 
been observed in rats (Bickel and Weder, 1968). A 
difference has been reported in the relative excretion 
of metabolites in urine, bile, and faeces. In man, 
70-90% of the radioactive dose of 
14C-imipramine 
was 
eliminated in urine, and only small amounts in faeces. 
In rats 30-70% of the dose is eliminated in faeces 
(Crammer et al., 1963). In vivo and in vitro studies of 
the biliar. 7 excretion in rats has shown that, besides 
large amounts of glucuronides, the bile also contains 
unchanged imipramine and DMI (Bickel and Minder, 1970). 
As imipramine and DMI are readily reabsorbed from the gut, 
enterohepatic circulation may play some role. Biliary 
excretion has not been systematically studied in man. 
It is generally'accepted that liver is the main 
site of biotransformation of imipramine. This has been 
studied in hepatectomised rats in vivo and in homogenates 
from different tissues in vitro 
' 
(Minder, et al., 1971). 
It was shown that imipramine was metabolised mainly in 
the liver, and only to a minor extent in other tissues. 
Demethylation of imipramine was, however, demonstrated in 
many organs and was particularly pronounced in the gastro- 
intestinal tract. Further studies in vitro indicated that 
demethylation was catalysed by the intestinal contents. 
The reverse reaction7 methylation of DMI forming imipramine, 
has been demonstrated in rabbit lung in vivo (Dingell and 
Sanders, 1966) but not in rat lung. N-Oxide formation was 
observed using homogenates from liver, kidney and lung of 
rats (Minder, et al., 1971). IPNO is reduced to imipramine 
in many organs and in blood (Bickel, 1968,1969). To a 
lesser degree, IPNO is also demethylated to DMI. 
The-most important enzyme for imipramine metabolism 
is the microsomal mixed function oxygenase system 
(Dingell, et al., 1964). This system7 requiring NADPH and 
0 2, and involving cytochrome P450 as the terminal oxidase 
is a non-specific system'which catalyses a varieýy of - 
oxidative reactions (Gillette7 1971). All the pathways of 
biotransformation of imipramine are HADPH dependent 
-32- 
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oxidative reactions catalysed by liver microsomes 
(Dingell, et al., 1964; Bickel and Baggiolini, 1966). 
IT-Oxidation differs from the other reactions in that it 
is not inhibited by cytochrome P450 inhibitors such as 
CO and SKF 525A and is not stimulated by phenobarbital 
administration (Nakazawa, 1970; Bickel, 1971, Gigon and 
Bickel, 1971; Perel, et al.,, 
-1973)., 
N-Oxidation is 
predominantly located in microsomes of liver but those 
of lung and kidney also show activity (Bickel, 1969). 
Glucuronide formation is dependent*upon the enzyme 
UDP-glueuronyltransferase which is located in the 
microsomal fraction, of liver, kidney-cortex and gastro- 
intestinal mucosa (Dutton, 1971). Glucuronide metabolites 
of imipramine are apparently formed only in the liver as 
no glucuronides were formed in hepatectomised rats. 
Glucuronidase activity (of imipramine glucuronides) has 
been supposed to be present in the gastro-intestinal 
tract and has been shown in vitro in homogenates from 
liver-and intestine (Bickel and Weder, 1968). 
The pharmacokinetic characteristics of imipramine 
in man display marked inter-individual variations. 
Imipramine undergoes an extensive "first-pass" effect and, 
coupled with extensive protein binding, plasma levels 
(steady-state) following imipramine in doses of 3.5mg/day 
are in the range 6-356^g/l for imipramine and 
28-659, Ag/l for DMI (Gram, 1977). The biological half- 
life values are, for imipramine, between 4-17.6h and 
for DMI, 13.5-61.5h (Nagy, 1975). In the rat imipramine 
is rapidly converted to DMI with a half-life of ---2.5h 
(Dingell. 
-et. al., 1964) which is then only slowly 
metabolised further (ti, DMI o-19h), to 2-hydroxydesmethyl- 
7 imipramine and didesmethylimipramine. In man also, DMI is 
metabolised more slowly than imipramine (see above), but 
in rabbits and mice, both compounds are metabolised 
rapidly; rabbit tI ^12h, DMI . -lh, in mice t. 1, 7 
1 --50 minutes, DMI , -50 minutes. In the rabbit the 
primary metabolite is probably2-hydroxy-imipramine 
(Dingell, et al., 1964). The differences in rates of 0 
metabolism result in the accumulation of DMI in the tissues 
-33- 
of man and rat but not in those of rabbit and mouse, 
and this is in accord with the observed species 
variation in pharmacological response to imipramine. 
Table 1.2. ý Species-Variation in the Pharmacological 
Effects of Imipramine and Desmethylimipramine 
Species Metabolism Pharmacological Effect 
Imipramine(I) Desmethyl- 
imipramine(DMI) 
Immed- Pre- 
iate treated 
Rat I DMI 
Mouse I DMI 
Rabbit I DMI 
Cat I I/ 
Human I =ý DMI -4 
From Bickel (1972) 
Thicker arrows indicate faster reactions. 
CNS-stimulant, antidepressant 
CNS-depressant, neuroleptic (mild sedative effect). 
The cat is a particularly interesting species because 
it appears not to metabolise imipramine to an appreciable 
extent, and exhibits a neuroleptic effect (similar to the 
phenothiazine tranquillisers) which would support the 
hypothesis that imipramine is a tranquilliser whose properties 
are not demonstrated due to its rapid demethylation to DMI. 
Maxwell (1961) showed that in the rat; low doses of 
imipramine, ('<lo mg/kg) exhibited no sedation, whereas with 
higher doses (20-40 mg/kg) most rats were sedated. Coupled 
with the structure-activity relationships of the tricyclic 
antidepressants, the species variation-of metabolism on 
pharmacological effect provide impressive evidence that 
imipramine has tranquillising properties which, as a result 
of metabolism, are not demonstrated. 
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Deuteration of Imipramine 
Thus the application of deuterium labelling of 
imipramine could lead to the development of a better 
antidepressant drug, in that it is possible that by 
slowing N-demethylation a drug could be developed which 
would sedate the patient more before exhibiting 
antidepressant properties. This 2-stage action of 
imipramine is preferred, by many patients and 
psychiatrists, over existing antidepressant drugs, such 
as DMI, which are rather harsh acting. 
Imipramine also offers several possibilities for 
deuteration which could demonstrate the individual 
effects of specific deuteration at the sites of aromatic 
hydroxylation and N-demethylation: 
a) Deuteration of one N-methyl group, one rather than 
both N-methyl groups would be deuterated in order to 
minimise the effects of increasing affinity of the drug 
for the metabolising enzymes as a result of incrdased 
van der Waals forces and increased basicity. Deuteration 
of both methyl groups may cause an isotope effect which is 
completely masked by stronger affinity of the drug for 
the enzyme. Deuteration of one N-methyl group may lead to 
an isotope effect on N-demethylation, the predominant 
pathway of imipramine metabolism. A build up of the levels 
of imipramine relative to DMI might occur which may enable 
imipramine to exhibit tranquillising properties. Even if 
metabolic switching occurred so that metabolism via 
aromatic hydroxylation and N-oxidation was enhanced, this 
may still result in increased tranquillising properties 
for imipramine, since both these metabolites have been 
shown to possess pharmacological properties similar to 
imipramine (Sigg, et al-I 1963; Nagy, 1980). 
b) Deuteration at the 2-position, this may lead to an 
isotope effect on aromatic hydroxylation, again causing a 
build up of imipramine. Although N-demethylation would be 
unaffected, it is possible that a large isotope effect on 
aromatic hydroxylation would block metabolism at the 
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2-position; as significant proportions of 2-hydroxylated 
metabolites are formed normally, deuteration may cause 
imipramine to build up if the N-demethylating route 
cannot compensate. By the same reasoning, the 
2-hydroxylation of D14I may be slowed which would 
dramatically extend the duration of action and potency of 
the antidepressant properties of imipramine. Combined 
effects of slower 2-hydroxylation of imipramine and DMI 
could produce initial tranquillising properties for 
imipramine and enhanced antidepressant properties. 
c) Both regions deuterated, combining the postulated 
effects of N-methyl deuteration and aromatic deuteration 
could lead to a long acting antidenressant driim whinh 
initially performs as a good tranquilliser. However these 
possibilities tend to rest on the production of relatively 
large isotope effects which, up to now, have not been 
observed in these types of metabolism. It is conceivable, 
however, that a small isotope effect on N-demethylation 
only, could enhance the tranquillising properties of 
imipramine. This mixture, a drug initially sedating the 
patient followed by relieving the patient's anxiety would 
be extremely valuable in the treatment of endogenous 
depression. 
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Aims of this Thesis 
It is proposed to investigate the effect of 
deuteration on the metabolism and pharmacological 
activity of two short acting drugs, nitroglycerin and 
imipramine. For nitroglycerin, it is proposed to slow 
its elimination, by per-deuteration, so extending its 
duration of action and making it a more effective drug, 
particularly when administered orally. For imipramine, 
it is proposed, by specific deuteration, to slow the 
metabolic transformation of this drug to its active 
metabolite (desmethylimipramine), so allowing a build 
up of imipramine levels relative to desmethylimipramine 
levels, which may lead to enhanced tranquillising 
properties for imipramine. An extremely valuable drug, 
a tranquillising - antidepressant would thus be formed. 
As a result of the lack of reproducible, 
sensitive and specific analytical methodology capable of 
determining these drugs in the small volumes of 
biological fluids obtainable from small animals, very 
few studies have been conducted concerning their 
pharmacokinetic properties. Using improved methodology, 
it is proposed to conduct detailed investigations into 
the pharmacokinetic properties of the drugs in a number 
of species. 
Some confusion exists in the literature about the 
intracellular site, tissue sites and nature of the 
enzyme(s) responsible for biotransformation of 
nitroglycerin. An investigation (in Litro) is thus 
undertaken with the aim of clarifying this situation. 
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CHAPTER 2 
SYNTHESIS OF DEUTERATED ANALOGUES 
OF NITROGLYCERIN AND IMIPRAMINE 
INTRODUCTION 
In order to conduct an investigation into the 
effects of deuterium labelling on the pharmacokinetic and 
pharmacological properties of nitroglycerin (glycerol 
trinitrate) and imipramine (Chapters 4 and 7), a number of 
deuterated analogues of these drugs were synthesised. The 
present chapter describes these syntheses and the problems 
encountered during the preparation of analogues of 
desmethylimipramine. Initially, it was proposed to 
synthesise completely deuterated glycerol trinitrate and 
both, ring-deuterated and N-methyl-deuterated analogues of 
imipramine and desmethylimipramine. 
The first reported synthesis of glycerol trinitrate 
was that of Ascanio Sobrero in 1846, and the synthetic 
method has changed little since that time. This involves 
the nitration of glycerol with a mixture of sulphuric and 
nitric acids (Laurie, 1928) and a similar procedure, 
developed by Biorez Laboratories Ltd., was used here; this 
procedure permits the rapid synthesis of small quantities 
(mg) of glycerol trinitrate. Glycerol trinitrate is 
prepared by this means and pentadeuteroglycerol trinitrate 
(GTN-d5 
I A) similarly prepared after initially synthesising 
pentadeuteroglycerol (Slycerol-d 5' B) by reduction of 
diethylketomalonate (C) with lithium aluminium, deuteride: 
Scheme 1. 
cooc 2H5 CD 2 OH CDý01T02 
C =-- 0 CDOH CDONO 2 
COUC 2ý5 
CD20NO 2 
(G) 
The syntheses of imipramine and desmethylimipramine 
were first reported by Schindler and Hafliger (1954), the 
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Scheme 2. 
HOCH2CH 2 CH i 1H 2 --ý HOCH 2 CH2CH2NHCH2C 6ý5 --ý 
where R= CH 3 or CD 3 
"Ts = Tosyl group 
CN 
zR 
HOCH2ýH2ýH2ý 
Nýl 
CH 2ý6ý5 1 
TS, OCH2CH2ý112N 
CH2C 6ý5 
H 
dndn dnre dn 
NN 
I 
I'll, 
R 
I-le 
R 
CH2ýH 2 CH2N ,"HNN.. CH 2c 6115 
(G) 
I 
dri., f dn dn "I, < dn 
lolý ,, 
Zý., )I . 0ý 
C', 
-NI.. NN 
I 
,/RI I/ 
R 
un2Cli2CFl2N,,,, 
COOC2H5 
'; 112ý112ýH2ý 
CH 
R= CD3 (F) IR= CH3 (D) ,n=0 and R= CD 3 
(E) 
where dn is the number of deuterons inserted into the aromatic ring 
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preparation involved condensation of iminodibenzyl with 
3-dimethylamino-l-chloropropane. Procedures for the 
insertion of deuterium at specific sites in the imipramine 
and desmethylimipramine molecules have been reported 
(Heck et al, 1977; Shaw and Markey, 19? 7; Hanzlik et al 
19? 9) and a number of methods are available for deuteration 
of the aromatic rings of compounds with similar structure 
. 
(Tý arsen and Changl, 1978; Elvidge et al, 1979). Based on 
the availability of such methods, it was proposed to 
synthesise, a) ring-deuterated imipramine (D) containing 
as many aromatic deuterons as possible, b) N-methyl- 
deuterated imipramine (E), consisting of one methyl group 
only deuterated, c) the combination, ring-deuterated and 
N-methyl-deuterated imipramine (2), and d) desmethylimipramine 
similarly deuterated at both positions (G). Starting from 
iminodibenzyl and using the syntheses described by Shaw 
and Markey (1977), Scheme 2. was used for the syntheses. 
A number of problems were encountered with this 
sequence of reactions and an alternative sequence was 
sought. Attention was focussed on the synthesis of 
deuterated analogues of imipramine and the final reaction 
scheme, which now started with desmethylimipramine, 
involved: 
Scheme 
H 
CH 2 CH 2CH2N 
CH 
N COOCH, 1 
11*1 e- 7 '-; lYH 2CH2ý ", CH 3 Nlsýl 
CH 
dn d- 
Uli 2u"2ý't2 ý 
R 
n 
11; 1021 CH 
R=CD 3 (E) 
Uli 2UM2UH2 N , ', 
R= CD 3 (F), R= CH 3 (D) 
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This procedure is used for the synthesis of imipramine-d 3 
(E), imipramine-d4 (D) and imipramine-cL7 (F). Problems - 
associated with Scheme 2. are described and suggestions 
made as to the causes of these problems, and in some cases 
the solutions are indicated. 
N. m. r. spectrometry is used as the primary tool 
for monitoring the reactions involving imipramine and 
desmethylimipramine. The above two sequences of 
reactions (Schemes 2 and 3) are very amenable to this 
approach since relatively simple, easy to interpret, 
n. m. r. spectra of the compounds involved can be obtained. 
Integration of the relevant bands of the spectra also 
permits a preliminary calculation of the success of, and 
degree of, deuterium insertion. N. m. r. studies used 
for following reaction steps are supported by t. l. c. and 
i. r. spectrometry where necessary. 
Following purification, the products are 
characterised by t. l. c., S. l. c. and h. p. l. c. (see 
Chapters'3,7), i-r- spectrometry, n. m. r. spectrometry, 
mass spectrometry and by melting point determination 
where possible before being used in subsequent studies. 
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EXPERIMENTAL 
MATERIALS 
Iminodibenzyl, imipramine (hydrochloride) and 
desmethylimipramine (hydrochloride) were donated by 
Biorex Laboratories Ltd. (London). Adams catalyst (Pt02) 
was obtained from Koch Light Laboratories Ltd., (Colnbrook, 
Buckinghamshire) and deuterium sources, LiAlD 4 (> 99%D) 
were obtained from the BDH Ltd. (Poole, Dorset) and 
D2 0( >99.8%D) and CDC1 3 from Nuclear Magnetic Resonance 
Ltd., (High Wycombe, Buckinghamshire respectively). 
t-Butanol, methyl iodide, sodium boro-hydride and 
p-toluenesulphonyl chloride were purchased from the 
Aldrich Chemical Company Ltd. (Gillingham, Dorset); all 
other solvents and chemicals were obtained from the BDH 
Ltd. Gases used, hydrogen and hydrogen chloride, were 
supplied by the B. O. C. Ltd. (Crawley, Sussex). 
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METHODS AND RESULTS 
A. Synthesis of Glycerol trinitrate and Pentadeutero- 
glycerol trinitrate 
Synthesis of Glycerol trinitrate 
A 3.7% (W/v) solution of glycerol in acetone was 
prepared, 1.0 ml of this (37 mg, 0.4 mmol of glycerol) 
was evaporated to dryness and the residue cooled to OOC. 
A mixture of 1.2 ml of 201% oleum and 0.8 ml of 70% (w/w) 
nitric acid was added, mixed and maintained at OOC for 
5 minutes. After addition of ice-water (40 ml) to quench 
the reaction, the solution was extracted with ethyl 
acetate (2 x 20 ml), and the extracts were pooled and 
washed with saturated aqueous NaHCO 3 solution (10 ml), 
then water (10 ml) and finally dried over anhydrous 
sodium sulphate. The ethyl acetate extract thus obtained 
contained a mixture of glycerol trinitrate, glycerol 
dinitrates and glycerol mononitrates. 
CH20H CH 20N02 
JINO 3 
CHOH 11 2SO4 
CHONO 2 
CH29H 
Reaction Profile. The synthetic method for glycerol 
trinitrate (GTN) designed by Biorex Laboratories Ltd. 
states the yield of GTN as 95-98% theory. Presumably this 
yield is estimated by assaying the product (assumed to be 
mostly GTN) for nitrate groups and, as no purification 
step is involved, takes no account of the presence in the 
product of nitrate groups from glycerol dinitrates (GDN) 
or glycerol mononitrates (GMN). Thus a yield of nitrate, 
95% theory for GTN, could mean that the product is 
contaminated with GDN e. g. this could be 85%6 GTN and 
15% GDIT. T. l. c. examination of the reaction product 
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confirmed the presence of a significant proportion of 
GDN (> 10%). 
An investigation was therefore carried out in 
order to confirm the optimum reaction time of five 
minutes determined at Biorex Laboratories Ltd; their 
studies had involved removal of aliquots of the reaction 
mixture at various times and assaying these for total 
nitrate content, rather than for GTN content. 
The reaction profile was thus followed using 
t. l. c. analysis of the reaction mixture. T. l. c. conditions 
were as follows: 250/6 silica gel plates were used and 
the solvent system consisted of benzene, ethylacetate, 
acetic acid (16: 4: 1 by volume) with chamber saturation. 
Following development of the chromatogram, visualisation 
was achieved by spraying with 1% diphenylamine in ethanol 
and irradiation for several minutes with short wavelength 
ultraviolet light until the spots (green) appeared. 
R. values: GTN 0.63 
112 GDH 0.36 
1,3 GDN 0.47 
GMN 0.10 
The effect of reaction time on the, proportion of 
GTN formed (relative to GDN) was qualitatively assessed 
by removing aliquots of the reaction mixture at various 
time intervals. T. l. c. showed that the highest 
proportion of GTN (relative to GDN) was present at 
3 minutes and 5 minutes, after which time there was a 
gradual increase in the proportion of GDN present; at 
30 minutes the relative proportions were estimated as 
60%'GTN and 40% GDN. Thus a reaction time of 5 minutes 
was confirmed, but the presence of. impurities was 
demonstrated., 
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Synthesis of Pentadeuteroglycerol trinitrate 
Pentadeuteroglycerol was first synthesised. 
Diethyl ketomalonate (500 mg, 3.3 mmol) in sodium-dried 
diethyl ether (5 ml) was added dropwise to a solution of 
LiAlD4 (300 mg, 7.2 mmol) in sodium-dried ether (5 ml) and 
the mixture was refluxed for one hour and allowed to cool 
to room temperature. Excess LiAlD. was eliminated. by 
dropwise addition of water-saturated ether (5 ml). Water 
(5 ml) was then added to the mixture and the ether 
evaporated. The aqueous solution remaining was passed 
through a coDimn (15 x1 cm) of cation exchange resin 
(HG50W-XS, 100-200 mesh), in the hydrogen form, and eluted 
with 60 ml. of water. The water was evaporated and the 
remaining viscous liquid dissolved in acetone which was 
also evaporated. Part of the deuterated glycerol (45 mg) 
was treated with the mixed acid (1-5 ml oleum + 1.0 ml 
nitric acid) as described earlier for the glycerol 
trinitrate synthesis. 
COOC2ý5 CD 20H CD20NO2 II, I' - 
C == 0 LiAlD4 CDOH ENO 3 CDON02 
I- 
Jor I H2SO4 
I 
COOC2H5 CD2ýH CD201; 02 
Purification of Glycerol trinitrate and Glycerol trinitrate-d 
Purification of GTN can be accomplished by 
preparative t. l. c., using the solvent system described 
earlier. Deuteration of GTN produced no detectable change 
in its t. l. c. characteristics, however, GTN is quite volatile 
and this procedure results in some loss of the product and 
low yields. 
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Purification by solvent extraction is a much 
simpler method. Such a method was designed by taking into 
account the relative solubilities of GTN and GDN in water 
and various organic solvents. Hexane was chosen as the 
solvent; the reaction product was not very soluble in this 
solvent, so sufficient ethyl acetate was retained (2 ml), 
on concentration of the above extracts, to ensure complete 
dissolution in hexane (25 ml). The mixture was then 
extracted several times with water (10 ml), q. portion of 
the organic phase being submitted for t. l. c. analysis after 
each two extractions. After four extractions, only traces 
of GDN remained but 12 extractions were required for 
complete purification (> 99%). The purity was also 
confirmed by g. l. c. (Chapter 3). Loss of GTN during this 
procedure was not estimated. This procedure was used for 
purification of both analogues of GTN. 
Characterisation of Glycerol trinitrate and Glycerol 
trinitrate-d 5 
These products were initially characterised by 
t. l. c. and g. l. c. as described above. Infra-red 
spectrometry, using a Pye Unicam SP1000 i. r. spectrometer 
with KBr plates (thin-film) confirmed the structures of 
GTN (Fig. 2.1A) and GTN-d 5 (Fig. 2.1B), and notably 
indicated a shift to lower frequency for the C-H (D) 
stretch bands (fromo-2900 cm-1 to , -2000 cm-1). The 
i. r. spectra of both compounds show maxima at 1670 cm-1 
(assymetric No 2 stretch, at 1275 cm-1 (symmetric N02 
stretch) and at 840 cm7l (CO-N stretch). Low resolution 
mass spectra were recorded using an AEI MS12 instrument 
(ionisation potential 7OeVj source temperature 150-10000 
in order to confirm the structures and to determine the 
incorporation of deuterium (see Appendix 3). The direct 
insertion mode was used with CC14 as the solvent. 
Unfortunately, due to the low thermal stability of these 
compounds, a molecular ion was not observed. The mass- 
spectra showed a base peak of m/e = 46 (NO'), fragments 2 
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Fig. 2.1 Infra-red Spectra of Glycerol trinitrate and 
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of <1% relative abundance of the base peak were not 
included (Fig. 2.2). Since no species of m/e-1 or 
m/e-2 for the deuterium containing ions were observed 
(i. e. containing H rather than D), one can assume that 
deuteration was virtually complete (>99%D). The yield 
of deuteroglycerol was 41%. Following purification and 
characterisation, both compounds were dissolved in 
propylene glycol and assayed by a colorimetric method 
(British Pharmacopoeia, 1973). 
Determination of glycerol trinitrate 
-ýý5)* 
Aliquots 
(0.1 ml) of the propylene glycol solutions and of suitable 
standards (0-10 mg ENO 3 
/ml), in duplicate, were individually 
mixed with 5 ml of glacial acetic acid, and mixed for one 
hour in a reciprocating shaker. Aliquots (1 ml) were 
removed and thoroughly mixed with 2 ml of phenoldisulphonic 
acid solution in conical flasks and allowed to stand for 
15 minutes. The flasks were transferred to an ice-bath 
and 8 ml of water added to each. The solutions were then 
made alkaline by dropwise addition of 25% w/w ammonium 
hydroxide and the final volume adjusted to 20 ml with 
water. The absorbance of 430 nm was determined using a 
Pye-Unicam SP1800 spectrophotometer. Standard curves were 
constructed and GTN concentration determined from these, 
using a correction factor of 0.7492 (as KITO 3 was used as 
the standard). The yield of GTN was 24% and of GTN-d 5 
was 101j'55, the low yields being essentially due to the 
purification procedure. 
B. Deute'ri= Labelling of the Aromatic Rings of 
Iminodibenzyl and Imipramine 
Deuterium Labelling of Iminodibenzyl 
Iminodibenzyl (10,11-dihydro-5H-dibenz[b, flazepine) 
was purified by recrystallisation from dichloromethane, 
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toluene and finally absolute alcohol. Several procedures 
were adopted for deuteration of the aromatic rings of 
iminodibenzyl. 
Use of BF -D, O mixtures. The procedure described by 3--ý_- 2 Larsen and Chang (1978) was initially used. The BF 3- D20 
mixture was prepared as follows: A weighed amount of D20 
(19,50 =01) was cooled in an ice-water bath and BF 3 
bubbled through the liquid until a 1: 1 molar ratio was 
achieved as measured by the weight increase. To this was 
added iminodibenzyl (500 mg, 2.6 mmol) and the mixture 
stirred at 90 0C in a tightly stoppered flask for 18 hours. 
Several such experiments were carried out, and these showed 
(after isolation of iminodibenzyl by extraction with 
chloroform) the incorporation of deuterium to vary 0- 10% 
as determined by n. m. r. spectrometry. The low incorporation 
may have been due to the poor stability of iminodibenzyl 
in the BF3-D20 mixture, and so t-butanol (200 mg) was 
included to facilitate solubilisation; no improvement 
oce urr ed. An alternative approach, involving the use of 
evacuated-sealed tubes with the same reaction mixture (but 
including 500 mg of t-butanol in; ste4d of 200 mg), produced 
no improvement, and resulted in charring of the reaction 
mixture. 
Use of trifluoroacetic anh7dride - D20 mixtures. Iminodi- 
benzyl (500 mg, 2.6 mmol), D20 (19,50 mmol) and 
trifluoroacetic anhydride (0.6g, 2.7 mmol) were placed in 
a test-tube which was then placed under vacuum, sealed 
and heated at 950C for 18 hours. Alternatively, iminodi- 
benzyl (500 mg, 2.6 mmol), D20 (59,250 mmol) and 
trifluoroacetic_. anhydride (1 ml, 6.2 mmol) were placed in 
a flask and refluxed for 36 hours. In neither case did 
significant deuteration occur, again due to the insolubility 
of iminodibenzyl in the reaction mixture. 
Thus attention was focussed on deuterium labelling 
of imipramine itself, since the hydrochloride of imipramine 
should be soluble in this reaction mixture. 
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Deuterium LabellinS of Imipramine 
Deuterium labelling of imipramine (HC1) proved to 
be more successful. Based on the procedure described by 
Heck et al, (197? ) and Hanzlik et al, (19? 9), imipramine 
hydrochloride (1g, 3.1 mmol) was added to a mixture of 
D20 (59,250 mmol) and trifluoroacetic anhydride (1 ml, 
6.2 mmol) or heptafluorobutyric acid (HFBA,, 1 ml, 6.2 mmol), 
and refluxed for 48 hours. Water (10 ml) was added to the 
reaction mixture and the resulting solution made alkaline 
with 5M NaOH. Imipramine (free base) was then extracted 
into diethyl ether (2 x 10 ml) and the combined extracts 
dried over anhydrous Na2W4 and evaporated (rotavapor, 50 0C) 
to an oil (, -, 600 mg, yield = 68%). N. m. r. spectrometry 
indicated 50% replacement of the aromatic protons by 
deuterium. Both trifluoroacetic anhydride and HFBA produced 
similar results, although it had been hoped that HFBA 
would lead to > 50% incorporation. Further insertion of 
deuterium could not be achieved even when imipramine 
hydrochloride (5001,16D) was further-treated with D20-HFBA as 
described above. In all subsequent experiments to 
deuterate the aromatic rings the method used was as 
described above and employed HFBA rather than 
trifluoroacetic anhydride. 
C. Synthesis of 5-[3-(Methy_l- 3- 10, 
11-dih7dro-5H-dibenzCb, flazepine-. (desmethZl- 
imipramine-d 3) 
It was intended to follow the reaction sequence 
outlined in the introduction to this chapter (Scheme, 2); the 
starting compounds were iminodibenzyl and 3-amino-l-propanol, 
and the syntheses outlined by Shaw and Markey (1977) were 
used. However, these workers started with 3-benzylamino-l- 
propanol which is not readily available here. Thus 
3-benzylamino-l-propanol had to be synthesised and this was 
achieved with some difficulty. 
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Synthesis of 3-Benzylamino-l-propanol 
This intermediate is required in the reaction 
scheme since a blocking group is necessary in 
3-amino-l-propanol to prevent incorporation of 2 methyl 
groups at the methylation stage. Several approaches to 
the synthesis of this compound were attempted. 
Literature procedures (Freifelder et al, 1953; Vaughan 
et al, 1961) all involve the catalytic hydrogenation of 
3-benzylimino-l-propanol which is initially formed by 
reacting benzaldehyde with 3-amino-l-propanol. 
Synthesis of 3-benz7limino-l-propanol. 3-Amino-l- 
propanol (75-19,1 mol) was added slowly to benzaldehyde 
(106.16,1 mol) dissolved in 100 ml of dry benzene, 
(cooled in an ice bath). The mixture was refluxed 
azeotropically until no further water appeared in the 
collecting tube; 17.8 ml. of water (, -l mol) was produced. 
The solvent was then removed by distillation (rotavapor, 
500C) to leave an oil which was cooled to room 
temperature and dissolved in absolute ethanol (200 ml). 
// 
0 CH =NCH 2 CH 2CH 2011 C\ 
-c\+H 2NCH2CH2CH 20H )I '*ý + H20 
Hydrogenation of 3-benzylimino-l-propanol. The imine was 
hydrogenated under a pressure of 3 atmospheres over PtO 2 
(Adams catalyst, 0.5g) for 7 hours; Pt02 was removed by 
filtration. During hydrogenation the mixture had changed 
colour from pale yellow to grey-black. Following evaporation 
of the alcohol, the oil was dissolved in H20 (180 ml) and 
concentrated hydrochloric acid (120 ml) added; neutral 
compounds (e. g. benzaldehyde) were removed by extraction 
into ethyl acetate (3 x 100 ml). 5M NaOH (250 ml) was 
added to precipitate free-base containing compounds, which 
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were extracted with ethyl acetate (3 x 100 ml). The 
pooled extracts were washed with water (2 x 100 ml) to 
remove 3-amino-l-propanol, dried over anhydrous Na 2SO41 
and evaporated to an oil (19.4g). N. m. r. spectrometry, 
i. r. spectrometry and t. l. c. (solvent system petroleum 
ether, ether, acetone. 8: 1: 1 by volume) showed this oil 
to be composed of primarily 3-benzylamino-l-propanol 
but contaminated with some 3-benzylimino-l-propanol. 
Also-, benzaldehyde (77-99,0.73 mol) was produced during 
the hydrogenation, and the yield of 3-benzylamino-l- 
propanol was only 11.8%; production of 0.73 mol of 
benzaldehyde from 3-benzylimino-l-propanol requires 
13.5 ml of water and this could only come from the 
hydrogen or alcohol used during hydrogenation. The 
entire sysnthesis was repeated, using fresh reagents, 
but similar products were obtained. An alternative means 
of synthesising 3-benzylamino-l-propanoll in higher 
yield, was thus sought. 
CH= NCH2CH2C%OH H2 CH2NMH2CH2CH20H 
Pt02 
Reaction of benzyl chloride with 3-amino-l-propanol. 
Benzyl-chloride (12g, 0.1 mol) was added to 3-amino-l- 
propanol (7-59,0.1 mol) in an ice-bath. The mixture was 
allowed to warm to room temperature and was stirred for 
18 hours. Water (40 ml) and conc. HC1 (5 ml) were added 
and this mixture was extracted with ethyl acetate (40 ml). 
The organic extract was washed with water (10 ml) which 
was then combined with the 40 ml aqueous phase. The 
combined aqueous phase was rinsed with ethyl acetate (5 ml) 
and then made alkaline with 5M NaOH. This mixture was 
extracted with ethyl acetate (1 x 40 ml, 1x 20 ml), the 
extracts combined, washed with H29 (2 x 10 ml) before 
drying over anhydrous Na2SO4. T. l. c. (petroleum ether, 
ether, acetone. 8: 1: 1) indicated the presence of one band 
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only and n. m. r. spectrometry and i. r. spectrometry 
showed this to be 3,3-dibenzylamino-l-propanol rather 
than 3-benzylamino-l-propanol 9-CH 
CH2C' 2**ý 
2+H2 NCHýC'12 CH 2 OH _.. *, 
NCHýCHýCH20H 
Ir CH 2 
+ 2HC1 
Obviously the reaction continued beyond 3-benzylamino-l- 
propanol to the tertiary amine 3,3-dibenzylamino-l-propanol. 
This route was abandoned in favour of synthesis of 
3-benzylimino-l-propanol and reduction with NaBH4* 
Reduction of 3-benzylimino-l-propanol with NaBH,,. 
3-Benzyl-imino-l-propanol was prepared as described above, 
with the exception that 0.25 mol of each starting compound 
was used and these were dissolved in 40 ml of dry benzene; 
4.6 ml of water (0-26 mol) were obtained. Following 
removal of the benzenelthe oil was dissolved in methanol 
(400 ml) and stirred at room temperature. NaBH4 (4.84g, 
0.13 mol) was added over 5 minutes and the mixture stirred 
for 1 hour. Excess NaBH4 was destroyed by addition of 10% 
H2 S04 (200 ml). Most of the methanol was removed 
(rotavapor, 60 0 C) and the remaining solution extracted 
with ethyl acetate (2 x 100 ml) to remove neutral compounds, 
then made alkaline with 5M NaOH and the free bases 
extracted with ethyl acetate (2 x 200 ml). These extracts 
were pooled, washed with water (3 x 200 ml) and dried 
over anhydrous Na 2SO4* Ethyl acetate was removed (rotavapor, 
500C) and the oil so produced was distilled under vacuum 
(, v3= Hg, 134-136 0 C) to produce a colourless oil which was 
identified by n. m. r. spectrometry and i. r. spectrometry as 
3-benzylamino-l-propanol (see Fig. 2-3). The yield was 57%. 
CH= NCH 2 CH2CHýOH NABH4 . 
CH2NHCH 2 CH 2 CH20H 
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S7nthesis of 3-benzylmethylamino-l-propanol. The method 
described by Shaw and Markey (1977) was used. NaOH (6g) 
was dissolved in 50 ml of water-methanol (1: 1) and 
3-benzylamino-l-propanol (159,92 mmol) added. This 
mixture was stirred at 0- 50C and iodomethane (? ml, 
110 mmol) slowly added. The mixture was allowed to warm 
to room temperature and stirred for 20 hours in a 
stoppered flask. 50 ml of water was added, the mixture 
extracted with CHU 3 (2 x 100 ml) and dried over 
anhydrous Na2S04o Following removal of the solvent 
(rotavapor, 50 0 C), ?. 2g of an oil remained; yield 44% 
(literature - 93%). N. m. r. spectrometry showed a 
smaller integration for the methyl group than expected 
for this compound and even when the synthesis was repeated 
the same result was observed. If the integration of the 
methyl group and the benzyl group are compared, then the 
correct ratio of protons is observed, and, since 
consistent integration was obtained in all the syntheses, 
it was assumed that the product is 3-benzylmethylamino-l- 
propanol. 
C6 H5 CH2NHCH2ýHýCHýOH C6ý502N(CH 3 )02ýH20ýOH 
CH 31 Hi 
Synthesis of 3-(benzylmethylamino)propyl-p-toluenesuphonate. 
To a solution of 3-(benzylmethylamino)-l-propano1 (59, 
27.4 mmol) in pyridine (30 ml) at OOC (ice-water bath) was 
added p7toluenesulphonylchloride (10.4g, 54.4 mmol) over 
5 minutes. The reaction was then capped and left at 20C 
for 20 hours. The mixture was poured onto ice (200g) and 
stirred for one hour to produce an oil which was extracted 
into CHCl 3 
(2 x 50 ml). The pooled extracts were washed 
with 2M HU (4x 25 ml), 1M NaOH (2 x 25 ml) and H29 
(3 x 25 ml), dried over anhydrous Na2SO4 and evaporated to 
an oil (4.0g). N. m. r. spectrometry did not show clearly 
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that the praduct was as stated, but indicated a mixture 
of 3-(benzylmethylamino)propyl-27toluenesulphonate and 
27toluenesulp. 4onyý. chloride. Further purification 
(e. g. by distillation) could not be achieved, due to the 
lability of the tosyl group and so the oil was used for 
the next reaction in this form. 
C6ýýCH2N(CH 3 )CH 2 CH2ýH20H, + CH 3 
Cýý5 CH2ý(CH 3 )CHýCHýCH20S02 -1 H- 3+ HU 
Synthesis of 5-13-(benzylmethylamino)propyl]-10,. 
11-5H-dibenz[b-, flazepine. 
To a stirred suspension of sodium hydride (0.6g, 25 mmol) 
in 20 ml of dry benzene was added iminodibenzyl (1.259, 
6.4 mmol) over 5 minutes and the mixture refluxed for 
hours. The reaction was cooled and a solution of 
3-(benzylmethylamino)propyl-p7toluene sulphonate (2.6g, 
8.2 mmol) in 20, ml dry benzene was. added over 5 minutes. 
The mixture was refluxed for 2 hours. Analysis of the 
resulting mixture showed that this reaction had not 
proceeded. 
iTa' 
C6ý5 CH2N(CH 3)CHP2ýH20S02 
CH 3 
+ 
( CN 
-0 
- 
CH - 
+, 
1 
jý 
3 
Uli 2C1I2CH 2N CH2C j5 
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ý2SONa 
CH 3 
-ý This sequence of reactions, leading to desmethyl- 
imipramine-d 3, was postponed for later study since it 
appeared that much time was required to solve these 
problems; attention was focussed on the synthesis of 
deuterium labelled analogues of imipramine. 
D. Synthesis of Deuterated Analogues of Imipramine 
Scheme 3, outlined in the introduction to this 
chapter, was used. For the synthesis of imipramine-d 3 
(IT-deuteromethyl) the preparation described by Shaw and 
Markey (1978) was used. Aromatic ring deuteration was 
achieved as described earlier to produce a compound which 
was designated imipramine-d4. Deuteration of both these 
regions produced a compound designated imipramine-d7. 
S hesis of 5-13-(methylmethyl-d 3 -amino)Dropyll-10, 
11-dih7dro-5H-dibenzf. b, flazei)ine. (imiDramine-d 3)* 
To a solution of desmethylimipramine hydrochloride (2.59, 
8.2 mmol) in pyridine (50 ml) was added ethyl chloroformate 
(1.8g, 16.5 mmol) and the mixture stirred for 20hours at 
room temperature. Following addition of HýO (50 ml), the 
product was extracted with ethyl*acetate (100 ml) and this 
extract washed with dilute HU (5 x 50 ml), dilute NaOH 
(2 x 50 ml) and HýO (3 x 50 ml) and dried over anhydrous 
0 
Na 2SO4 before being evaporated to dryness 
(rotavapor, 50 C). 
The crude carbamate was dissolved in anhydrous 
tetrahydrofuran (20 ml) and added dropwise to a stirred 
suspension of LiAlD4 (? 00 mg, 16.8 mmol) in tetrahydrofuran 
(40 ml). The mixture was refluxed for 8 hours. The excess 
LiAlD4 was destroyed by dropwise addition of water and the, 
mixture was filtered to separate the salts which were'rinsed 
with fresh tetrahydrofuran (2 x 10 ml). The combined 
tetrahydrofuran extracts were concentrated and dissolved 
in CH01, (50 ml) and this solution washed with dilute HU 
(2 x 20 ml) aný HýO (3 x 20 ml) before drying over anhydrous 
Na2SO4. The solvent was removed (rotavapor, 500C) to produce 
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a solid (1-659, yield = 70.4%) which when analysed by 
n. m. r. spectrometry was shown to be imipramine-d 3 and in 
a relatively pure condition. 
Synthesis of 5-13-(methylmethyl-d 3 -amino)propy33-10L 
11-dihydro-5H-dibenz[b, flazepine-d,,. (imipramine-d, I 
Imipramine-d 3 was prepared as described above but using 
half quantities (4-1 mmol of desmethylimipramine 
hydrochloride). All the imipramine-d 3 so produced was 
used for the. aromatic deuteration step which was as 
described earlier. The product was isolated (0-59, 
yield 42%) and n. m. r. spectrometry showed this to be 
imipramine-d. - 
Formation of Hydrochlorides of All the Deuterated Analogues 
of Imipramine 
An acetone-HC1 mixture was prepared by bubbling HU gas 
through cold acetone (100 ml) for 5 minutes; a 12g 
increase in weight occurred. The HU content of this 
mixture was determined by titration against 1M NaOH using 
phenolphthalein as indicator, and found to be 3.3 m mol. 
HC1/ml of mixture. Each deuterium labelled analogue of 
imipramine was dissolved in acetone (20-100 ml, imipramine-"1.7 
and imipramine-d 3 were relatively insoluble) and a slight 
excess (on a molar basis) of the acetone-HC1 mixture added. 
The hydrochlorides crystallised out within 24 hours of 
standing in a cold room and these were purified by 
recrystallisation from acetone. Purity ( >99%) was indicated 
by t. l. c. using the following solvent systems, 
a) chloroform, n-propanol, 25% ammonia (100: 100: 2 by volume), 
b) chloroform, toluene, acetone (50: 40: 5 by volume) and ' 
c) petroleum ether, ether, acetone (8: 1: 1 by volume). The 
free base form was used in each case; isotopic fractiona- 
tion was observed. 
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Overall Yield 
imipramine-d 4 56% 
imipramine-d 3 46% 
imipramine-. d? 34% 
Characterisation of the Deuterated Analogues 
Characterisation of each of the deuterium labelled 
analogues of imipramine was achieved by t. l. c. (see 
earlier), h. p. l. c. (Chapter 7), i. r. spectrometry, n. m. r. 
spectrometry and mass spectrometry; in each case the 
free-base forms were used. Melting points (uncorrected) 
of the hydrochlorides were determined using an 
Electrothermal Melting Point apparatus-and found to be: - 
imipramine-d3 (174-1750C), imipramine-d4 (174-1760C), 
imipramine (174-1760C), imipramine-d7 (174-1760C) and 
desmethylimipramine (214-215 0 C). 
Infra-red spectra of each compound (Fig. 2.4) were 
determined using liquid film cells with CC14 as the solvent 
and a Pye-Unicam SP1000 instrument. The most striking 
difference between the i. r. spectra of imipramine and its 
deuterated analogues is the frequency of the aliphatic 
C- H(D) stretch band which has shifted from 
'ý12800-3000 
cm-1 
to 2000-2300 cm-1. The maxima at --3050 cm-1 and 
1580-1600 cm-1 are due to aromatic C-H stretching and 
aromatic C=C stretching respectively. Bands due to the 
tertiary amine functions are not easy to identify. 
N. m. r. spectrometry was conducted on all the 
compounds indicated, using a 60 MHz Varian EM-360 spectro- 
meter with a 10 ppm sweep width; the solvent used was 
invariably CDC1 3 but D20 (0-05 ml) was added before a second 
determination, in order to indicate the presence of 
exchangeable protons. Spin-spin decouple (Fig. 2-5) was 
used to identify the bands corresponding to the individual 
CH2 protons of 3-benzylamino-l-propanol (and thus of imipramine). 
N. m. r. spectrometry confirmed the identity of the deuterated 
analogues and indicated their deuterium content as 3,4 and 7 
for imipramine-d 3' imipramine-d4 and imipramine-cL? 
respectively. 
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Mass spectrometry was carried out as described 
for glycerol trinitrate, with CC14 as the solvent but 
using the instrument in two modes. Operating with an 
ionisation potential of 7OeV (source temperature, 200OC; 
inlet, 400C) the mass-spectrum of each compound was 
determined (Fig. 2.6) and their identity confirmed (see 
Appendix 3 for interpretation). Operating with an 
ionisation potential of lOeV (source, 200OC; inlet, 40 0 C) 
and repetitively scanning the molecular ion region, it was 
possible to determine the isotopic distributions of each 
deuterate; i species as: 
Mole % species d2 d3 d4 d5 d6 Cý 
imipramine-d 3 2.2 97.8 - - 
imipramine-d4 5.8 2?. 7 66.5 - - 
imipramine-d,? 1.8 11.3 38.0 48.8 
I 
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-Nomenclature 
-The compounds 
listed below will normally be referred to 
by the shortenedmame indicated. 
glycerol trinitrate 
CH 2 ON02 1 
"ýllu"U2 1 
CH20N02 
pentadeuteroglycerol 
CD 2 ON02 I 
nitroglycerin 
trinitrate 
CDONO 2 glycerol trinitrate-d 5' nitroglycerin-d 1 
CD20NO2 
5- [3-(methylmethyl-d3-amino)propyl]-lo, 
[b, f]azepine 
CCIT 
CD 13 CH2CH2CH2N 
11-dihydro-5H-dibenz 
imipramine-d 
CH 3 
5- [3-dimethylaminopropyl]-101-11-dihydro-5H-dibenz [b, flazepine-d4 
d2 d2 
N CH 
13 imipramine-d C'1272C'12ý 
CH 34 
- 5- 
[3-(methylmethyl-d 
3 -amino)propyll-10,11-dihydro-5H-dibenz 
ý, f] 
_azepine-d4 
d2 d2 
CD 3 
CHýCHýCH2N 
%% 
imipramine-d? 
CH 3 
Irn 
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DISCUSSION 
Synthesis of Glycerol trinitrate and Glycerol 
trinitrate-d 5 
Preparation of glycerol trinitrate and its 
deuterium labelled analogue (pentadeuteroglycerol 
trinitrate) proved to be quite straightforward and 
this synthesis (as yet unpublished) appears to be quite 
useful for the rapid preparation of milligram 
quantities of these compounds. The only problems 
encountered during the glycerol trinitrate (d 5) 
preparative work were the low yields obtained, and the 
apparent breakdown of these compounds within the mass- 
spectrometer. The low yields can be attributed to the 
purification stage where some glycerol trinitrate must 
be lost into, the aqueous phase, and this loss may be 
assisted by the presence of, ethyl acetate. 
Lack of a molecular ion in the mass spectra of 
organic nitrates has been observed by, other workers 
(Fraser and Paul, 1968) who also found no species of 
m/e > ?6 for glycerol trinitrate, as did we. This makes 
calculation'of-the deuterium incorporation into deutero- 
glycerol trinitrate difficult to estimate. ý For accurate 
calculation, the molecular ion is required; however, in 
the case of glycerol trinitrate-d 51 the mass spectrum 
showed no bands which could be attributed to the protium 
containing analogue, suggesting complete deuterium 
incorporation., Also, as the source of deuterium, LiAlD4, 
was'> 99%D, and since no exchangeable protons were 
present in the reaction mixture, it must be assumed that 
deuterium-replacement was->99%. The i. r. spectrum of 
glycerol trinitrate-d 5 supports this contention., 
Synthesis of Desmethylimipramine-d 3- 
The original proposal was to synthesise both 
imipramine-d 3 and desmethylimipramine-d 3, but since many 
problems, were encountered with the synthesis of the latter 
compound, attention was focussed on the synthesis of 
imipramine-d 3* The initial problem was the synthesis of 
3-benzylamino-l-propanol, which is generally prepared 
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(Vaughan et al, 1961) by catalytic hydrogenation of 
3-benzylimino-l-propanol. This could not be achieved, 
the major product obtained proved to be benzaldehyde, 
apparent reversal of the reaction; 
benzaldehyde + 3-amino-l-propanol 
3-benzylimino-l-propanol + H20 
this would require f-14g of water (see earlier) which 
could only be supplied by the solvent for hydrogenation 
(absolute alcohol) or the hydrogen used. Both were 
highly pure forms and even when changed, the same result 
occurred. This is difficult to explain, but one must 
assume that sufficient water was supplied by these 
sources, and hydrogenation conditions were suitable, for 
the reverse reaction to occur. The yield of 12% for this 
reaction does not compare favourably with the yields 
obtained in the original syntheses (60-80%) and these 
workers do not mention any such problems. 
In no step of this reaction sequence (Scheme 2) 
was a deuterated compound used; the protium, forms were 
used throughout since these reactions were initially 
conducted in order to identify and overcome associated 
problems, before use of the expensive deuterium 
containing forms. 
Tosylation of 3-benzylmethylamino-l-propanol is 
necessary in order to insert a good leaving group 
(tosyl group) into the 3-benzylmethylamino-l-propanol 
molecule to ensure reaction with iminodibenzyl (sodium 
salt). There is some doubt as to whether this reaction 
occurred successfully; initial syntheses failed to 
produce the tosylated compound but later preparations 
(using the method described) indicated some success, 
although this could not be demonstrated due to apparent 
contamination with p-toluenesulphonyl chloride, which 
could not be removed. The problem was attributed to the 
lability of the tosyl group, and so any purification 
procedures liable to cause decomposition of the 
tosylated compound (e. g. distillation) were avoided. To 
give an indication of whether tosylation had occ&red, 
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the product of this reaction was used in the next step, 
reaction with iminodibenzyl (sodium salt). No reaction 
occurred, which suggests either that the compound used 
was not the tosyl derivative of 3-benzylmethylamino-l- 
propanol or that the sodium salt of iminodibenzyl had 
not been formed. Reaction between these two compounds 
should be quite efficient and the yield quoted in the 
literature (Shaw and 
* 
Markey, 1977) is > 50%. Obviously, 
further work was required to identify the source of 
these problems, or to design alternative routes, and so 
attention was switched to the deuteration of imipramine. 
Synthesis of Deuterium Labelled Analogues of Imipramine 
Although deuterium labelling of the aromatic rings 
of iminodibenzyl proved unsuccessful, labelling of 
imipramine proved quite straightforward. Deuterium 
labelling of iminodibenzyl would have been preferable to 
labelling of imipramine, since large quantities of 
iminodibenzyl were available and it was expected that the 
quantity of imipramine-d 3 obtained would be limited (cost 
of deuterium source, and low yields produced by 
successive reaction steps); successive deuteration steps 
wouldlead to low yields of imipramine-d,. 
The problem associated with the labelling of 
iminodibenzyl was that of insolubility in the deuterating 
mixture; solubility could not be enhanced, and iminodi- 
benzyl appeared not to be sufficiently volatile to allow 
vapour phase deuteration to occur. Imipramine (hydro- 
chloride) was soluble in the deuterating mixture and 50% 
incorporation occurred. Since replacement of 4 protons 
was relatively simple, but further deuteration was 
difficult, it must be assumed that deuterium replacement 
occurred at the chemically most active positions, that is, 
the 2(8) and 4(6) positions. 
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9 10- ý* 11 
82 
N CH 
I- 4' 3 
CH2CH2CH2N 
CH 3 
Arrows indicate chemically active 
positions, due to activating 
effects of the ethylene bridge 
(meta directing) and the nitrogen 
bridge (ortho and para directing). 
Mass spectrometry supports this since, although 
imipramine-d 4 was actually a mixture of primarily 
imipramine-d2 I -d 3 and -d 41 the species in greatest 
abundance was imipramine-d4. Even though imipramine-d 4 
is a mixture, it was designated thus in order to 
simplify nomenclature; imipramine-d4 is the most 
abundant species and n-m. r. spectrometry indicated an 
average of 4 deuterons in the molecule. 
Preparation of imipramine-d 3 was straightforward 
and good yields of all 3 analogues (imipramine-d 3' -d 4 
and -d? ) were obtained. N. m. r. spectrometry and mass 
spectrometry proved the identity of these compounds and 
confirmed that deuterium incorporation was as indicated. 
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CHAPTER 
DETERMINATION OF NITROGLYCERIN IN PLASMA BY 
GAS LIQUID CHROMATOGRAPHY 
INTRODUCTION 
Gas liquid chromatography (g. l. c. ) is one of the 
most widely used techniques today. The success of this 
technique has been due to such features as simplicity, 
specificity, rapidity of analysis, efficiency of 
separations and the high sensitivity of detection systems 
such as the electron capture detector (E. C. D. ) which can 
facilitate the estimation of picogram quantities of 
certain compounds. 
A number of problems associated with g. l. c. have 
been encountered during the development of an analytical 
procedure for nitroglycerin (glyceroltrinitrate, GTN)- 
The major problems included; a) contamination of the 
electron capture detector, primarily due to the lack of 
a suitable carrier gas purifying system and, b) activity 
of the g. l. c. columns used in the analyses, due primarily 
to adsorption of nitroglycerin within these columns. 
Associated with the development of a good analytical 
procedure, was the need to develop an efficient means of 
inhibiting the degradation of nitroglycerin in blood 
samples - 
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Contamination of the Electron Capture Detector 
The electron capture detector (E. C. D. ) is a 
selective and highly sensitive detector towards compounds 
with high electron affinity such as halogenated compounds, 
nitrates, conjugated carbonyls and certain organometallic 
compounds. The selectiyity of this detector for 
halogenated compounds has led to its extensive use in the 
field of pesticide research. For compounds such as 
lindane and aldrin, the E. C. D. can detect quantities as 
low as 0.1 pS, making it perhaps the most sensitive g. l. c. 
detector available. 
The E. C. D. utilises the fundamental observation that 
the conductivity of gases in an ionisation. chamber can be 
greatly altered by the presence or absence of contamination 
in the gas. Thus the E. C. D., consists of an ionisation 
chamber containing a radioactive source, usually H3 or 
Nj63, with a stream of inert gas, usually nitrogen or argon, 
flowing through it. The Aýf-ray emission from the source 
causes ionisati-on 61--ýS6--inert -gas w-Ith-'e-ons-equelif 
liberation of free electrons: 
N2 + 16 -ray %' 
N2 ++e 
These electrons migrate to the anode where collection 
occurs and a current flow is, established. In the steady 
state a constant current, known as the standing current, 
can be measured flowing in the chamber. 
If an electrophilic compound is introduced into the 
chamber a reaction will occur between this compound and the 
free electrons as follows: 
e-+ AB N 
AB_ non-dissociative 
0'r e+ AB Ao +B dissociative 
As a result of these reactions, the fast moving 
electrons are replaced by slow moving negative ions which 
take longer to migrate to the anode and so have a higher 
probability of recombination with positive ions before 
reaching the anode than the electrons. The net result will 
be a decrease in the amount of current flow in the chamber. 
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The current present in the detector in any given 
situation will be at equilibrium before the introduction 
of an electrophilic compound. The magnitude of this 
current will depend on the value of the applied potential 
to the ionisation chamber. If a plot is made of current 
flow against potential, firstly for pure gas and 
secondly for pure gas plus a constant level of contamina- 
tion (i. e. electrophilic compound) the two curves shown 
in Fig. 3.1 will be obtained. 
In a dynamic situation where a sample is introduced 
into a flow of pure gas, as at the exit of a g. l. c. column, 
with a set value of applied potential x, the current flow 
will alter and will. followthe pattern shown by the dotted 
line C. In consequence the current measuring device will 
record the emergence of a peak. It is on this fundamental 
observation that E. C. D. Is are constructed and operated. 
Obviously, if the E. C. D. was in a state of contamina- 
tion (due, for example, to impure gas) i. e. if curve A 
tended towards curve B, then when an electron capturing 
compound was introduced little, or no peak (C) would be 
observed. The effect of detector contamination can bel'at 
worst, to completely "knock-out" the detector such that 
whatever amount of electron capturing material is introduced, 
no peak would be observed. Obviously the level of detector 
contamination governs the loss of detector response to such 
a compound. (e. g. in Fig. 3.1, response decreases as curve 
A tends to curve B). 
, 
When the detector, standing currents were measured 
(Fig. 3.2) it was obvious that our instrument was 
contaminated. and had not been correctly, installed, it had 
been connected. directly to the gas supply., Very poor 
response was obtained from, this instrument, for lindane-(a 
test. compound for the E. C. D. ) which should produce a, 
detector response when -<, 1 pg is injected. Upon dismantling 
the E. C. D. it appeared that the central probe was 
extensively corroded suggesting that the carrier gas was not 
free of oxygen or water; in this state the detector cannot 
perform adequately. 
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ýr 
0 
r-I P4 
0 
Applied Potential 
A,,, - - 
Curve for pure gas 
B- Curve for pure gas plus a small percentage of 
contamination 
C- Curve produced when a small peak of-contamJ33ation 
is introduced into the gas flow and reaches at peak 
maximum the percentage of contamination present in 
curve B 
Fig. 3.1 Current Flow as a Function of Applied Potential 
for the Electron Capture Detector 
Cleaning of the E. C. D. was accomplished"by 
dismantling the detector and cleaning its component parts 
separately: 
The detector shell (housing radioactive foil) was rinsed 
four times with 51516 KOH in methanol-water (1: 1) at 60 0 C, 
then five times with water, two of these at 60OC; this 
procedure was repeated. - The detector shell was ultra- 
sonicated for 3 minutes in methanol-water (1: 1) followed 
by rinsing with methanol several times and finally dried 
by passing pure nitrogen through for 30 minutes. 
-67- 
Fig. 3.2 Detector Standing Current as a Function of Pulse 
Space Setting 
The detector standing current was monitored in the pulsed mode at 
each of the pulse space settings, 5,15,50,150 and 500/us. For 
a clean system the standing current at 500/-cS should be > 50% of 
that at 15 US. Obviously A is a clean system and B is 
contaminated; A is the result of detector cleaning and the gas 
purifying system, B is the original system. 
represents the value of the standing current (% full scale 
deflection) at the pulse space setting indicated. 
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Recorder Response 
The central probe (electrode) was polished to a mirror 
finish using successively finer grades of emery paper. 
The detector was then reassembled and purged 
with nitrogen for 12 hours at 350 OC. 
The poor condition of the detector was due to the 
lack of a purification system capable of removing water 
and oxygen from the carrier g. as, to which the E. C. D. is 
very sensitive (< 1 ppm will reduce the standing current 
and, in the presence of water, will corrode the detector). 
The major effects of detector contamination are: - 
1. Loss of sensitivity - as the standing current is 
reduced by the presence of contamination in the carrier 
gas (e. g. 02 9H 20) then sensitivity is lost; in the worst 
case, the detector will not respond to any amount of 
electron capturing compound. 
2. Reliability of detector response - in a system where 
standing currents are constantly fluctuating due to 
changing levels of carrier gas contamination or perhaps 
due to deposits of contaminants gradually clearing from 
the radioactive foil, one cannot rely on the detector to 
produce a reliable or accurate response. On a sloping 
baseline*, (i. e. where the standing current is fluctuating) 
the ability of the detector to respond will differ at 
different retention times which may lead to inaccuracies 
in calibration curves etc., and interpretation of results 
obtained under these conditions. This effect is even 
more undesirable if an internal standard is not used; it 
is difficult to see how a reliable result could be obtained 
under these conditions. 
*sloping baseline - sloping upwards is defined as in the 
direction of response, e. g., to an electron capturing 
compound; sloping downwards is the converse. These are 
both caused by variation in the magnitude of the standing 
current. 
3. Ghost peaks - often during the course of an analysis, 
peaks appear that do not fit the expected pattern of the 
chromatogram. These "ghost peaks" are often not resolved 
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and are generally present in small quantities, sometimes 
resembling baseline noise as they emerge together with 
the large peaks of the chromatogram. These peaks are 
usually due to contaminated gas. 
4. Incorrect potential across the detector - this may be 
caused by corrosion of the electrode and may result in 
fluctuating potentials across the detector and thus 
unreliability of the system. 
5. Noisy baseline - this may be caused by electron 
capturing compounds in the carrier gas passing through the 
detector, and is often seen as random spikes on the 
chromatogram. 
6. Deposits of contaminants on the detector (e. g. hydro- 
carbons) - hydrocarbons are not normally detected by the 
E. C. D. but deposits on the radioactive foil may affect 
performance by interfering with the potential across the 
detector. 
As demonstrated above, it is of great importance to 
maintain a clean system for electron capture - g. l. c. It 
is generally recognised that the purity of the carrier gas 
should be at least 99-9955/6 for best results. Contaminants 
commonly found in carrier gases are H20,02 , hydrocarbons 
(often halogenated), CO 2 and inert gases. , 
The purifying 
system we installed was capable of removing the majority 
of these (all except the inert gases) and consisted of two 
large molecular sieves coupled to an oxygen trap (Fig. 3.3). 
The oxygen trap comprised a tube filled with copper wool at 
4500C through which the carrier gas was passed. Also the 
type of carrier gas was changed for a purer grade 7 Air 
Products nitrogen as opposed to B. O. C. "white spot" 
nitrogen. All contaminated pipelines had to be chemically 
cleaned. At the very least this system serves a fail-safe 
function ensuring protection of the detector if a very 
impure cylinder of nitrogen is used. 
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Not only was this system essential to protect the 
E. C. D. but also to, protect both the sample injected and 
the column used. An effect of 02-and H20 entering the 
gas flow system can be the rapid deterioration of certain 
types of column substrates (liquid phases) such as 
polyesters and other polar liquid phases especially at 
elevated temperatures. Oxygen and H20 can also-cause 
sample decomposition, for example through oxidation at 
high temperatures. Many workers do not appreciate the 
effects of detector contamination and the need f 'or a highly 
pure carrier gas, and as a consequence attempt S. l. c. 
analyses with inferior systems which produce unreliable 
results. 
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B. Gas Liquid Chromatography of Nitroglycerin 
At the present time, electron capture-g. l. c. 
provides the only suitable method for determination of 
nitroglycerin (GTN) in biological fluids. Unfortunately, 
this drug is extremely difficult to chromatograph and 
the available methods (Rosseel and Bogaert, 1973; Neurath 
and D=ger, 1977; Givant and Sulman, 1978; Laufen et al., 
1978; Yap et al., 1978; Armstrong et al., 19? 9) have proved 
difficult to reproduce; nitroglycerin can be detected, but 
only in high concentration (> 1 ng, on coliimn injection). 
An assay system suitable for use in pharmacokinetic studies 
of this drug necessitates an on colilmn injection of < 50 Pg 
to be detected and quantified. High sensitivity is required 
due to the low plasma levels of this drug present in the 
experimental animal. ) and the small blood samples obtainable. 
A further problem associated with the determination of 
nitroglycerin in blood samples, is its metabolism by 
enzymes of plasma (notably rat plasmai. DiCarlo and 
Melgar, 1970)2 and therefore an efficient means of 
terminating this metabolism had to be developed. 
This chapter describes the problems associated 
with reproducing several of the published methods 
(Rosseel and Bogaert, 1973; Neurath and Dunger, 19? 7; 
Givant and Sulman, 1978; Laufen et al., 19? 8; 
Yap et al., 19? 8) and the modifications to one of these 
methods (Yap, et al., 1978) required to achieve a working 
assay sytem, and includes an improved means of 
stabilising nitroglycerin in whole blood samples. 
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EUERIMENTAL 
RATERIALS 
All reagents were analytical grade (B. D. H., 
Poole, Dorset) unless otherwise stated. Hexan6 used for 
extractions of plasma was glass distilled grade from 
Rathburn Chemicals Limited (Walkerburn, Peebleshire) 
and extractions were carried out in Durobax glass test 
tubes purchased from Glass 11holesale Supplies (London). 
Pooled extracts and standard solutions for chromatography 
were stored in 3.5 ml screw-cap septum vials Phase 
Separations Ltd., (Queensferry, Clwyd), the septa for 
which are teflon coated to render them inert. All 
columns were supplied by Phase Separations Ltd. Packings 
were either from Phase Separations Ltd. or prepared in 
the laboratory; one packing was supplied by B. D. H. 
Lindane was supplied by Sigma Chemicals Ltd., (Poole, 
Dorset). DDT, DDDI DDI-TU and DDE were supplied by Aldrich 
Chemicals Ltd. (Gillinghamg Dorset). Isosorbide dinitrate 
was kindly donated by Ayerst Laboratories Ltd. (Farnborough, 
Hants). Nitroglycerin was prepared as described earlier 
(Chapter 2). All glassware used was silanised overnight 
in 5jOj' dichlorodimethylsilane in toluene. Prior to use it 
was rinsed with toluene, then water, methanol, and finally 
with hexane; it was dried at 800C after each rinse. This 
procedure is used to prevent loss of nitroglycerin due to 
adsorption on the surface of glass. 
Chromatography. This was carried'out using a Pye model 
104 chromatograph fitted with heated electron capture 
detector (Hi 63). 
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METHODS 
Chromatography 
The published methods for determination of 
nitroglycerin have used colilmns conteJ33ing the following 
types of liquid phase: OV210 Rosseel and Bogaert, 1973), 
OV17 (Neurath and Danger, 1977), SE30 (Givant and Sulman, 
1978), OU (Laufen et al., 1978) and SP2401 (Yap, et al'., 
1978). The supports have been either gas chrom Q 
(Rosseel and Bogaert, 1973; *Givant and Sulman, 1978; 
Laufen et al., 1978), glass beads (Neurath and Danger, 19?? ) 
or supelcoport (Yap, et al., 1978). 
On this basis the following packings were tested 
for use in the analysis of nitroglycerin: 
1% OV17 on 100/120 mesh chromosorb W. AW. DCMS. 
4% OU on supelcoport 100/120 mesh 
3.8% SE30 on celite 
10% SE30 on supasorb (B. D. H. ) 
glass beads washed with a 0.4% solution of OV17 
2% OV210 on gas chrom Q 
3% SP2401 on supelcoport 
In each case 1.5m, silanised glass coliimns (2mm. or 
4mm. I. D. ) were packed by suction, conditioned for 48 hours 
at 200-3000C (depending on the liquid phase), and tested 
for their ability to separate, and allow passage through 
the column of lindanev nitroglycerin, isosorbide dinitrate 
(ISDN) and a mixture of chlorinated insecticides containing: 
lindane V-benzene hexachloride 
DDMU 1-chloro-2,2-bis(p-chlorophenyl)ethylene 
DDE 1,1-. dichloro-2,2-bis(p-chlorophenyl)ethylene 
DDD 1.1--dichloro-2,2-bis(p-chlorophenyl)ethane 
DDT 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethylene 
All 100 pg//41. 
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Each column produced good results for lindane and 
the above mixture (see results), but in most cases no 
peak for nitroglycerin was observed when < 2ng were 
injected, and only a small peak for 50OP9 of isosorbide 
dinitrate was observed. The 31% SP2401/supelcoport column 
was the most sensitive system of those tried, but this 
was still far from good. In all cases, after initial 
failure to detect nitroglycerin, saturation of the col umn 
was attempted by repeated on-column injections of nanogram, 
amounts of nitroglycerin but no improvement occurred in 
all cases except for the 356 SP2401/supelcoport column when 
slight improvement (increased sensitivity) was observed. 
Attention was focussed on the 351P SP2401 system - 
the method of Yap, et al. (1978), and the system modified 
in order to obtain a sensitive detection method. The 
indices of column performance used were: 
1. The presence of nitroglycerin and isosorbide dinitrate 
peaks for subnanogram. amounts and the size of these peaks 
relative to the attenuation (electrometer setting) used. 
2. The linear range of the detector - this is a good 
index of how much electron capturing compound is reaching 
the detector, but is to some extent dependent upon peak 
efficiency. 
3. Peak height ratios, nitroglycerin: isosorbide dinitrat e 
again this is to some extent dependent upon relative peak 
efficiencies. This index was used because nitroglycerin 
tended to be adsorbed more than isosorbide dinitrate in 
poor columns. 
4. Peak shape - tailing of the chromatographic peak is a 
good-indicator of adsorption. 
As shown in Fig. 3.4, a packed column for the 
Pye 104 chromatograph consists of: 1) a pyrex glass column, 
connected to the detector through 2) a glass to metal seal 
(i. e. outlet), 3) a glass wool plug at the injection end, 
and 4) the packing material. 
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Fig. 3.4 Packed Column for the Pye model 104 
Chromatograph 
Problems were encountered with each of these: 
Glass column. These are often the cause of adsorption 
problems in g. l. c. In most cases silanisation is employed 
to achieve an inert surface and this procedure is 
essential in trace analysis. Initially, in the present 
studies, columns were silanised by procedure A, but later 
the more rigorous procedure B was adopted (see overleaf). 
Procedure B proved sufficient for the first columns 
used, but for the eventual working system, glass-lined 
tubing was introduced and a new column used. Even after 
silanisation, adsorption still occurred. Testing of the 
latter column was carried out with the assistance of Phase 
Separations Limited. The procedure involved two columns 
in series; the-empty test column being between detector 
and f' irst column. In this way loss of a series of 
chemical probes, compounds which are adsorbed on active 
glass surfaces (i. e. 2,6-dimethoxyphenol, 2,6-dimethoxy- 
anilene, cis, trans-2-propylcyclohexanol and hydrocarbons 
C10 - C14) within the column could be estimated by 
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including or excluding the test column in the system. 
Repeated silanisation did not improve the performance of 
this. column, and eventually the inner surface was further 
modified in order to ensure its inertness. The technical 
details are confidential, but are based on the procedure 
used by De Nijs et al., (1978) to inactivate SE30 open 
tubular columns and capillary columns. This procedure 
involves bleeding carbowax 20M degradation products 
through the column. This is achieved by heating a 
pre-column containing carbowax 20M above the maximum 
temperature for this liquid phase, so that degradation 
products flow out of the pre-column and into the empty 
column to deposit on active sites and so inactivate these. 
Glass to metal seal. This consists of a short metal tube 
1/16 11 in diameter. Losses due to adsorption at this 
source were checked by emptying the column and soaking the 
outlet (glass to metal seal) in 2% carbowax: 20M/CHC1 3 for 
10 minutes. Excess liquid was shaken out and the empty 
column heated to 2500C for 10 minutes with a low flow rate 
of N2 passing through it. This procedure was repeated 
twice and the column repacked and conditioned for 5 hours 
at 180 0 C. This procedure provides a short term masking of 
any active sites on the metal surface. Nitroglycerin standards 
(0-5-2.0 ng/ýLl) were run before and after this treatment. 
Further tests could not be carried out due to the short 
duration of the masking. 
Glass wool plug. Column performance was simply tested 
before and after its removal. 
Packing material. The original packing was replaced by 
several batches of 3556 15ý2401/supelcoportj most of which 
were previously known to produce good chromatographic 
results with a number of other compounds. Finally a thicker 
liquid phase loading - 5% SP2401/supelcoport 100-120 mesh - 
was used in the hope of masking the active sites. This 
-7? - 
packing produced good results but only after saturation, 
which involved 20 on-column injections of. 3-75 ng of 
nitroglycerin over a period of two days. 
The column performance improved with use but, as 
a precaution, initial saturation with 3.75 ng of nitro- 
glycerin was carried out before any analyses were 
attempted. 
Extraction from Plasma 
Di Carlo and Melgar (1970) showed that nitroglycerin 
is rapidly degraded in rat serum. Moreover, nitroglycerin 
degradation can be significantly inhibited by iodoacetamide, 
silver nitrate and p-chloromercuribenzoate. Iodoacetamide 
was used for stabilisation of nitroglycerin in rat blood. 
To 0.5 ml of heparinised whole rat blood containing nitro- 
glycerin, 0.2M iodoacetamide (10^1) was added to give a 
final concentration of 4mM. The blood was centrifuged for 
five minutes at full speed in a bench centrifuge and 
aliquots of plasma (200/41) extracted 12 times with 
hexane (200,, A. 1 portions). Internal Standard (ISDN - l.? 8 ng) 
was added to the pooled extracts before the mixture was 
concentrated, to, 20-100/. tl; 1-4ýcl was chromatographed and 
peak height ratios were measured. 
Reproducibility and recoveries for the procedure 
were determined by adding Imown amounts of nitroglycerin 
to 200/Al aliquots of plasma and to pure solvent, and 
processing these as described above. These were compared 
with a series of pure solution standards containing amounts 
of nitroglycerin and isosorbide, ýdinitrate, equivalent to the 
plasma samples/extracts. The effect of iodoacetamide on 
the stability of nitroglycerin in plasma was tested as 
follows: fixed amounts of nitroglycerin were added to plasma 
containing 4mM iodoacetamide and to untreated plasma; after 
five hours incubation at room temperature, the nitroglycerin 
content of these plasma samples was compared. 
-78- 
RESULTS 
Development of a Chromatographic Method 
Typical chromatograms obtained for nitroglycerin, 
lindane and the mixture of chlorinated insecticides using 
columns unsuitable for nitroglycerin analysis in plasma, 
are shown in Big. 3.5 and 3.6. In most cases no peaks 
for nitroglycerin were observed for on-column injections 
of < 1-2 ng. Also shown (Fig. 3.7) are chromatograms 
obtained using the final system. 
Studies with SP2401 columns 
Deactivation of the Empty Column. Unless silanisation 
procedure B was used, no peaks for nitroglycerin could be 
observed for on-column injections of subnanogram amounts. 
Moreover, significant tailing of the peaks was apparent. 
This silanisation procedure appeared sufficient to render 
inert the first col umn s used. Nevertheless, with these 
columns other problems still occurred, (i. e. glass to 
metal seal and packing), and a new column, which 
contained a glass-lined glass to metal seal, had to be 
purchased for further study. It is therefore uncertain 
whether procedure B is sufficient for most columns, 
although this is likely. 
The requirement for this modified column, in which 
no metal was in contact with the sample injected, was 
shown by an increased peak height ratio for nitroglycerin 
standards after carbowax 20M treatment compared with 
before treatment; also an increased peak size for 
nitroglycerin (but not isosorbide dinitrate), relative to 
electrometer setting, was apparent. E-ýen with this new 
column the glass surface still caused adsorption problems. 
With the assistance of Phase Separations Limited it was 
demonstrated that extensive adsorption of a series of 
chemical probes still occurred after repeated silanisation, 
and was only overcome by treatment of the column with 
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carbowax 20M. Fig. 3.8 shows peak height ratios for 
a series of nitroglycerin standards, using columns 
treated in these different ways. 
It is obvious that the modifications were 
necessary, as witnessed by the increasing peak heights 
(relative to electrometer setting); column A producing 
relatively smaller nitroglycerin peaks than column B, 
and column C producing the largest nitroglycerin peaks. 
Column A is not easily compared with columns B or C as 
these were different columns (i. e. one contained glass- 
lined tubing); however, columns B and C can be compared. 
It is obvious that column B was causing extensive 
adsorption of nitroglycerin (see Fig. 3.8). Consider 
the-nitroglycerin standard 3575 pg nitroglycerin + 
356 pS isosorbide dinitrate; isosorbide dinitrate has 
two nitrate groups per molecule whereas nitroglycerin 
has three (both have similar molecular weights), and the 
columnd'used produced more efficient (sharper) nitroglycerin 
peaks than isosorbide dinitrate peaks. Thus one would 
expect on this basis a peak height ratio (GTU/ISDN) for 
this standard of at least 1.5 rather than 0.88 for 
column B and 1.14 for column C. Thus although neither 
column was working as predicted the carbowax 20M treatment 
had produced a significant improvement in overall column 
performance. Also, the linear range for columns B and C 
was too large; the linear range for electron capture 
detectors should not exceed 500: 1 and, using a pulse 
space of 500 /4S, the linear range should be lower than 
observed with these columns - i. e. the detector should 
saturate at on-column injections of much less than 
500 pg nitroglycerin. Yet another indication of poor 
column performance is the interception of the plot with 
the abscissa rather than the origin. This suggests that 
no response would occur for an on-column injection of 
50 pS of nitroglycerin and hence extensive adsorption of 
nitroglycerin is occurring. The cause of this problem 
could now only be due to the packing material. - 
N. B. 
1. Detector function was found to be relatively constant 
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during all determinations, that is detector standing 
currents were checked before and after each treatment 
and found to be constant. 
2. The affinity of metal for nitroglycerin has been 
demonstrated by other workers (personal communications 
A, B and C). In view of these findings, that part of 
the chromatograph connecting column to detector - the 
detector union pipe - had to be replaced with glass- 
lined tubing. There was thus no metal in the system 
capable of adsorbing nitroglycerin other than the 
microlitre syringe used for injections. To overcome 
potential problems from this source new needles were 
soaked for a time in a solution of nitroglycerin in 
ethylacetate and, prior to use, the syringe was rinsed 
several times with such a solution, followed by rinsing 
with pure solvent. In this way it was hoped to render 
the syringe inert towards organic nitrates. - 
Glass Wool Plug. This was the first problem overcome. 
Simply by removing this plug the nitroglycerin peak 
produced by a given standard increased in height; 
standing currents were constant before and after this 
procedure. Also observed was the disappearance of a 
broad flat peak close to nitroglycerin (having lower 
retention time). It was inferred that the glass wool 
plug may be adsorbing nitroglycerin and perhaps catalysing 
its decomposition. Problems caused by glass wool plugs 
have been encountered by other workers chromatographing 
nitroglycerin (personal communication - B). 
Packing Material. Packings from several batches of 
30 SP 2401/supelcoport were used, but in no case was good 
column performance obtained even after saturation of the 
column, with nitroglycerin. Fig. 3.8 column C shows the 
best results obtained for a 35 liquid phase loading. Thus 
a 5s, SP2401/supelcoport packing was used; after initial 
saturation with nitroglycerin, this column produced very 
good results. Fig. 3.9 compares peal-, height ratio response 
for this column with those obtained for the best 3% column. 
Figs. 3.5 and 3.7 show the vastly increased peak heights 
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produced by this column compared with earlier columns. 
The linear range for the 57o column is greatly reduced to 
the expected range. The 5516 column initially improved 
with use (i. e. peak size increased, linear range 
decreased) and we were forced to retreat to a pulse space 
of 50 /XS in order to increase the linear range. Time 
was allowed for the column to stabilise and it was then 
tested on ten consecutive days for reproducibility. 
Retention times, peak height ratios for a series of 
standards, and peak efficiencies (number of theoretical 
plates) were monitored and found to be constant. 
Conditions for g. l. c. 
The conditions for g. l. c. were optimised and a 
comparison of these with the conditions used in the 
original method (Yap et al., 1978) is made below: 
Modified Method Original Method 
column glass, carbowax 20M 1.5m x 4mm. I. D. 
treatedpincluding glass 
glass-lined t1ibing 
and excluding a 
lass wool plug ýl 
- 5m x4 mm. I. D. ) 
packing 5% SP2401/supelcoport 3% SP2401/supelco- 
(100-120 mesh) port (100-120 mesh), 
injection port 
temperature 1600C 
column 
temperature 1450C 1400C 
detector 
temperature 0 180 C 0 180 C 
N2 flow rate 75 ml/min. 60 ml/min. 
detector 63 Iii 50 AS(pulsed) 63 Ni I 4OV. D. C. 
electrometer 1-2 x 10_9A 
1 
retention. 
times, t R GTN 4 .5 min. 6.0 min. ISDN 
I- I 
9.7 min. 13.0 min. 
I 
__ 
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The linear range for-the modified method was 
0-450 pg nitroglycerin (on-column injection) for 50 
/"S - 
pulse space, and 10 pg or less of nitroglycerin could be 
detected relatively easily; using 500 14-S - pulse space, 
sensitivity was increased but a much smaller linear range 
ensued. 
Analysis of Nitroglycerin in Rat Plasma 
The observed recoveries 
' 
of nitroglyce?? in from water 
and rat plasma were 88/lo and 75-8011,6 respectively, and 
recovery from plasma was unaffected by the addition of 
iodoacetamide. 
Fig. 3.10 shows a calibration curve; peak height 
ratios obtained from varying levels of nitroglycerin in 
rat plasma, and Fig. 3.7B'a typical chromatogram obtained 
with the working system. 
Chromatography was selective for the two organic 
nitrates, no peaks were observed at tR 4.5 min and 9.7 min. 
when blank plasma was extracted and chromatographed. 
Reproducibility of the method is shown in Table 3.1. 
The limit of detection was arbitrarily set at 
100 pg/200.4el plasma, or if a larger plasma sample was, 
available the sensitivity could be extended, e. g. for 
1 ml. of plasma, to 100 pg/ml. plasma. 
Stabilisation of Nitr6glycerin in Whole Blood 
Iodoacetamide is not extracted by the procedure used 
and thus does not interfere with chromatography. Stability 
studies were usually conducted in plasma, but addition of 
nitroglycerin to whole blood treated with iodoacetamide 
produced no decomposition of nitroglycerin-after-4 hours'at 
room temperature, compared with untreated whole blood. 
Table 3.2 demonstrates the inhibition of nitroglycerin 
degradation in plasma samples by iodoacetamide; virtually 
complete stability for the nitroglycerin content of plasma 
is ensured for up to 5 hours if this concentration of 
iodoacetamide (4mM) is used. 
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Fig. 3.10 Calibration Curve for Nitroglycerin Extracted 
from Plasma 
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Varying quantities of nitroglycerin were added to 200 Al of 
plasma and these extracted and chromatographed. Peak height 
ratios (GTN: ISDIT) were calculated from the chromatograms. 
Table 3.1 Reproducibilit7 of the Anal7tical Method 
ng GTN added -mean S. D. 
assay 
(ng) range 
(ng) 
coefficient 
of variation 
M 
0.375 0.3? 0.04 0.31 - 0.43 11 
0.? 50 0.? 5 0.08 0.66 - 0.85 9 
3.? 5 3.74 0.12 3.60 - 3.90 3 
7.50 ?. 58 0.29 ?. 10 - ?. 80 4 
Varying quantities of nitroglycerin were added to plasma and 
these standards assayed for nitroglycerin content. Four 
determinations were made at each level. 
Table 3.2. Inhibition of_Nitro5ýlycerin Metabolism 
by Iodoacetamide 
Drug added 
to plasma(ng) 
Iodoaceta- 
mide (4mM) 
Drug recovered 
from plasma(ng) 
156 unmetabol- ised drug 
3.75 0.93 25 
7.50 2.00 26 
1.50 + 1.50 100 
3.75 + 3.70 98 
7.50 + 7.00 93 
37-50 + 37-50 100 
Nitroglycerin was added to plasma (in the presence or 
absence of iodoacetamide) and left at room temperature for 
5 hours. The plasma samples were then assayed for nitro- 
glycerin content. Duplicate determinations were made. 
DISCUSSION 
Inhibition of Plasma Degradation of Nitroglycerin 
Nitroglycerin is enzymically degraded in rat serum 
with a half-life of 20 minutes (Di Carlo and Melgar, 1970). 
This degradation can be inhibited by silver nitrate, 
iodoacetamide, or p-chloromercuribenzoate (Di Carlo and 
Melgar, 1970), and we have shown complete inhibition (for 
up to 5 hours) of nitroglycerin degradation by addition 
of iodoacetamide (final concentration, 4mM). This is a 
marked improvement over the method of Yap et al., (1978) 
using silver nitrate as this caused gelling of blood, and 
for obvious reasons it was preferred to use whole blood 
rather than plasma. 
The Chromatographic Method and Associated Prohlpmq. 
Many problems occur when packed columns are used 
for g. l. c. The experienced chromatographer will know only 
too well of these, but the biochemist, pharmacologist or 
toxicologists perhaps having, little experience with this 
technique, will have no knowledge of such problems. This 
chapter has indicated many of the problems likely to be 
encountered in trace analysis particularly when using a 
highly sensitive detector such as the E. C. D., and 
suggests methods of testing and overcoming these problems. 
The variability of columns is the great "bug-bear" 
of S. l. c. Many chromatographers do not take enough time 
or care in column preparation, and as a result spend 
considerable amounts of time and money trying to achieve 
difficult, separations using a mediocre column. Contrary 
to conjecture, column preparation is indeed a science. 
Duplicate columns prepared from the same set of components 
should be very similar in properties, but prepared from 
differing sets of components (i. e. different batches) will 
undoubtedly differ. No two glass columns are the same; 
each must be modified to accommodate the problems they 
produce. Generally a simple silanisation procedure 
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(e. g. procedure A) will-suffice for most columns and most 
compounds to be chromatographed, and produce an inert 
surface to the column. - However., many exceptions occur 
(e. g. the column'finally used in these studies) and the 
remedy found in this case was carbowax 20M treatment. 
No two packings are identical, and it may be difficult 
to repeat a published method when a low loaded column is 
required. The original procedure may use a 3% liquid 
phase loading but this-can be, quite meaningless. The 
performance of a packing depends fundamentally upon the 
thickness of liquid phase on the particles of support and 
this is dependent upon the density of the support. As 
packings are prepared on a (%) wt: wt basis (liquid 
phase: support), the variability in density of support 
will lead to variation in layer thickness and thus-in 
column characteristies,, e. g. a 6% packing may be equivalent 
to a 4,16 packing if different batches of support are used; 
a 4% packing prepared using the same batch of support 
used to prepare the above 61,66 packing, may exhibit far more 
adsorption than the original 4% packing. Commercial 
suppliers of solid supports recognise that each batch 
differs in density, that standardisation is virtually 
impossible and so unavoidable difficulties occur in 
reproducing published methods. The packing material 
produces the greatest problems for chromatographers and is 
one of the main reasons why many workers are presently 
using capillary columns. 
Because of its inert nature pyrex glass is the, best 
available material for g. l. c. colilmns, and for many 
compoundsj, columns of high efficiency can be, prepared. ý 
However for, some, compounds (e. g. many polar compounds, 
and-, as we find, nitroglycerin) the surface of glass 
exhibits undesirable activity. This activity is caused to 
a great-extent by boron, potassium, Cu2+ and hydroxyl groups 
(Filbert and Ha=l 1968; Hair and Hertl, 1973) which 
results in tailing of chromatographic peaks, and often 
in complete adsorption of the compound (Grob, 1968,1974; 
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Franke and Trijbels, 1974; Schomberg et al., 1974; 
Blomberg and Widmark, 19? 5). By silanisation, one tries 
to convert glass columns having heterogeneous properties 
into columns having similar (inert) properties, but this 
procedure will only inactivate hydroxyl groups, and 
problems arising from other constituents of glass, have 
to be treated by alternative means. For the present 
studies carbowax 20M treatment proved successful. This 
type of treatment has been found to give the best results 
for deactivation of glass capillary columns and more 
recently has been employed with paaked columns (De Nijs 
et al., 1978). Metal surfaces are far more active 
towards most compounds and often irreversible adsorption 
or decomposition occurs (Desty, 1965; Grob, 1965a, b; 
Flath and Forreyt 1970; Aue et al., 1973); nitroglycerin 
can now be added to the list of such compounds. 
The active sites of the solid support present 
similar problems which tend to be more prevalent. Most 
supports are acid washed to remove metals and metal 
complexes. It is recognised that unsilanised supports are 
not inert and differ significantly in adsorption (tailing 
and distortion of peaks) and catalytic activity (giving 
rise to unexpected peaks). Silanisation converts surface 
silanol. (SiOH) groups to silyl ethers which greatly reduces 
adsorption. Acid washing followed by silanisation is the 
best inactivation procedure and most supports undergo this 
treatment. Even so it is unlikely that such supports are 
completely inert. The most efficient means of inactivating 
a support is to give it a thick coating of liquid phase. 
This, however, is impractical as retention times become far 
too long. For most applications low loaded columns are used 
and these consist of particles of support coated with a 
layer of liquid phase which, when one considers the 
surface area of the support and the amount of liquid phase, 
can only be a few molecules thick. It is unlikely that 
the support will be perfectly coated (i. e. no gaps in the 
layer) since the natural forces of cohesion and adhesion 
are involved during preparation of the packing, and 
exposed areas of support are inevitable. This leads to the 
active site problem encountered with nitroglycerin. 14hen the 
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support is glass beads as used by Neurath and Dunger 
(1977) such problems are more apparent and these are 
the hardest supports to coat efficiently. The active 
site problem of supports can be overcome to some extent 
by using polar liquid phases which tend to mask these 
sites. SP2401 is a moderately polar liquid phase and, 
using a thicker liquid phase, the combination of these 
two effects is undoubtedly the reason for success with 
this packing. 
It would also appear that there is a property of 
nitroglycerin which makes it susceptible to these effects. 
Although not a strongly polar compound, it is a small 
compact molecule containing three nitrate groups. These 
groups could be described as bipolar, i. e. 
R -0 -NIý> 
+ --, 0 
and it may be the unique combination of structure and 
polarity which makes this compound so hard to chromato- 
graph. Isosorbide dinitrate is less compact and contains 
fewer nitrate groups per molecule and this compound was 
less strongly adsorbed by the columns used. Lindane and 
other pesticides appeared not to be affected by columns 
which would retain nanogram amounts of nitroglycerin. 
Unfortunately there are no publications which 
adequately describe these problems, although such problems 
are common. It would be of great benefit to researchers 
if, when problems have been encountered in the development 
of a method, the authors would emphasise these problems, 
their sources and remedies. Bearing in mind the problems 
encountered presently it is difficult to see how thinly 
coated non-polar liquid phases, e. g. OV1, SE30 (Givant and 
Sulman, 1978; Laufen et al., 1978) could have succeeded 
for nitroglycerin; a moderately polar, reasonably thick 
liquid phase appears to be required. Several workers, 
having failed to repeat published methods for nitroglycerin 
are now investigating the use of capillary columns to 
develop sensitive and reliable methods for determination of 
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nitroglycerin in human plasma. The modern capillary 
column is made from pure silica, this produces a highly 
inert surface which can be further inactivated by 
procedures such as carbowax 20M treatment prior to 
coating with liquid phase. Thus the capillary column is 
highly inert, it is not made from pyrex, contains no 
support (most capillary columns are wall coated) and 
contains no metal. This type of column exhibits none 
of the problems associated with packed columns and it is 
with these that the future of chromatography of problem 
compounds lies. 
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CHAPTER 4 
EFFECTS OF DEUTERATION ON THE METABOLISM AND 
PHARMACOLOGICAL ACTIVITY OF NITROGLYCERIN. 
ATTE14PTED INHIBITION OF NITROGLYCERIN METABOLISM 
INTRODUCTION 
As a result of the kinetic isotope effect, the rate 
of metabolism of some drugs may be substantially altered 
by substitution of their hydrogen atoms with -the heavy 
isotope deuterium (see Chapter 1). Per-deuteration of 
nitroglycerin was therefore undertaken (Chapter 2) in 
order to delay the elimination, and increase the 
bioavailability of this drug. 
Numerous experiments on the metabolism of organic 
nitrates in rats, dogs and humans have shown that following 
oral administration, essentially none of the parent 
compound is present in the circulation to relax vascular 
smooth muscle (Needleman, 1975). The organic nitrates are 
efficiently extracted from the hepatic-portal circulation 
and rapidly degraded by the liver. Many clinical studies 
have shown the ineffectiveness of orally administered 
organic nitrates (Aronow, 1975). Sublingual administration 
still remains the only clinically effective route of 
administration for the organic nitrates, in particular 
nitroglycerin. 
Until the present studies, the approach to the 
problem of developing a long acting organic nitrate has 
been chemical synthesis of nitrate containing organic 
compounds, which are then tested for pharmacological 
potency and oral stability; however, according to Modell 
(1970), "the history of failure with so-called long acting 
nitrates is an unbroken one". Recently an alternative 
approach, the sustained-release formulation, has been 
investigated but the usefulness of this approach is 
questionable when one considers the conflicting evidence 
for the efficacy of the oral route of administration. Our 
approach has been to apply the theory of kinetic isotope 
effects, and associatedphysico-chemical effects of 
deuteration, to extend the duration of action of nitro- 
glycerin. Pharmacokinetic comparisons of the deuterium 
labelled and unlabelled analogues are conducted using two 
routes of administration, intravenous and sublingual, and 
these are supported by pharmacological comparisons of the 
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two forms both in vivo and in vitro. 
Two additional approaches to slowing nitroglycerin 
metabolism are investigated: 
a) depletion of hepatic glutathione - this compound is 
widely accepted as being a co-substrate in the metabolism 
of nitroglycerin by organic nitrate reductase (Needleman 
and Hunter, 1965). The effect of depletion of glutathione 
levels, by diethylmaleate and paracetamol, is therefore 
investigated. An in vivo system, reflecting primarily 
hepatic metabolism is used (see Chapter 6) 
b) direct inhibition of the enzyme - one could classify 
nitroglycerin metabolism as de-esterification, since 
nitroglycerin is an ester and its metabolic products are 
an alcohol and nitrite. Thus a number of esterase 
inhibitors such as physostigmine, edrophonium. and aspirin 
are investigated for their ability to slow the denitration 
of nitroglycerin. A compound, dichloroacetate, which has 
a similar structure to iodoacetamide, is also tested for 
its ability to inhibit metabolism of nitroglycerin; this 
compound was once tested as a drug and reached clinical 
trials before being withdrawn. Iodoacetamide is used in 
the present analytical methods, for the inhibition of 
nitroglycerin metabolism in plasma (Chapter 3). 
Since plasma has been shown to metabolise 
nitroglycerin at a relatively fast rate (Di Carlo and 
Melgar, 19? 0)1 an in vitro buffered-plasma system is used. 
Although the enzymes of plasma and liver are quite 
different, this system is used for its simplicity and as 
an initial screening; successful inhibitors of the plasma 
organic nitrate reductase were intended for application to 
an in vivo system, or to an in vitro system utilising the 
hepatic enzyme. 
-90- 
EXPERD=AL 
MATERIALS 
All drugs, chemicals and solvents were analytical 
reagent grade obtained from the B. D. H. Ltd. (Poole, 
Dorset) unless otherwise stated. Tubing for cannulae was 
size 800/200/100/100, supplied by Portex Ltd. (Hythe, 
Kent). Glutathione was supplied by Sigma Chemicals Ltd. 
(Poole, Dorset) and sagatal obtained through May and 
Baker Ltd. (Dagenham, Essex). Nitroglycerin and 
nitroglycerin-d 5 were prepared and purified as described 
in Chapter 2. Edge-cutting scissors (De Weckers) and 
surgical cotton were both obtained from Holborn Surgical 
(Broadstairs, Kent). Atropine sulphate was synthesised 
and purified by Biorex Laboratories Ltd. (London). 
Edrophonium was supplied by Roche Products Ltd. (Welwyn 
Garden City, Hertfordshire) and theophylline was kindly 
donated by Courtin and Warner Ltd. (Lewes, Sussex). 
Medical oxygen was supplied by the B. O. C. Ltd. (Crawley, 
Sussex. 
The Langendorff-preparation, perfusion equipment 
was supplied by Scientific Retail Instruments (London). 
The physiograph was a model Six-B from Narco Biosystems 
Inc. (Houston, Texas, USA), and the blood pressure 
transducer was supplied by Statham Transducers Inc. 
(Houston, Texas, USA). 
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METHODS 
Pharmacokinetic-Comparison of Nitroglycerin and 
Deuteronitroglycerin 
Adult male Wistar-albino rats (240-320s) were 
anaesthetised with sagatal (pentobarbitone sodium - 
60 mg/kg) given intraperitoneally prior to the experiment. 
The right external jugular vein and right common carotid 
artery were, cannulated using Portex tubing (800/200/100/ 
100). Nitroglycerin or nitroglycerin-d 5 was then- 
administered intravenously at a dose level of 0.75 mg/kg, 
and blood samples (0-5 ml) obtained from the arterial 
cannula at regular intervals. The drugs were also 
administered sublingually, to anaesthetised rats, in 
<O. lml propylene glycol at the same dose level, and 
blood samples again obtained by artery cannulation. In 
one experiment, following intravenous administration of 
the drug,, serial cardiac puncture was used to obtain 
blood samples. All blood samples were collected into 
heparinised tubes containing 10 
', "l of 
0.2M aqueous 
iodoacetamide solution. 
Plasma was obtained by centrifugation of the blood 
samples, and 200., *l aliquots processed as described, in 
Chapter 3; 1-2 /cl were injected into the g. l. c. Recoveries 
and g. l. c. response factors were identical for both nitro- 
glycerin and nitroglycerin-d 5* Comparison with a series of 
standards enabled nitroglycerin-d 5 concentration-time 
curves to be obtained and plotted using linear-regression 
analysis. 
Preparation of Heparinised Tubes - L. P. 3, tubes, were rinsed 
with heparinised saline (19000 U/ml). and then dried in 
an oven at 500C. In this way, sufficient heparin was 
deposited on the-walls of the tube to prevent blood' 
clotting. 
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Cannulation of the Jugular Vein - skin overlying'the 
right external Jugular vein was pared by blunt dissection 
to expose the vessel which was then cleared of connective 
tissue. The vein was ligatured peripherally, using 
surgical cottong and a loosely tied ligature placed 
centrally (the end nearest the heart). A small cut was 
made using edge-cutting scissors (De Weckers) and the 
cannula - previously filled with heparinised saline 
(50 U/ml) - inserted and tied. Injections of drug 
solutions could be accomplished by means of a 16mm(x5/10) 
needle inserted into the free end of the cannula, and 
a1 ml. syringe. Because of the dead-space volume of the 
needleýand cannula, saline was flushed through, following 
drug administration, to ensure that the entire dose had 
been administered. 
Cannulation of the Carotid Artery - the animal was 
initially given heparin (1,000 U/kg) intravenously to 
prevent arterial blood clots forming. A 2-3cm mid-line 
incision was made in the region of the larynx, and the 
right common carotid artery located and cleared of 
connective tissue. A ligature was tied peripherally and 
the artery clamped centrally (using a "bulldog-clip"). A 
small cut was made on top of the artery and the cannula 
inserted and tied in position. The artery clamp was 
removed and blood allowed to flow into the cannula; this 
was flushed back with heparinised saline (50 U/ml) and 
the cannula kept patent by maintaining it full of 
heparinised saline. Blood samples could be removed by 
means of. 'a syringe and needle inserted into the free end 
of the cannula. After each sampling, heparinised saline 
was flushed through the-cannula. 
Serial Cardiac Puncture. This is a simpler alternative 
to carotid artery cannulation. Blood samples can be 
obtained using a1 ml. syringe and 16mm. (x5/10) needle. 
The heart is punctured by entering the thoracic cavity 
through the left side of the rib cage. In this way small 
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(0-5 ml) blood samples can continually be obtained wiýhout 
causing extensive damage to the heart. 
Pharmacological Comparison of ITitroglycerin and 
Deuteronitroglycerin 
The pharmacological comparison was carried out both 
in vitro and in vivo: 
Isolated-perfused rat heart 
A modified version of the classic Langendorff 
preparation was used (Langendorff, 1895; Livingstone, 1970a) 
for this in vitro experiment. 
The perfusion apparatus was prepared as shown in 
Fig. 4.1 and 
' 
allowed to attain 3? OC. Two male Wistar- 
albino rats were killed by cervical dislocation and their 
hearts quickly dissected out, ensuring that a long length 
of aorta remained. Each heart was immediately placed in 
a dish of Ringer-Locke solution (Appendix 2) containing 
heparin (100 U/ml) at room temperature. The preparations 
were squeezed several times in order to-remove as much 
blood as possible. The aorta was located, dissected free 
and then tied to a cannula (which included a fitting for 
the perfusion apparatus) and all remaining blood vessels 
were trimmed away. The cannula was ligatured below the 
point where the aorta divides. Care was taken to ensure 
that air bubbles did not enter the aorta and any that 
formed in the cannula were removed. The cannula was then 
attached to the perfusion apparatus, the jacket (370C) 
placed around it, and parafilm placed over the jacket to 
retain heat and humidity. The heart was then allowed to 
warm to 370C with Rin-er-Locke solution (oxygenated) 
flowing through for 1 hour at a constant pressure 
(50-56 mm Hg) from the reservoir. 
The pressure of perfusion fluid closes the aortic 
valve so that fluid passes only through the coronary vessels 
and escapes from the inferior vena-cava. It was collected 
by a funnel placed beneath the lower chamber and the rate 
of flow measured using a small graduated cylinder and 
stopwatch. 
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Fig. 4.1 Isolated-Perfused Rat Heart Preparation. 
Experimental Set-up 
perfusion fluid 
reservoir, 
02 drug 
4- 
manometer 
heating jacket 
- thermometer hear 4- H0 01 3? C 
r1p 
.b 
amplifier -L-J. Y 
graduated cylinder 
recorder 
strain gauge 
When the heart appeared to have regained its 
regular beat and rhythm, a clip was attached to the apex 
of the heart and this was in turn connected by a cotton 
thread to a strain gauge. The strain gauge was connected 
through an amplifier to a recorder. 
The effects of two standard compounds (adrenaline 
and theophylline) add the two test solutions (nitroglycerin 
and nitroglycerin-d 5) on coronary flow, heart rate and 
force of contraction were monitored. Additions were only 
made when the heart had clearly re-stabilised. Only two 
rat hearts were used since virtually identical results 
were obtained with each. 
The followinE; parameters were measured: 
a) Heart Rate (H. R. ) - the number of contractions were 
counted over two 6-12 second periods, 30 seconds apart 
during either the obvious control period or when a response 
to an addition Was clearly indicated on the recorder., 
b) Coronary Flow (C. F. ) - was measured over two 30 second 
periods, 30 seconds apart. 
c) Force of Contraction (F. O. C. ) - the size of the 
recorder response was directly proportional to-the force 
of contraction. Thus the increase in force of contraction 
was taken as a direct ratio: 
deflection(after drug)/deflection(control) x 100,1^o 
Drug Solutions used: - 
Nitroglycerin, 
Nitroglycerin-d 5,5 j4M and 50. /41'1 0.2ml injected 
Adrenaline 10 /46/mi O. lml injected 
Theophylline 10 ME/mi O. lml'injected 
Solvent - Ringer-Locke solution 
Rat-blood pressure preparation 
This in vivo experiment was essentially as described 
by Livingstone (1970b). Two male Wistar-albino rats 
(^-, 300g each) were used. Each was anaesthetised with urethane 
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Fig. 4.2 Rat-Blood Pressure Preparation. 
Experimental Set-up. 
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(0.6ml/100g, 0.3ml intraperitoneally and 0.3ml 
subcutaeneously, of a 25P/6 %v1v aqueous solution) one 
hour before the experiment. 
The rat was placed on its bacIt on the operating 
table. The trachea was exposed and cut and a plastic 
cannula inserted and firmly tied in place; cannulation 
of the trachea was achieved in order to assist 
respiration. Any accumulation of mucous was removed 
using a feather. The right femoral vein was cannulated 
(as described earlier for the jugular vein) and heparin 
injected. The carotid artery was then cannulated (see 
earlier), this time with larger (heparin-filled) tubing 
connected to a Statham blood pressure transducer, taking 
care to exclude air from the system; the system was then 
calibrated. Electrodes were inserted into various 
muscles of the rat in order to record the-electrocardio- 
gram. The complete system is shown in Fig. 4.2. 
Continuous recording of the exc-periment was achieved using 
a physiograph. 
The following parameters were monitored: 
Blood pressure (mean arterial blood pressure), heart rate, 
force of contraction (, co' change over control) and respira- 
tion rate. 
Drug Solutions used: 
Nitroglycerin, 
Nitroglycerin-d 5 0.38 mg/kg, 0.75 mg/', ", g 
Nor-adrenaline 10 )"g/ml, 0.1 ml 
Atropine-sulphate 2 mg/ml, 0.1 ml 
Nor-adrenaline and atropine sulphate were used as 
controls. All solutions were administered, as a single 
bolus, through the femoral vein. 
Depletion of Hepatic Glutathione b7 Dieth7lmaleate 
Boyland and Chasseaud (1970) demonstrated that 
glutathione levels in rats could be depleted quite 
dramatically by diethylmaleate (0.69 mg/kg). Glutathione 
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(GSH) levels were determined in the present study by the 
method of Hissin and Hilf (1976) as follows: 
Male Wistar-klbino rats were killed by cervical 
dislocation. The livers were removed, blotted, weighed 
and a 250 mg portion immediately used, or immediately 
frozen and stored in liquid nitrogen until required. The 
liver portion was homogenised in 3.75 ml of ice-cold 0.1M 
sodium phosphate - 0.005M E. D. T. A. buffer (pH 8.0) and 
1.0 ml of 25% jeta-phosphoric acid. The total homogenate 
was centrifuged at 40C and 100,000g for 30 minutes 
(M. S. E. Super Speed 50,10 x 10 ml. rotor) to obtain the 
supernatant for assay of GSH. 
Determination of Hepatic GSH. To 0.5 ml of the 100,000g 
supernatant, 4.5 ml of the phosphate - E. D. T. A. buffer was 
added. The final assay mixture (2.0 ml) consisted of 
100 
., al of 
the diluted tissue supernatant, 1.8 ml of 
phosphate - E. D. T. A. buffer and 100., Al of O-phthalaldehyde 
(OPT) solution (prepared freshly in absolute methanol 
before use)t containing 100 /Ag OPT. After thorough mixing 
and incubation at room temperature for 20 minutes, the 
solution was transferred to a quartz'cuvette. Fluorescence 
at 420 nm was determined with activation at 350 nm using 
a Perkin-Elmer MPF-3 spectrophotofluorimeter. Linearity 
and recovery for the assay were determined over the. 
required range. For standards/recovery experiments, 
homogenates were spiked with varying amounts of GSH in 
phosphate-EDTA buffer (prepared freshly before use) and 
compared with the appropriate tissue blanks and pure 
solution standards processed in a similar manner. 
This assay was shown to be linear over the required 
range (Fig. 4.3) and recovery from liver homogenates was 
'-- 91%. 
Time Course for Depletion of Hepatic GSH by Diethylmaleate. 
A time course study of the effect of diethylmaleate on 
hepatic GSH levels was conducted. Six anaesthetised rats 
were given diethylmaleate (0.69 mg/kg) intraperitoneally 
and the GSH concentrations in three were determined at 
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Fig. 4.3 Glutathione Standard Curve 
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Varying quantities of glutathione were added to either 
buffer (total volume 4 ml, R) or, liver (250mg homogenised 
in buffer - 4ml total, o) and these carried through the 
extraction and derivatisation procedures (see methods). 
Fluorescence was determined at 420nm with an attenuation 
of 3%. From this plot, recovery of GSH from liver =, 91%. 
30 minutes and in three at 90 minutes after administration. 
Three control rats were also killed; the GSH concentration 
in each was determined as described. 
Effect of Diethylmaleate on Nitroglycerin Elimination. 
To determine the effect of GSH depletion on 
nitroglycerin elimination, eight rats were used. Following 
anaesthesia induced by sagatal (60 mg/kg, intraperitoneally), 
five rats were given diethylmaleate (0. (ý9 mg/kg intra- 
peritoneally), 40 minutes prior to an intravenous dose of 
nitroglycerin (0-75 mg/kg). Blood samples were removed by 
serial cardiac puncture at regular intervals. The 
experimental procedures for this type of experiment have been 
described earlier. A control group of three rats was used; 
these rats received nitroglycerin but not diethylmaleate- 
In all cases, hepatic GSH concentration was determined at the 
end of the kinetic experiment. 
Effect of Paracetamol on Nitroglycerin Elimination. 
Paracetamol is well known to cause glutathione 
depletion when administered in high doses (Tredger et al., 
1980); ordinarily1metabolism of paracetamol occurs 
principally by conjugation, although some of the drug is 
transformed to an unstable derivative (by cytochrome P-450) 
which is normally detoxified by conjugation with glutathione. 
Ingestion of large amounts of paracetamol causes the capacity 
for hepatic conjugation to be exceeded and so large amounts 
are metabolised by the alternative pathway, which leads to 
depletion of cellular glutathione and eventually to liver 
damage. 
Four male rats (210-2509) were used in each group; 
anaesthesia was achieved by intraperitoneal administration, 
of sagatal at a dose level of 60 mg/kg. To the test group, 
paracetamol in propylene glycol was administered intra- 
peritoneally (200 mg/kg, 3 ml/kg), 45 minutes prior to 
jugular vein administration of nitroglycerin in saline 
(0.? 5 mg/kgl 0.5 ml/kg) and blood samples removed, at 
regular intervals by serial cardiac puncture. The control 
group received propylene glycol and nitroglycerin only. On 
completion of the kinetic experiment, livers were removed 
and assayed for GSH content. Analysis was carried out as 
described earlier. 
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Nitroglycerin Metabolism in vitro - Inhibitor Studies 
A buffered plasma system, based on that of Di Carlo 
and Melgar (1970) was used. 
Blood samples were obtained from sagatal anaesthetised 
rats by cardiac puncture, and collected in ice-cold 
heparinised tubes. The blood was immediately centrifuged 
for 5 minutes at 2,000g (Beckman J6,40C) and the plasma 
was diluted with 0.2M potassium-phosphate buffer (PH 7.4) 
(1: 1). The buffered plasma was divided into 0.5 ml Portions 
and brought to 370C in a shaking water bath. 
The incubation system was characterised by following 
nitroglycerin degradation at regular time intervals for 
15 minutes, at two initial nitroglycerin concentrations 
(1.0 /14M and 0.1 /&M). Suitable dilutions of buffered plasma 
were made so that the effect of variation in enzyme 
concentration could be observed; buffered plasma 1: 1 was 
diluted up to ten fold for this study. In all cases 
reactions were initiated by addition of the substrate in 
l0, j, l buffer, and terminated by removal of 200 /41 
incubate into 10 /41 of iodoacetamide solution. The- 
incubations were carried out in duplicate., Linearity of the 
incubation system was demonstrated with respect to enzyme 
concentration and incubation time (Fig. 4.4). 
The final system used for inhibition studies involved 
determination of nitroglycerin degradation at five initial 
substrate concentrations (0.1, 
'0.25,0.5,0.75, 
and 1.0 /-ýM) 
and three inhibitor concentrations (10-3M, 5x 10-51,1,10-6M). 
Controls consisted of nitroglycerin with no inhibitor 
present. Inhibitor, in a volume of 10 , ^l, was pre-incubated 
for 5 minutes-prior to initiation of the reaction with 
nitroglycerin. Incubation time was 10 minutes. 
200,, Al aliquots were removed into iodoacetamide 
solution and assayed for nitroglycerin content by g. l. c. 
(Chapter 3). Plots of 1/v against lls were constructed 
from which enzyme parameters were calculated. The inhibitors 
used were: physostigmine, edrophonium, aspirin and 
dichloroacetate. 
Protein content of plasma samples was determined by 
the method of Lowry (see Chapter' 6). 
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Fig. 4.4 Characteristics of the Incubation System for Plasma 
Nitroglycerin Metabolism 
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RESULTS 
Pha=acokinetics Presentation of Results 
Table 4.1 - 4.31 4.79 4.8; Pig. 4.5 - 4.71 4.9 and 
4.10. 
Results are expressed an both concentration-time 
curves (los-linear axes) for nitroglycerin (GTII) and 
deuteronitroglycerin (GTN-d 5) and as tabulated 
phar-macokinetic parameters derived from these figures. 
Tables are placed opposite the corresponding figure and 
the legend is placed with the appropriate table. Results 
, for 
individual rats (labelled A- Z) are presented and 
this notation is consistent for both the figure and its 
corresponding table. 
The concentration-ti=o curves have been interpreted 
in terms of a one compartment model and first order 
elimination or nitroglycerin (see Appendix 1 and Chapter 
In the case of sublingual administration, the came aquationo 
governing oli=ination following intravenouz administration 
are used. Thus half-life (tq) and initial plazma, 7 
concentration (Co, by extrapolation) are obtained directly 
from the concentration-tiza curves, and the remaining 
parameters calculated an followat 
voluze of distribution, VD 0 Doan 
Co 
olizinution rate conatant, kol 0.6c, )7j 
tq 
total area =der the 
plasmat concontration-ti. -. o 
curve Auctot 0 CO 
kol 
The correlation coefficient of the atraight line ploto ic 
obtained by linear-regrension anal, 7nin of the data. 
total systemic clearanco, ci 
Auctot 
where Xo in the administered done. 
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Effect of Deuteration on the Pharmacokinetics oL 
Nitroglycerin 
A significant difference between the two forms of 
nitroglycerin is not apparent. Statistical analysis of 
the tabulated data (using Students t-test) indicates the 
lack of a difference in half-life for the intravenous 
route (tj; nitroglycerin - 6.7 t 1.0 min., 
nitroglycerin-d 6.6 :t2.0 min. ), and a small, but' 
statistically insignificant difference (0. l,. <p<0.2) for 
the sublingual route (ti; nitroglycerin - 14.3 
t 3.4, 
nitroglycerin-d 5- 17.4 
t 1.6). Mean values showed a 
lower initial plasma level, larger volume of distribution, 
for the deuterium labelled analogue; again this was not 
statistically significant. A decreased bioavailability 
for nitOroglycerin-d 5 was indicated in the intravenous 
experiment (Fig. 4.51 4.6, Table 4.1,4.2) but the 
sublingual experiment does not support this observation 
(Fig. 4.7, Table 4-3). Systemic clearance was unaffeotea, 
E "feet of Deuteration on the Pharmacology of ITitroglycerin . IL 
The results demonstrate quite conclusively, the 
lack of a pharmacological difference between nitroglycerin 
and its deuterated analogue (Fil.. 4.8, Table 4.4,4-5) 
confirming the pharmacokinetic observations. 
For the in vitro system, both forms of nitroglycerin 
caused an increase in heart rate, coronary flow and force 
of contraction to approximately the same extent. Two drug 
concentrations were used butýonly a small dose-response 
was observed. Usin- the in vivo system, both forms of 
nitroSlycerin caused a significant fall in blood pressure, 
but very little effect on heart rate. Respiration rate 
and force of contraction were increased significantly. In 
this experiment, however, a dose-response was not observed. 
Atropine and nor-adrenaline were used as positive controls 
to indicate the viability of the response of the 
preparation; atropine causes a decrease in blood pressure 
whereas nor-adrenaline causes an increase. 
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Table 4.4. Comparison of the Effects of Nitroglycerin 
and Deuteronitroglycerin on the Isolated 
Perfused Rat Heart 
Two isolated rat hearts were perfused with Ringer-Locke 
solution and the effects of nitroglycerin and deutero- 
nitroglycerin on heart rate, coronary flow and force of 
contraction monitored. 
Pressure in heart: Rat A- 56mm Hg, Rat B- 50= Hg. 
Results'are presented as the mean values for two 
experiments; in each experiment two determinations were 
made. After an initial increase in heart rate due to 
nitroglycerin-d a transient fall in heart rate below 
control values 
5ýto 88 contractions per minute) was 
observed; duration 1 minute. 
Compound added to 
perfusion fluid 
Coronary Flow 
(ml/min) 
Heart Rate 
(Contrac- 
tions/min) 
% Increase 
in force of 
contraction 
0.75 109 
adrenaline, 144-_- 0.88 177 62 
0.75 107 
0.75 105 
theophylline, 1 mg 0.84 164 35 
0.75 109 
0.75 112 
GTN 5 IdI 0.95 176 63 
0.75 108 
GTN-d 5' 5/, M 0.95 174 67 
0.75 105 
adrenaline, 11AS; 0.83 -172* 61 
0.73 102 
GTN , 50tAJ1 1.00 178 56 
0.73 99 
GTIT-d 5,501,4-1 1.00 178 58 
0.73 99 
adrenaline, 11AS 0.83 173 65 
denotes control value. 
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Fig. 4.8. 
The blood pressure response to nitroglycerin, 
deuteronitroglycerin, atropine and nor-adrenaline are 
presented. These are given in chronological order since 
the mean of the response to a series of administrations 
is not valid when accilmmulation of the drug or its 
metabolites occurs within the preparation. Urethane 
anaesthetised rats were used and the drugs administered 
intravenously; blood pressure was monitored in the 
carotid artery. 
Chronological order of administrations: 
Fig. 4.8A 0.? 5 mg/kg, rat A 
nitroglycerin 01 deuteronitroglycerin m 
nor-adrenaline m 
Fig. 4.83 0.38 mg/kg, rat A 
deuteronitroglycerin v nitroglycerin c 
deuteronitrob-lycerin o nitroglycerin a 
Fiog. 4. SC 0.38 mg/kg, rat B 
nor-adrenaline aI deuteronitroglycerin 0 
nitroglycerin a 
Fig. 4. SD 0.? 5 mg/lcg, rat B 
nor-adrenaline e, nitroglycerin v 
deuteronitroglycerin A. , atropine a 
Fig. 4.8 Rat Blood Pressure Response to Nitroglycerin and 
Deuteronitroglycerin 
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Fig. 4.8 (Cont'd. ) 
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Results are also presented as blood pressure-time 
curves for individual experiments (Pig. 4-3). The effect 
of each administration to the animal is monitored and the 
chronological order noted. This was necessary since the 
preparation could not be cleared of the previous 
administration, other than by metabolism. Consideration 
of the half-life for nitroglycerin allowed a recovery time 
to be estimated. Even so, some of the previous dose, or 
metabolites, would still be present in the rat. Thus, as 
blood pressure was the parameter most significantly 
affected, these results have been presented individually 
rather than as the mean t S. D. The other parameters 
monitored have been tabulated as mean values of all the 
results-obtained for each compound and, since a 
dose-response was not observed, results for each dose 
level have been combined. 
Effect of Glutathione DeDletion on the Pharmacokinetics 
of Nitroglycerin 
Diethylmaleate. Intraperitoneal administration of 
diethylmaleate (0.69 mg/kg) caused a rapid decrease in 
glutathione levels to approximately 20j6 of the control 
level within 30 minutes. This continued to decrease, and 
after 90 minutes the glutathione levels were only 7% of 
controls (Table 4.6). 
The pharmacokinetic experiment was thus conducted 
at 40 minutes after administration of diethylmaleate. 
Elimination of nitroglycerin was significantly lowered by 
diethylmaleate pre-administration; a 63% decrease in 
eliminationýrate (tj slowed from 4.8 t 0.7 minutes to 
7.8 t 2.0 minutes), and a doubling in bioavailability was 
observed (Fig. 4.9, Table 4.7). The slowest rates of 
nitroglycerin elimination occurred in the rats possessing 
the lowest Slutathione levels. Total systemic clearance 
was decreased but all other pharmacokinetic parameters 
remained unaffected. 
-102- 
Paracetamol. Upon completion of the pharmacokinetic 
experiment, glutathione levels following combined 
administration of nitroglycerin and paracetamol were 
approximately 5Cý6 of those following administration of 
nitroglycerin alone. A 581col decrease in the elimination 
rate of nitroglycerin was apparent (tj slowed from -9 
5.7 t 1.8 minutes to 9.0 : t. 2.1 minutes), but all other 
parameters remained unchanged (Fig. 4.10, Table 4.8). 
Effect of Possible Inhibitors on Nitroglycerin 
Metabolism in vitro 
ITone of the compounds tested caused inhibition of 
nitroglycerin metabolism, at any level of substrate or 
inhibitor (Table 4.9). Values for K ranged from m 11 
11.1 to 20.2 /414 and Vmax ranged from 0.76 x 10- to 
3.3 x 10-11 mol/min/mg protein. 
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Table 4.6. The Effect of Diethylmaleate on Hepatic 
Glutathione Levels. 
Diethylmaleate (0.69 mg/kg) was administered intra- 
peritoAeally to six male rats. The hepatic reduced 
glutathione (GSH) levels in three rats were determined 
at 30 minutes and in three rats at 90 minutes after 
dosage. A control group of three untreated rats 
(time =0 min) was also examined. 
Time after 
diethylmaleate (min) SH /. 4g GS /g liver clo control 
0 1143 :t 156 
30 148 21* 13.0* 
300 237 26.0 
1 
90 
1 
80 t 26 
1 
7.0 
Results are presented as mean + standard deviation for 
three determinations except here wýere two determinations 
are used (one animal deviated markedly from the other two). 
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Table 4.9. The Effect of Various Compounds on 
Ilitroglycerin Metabolism in vitro. 
A buffered plasma system was used. Nitroglycerin 
metabolism at five initial concentrations was monitored 
in the presence or absence of inhibitors - 
physostigmine, edrophonium, dichloroacetate or aspirin - 
each at three concentrations. Inhibition of nitroglycerin 
metabolism by these compounds was examined by constructing 
L-ineweaver-Bur. ke plots. The enzyme parameters calculated 
from these plots are summarised here. 
+ Inhibitor Michaelis Constant 
'4'm) M 
(' K 
Maximum Initial 
Velocity, Vmax 
(mol/min/ing 
protein) 
20.2 3.3 x 10-11 
" physostigmine 20.2 3.3 x 10-11 
11.1 0.76 x 10-11 
" edrophonium 11.1 0.76 x 10-11 
13.2 1.531) x 10-11 
" dichloroacetate 13.2 1.53 x 10-11 
" aspirin 13.2 1.53 x 10-11 
, denotes control; that isImo inhibitor present. 
DISCUSSION 
Deuterium Labelling of Nitroglycerin 
Replacement of hydrogen with deuterium in 
nitroglycerin appears not to cause a significant effect 
on either the pharmacokinetics or pharmacological 
properties of this drug. Pharmacological comparison showed 
that the two drug forms were identical, and statistical 
analysis of the pharmacokinetic data shows no difference 
in half-life following intravenous administration. 
Following sublingual administration, there was a slight 
difference in half-life and larger volume of distribution 
for nitroglycerin-d 5 but these were statistically 
insignificant and may be attributed to the higher 
lipophilicity of the deuterium labelled form. 
The lipoid nature of , 
biological membranes has been 
confirmed by chemical analysis (Cohn, 1971). Membrane 
transfer of drugs is thought to take place by the initial 
dissolving of the molecule in the membrane (Moffat, 1978); 
hence the greater the lipid solubility, the higher the 
concentration in the membrane. This similarly applies to 
cellular lipid deposits and adipose tissue in general. 
The possibly enhanced lipophilicity for nitroglycerin-d 5 
may account for the slower biological half-life observed 
for the sublingual route; if the absorption rate is 
increased (by increased lipid solubility), whilst the rate 
of metabolism is unchanged, then the possibility exists 
for a slower elimination half-life to be observed (this 
assumes an already slow absorption rate for the non- 
labelled form). Obviously the half-life determined for 
this route is only the apparent elimination half-life 
since it is not equal to that obtained following intravenous 
administration, and probably represents a combination of 
absorption and elimination; absorption is perhaps hindered 
by the propylene glycol which acts as the vehicle and 
'flip-flop' kinetics may operate (see Appendix 1). An 
enhanced lipid solubility may also explain the lower initial 
plasma levels (larger volume of distribution). But, since 
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nitroglycerin in already highly lipid soluble, an effect 
on this property would necessarily be small and lead to 
statistically insignificant effects which are, nevertheless, 
real and this may have occurred in the present study. 
The lack of a significant kinetic isotope effect is 
perhaps not surprising as only a secondary isotope effect 
could be expected for the type of metabolism undergone by 
this drug (Chapter 1). The maximum secondary isotope 
effect for deuterium substitution is 1.25. Secondary 
isotope effectst although small, may be important in 
biological systems which are sensitive to kinetic changes, 
and it was hoped that a small isotope effect in combination 
with altered lipid solubility characteristics may have 
modified the kinetics of this drug in such, a way as to 
render it therapeutically more useful. 
An expected effect of deuterium labelling to 
increase the potential van der Waals forces between the 
drug and proteins such as receptors, binding proteins and 
the enzyme responsible for its metabolism, is not obvious. 
Increased affinity of nitroglycerin-d 5 for the denitrating 
enzyme may have produced a faster rate of metabolism; if 
opposed by a kinetic isotope effect, the combination of 
the positive (increase in van der VJaals forces) and 
negative (kinetic isotope effect) contributions to 
metabolism may result in no overall isotope effect on the 
pharmacokine-tics of nitroglycerin being observed, as was 
the case. An explanation for the small increase in volume 
of distribution for nitroglycerin-d 5 may also lie here, 
that is, increased affinity for tissue proteins may lead to 
a small decrease in the plasma level of the drug. A 
suitable experiment was not conducted to test the effects 
of deuteration of nitroglycerin on its lipid solubility 
and protein binding characteristics in order to elucidate 
the contributions of the effects postulated above, and 
indeed to check whether these effects occurred. 
Since no change in pharmacological properties was 
observed (either in vitro or'in ZiLyo) one may conclude that 
drug-receptor interaction remained unaltered, that is, 
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there was no efL 'ect on lipid solubility or protein 
binding. However, the drug concentrations used may have 
been too high for such an effect to be observed; a dose- 
response did not occur in vivo. To detect small changes 
in drug-receptor interaction'it would probably be necessary 
to use 'Lar lower drug concentrations within a range shown 
to produce such a dose-response. The dose levels used 
were chosen in order to correlate the in vivo plasma 
level of the drug with the in vivo pharmacological 
response. 
Correlation between the plasma levels of nitroglycerin 
and the pharmacological response is reasonably good since, 
the pharmacological effect is lost within 5-10 minutes of 
drug administration and the half-life for nitroglycerin 
is of-the order of 5 minutes. Thus, the initial 
pharmacological effects on force of contraction, blood 
pressure and respiration rate persist only while the drug 
is in reasonably high concentration, and gradually decreases 
as the drug is eliminated from the system. The correlation 
between in vivo and in vitro experiments is, however, poor. 
In the in vitro experiment, nitroglycerin caused a dramatic 
increase in heart rate which was not observed during the 
in vivo experiment. This effect has been observed by other 
worhers (Vatner et al., 1974) and is probably due to the 
loss of innervation in the isolated heart preparation and 
an effect of anaesthesia in the intact preparation. The 
other parameters which were monitored correlated well. 
Depletion of Hepatic (reduced) Glutathione Levels 
Glutathione (GSH) is believed to be required for 
the metabolism of nitroglycerin (GTIT), the mechanism for 
i, -ihich is thought to involve glutathione reductase and 
possibly the glutathione-S-transferase system (Needleman 
and Hunter, 1965; Jakoby, 19? 8) in the following manner: 
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GTN + 2GSH --- ) GSSG + GDN + No 2+ H+ GSH-S-transferase 
GSSG + 21TADPH 2GSH + 21TADP - GSSG-reductase 
GDN - glycerol dinitrate 
Thus if GSH levels can be depleted, one would expect 
the metabolism of nitroglycerin to be significantly inhibited. 
This occurred in both experiments, but the degree of 
inhibition was smaller than expected, considering the low 
levels of GSH remaining; in some cases GSH levels fell to 
40 /Ag/g liver (~5% of the control value) whereas the half- 
life was-only decreased from -4.8 minutes to ?. 5-11.2 
minutes. 
A 63% decrease in elimination rate, and doubling of 
bi0availability, was observed following diethylmaleate 
pre-administration and a 58016 increase in half-life 
observed following paracetamol pre-administration, and it 
is interesting to note that the slowest rate of elimination 
occurs in rats having the lowest GSH levels. Similar GSH 
levels are achieved following pre-administration of 
either diethylmaleate or paracetamol and this results in 
a similar decrease in elimination rate (/-160%). 
Nevertheless, the speed with which nitroglycerin is 
eliminated is still very fast. Even so, it may be advisable 
to check for inhibition of nitroglycerin elimination by 
therapeutic doses of paracetamol; this may be of importance 
clinically in the safety evaluation of such a drug 
combination. 
Nitroglycerin is believed to be denitrated at 
receptors (Needleman et al., 1973) and this metabolism is 
thought to require sulphhydryl groups of the receptors rather 
than GSH; this may account for the continued high elimination 
rate following GSH-depletibnj or perhaps the residual GSH 
levels are sufficient to allow fast nitroglycerin metabolism 
(GS11 levels of 40 /zg/g liver would still vastly exceed the 
expected tissue level of nitroglycerin, possibly in the 
range 5-10 1Ag1g). Another explanation for this continued 
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rapid metabolism is the contribution from blood. Di Carlo 
and Melgar (1970) reported a fairly rapid metabolism of 
nitroglycerin*by rat serum (tl, -, 20 minutes) and, more 2' 
recently, Armstrong et al., (1980b) have reported 
metabolism of nitroglycerin by whole human blood' 
(t, 4., 6 minutes). It is more likely that the residual 
metabolism is mediated by all three processes, the most 
important of which is probably metabolism in the blood. 
These studies confirm the involvement of GSH in 
nitroglycerin biotransformation. A kinetic effect of a 
drug interaction is unlikely, in the case of paracetamol, 
to be due to competition for metabolising enzymes since 
nitroglycerin is metabolised by GSH-S-transferase and 
paracetamol by the mixed function oxidases. Diethylmaleate 
is removed by glutathione-S-alkenetransferase and so 
competitive inhibition is possible in this case. An 
application to human therapy of this approach to slowing 
nitroglycerin metabolism is unlikely, since GSH levels have 
to be lowered to an extent tfhich, in the human, may be 
dangerous if not fatal (GSH is required for a multitude of 
physiological functions in the normal human). Paracetamol 
would be a more suitable candidate for a drug combination 
and it would be interesting to see the e'Lfect of this 
compound, at a far lower dose level, on nitroglycearin 
pharmaco"Icinetics. The dose used here was chosen since 
this level of paracetamol is known to significantly lower 
GSH levels in the experimental animal (lKepetanovic and 
Mieval, 1978,1979). However, in order to ensure the safety 
of such a drug combination, it would be necessary to use 
a low dose of paracetamol. 
Effect of Inhibitors in vitro 
Problems were encountered during setting up the 
in vitro buffered-plasma incubation system, mainly due to 
inhibition of metabolism by propylene glycol when high 
nitroglycerin concentrations (0.1 - l. OmM) were used; the 
only supply of nitroglycerin available at that time was 
dissolved in propylene glycol. This was overcome by use 
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of much lower nitroglycerin concentrations (0.1 - 1.01AM). 
This concentration range is, however, more meaningful since 
it is in this range that nitroglycerin plasma levels lie 
following intravenous administration to rats (0-75 mg/. C%. '-S) 
and therefore inhibition studies are best conducted at 
these concentrations. 
The inhibitors were chosen on the basis of: 
a) esterase inhibitors, e. g. the anticholinesterases 
edrophonium. and physostigmine, or aspirin which is 
metabolised, in part, by a plasma esterase, and 
b) a compound, dichloroacetate, which is structurally 
related to iodoacetamide; a 1mown inhibitor of plasma 
nitroglycerin metabolism (Chapter 3). However, no 
inhibition was observed for any of these compounds. The 
results obtained with this in vitro system indicate odd 
values for Km and Vmax, with a low Km but a very slow 
Vmax (compare. with Chapter 6). Since viability of the 
incubation system was demonstrated (Fig. 4.4) an unreliable 
eiqerimental system cannot account Lor these values. 
However, it must be noted that determinations made at very 
low substrate concentrations generate rather inaccurate 
values for Km and Vmax when analysed by a Lineweaver-Burke 
plot, but no alternative was available. The incubation 
system will, nevertheless, give an indication of a 
significant deggree of inhibition. 
It was hoped that this simple in vitro system would 
be a reasonable model of hepatic metabolism and could be 
used for screening possible inhibitors of the hepatic 
enzyme (this enzyme accounts for the primary in vivo 
metabolism of nitroglycerin). But with the growing evidence Cý 
for nitroglycerin metabolism by the glutathione-S-transferases, 
including in whole blood, this is unlikely. Significant 
inhibition of the plasma enzyme alone may lead to an 
extended half-life for nitroglycerin, since the contribution 
from this enzyme to overall in vivo elimination of 
nitroglycerin has not been elucidated. It is also possible 
that Slutathione-independent organic nitrate reductase 
occurs in other tissues, such as liver i. e. a sister enzyme 
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of the plasma enzyme. One recent report, (Stein et al., 
1980) demonstrated a 50-lOOP' increase in half-life, in the 
rat, when cephalothin, penicillin G or probenecid were 
pre-administered before intravenous nitroglycerin. This 
inhibition is described as a direct effect on the 
enzymes GSH-S-transferases, and is an approach similar to 
that used in the present studies. 
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CHAPTER 
PHARMACOKINETICS OF NITROGLYCERIN 
INTRODUCTION 
Nitroglycerin (GTN) is one of the oldest drugs still 
regularly prescribed today. Although it has been used for 
over a century to alleviate the symptoms of angina pectoris, 
still little is known about its pharmacokinetic properties. 
This is essentially due to the lack of a sensitive and 
specific method for the determination of nitroglycerin in 
blood at therapeutic levels; such a method has now been 
developed (Chapter 3). 
Interest in the clinical pharmacokinetics of this 
drug, and organic nitrate drugs in general, was stimulated 
only recently by the development of accurate methods which 
were sensitive enough to be applied to measurement of drug 
concentrations occurring in plasma following administration 
of therapeutic doses. At present, clinical pharmacokinetic 
studies with nitroglycerin have been limited to preliminary 
studies, involving determination of human plasma levels 
following administration by different routes (Blumenthal, 
et al. 1977; Neurath and Dunger, 197?; Givant and Sulman, 
19? 8; Armstrong et al., 19? 9; Wei and Reid, 1979) and, in 
animals, only the kinetics in the male rat have been 
investigated (Johnson, et al., 1972; Yap and Fung, 1978). 
The present studies compare different routes of administra- 
tion in the rat, the effect of dose, sex and species and 
the presence of other drugs on the pharmacokinetics of 
nitroglycerin. 
The following routes of administration are 
investigated: intravenous, intracardial, sublingual and oral. 
A comparison is made of two types of oral preparation, the 
standard preparation and a sustained-release preparation, 
in order to evaluate whether these preparations of 
nitroglycerin are superior to the normal dosage form. The 
oral route of administration of nitroglycerin is used 
primarily for the-prophylaxis of angina, and at present it 
is unclear whether oral-sustained-release preparations 
provide a superior means of administration. The efficacy 
of these preparations, and of the oral route of administra- 
tion itself, are controversial points;. )lepatic extraction 
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of nitroglycerin during its first passage through the liver 
has been the central point against the efficap y of the oral 
route, although detailed pharmacokinetic information is 
not available. The present studies are intended to provide 
an insight into this situation. 
Comparison of the pharmacokinetics of nitroglycerin 
in the presence and absence of a number of drugs which are 
regularly co-administered with nitroglycerin is conducted 
in order to evaluate the safety of these drug combinations. 
The drugs used are propranololl theophylline, quinidine 
sulphate and digitoxin. A further reason for'studying the 
pharma6okinetics of these combinations is to determine 
whether the presence of another drug can alter the elimina- 
tion of nitroglycerin in such a way as to improve the 
therapeutic properties of this compound. 
The pharmacokinetics of nitroglycerin in several 
species (3Zat, hamster, guinea-pig, rabbit and ferret) are 
investigated. Males of the species are used except for the 
rat and rabbit where both sexes are examined. This type of 
investigation is important to further understanding of 
species variation in drug metabolism and pharmacokinetics, 
so that more confident predictions of human response can be 
made by consideration of data from animal studies, and so 
that suitable animal models for man can be chosen in 
toxicity studies. 
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0 
EXPERIMENTAL 
MATERIALS 
Unless otherwise stated, the sources of the 
reagents and chemicals used here have been described in 
Chapter 4. 
Sustac was donated by Pharmax Ltd. (Crayford, Kent), 
theophylline, quinidine sulphate and digitoxin were supplied 
by Courtin and Warner Ltd. (Lewes, Sussex) and propranolol 
was donated by I. C. I. Ltd. (Macclesfield, Cheshire). 
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METHODS 
Detailed surgical procedures for the pharmacokinetic 
experiments have been described earlier (Chapter 4). 
Administration of Nitroglycerin to the Rat 
Intravenous and Sublingual Administration. Adult Wistar- 
aibino rats (210-340g, -8 weeks old), both male and female, 
were anaesthetised with sagatal (60 mg/kg) given 
intraperitoneally prior to the experiment. The right 
external jugular vein was cannulated and nitroglycerin 
(0.5ml/kg, dissolved in saline-diluted propylene glycol) at 
three dose levels, 0.25,0.50 and 0.75 mg/kg, was then 
administered intravenously. Blood samples (0-5 ml) were 
removed at regular intervals, from either the carotid 
artery or by serial cardiac puncture (Chapter 4) into 
heparinised tubes containing iodoacetamide (10A1,0.2M). 
Nitroglycerin (0.? 5 mg/kg) was also given sublingually in 
<O. lml of propylene glycol and blood samples obtained from 
the carotid artery. 
In one experiment to examine the effects of age on 
the pharmacokinetics of nitroglycerin, older rats (465ý-5159, 
/-6 months old) were used. The methods were as described 
above, using the intravenous route, a dose level of 0.? 5mg/kg, 
and blood samples were obtained by serial cardiac 
puncture. 
Intracardial Administration. This procedure is similar to 
that described for serial cardiac puncture (Chapter 4). In 
this case, once the heart has been punctured, slight 
suction is applied and the syringe moved slowly outwards. 
Entry of blood into the syringe is an indication of correct 
placement of the needle; the dose is then injected, taking 
care not to displace the needle. 
Oral Administration. Two types of oral preparation were 
administered in these experiments; a standard oral dose of 
_11L. _ 
nitroglycerin (7-5 mg/kg, 4 ml/kg) dissolved in water- 
diluted propylene glycol, and an equivalent dose of the 
prolonged-release nitroglycerin preparation - sustac. In 
each experiment, groups of four male Wistar-albino rats 
(230-320g) were used. Blood samples (0.5ml) were removed 
from the tail vein, by removing the tip of the tail; in 
this way small volumes of blood could regularly be obtained 
without unduly distressing the animal. Blood samples were 
collected at regular intervals into heparinised tubes 
containing iodoacetamide for up to one hour (nitroglycerin) 
or, up to 4 or 12 hours (sustac). 
Administration of Nitroglycerin to Other'Species 
Adult male, DSN - golden hamsters (118-1359), 
Dunkin/Hartley guinea pigs (445-600s) and albino (Mustela 
putorius furo) ferrets (1050-16009) were used. Each was 
anaesthetised with sagatal (40-120 mg/kg, depending upon 
the species) given intraperitoneally, and both the right 
external jugular vein and right common carotid artery were 
cannulated. Nitroglycerin (0-75 mg/kg) was then administered 
intravenously and blood samples (0.25ml hamster or 0-5ml 
other species) obtained from the carotid artery and collected 
into heparinised tubes. Since iodoacetamide did not inhibit 
plasma. metabolism of nitroglycerin in the ferret, the blood 
samples were kept at OOC and plasma samples frozen to -400C. 
Each sample was extracted immediately upon thawing. 
Adult male and female miniature Dutch rabbits 
(Dutch Fl hybrid, 1400-1900g) were used. Nitroglycerin 
(0-75 mg/kg) was administered through the marginal vein of 
the left ear and blood samples (0-5ml) removed from the 
marginal vein of the right ear into heparinised tubes. 
lodoacetamide was not added since nitroglycerin degradation 
in rabbit plasma was not inhibited by this compound; instead, 
blood samples were kept at OOC and plasma samples frozen 
(-4, OOC). 
Inhibition of Plasma Metabolism. The effect of species 
variation on the ability of iodoacetamide to inhibit the 
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Table 5-1. -- Effect of Iodoacetamide on Nitroglycerin 
Metabolism in Plasma of Various Species. 
Results are presented as the mean of two determinations. 
Species lodoacetamide 
(0.4mM) 
'Nitroglycerin 
added to 
200/. 41 lasma 
(ngý 
Nitroglycerin 
recovered 
after 5h (ng) 
% 
remaining 
Rat 3.? 5 0.93 25 
? -50 2.00 28 
+ 3?. 50 37-50 100 
+ 7.50 ?. 00 93 
+ 3.75 3.? 0 99 
+ 1.50 1.50 100 
Hamster 15-00 13-00 87 
+ 15-00 15-00 100 
Guinea Pig 15-00 11-50 ?7 
+ 15-00 15-00 100 
Ferret 30-00 8.40 28 
+ 30-00 8.10 27 
Rabbit 30-00 23-40 ?9 
+ 30-00 24.60 82 
Data for the rat was obtained from Chapter 3, and is used 
here for comparative purposes. 
degradation of nitroglycerin in isolated plasma was tested. 
Varying quantities of nitroglycerin were added to 200 /Al 
aliquots of plasma obtained from each species, and these 
incubated for five hours at room temperature in the 
presence of iodoacetamide (10 /, Ll, O. 2M). On completion 
of the incubation period, the nitroglycerin content was 
determined. Duplicate incubations were performed. 
Table 5.1 shows the effect of iodoacetamide on 
nitroglycerin stability in plasma samples. Iodoacetamide 
proved effective in protecting nitroglycerin from 
degradation by plasma of all species other than ferret and 
rabbit. Ferret plasma appears to rapidly degrade 
nitroglycerin at approximately the same rate as untreated 
rat plasma. 
Recoveries from Plasma. Recovery of nitroglycerin from the 
plasma of each species was determined by addition of 
varying quantities to aliquots of plasma, 100 /-tl (hamster) 
or 200 141 (other species), in duplicate; each was then 
extracted and its nitroglycerin content determined. By 
comparison of these with equivalent pure solution standards, 
it was possible to construct standard curves and, by 
comparison, to calculate the recoveries from these. 
Recovery of nitroglycerin from plasma varied 
slightly depending upon the species: 
Rat, 75-81%; Hamster, 34%; Guinea-pig, 71%; Rabbit, 700,69 
Ferret, 81%. 
Drug Interaction Studies 
Adult male Wistar-albino rats (220-3309) were used. 
Each was anaesthetised with sagatal, (60 mg/kg) given 
intraperitoneally. The following drugs were administered 
intravenously through a jugular vein cannula, five minutes 
prior to intravenous administration of nitroglycerin 
(0-5 mg/kgl 0.5 ml/kg). 
a) Propranolol, three dose levels 0.1,0.5 and 5.0 mg/kg 
were used. At the higher dose levels, many mortalities 
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occurred upon administration of nitroglycerin; this may 
be the result of a synergistic effect of the two drugs on 
the heart and/or respiration. At the 0.1 mg/kg dose level, 
few mortalities occurred when nitroglycerin was administered. 
Cannulation of the carotid artery accentuated the number of 
mortalities at the higher dose levels of propranolol. 
b) Theophylline, dose -2 mg/kg. 
c) Quinidine sulphatel dose - 1.0 mg/kg 
d) Digitoxinj dose - 0.1 mg/kg, using a vehicle that 
consisted of 50% aqueous ethanol. The control group was 
given 50% ethanol, five minutes prior to nitroglycerin 
administration; each administration was on the basis of 
0.5 ml/kg and so , --50le4l of ethanol entered each animal. 
The above dose levels were chosen in order to reflect 
the drug/nitroglycerin dose ratio used in human therapy. 
Control groups (nitroglycerin only) were used in each 
experiment to account for animal variation. Blood samples 
(0-5 ml) were collected at regular intervals by artery 
cannulation or by serial cardiac puncture into heparinised 
tubes containing iodoacetamide. 
Determination of Nitroglycerin 
All plasma samples were extracted and chromato- - 
graphed as described in Chapter 3. Suitable standards were 
prepared, and by comparison with these, the nitroglycerin 
content of each plasma sample was determined. 
Statistical Treatment of the Data 
All plots, or linear portions of the plots, were 
constructed using linear-regression analysis. Statistical 
comparisons were accomplished by use of Studenf's t-test. 
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RESULTS 
Pharmacokinetics - Interpretation and Presentation of Results 
Results are presented for individual rats (A-Z) as 
plasma concentration (c) - time (t) curves (plotted on 
log-linear axes) for nitroglycerin, following administration 
by various routes (Fig. 5.1,5.2,5.10) at different dose 
levels (Fig. 5.5,5.11 - 5-14) in various species 
(Fig. 5.6 5-9) and in the presence of other compounds 
(Fig. 5.11 5.14). Pharmacokinetic data are obtained from 
the plasma concentration-time curves which demonstrate that 
nitroglycerin is eliminated by first-order kinetics for a 
one-compartment model, and this model is used for 
interpretation of the data obtained following oral administra- 
tion. Brief experimental details are given with the tables 
rather than with the figures, and tables are placed opposite 
the appropriate figures. The pharmacokinetic parameters 
were calculated as follows: 
(See Appendix 1 for a more detailed description of the 
pharmacokinetic analysis). 
for intravenous and intracardial administration, 
Co e 
-k el 
t 
Biological half-life (tj) and initial 
concentration (Co, by extrapolation) were obtained directly 
from the plots. The other parameters were calculated as 
f ollows: 
volume of distribution, VD= 
XO 
Uo 
where Xo is the-administered dose. 
elimination rate constant, k 0.693 el. 
ti 
total area under the curve, AUCtot Co 
(bioavailability) k 
el 
total systemic clearance, Cl 
Xo 
AUC tot 
-118- 
for oral administration, C kaFXo e -k at _e -kelt) 
VD (k 
el-k a) 
In this case the 'flip-flop' model is used since the 
half-lives calculated for the intravenous and oral routes 
(terminal-linear portion of the concentration-time curves) 
are not equal. The terminal-linear portion of the 
concentration-time curve in this case generates absorption 
parameters, absorption rate constant (k a) and 
half-life 
of absorption (t ), and I (intercept on concentration axis, 
by extrapolation The remaining parameters were 
calculated as follows: 
VD FXO 
k 
el 
AUC tot 
where k 0.16 min- (from the intravenous el '2 
. experiments) 
AUCtot 
k1k1 1 aeI 
fraction of the dose reaching the systemic 
circulation, 
AUCtot - oral 1 100 
x-x 
AUCtot - intravenous 10 
the factor 10 is the dose correction factor 
(oral dose/intravenous dose) 
ka0.693 
ti 
C, FXO 
AUCtot 
for sublingual administration. Initially, the pharmacokinetic 
data was calculated by using the equations describing 
-119- 
intravenous administration (see Chapter 4). However, it is 
probably more realistic to interpret these concentration- 
time curves using the 'flip-flop' model for kinetics 
following oral administration, since half-life for the 
intravenous and sublingual routes are not equal. The 
tabulated data (Table 5.14) is calculated on the basis of 
the 'flip-flop' model; in Chapter 4, the sublingual data 
was calculated-using the equations governing intravenous 
administration, and assuming that absorption is rapid. 
Pharmacokinetics of Nitroglycerin 
The pharmacokinetics of nitroglycerin are 
characterised by relatively low plasma levels of the drug, 
a large volume of distribution (8.8-25.0 lkg-') and rapid 
elimination with a biological half-life in the male rat of 
the order of five minutes (ti, 3.2 - 6.7 minutes) and a 
total systemic clearance of 1.6 - 4.0 lkg-1 min-1 
(Tables 5.3,5.5,5.6,5.13 - 5.20, 'Fig. 5.2t 5.4,5.5, 
5.10 - 5.14). Comparison of Tables 5.19 and 5.20 show 
extensive variation, both within and between batches of 
animals, which accounts for the large standard deviation 
observed for most of the parameters measured. In all species, 
elimination of nitroglycerin followed first-order kinetics 
for a one-compartment model (Table 5.3,5.7 - 5.10,5.11; 
Fig. 5.2t 5.6 - 5-9), and this was independent of the dose 
administered (Table 5.6,5.10; Fig. 5-5). Older male rats 
(, *-, G months) showed no difference in pharmacokinetic 
properties from the other groups of male rats (,,, 8 weeks old). 
Comparison of the kinetics in the male and female 
rat (Table 5.3,5.4,5.12; Fig. 5.2,5-3) indicates a sex 
difference in the metabolism of nitroglycerin; in the 
female rat, the biological half-life is significantly longer 
N, male - 4.4 t 0.? minutes, female - ?.? t 1.2 minutes, 
p<o. ool), these rats have a greater volume of distribution 
(VDI male - 9.5 :t7.4 lkg-1, female - 18.9 ± 6.5 lkg-ll 
p<0.01), but total tystemic clearance (1.6-l.? lkg-lmin-1) 
was unaffected. A sex difference in half-life in rabbits 
(Table 5.10,5.12; Fig. 5-9) was not observed, although 
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there is an indication of a larger vol=e of distribution 
in the female rabbit (V D1 male - 44 
t 19 lkg-ll 
female - 55 
t 10 lkg-'); however, this was not statistically 
significant. 
Several routes of administration have been 
investigated (Table 5.2,5.3,5.13,5.14,5.20; Fig. 5.1, 
5.2,5.10), and these indicate that the intracardial route 
produces the greatest bioavailability, but rather a high 
value for half-life and a low value for volume of 
distribution; the intracardial route probably does not give 
a true reflection of pure drug elimination as the intravenous 
route wouldý since there may be leakage of the dose from 
the heart and subsequent reabsorption. Pharmacokinetics 
following oral administration (Table 5.13; Fig. 5.10) 
indicate that absorption was quite slow with a half-life 
of 30: tll minutes (k a 2" 
0.027 t 0.011 min-'), but an 
extensive 'first-pass' effect is undergone by nitroglycerin 
since the fraction of drug entering the systemic circulation 
was only - 5%. Similar values for the volume of distribution 
are obtained for intravenous, sublingual and oral routes of 
administration. The sublingual route of administration 
produced a similar bioavailability (area under the curve) 
to the intravenous route and the fraction of the dose 
absorbed was of the order of 85-96%; obviously sublingual. 
administration avoids the 'first-pass' effect suffered by 
an oral dose. If the fraction of the dose absorbed (F) is 
calculated using data interpreted on the basis of intravenous 
elimination kinetics, rather than 'flip-flop' kinetics, then 
a smaller value (-35%) is obtained. The 'flip-flop' model 
is probably more correct and leads to a value of 96,16 for F, 
but this is dependent upon the values chosen for kel and 
AUCtot (i. v. ); values of 0.16min-1 (k el 
) and 
313 ng min m1_1 (AUCtot-i. v. ) were used (Table 5.19) since 
these are representative of the average values for these 
parameters. Compare this with k el = 
0.1 min-' and 
AUC 560 ng min ml-1 (Table 5.20), this leads tot V. 
to a value for F of - 33% (using mean values for ka and Co 
from Table 5.20). Pharmacokinetics following sublingual 
-121- 
administration are probably described by the 'flip-flop' 
model which governs the pharmacokinetics of oral drug 
administration for compounds which are rapidly metabolised 
(i. e. where kel > ka)' In this case the value for half-life, 
-calculated from the terminal-linear portion of the 
concentration-time curves reflects absorption rather than 
elimination. It would thus appear that absorption by the 
sublingual route (tj = 14.3 ýý 3.4 min) is faster than 7 
absorption orally (tj =- 30 + 11 min). The data show far 
lower nitroglycerin plasma levels and bioavailability 
following an oral dose, compared with intravenous or 
sublinsual doses even though the dose used was ten times 
larger. 
A sustained7release oral preparation (Fig. 5.10B) 
appears to be a much better dosage form than a standard 
oral preparation; nitroglycerin plasma levels remained above 
1 ng/ml for up to 12 hours following an oral dose of sustac, 
whereas the standard oral dose produced plasma levels which 
dropped below 1 ng/ml within one hour. 
Species differences in the metabolism of nitroglycerin 
are shown in Table 5.7 - 5.10t 5.11 and Fig. 5.6 - 5.9; 
there appears to be a general trend for larger sized species 
to have a longer half-life, lower plasma levels and a 
greater volume of distribution; on the contraryt clearance 
was similar for each species except the ferret. The ferret 
exhibits higher plasma levels and a smaller volume of 
distribution than expected for this trend, shows a far 
greater bioavailability than*any of the other species, and 
a much lower systemic clearance (0.7 lkg-lmin-1 compared 
with /-2.4 lkg-lmin-1 for the other species) 
Half-life,, 
Hamster > Rat > Guinea-pig > Ferret > Rabbit 
VAume of distribution, 
Iý. Rabbit 
> Guinea-pig> Hamster > Rat'=Ferret 
Bioavailability, 
Ferret>> Rat > Hamster = Rabbit = Guinea-pig 
A plot of log (half-life) as a function of log (body weight), 
for male animals, was constructed and this shows a linear 
-122- 
relationship between half-life and body weight with a 
correlation coefficient of 0.975. (Fig. 5.15). 
Pharmacokinetics of Nitroglycerin in the Presence of Other 
Drugs 
There is little evidence for a drug interaction with 
any of the co-administered drugs (Table 5.15 - 5.18; 
Fig. 5.11 - 5.14). The half-life and systemic clearance 
for nitroglycerin were unaffected whichever drug was 
co-administered, but there is evidence for increased 
nitroglycerin plasma levels and a decreased volume of 
distribution, when quinidine sulphate was used (Table 5.17). 
However, statistical analysis of the data-showed these 
differences to be insignificant. 
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DISCUSSION 
Pharmacokinetics of Nitroglycerin in the Male Rat 
The elimination of nitroglycerin appears to follow 
first-order kinetics for a single compartment model, and 
'flip-flop' kinetics operate following oral administration. 
As one would expect for first-order kinetics, changing the 
administered dose of nitroglycerin has no effect on the 
biological half-life or volume of distribution. Nitroglycerin 
is rapidly metabolised and extensively distributed in the 
rat. The extensive distribution is undoubtedly due to the 
combination of the drugs lipid-solubility and ability to 
bind to tissue proteins; although binding to tissue 
proteins has not been investigated, Di Carlo and Melgar (1969) 
showed that nitroglycerin is extensively bound to rat plasma 
proteins (, 4-160% bound). 
The biological half-life, determined in the present 
studies, is of the order of five minutes and the volume of 
distribution is 10-20 lkg_1 with a total systemic clearance 
of 1.6 - 4.0 lkS_lmin_l. The analytical method used 
presently determines total drug in the plasma and thus gives 
a true reflection of the volume of distribution as compared 
with a method which determines only free (unbound) drug. 
Previous pharmacokinetic studies in animals have used the 
rat as the experimental model and investigated the intra- 
cardial and oral routes of administration (Yap and I. Fung, 1973) 
and have demonstrated a half-life similar to ours of 
4.2 1.5 minutes, although a smaller volume of distribution 
(3-0 0-9 lkg-') was observed. Following oral administra- 
tion, 'flip-flop' kinetics indicate an absorption half-life 
of 21.4 13.1 minutes and the fraction of the dose absorbed 
was 1.6 1.3%. Other studies (Johnson et al., 1972) using 
radiolabelled nitroglycerin administered intravenously, 
demonstrated that blood radioactivity constituted only a 
small fraction of the total dose (extensive distribution) and 
a half-life in the male rat of the order of one minute. This 
-124- 
is not consistent with the observations of either ourselves 
or Yap and Fung (1978)9'although support for such a short 
half-life has been indicated by Stein et al. (1980) using 
a large intravenous dose (2.6 mg/kg) of radiolabelled 
nitroglycerin; however, in the latter two studies the method 
of determining nitroglycerin was not very selective, 
involving extraction into petroleum ether as the only 
isolation step. 
Although, in the present studies, there was little 
evidence for a two compartment model which one might expect 
for a highly lipid-soluble drug such as nitroglycerin, when 
these are compared with the studies of Johnson et al. (19? 2) 
such an effect may be apparent. The latter experiments 
appear to have been conducted over a period of 2-3 minutes 
and show a distribution phase. with a half-life --, 20 seconds 
followed by a metabolism phase with a half-life of 
1-1.5 minutes. In the present studies, the first plasma 
samples were obtained at, --15 minutes (or occasionally at 
2-2.5 minutes); that is, we commenced the pharmacokinetic 
experiment at a similar time to the termination of 
Johnson's experiments. Perhaps this is evidence for a two 
Fig. 5.16 Two - Compartment Model - Intravenous 
Administration 
0 
0 
0 
Cd 
I 
r, ompartment model; the present studies may have monitored 
the terminal elimination phase (B), whereas Johnson et al. 
(1972) have monitored the distribution phase (A). There is 
-125- 
2.51 5 10 
Time (min) 
some evidence for this; when plasma samples were determined* 
at 2-2.5 minutes after intravenous administration 
(see Fig. 5.3,5.4) much higher nitroglycerin plasma levels 
were observed than expected. If a two-compartment model 
does operate, then the actual kinetics in the rat may 
involve a distribution phase and an elimination phase with 
half-lives of A,, 1.5 minutes and, ---5 minutes respectively. 
Extensive variation both within and between batches 
of animals is apparent for initial plasma levels, volume of 
distribution and half-life (half-life can vary from . 4-, 3 to 
,,.,, 8 minutes in male rats). This has been a common finding 
in nitroglycerin pharmacokinetic studies (Yap and Fung, 1978; 
Maier et al. 11980) and may be due to variation in hepatic 
enzyme activity. Maier et al. indicated plasma levels in 
the range 37 - 475 ns/ml (c9efficient of variation of 6856), 
following a 100 mg/kg oral dose of nitroglycerin. Such 
variation necessitated the use of a control group in all 
the present experiments where comparisons were to be. made 
(e. g. the drug interaction studies). 
An effect of age on the pharmacokinetics of 
nitroglycerin was not apparent. For such a difference to be 
observed it is better to use much older rats (1 -2 years 
old), but these were not available at the time of this study. 
However, the data does indicate that the size of the rat-has 
no effect on the pharmacokinetics of nitroglycerin. 
Comparison of Routes of Administration on Nitroglycerin 
pharmacokinetics 
Four routes - intracardiall intravenous, sublingual 
and oral'have been investigated. The intracardial route 
produces the highest'nitroglycerin bioavailability but is 
not an accurate method of administration since, when the 
dosing needle is removed from the heart, it is likely that 
some of the drug leaks out and is continuously re-absorbed 
throughout the period of the experiment. This may result 
in elevated nitroglycerin plasma levels (replenishment of 
metabolised drug) and a longer half-life than would be 
-126- 
produced by intravenous administration, and this is shown 
in the tables. 
Sublingual and intravenous routes can be compared, 
as the same sampling methodology was used in these 
experiments. If nitroglycerin had been administered 
sublingually in the usual tablet form, absorption would be 
quite rapid and a half-life similar to that for intravenous 
administration would be expected. It is likely that the 
propylene glycol (vehicle used for nitroglycerin) hinders 
drug absorption and leads to 'flip-flop' kinetics 
(Gibaldi and Perrier, 1975) being displayed for this route. 
The #flip-flop' model is usually applied to oral administra- 
tion'of drugs that are very rapidly eliminated, or for 
dosage forms that slowly release drug in an apparent first- 
order fashion. In 'flip-flop' kinetics, the absorption rate 
constant is smaller-than the elimination rate constant and 
interpretation of concentration-time curves leads to 
evaluation of absorption rather than elimination character- 
istics. Applying 'flip-flop' kinetics to sublingual 
administrationt indicates that absorption occurs with a 
half-life of -jl4 minutes and is significantly faster than 
oral absorption (ti. 30 minutes). 
Bioavailability for the sublingual route is similar 
to that for the intravenous dose; about 961j16 of the sublingual 
dose enters the systemic circulation. One might expect a 
much greater bioavailability for the parenteral route, but 
this does not'appear to be the case and is probably the 
result of the high lipid-solubility of nitroglycerin which 
facilitates efficient absorption into the systemic 
circulation. When one considers the simplicity of sublingual 
administration compared to intravenous administration there 
is no doubt that this is the most useful route, and these 
studies provide support, on the basis of pharmacokinetics, 
for this use of a well-established route which has previously 
been used on the basis of pharmacological or therapeutic 
response. 
A controversy exists about the efficacy of the oral 
route of administration, which is used primarily for the 
prophylaxis of angina. Needleman (1976b) has claimed that 
orally administered organic nitrates are rapidly degraded 
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by the liver and so cannot reach therapeutic plasma levels. 
This is supported by the studies of Stipe and Fink (1973) 
who found that less than 10% of patients with angina 
pectoris benefitted from oral administration of organic 
nitrates. However, Krantz and Leake (1976) and Winsor and 
Berger (1975) found that 47% of patients had significantly 
fewer and less severe attacks of angina following orally 
administered sustained-release nitroglycerin tablets. 
Jerie (1976) has provided corroborating evidence for the 
latter view with orally administered isosorbide dinitrate. 
our results suggest that although the majority of orally 
administered nitroglycerin undergoes a 'first-pass' effect, 
if a sufficiently large dose is administered then a useful 
therapeutic response may be obtained. The results obtained 
using sustac indicate that such a sustained-release 
preparation maybe, capable of maintaining this therapeutically 
effective plasma level for long time periods. 
Fig. 5.17 compares the two clinically used routes of 
administration, sublingual and oral: 
Fig. 5.17 Effect of Route of Administration on the Fate of 
Nitroglycerin 
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After. oral administrationpintact (parent) organic nitrate is 
absorbed from the gastro-intestinal tract and is delivered 
through the portal vein blood to the liver where it is 
metabolised by glutathione-organic nitrate reductase. The 
inactive metabolites are excreted in the urine. Sublingual 
administration permits exposure of the coronary and Peripheral 
vascular smooth muscle to intact (parent) organic nitrate 
ester prior to inactivation in the liver, kidney and blood. 
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Theýlfirst-passl effect, observed presently, allows 
only 5% of the administered dose to reach the systemic 
circulation. Yap and Fung (1978) showed a similar 
'first-pass' effect (, A-, l. 6? o' reaching the systemic 
circulation). These workers demonstrated a good correlation 
between the tfirst-pass' effect and the activity of organic 
nitrate reductase of liver, but not of other tissues. No 
metabolism by the intestine was observed and so they 
concluded that pre-systemic elimination of nitroglycerin 
after oral administration is primarily hepatic, and the 
activity of this enzyme governs the 'first-pass' effect 
which is observed. However, the present studies (Chapter 6) 
suggest a significant contribution from intestine towards 
this 'first-pass' effect. 
Another route of administration receiving much 
attention at the moment (Horhota and Fung, 1979) is topical 
application of nitroglycerin. The absence of organic nitrate 
reductase activity in skin has been demonstrated (Maier, 
et al., 1980) and this route is hoped to rival sublingual 
administration for the treatment of angina pectoris. In 
fact, good absorption and high plasma levels have been 
demonstrated after topical applications of this dosage form, 
and there is growing evidence for its therapeutic efficacy. 
Effect of Sex Differences on the Pharmacokinetics of 
Nitroglycerin 
A sex difference in the metabolism of nitroglycerin 
in the rat is apparent. Female rats have a longer half-life 
(p <0.001) and3arger volume of distribution (p<0.01), but 
a similar systemic clearance. Although a more similar 
half-life for male and female rats is shown in some tables 
(e. g. Table 5.18), this may be explained by the different 
sampling methodology used; even so a difference is still 
apparent (0.1<p<0.2). The larger volume of distribution 
for female rats may be due, at least in part, to the greater 
proportion of body fat in the female compared with the male; 
nitroglycerin is a highly lipid-soluble drug. In rats, sex 
differences in drug metabolism are very Prominent (Kato, 
et al. 1970). Females sleep considerably longer than males 
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after a given dose of hexobarbital because they metabolise 
the drug more slowly, 'and such differences have been 
correlated with the levels of sex hormones (Streicher and 
Garbus, 1955). 
Assuming that organic nitrate reductase is in fact 
glutathione-S-transferase (see Chapter 6) then there is 
some correlation between the sex difference in half-life 
and the activity of this enzyme. Differences in hepatic 
and renal GSH-S-transferase activity toward some substrates 
between male and female rats have been reported (Chasseaud, 
19? 9). Male rat liver apparently possesses up to three 
times more activity towards certain substrates than female 
rat liver (Darby and Grundy, 19? 2; Kaplowitz et al., 19? 5; 
Hales and Neims, 19? 6) whereas the converse mainly occurred 
in rat kidney (Clifton et al., 1975). Sex differences in 
GSH-S-transferase activity have also been shown in other 
rodents, such as the mouse (Hayakawa et al., 19? 4) and in 
the non-rodent, the tree shrew; females being more active 
towards the substrate 112-dichloro-4-nitrobenzene. However, 
no sex difference has been observed in humans (Darby, 1973). 
A sex difference in rats has also been observed for the 
serum GSH-S-transferase with males displaying 60% greater 
activity than females. 
-Curiously sex differences in the rates of drug 
metabolism have been observed in few species other than the 
rat. A difference in half-life between male and-. 41emale 
rabbits is not apparent, although there is some evidence 
for a greater volume of distribution in the female. If a 
sex difference in the plasma levels of nitroglycdrin exists 
asýa function of body fat, then this may be of importance 
in therapy and design of dosage-regimens. Few reports of 
sex differences in, human pharmacokinetics exist (Guidicelli 
and Tillement, 1977) but those which do, often involve-an 
effect on plasma, drug concentration rather than on 
half-life. 
Short, Dacre and Lee (19? 7) using in vitro rat liver 
homogenate systems demonstrated the absence of a sex 
difference in the activity of organic nitrate reductase. 
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An alternative for the observed in vivo pharmacokinetic 
difference may therefore involve differences in the 
availability of the drug for the metabolising enzymes as 
a result of a more extensive distribution in the female. 
There is also the possibility that the difference in 
activity of the extra-hepatic metabolising activity 
(e. g. serum enzyme, kidney;. see Chapter 6) may account 
for the sex difference in half-life. 
Species Variation in the Pharmacokinetics of Nitroglycerin 
Species variations in the rates of drug metabolism 
often follow a general trend where the larger animal 
metabolises more slowly; this appears to be the case for 
nitroglycerin. Such a trend is usually observed for drug 
metabolism involving mono-oxygenases (e. g. the cytochrome 
P-450 mixed function oxidase system)and, for this type of 
metabolism, a logarithmic plot of half-life or enzyme 
activity against body weight is linear. This was the case 
for nitroglycerin. It is generally accepted that the major 
cause of such species variation is dependent on body area 
as a function of body weight; thus, smaller animals have 
a greater relative body surface area than larger animals 
as a function of weight. 
The good correlation between half-life and body 
weight is perhaps surprising for nitroglycerin since this 
drug appears to be metabolised by a number of enzymes. 
There are at least six hepatic GSH-S-transferases, each 
showing different substrate specificities. In blood there 
are two independent enzymes, one in plasma the other in 
erythrocytes, which exhibit organic nitrate metabolising 
activity; one, requires no co-factors, the other is a 
further transferase. Further differences arise since a 
species variation in the plasma enzyme occurs; iodoacetamide 
has been shown not to inhibit the degradation of nitro- 
glycerin in ferret and rabbit plasma. There thus appears 
to be a multiplicity of enzymes--which vary with the species, 
and it is surprising that such a clear half-life to body 
weight relationship exists. 
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Utilising this relationship to predict the 
biological half-life in man (61 minutes),, one would 
expect a far slower elimination than has been observed. 
Studies to date indicate a half-life in man very similar 
to that in the rat and hamster (1.9 - 4.4. minutes), 
(Armstrong et al., 1979 and 1980a). The accuracy, of the 
latter determinations may be very poor; determination of 
human plasma levels, which are very low, necessitates the 
use of available assay techniques at their lower limit of 
sensitivity. 
Some information concerning the activities of 
GSH-S-transferase in a number of species is available. 
Hepatic GSH-S-transferase activity has been detected in 
the livers of all the species so far examined-(Chasseaud, 
1979). Enzymic activity in the livers of laboratory 
animals is generally greater than in those of humans. 
One fairly detailed study of GSH-S-transferase activity 
towards 1-chloro-2,4-dinitrobenzene, however, showed that 
the enzymic activity in rat and human liver was similar 
(Darby, 1973). In laboratory animals, observed trends in 
hepatic GSH-S-transferase activity correlate quite well 
with the present results for half-life: 
transferase activity (liver), 
Rat> Mouse> Guinea-pig> Hamster> Rabbit> Monkey 
half-life j 
Hamster> Rat> Guinea-pig> Ferret> Rabbilt 
transferase-activity (serum), 
Rat> Guinea-pig> Rabbit 
Only the hamster is anomalous. The mouse appears 
to be less active than the rat with respect to these 
enzymes; although, in mice the transferases are very active 
in other tissues such as kidney and the total transferase 
activity of mice does exceed that of rats. This is not so 
for the hamster, but serum activity which may be a major 
influence on biological half-life, has not been investigated 
in this species. 
Thus the present studies lend support for organic' 
nitrate reductase activity to be a property. -of the 
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GSH-S-transferases and species variation in half-life 
appears to be due at least in part, to species variation 
in the total activity of these enzymes. Although 
transferase activity in blood is only 1% of the hepatic 
activity (Mukhtar and Bend, 1977); the large volume of 
blood must contribute significantly towards nitroglycerin 
elimination.. The only study of species variation on the 
activity of hepatic organic-nitrate reductase activity has 
been conducted in vitro, by Short, Dacre and Lee (1977), and 
indicated the lack of a significant species difference in 
the activity of this enzyme although human and mouse 
activity appeared to be lower than that found in the rat, 
rabbit, dog and monkey. Significant differences between 
the proportion of isomers of glycerol dinitrate in various 
species was apparent however. 
A trend in volume of distribution (on a lkg basis) 
was also apparent. The volume of distribution increases as 
the size of the species increases, except in the ferret 
which has a higher initial plasma level (lower volume of 
distribution) than expected and a much lower systemic 
clearance. The ferret is a more muscular animal compared 
with the other species. Therefore as less fat is available 
for this lipophilic drug to distribute into, higher plasma 
levels and a decreased volume of distribution are observed. 
It is likely that for a highly lipid soluble drug 
such as nitroglycerin$ the availability of the drug for 
metabolism may have an effect on its elimination 
characteristics. Thus species differences are likely to be 
the result of a combination of the variation in enzyme 
activity and the relative proportions of lean body mass, and 
adipose tissue present in the particular species. Total 
systemic clearance for all these species (, - 2.4 lkg-lmin-1), is 
faster than hepatic blood flow (which is 1.5 1 min-lkg liver wt-1 
and for the rat, isA., 70-'ml kg-lmin-1) (Boxenbaum, 1930). 
This suggests a major contribution from extrahepatic, 
metabolism and this extrahepatic activity probably resides 
in the blood and to a lesser extent in the kidney (Chapter 6). 
Since clearance is similar in each species, it is likely that 
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the controlling factor for species variation in biological 
half-life is the magnitude of the volume of distribution. 
The volume of distribution increases (lkg-l basis) as the 
size of the species increases, clearance (Ikg-lmin-1 basis) 
is unchanged and thus half-life increases. The only 
non-rodent examined (ferret), differed markedly in volume 
of distribution and clearance, and this may reflect a 
variation in tissue composition and extrahepatic organic 
nitrate reductase activity. 
Effect of Co-administration of Drugs on the Pharmacokinetics 
of Nitroglycerin 
There is no evidence for a drug interaction with any 
of the co-administered drugs, apart from slightly increased 
nitroglycerin plasma levels, and a decreased volume of 
distribution, when quinidine sulphate was used. This lack 
of effect on elimination rate is 
_perhaps 
not surprising, if 
nitroglycerin is metabolised by an enzyme of the soluble 
fraction (GSH-S-transferase); the other four drugs are 
metabolised by microsomal enzymes. There is, however, 
evidence that compounds such as phenobarbital and SKF-525A 
(an inducer and an inhibitor of microsomal drug metabolism, 
respectively) do have pronounced effects on nitroglycerin 
metabolism. Phenobarbital pretreatment has been shown to 
enhance nitroglycerin metabolism by rat liver homogenates 
(Needleman and Krantz, 1965) and accelerate excretion of 
metabolites and decrease peak nitrite ion plasma levels in 
rabbits (Bogaert et al., 1970). Bogaert et al. (19? 0) also 
reported that SKF 525A pretreatment inhibited organic 
nitrate, metabolism in dogs and rabbits, and increased theý 
plasma levels of nitroglycerin. A reciprocal effect, that 
of nitroglycerin inhibition of pentobarbital metabolism 
(in ýLitro)has been shown by Di Carlo et al. (1967). Since 
there is an obvious influence by compounds which are 
metabolised by cytochrome P-450 on nitroglycerin'metabolism, 
an effect due to the co-administered drugs (also metabolised 
by cytochrome P-450) is possible. 
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Many drug interactions which lead to changes in 
pharmacokinetic properties are the result of competition 
of the two drugs for metabolism by the cytochrome P-450 
drug detoxification system. As biotransformation of 
nitroglycerin is believed not to be mediated by cytochrome 
P-450, an effect having this cause is improbable. It is 
more likely that the co-administered drug may have caused; 
a) direct inhibition of organic-nitrate reductase 
b) an effect on the circulation, for example. to increase 
(or decrease) blood flow (and thus drug supply) to the 
sites of metabolism 
c) binding; the co-administered drug may become bound to the 
same proteins which are required for binding of nitroglycerin 
to tissue and plasma proteins. In this case, distribution 
of nitroglycerin would be affected and higher plasma levels 
may be observed. 
The third possibility - protein binding - may well 
be the cause of the two fold higher nitroglycerin plasma 
levels observed after quinidine sulphate co-administration. 
One recent report (Stein et al., 1980) of the direct 
inhibition of organic nitrate reductase has been described 
in Chapter 4. In this case a drug interaction between 
nitroglycerin and both cephalothin or probenecid, due to 
direct inhibition of the enzyme, occurred which led to a 
significant increase in the biological half-life for 
nitroglycerin. 
Critical Appraisal of the Methodology 
Use of Anaesthetic. Use of anaesthetic appears not to have 
had an effect on the pharmacokinetics of nitroglycerin. 
Yap and Fung (1978) used ether as anaesthetic before 
administering nitroglycerin intracardially and then allowed 
the animal (rat) to regain consciousness before taking blood 
samples by orbital sinus puncture. Using this very temporary 
form of anaesthesial these workers obtained a half-life of 
4.2 t 1.5 minutes which is similar to the results presented 
here (e. g. ti *ý 4.4 t 0.7 min. - Table 5-3), and this is 
good evidence for the viability of the present e)Teriments 
utilising an anaesthetic. 
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Methods of Blood Sampling. The serial'cardiac puncture 
technique could be criticised on several accounts: 
a) a stress or shock effect due to repeated insertion of 
a needle into the heart 
b) extensive leaking of blood from the heart 
c) damage to the heart muscle. 
, 
However, the rat appears to be very resilient with 
respect to-a) and serial cardiac puncture can be carried 
out over twenty times in 45 minutes without the animal 
dying. Ifhen the thoracic cavity is opened after six 
cardiac punctures, little blood is present; apparently 
after the first cardiac puncture a clot forms outside the 
heart through which subsequent punctures are made. This 
technique is useful for obtaining small blood samples with 
relative easeq although artery cannulation is the classical 
approach to such studies. However, one would also expect 
a stress or shock reaction when this technique is used since 
major sugery is involved in isolating the carotid artery. 
Experience with the present experiments indicates that more 
mortalities occur upon administration of nitroglycerin , 
following artery cannulation, than using cardiac puncture. 
No pharmacokinetic differences are apparent between the two 
sampling procedures; this at first sight may be rather odd 
since the inhomogeneity of blood is well known, although the 
pronounced inter-animal variations observed may account for 
the lack of this effect. 
One might criticise cannulation of a common carotid 
ar tery when conducting a sublingual. experiment, but it is 
well known that when a common carotid artery is occluded, a 
collateral circulation, capable of compensating for this 
loss of blood flow to the head, is established within a 
very short period. 
Summar7- The elimination of nitroglycerin follows first- 
order kinetics for a one-compartment model. Nitroglycerin 
is extensively distributed, exhibiting a large volume of 
distribution (10-20. lkg-') and is rapidly metabolised with 
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a half-life of about 5 minutes and systemic clearance of 
, --2.4 lkg-1min-1. A sex difference is apparent in the rat 
but not in the rabbit, and species differences occur whereby 
the smaller species eliminates nitroglycerin more quickly 
than the larger species. The sublingual route compares 
favourably with the intravenous route but the oral route 
is very poor due to a 95% 'first-pass' effect. The 
prolonged-release preparation, sustac, provides a superior 
dosage form to a standard oral dose of nitroglycerin. No 
effect on the pharmacokinetics of nitroglycerin occurs when 
propranolol, quinidine sulphate, digitoxin or theophyline 
are co-administered. 
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CHAPTER 6 
LOCALISATION AND CIURACTERISATION OF 
ORGANIC NITRATE REDUCTASE 
INTRODUCTION 
As described in Chapter 1, there is conflicting 
evidence about the subcellular location, tissue sites and 
the nature of organic nitrate reductase. 
All previous studies on organic nitrate reductase 
activity have been conducted by indirect, or insensitive, 
methods - for example, by following the disappearance of 
NADPH or by monitoring production of N07- In the 29 
present studies, using g. l. c. to directly monitor 
substrate consumption, an obvious improvement is achieved. 
In the present studies it is proposed: 
1) to determine the subcellular location of metabolism 
2) to determine organic nitrate reductase activity in 
different tissues (liver, heart, kidney and intestine) 
and to correlate this with GSH-S-transferase activity. 
to investigate the metabolism of nitroglycerin by 
plasma. 
4) to study the response of organic nitrate re-ductase, 
GSH-S-transferase and GSSG-reductase to inducers of 
the mixed function oxidases such as phenobarbital and 
3-methylcholanthrene. 
to investigate the effect of nitroglycerin on 
GSH-S-transferase activity, using the substrate 
1-chloro-294-dinitrobenzene, since this appears to be 
the most active, it is easy to monitor and is 
conjugated with GSH by all the GSH-S-transferases of 
rat liver, albeit with differing relative rates. 
This series of experiments is designed-to clarify 
the situation concerning nitroglycerin biotransformation. 
By these studies, it is intended to show the tissue and 
intracellular site(s) for nitroglycerin metabolism, and 
to determine whether organic nitrate reductase is a 
property of the GSH-S-transferase enzymes. 
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EXPERITIMTTAL 
MATERIALS 
Glutathione (both oxidised (GSSG) and reduced 
(GSH) forms) was purchased from the Sigma Chemical 
Company (Poole, Dorset). Ethanol 68 0/ 
P 
(9655) was 
obtained from James Burroughs Ltd. (London) and 
3-methylcholanthrene from Aldrich Chemicals Ltd. 
(Gillingham, Dorset). All the remaining chemicals and 
solvents were "AR"grade from the B. D. H. Ltd. (Poole, 
Dorset). Nitroglycerin was synthesised as described 
in Chapter 2. 
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MBTHODS 
In all experiments, 3-4 male Wistar-albino rats 
(160-1859) were used. 
Subeellular Fractionation of Liver 
Preparation of the Homogenate (111: 7) 
Three rats were killed-by cervical dislocation and 
their livers quickly removed into ice-cold 1.1555 KC1 
solution. The liver was blotted dry, weighed and 59 placed 
' ice-cold 0.25M sucrose (containing 5mrl tris), in 15 MI oL 
pH7.4. The liver was then minced with scissors and 
homoSenised in a Potter-Elvehjem homogeniser (with cooling 
jacket) using three complete strokes. The homogenate was 
transL. erred to a measuring cylinder and made up to 25 ml, 
in this way a 201iý homogenate (designated H) was prepared. 
PreDaration of the Nuclear Fraction (N). 
The homogenate was placed in a 50 ml centrifuge 
tube and centrifuged for 10 minutes at 2,000 r. p. m. 
(400 x g) in a swing-out rotor in a bench centrifuge in 
the cold room. The supernatant was poured off into an 
ice-cold flask, and the pellet re-suspended in 5 ml- of 
0.2514 sucrose - 5rrd'l tris using a hand operated homogeniser. 
It was then re-centrifuged for 10 minutes at 400 x S. The 
supernatants-were combined and the pellet re-suspended in 
0.25M sucrose - 5mM tris using a hand operated homogeniser. 
Preparation of th-e-Mitochondrial Fraction (M). 
The combined supernatants were centrifuged for 10 0 
minutes at 6,000 r. p. m. (4,000 x S) in the 8x 50 ml angle 
rotor of an M. S. E. High Speed 18 centrifuge. The 
supernatant was taken off into an ice-cold flask and the 
pellet re-suspended in 0.25M sucrose -. 5mM tris. 
Preparation of the Lysosomal Fraction (L). 
The supernatant from the previous step was centri- 
fuged for 15 minutes at 12,000 r. p. m. (1?, Ooo % S) in the 
1I. S. E. High Speed 18 centrifuge. The Supernatant was 
decanted and the pellet washed with 4 ml. of 0.25M sucrose - 
5mN tris and then re-centrifuged for 15 minutes at 0 
177000 ý-. S. The supernatants were combined and the pellet 
re-suspended in 0.251, T sucrose - 5rim tris. 
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Preparation of the Microsomal Fraction (Mic) and 
Soluble Fraction (S) 
The supernatant from the previous step was placed 
in a 25 ml centrifuge tube of an 8x 25 ml high speed 
angle rotor. It was then centrifuged for 60 minutes at 
40,000 r. p. m. (105,000 x 9) in an M. S. E. Super-Speed 50 
centrifuge. The supernatant (S) was decanted and the 
pellet re-suspended in 0.25M sucrose - 5mm tris using a 
Potter-Elvehjem homogeniser at 2,400 r. p. m. (Mic). 
The following enzymes were assayed in each 
fraction: Organic nitrate reductase, succinate dehydro- 
genase, acid phosphatase, glucose-6-phosphatase and 
glucose-6-phosphate dehydrogenase. 
Subcellular Fractionation of Heart and Kidney 
Three rats were used; in each case, the heart and 
kidney were washed, weighed and homogenised (20%) as 
described above, except that more extensive homogenisation 
was required for these tougher tissues (5-6 strokes). 
Centrifugation was achievbd as described above, 
although smaller rotors (10 x 10 ml angle rotors) were 
used. The nuclear fraction was separated and discarded. 
Mitochondria and lysosomes were not separated from 
microsomes; centrifugation for 60 minutes at 40,000 r. p. m. 
of the post-nuclear supernatant, produced the soluble 
fraction and a pellet consisting of mixed M, L, and Mic 
fractions. This pellet was re-suspended in 0.25M sucrose- 
5mm tris- 
Subcellular Fractionation of Intestinal (Mucosal) Cells 
This was-achieved using the method of Shirkey 
et al., (19? 9),. Approximately 60 cm of intestine (the 
section duodenum to ileo-caecal valve) was removed from 
each of three rats into ice-cold 0.9% NaCl - O. lM tris 
pH 7.49 and fat and pancreas trimmed from the surface of 
the gut before everting 3x 20 cm strips over metal rods. 
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These were then vibrated for 1 minute in 0.9% NaCl - 
O. lM tris (200 ml) at a frequency of 50 Hz to remove 
mucous. The resulting solution was discarded and the 
everted gut then vibrated in 200 ml of 0.14M NaCl - 
5mM EDTA - O. lM tris, pH7.4 for 30 minutes. The 
resulting suspension was placed in tared centrifuge 
tubes and centrifuged at 1,000 xg for 2 minutes in a 
bench centrifuge in the cold room. The supernatant was 
discarded and the pellet (mucosal cells) weighed; 
approximately 2g of cells were obtained. The volume was 
adjusted to 25 ml by suspending the pellet in 9 ml of 
75mM sucrose - O. lM tris, pH7.4 and homogenising (10 
strokes) in a Potter-Elvehjem homogeniser, and then 
adding 9 ml of 0-52M sucrose - O. lM trisq PH7.4 and 7 ml 
of O-3M sucrose - O. lM tris, pH7.4. Fractionation of the 
homogenate was achieved as described for heart and kidney. 
The following enzymes were assayed in all three 
tissues: organic nitrate reductase and glutathione-S- 
transferase. 
General Considerations 
All centrifugation stages were conducted at 0- 40C, 
and re-suspension of pellets was made on a 2.5 ml/S fresh 
weight basis. At each stage the total volume of each 
fraction was noted. From each fraction, aliquots (up to 
1.5 ml) were removed for enzyme and protein assays. 
Incubation Systems and Assay Procedures 
Succinic dehydrogenase - marker for mitochondria. 
The assay procedure of Pennington (1961) was used. 
'Two incubations were required for each tissue fraction, 
one for the test incubation, the other for the tissue blank. 
All tubes were kept on ice until commencement of the 
incubation period. 
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The incubation system consisted of 
tissue fraction (diluted 
20 times) 
0.2M potassium phosphate 
buffer, pH7.4 containing 
INT* (1 . 25 mg/ml) ................. 
0.31-1 sodium succinate in 
buffer ........................... 
0-3M sodium malonate in buffer 
Total Volume 
ml. added to 
Test 
0.50 
0.25 
0.25 
Blank 
0.50 
0.25 
0.25 
1.00 ml 
* INT - 2-(p-iodophenyl)-3-(p-nitrophenyl)-5- 
phenyltetrazolium chloride. 
Following addition of substrate, the solutions were 
mixed and incubated for 10 minutes at 37 0C in a shaking 
water bath. Termination of the incubation was achieved by 
addition of 6 ml. of a mixture of 96jZ ethanol/ethylacetate/ 
101, ýý trichloroacetic acid (proportions 13/20/2). After 
thorough mixing the solution iý, ras centrifuged for 5 minutes 
at full speed in a bench centrifuge, to remove denatured 
protein, and the absorbance of the organic phase 
determined at 490r=i. Formation of product in this reaction 
was determined by assuming an extinction coefficient, of 
20,000 ! -1 cm 
Total acid-- 2hosphatase - marker for lysosomes. 
The incubation system for this assay was based on v 
the procedure of De Duve e-'- al., (1955). The tissue E-U 
fractions were diluted twenty-fold with 15ý Triton x 100 in 
0.25M sucrose - tris (5mM) pH7.4 in order to degrade the 
lysosomal membranes. To 0.1 ml of diluted tissue fraction, 
was added 1 ml. Of 0-0075M p-nitrophenylphosphate in 
0.09M citrate buffer, pH4.8, and the mixture incubated for 
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ten minutes at 370C in a shaking water bath. The reaction 
was terminated by addition of 5 ml. of 0.1M NaOH and the 
absorbance determined at 4-00nm, against a blank which 
' 0.1 ml of H20 taken through the above consisted o"L 
'raction. S#table procedure in place of diluted tissue L 
standards were prepared by adding 20-100/cLI of p-nitrophenol 
(l mg/ml) to 1 ml of H20 and 5 ml of 0.1M NaOH, and formation 
of product in the incubations determined directly from 
this standard curve. 
Glucose-G-phosphatase - marIcer for microsomes 
Determination of this enzyme was achieved by two 
procedures, that of Hinton et al. (1970) and a modified 
procedure described by Temple (1980) which involved 
addition of fluoride to the incubation system in order to 
inhibit acid phosphatase. 
Three tubes were used for each fraction, one for 
test assay, one for test assay plus fluoride and one for 
the tissue blan1%. 
Incubations consisted of: 
ml. added 
tissue fraction (diluted 20 times) ......... 0.5 
0. dimethyl glut arat e buf f er 
pH6.4 coin", aining 12.5miM EDTA t 6mM NaF ..... 0.4 
(pre-incubation for 10 minutep) 
0.051-1 glucose-6-phosphate (or H 20) ......... 0.1 
Total Vol=e 1.0 ml 
On addition of substrate, incubations were for 30 
minutes at 370C in a shaking jiater bath. The tissue 
blan]-c used water (0.1 ml) rather than tissue, and the 
substrate blaric used water (0.5 ml) in place of buffer 
and substrate. The reaction was terminated by addition of 
1.5 ml of ice-cold 6% trichloroacetic acidl. precipitated 
protein .. $as centrifuged off and the entire supernatant was 
submitted for estimation of its phosphate content. 
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Assay of inorganic phosphate. To the entire supernatant 
was added 3 ml of 0.65 ammonium molybdate in 5,55 perchloric 
acid and 1 ml of 0.2,15 ascorbic acid solution (prepared 
freshly). The resulting solution was thoroughly mL-. ed 
.0 
and left at room temperature for 30 minutes, whereupon 
the absorbance was determined at 700nm. 
Blan2c, and standards consisted of 0-1.0 ml of 
KH2 P04 solution (136/ag/ml) made up to 1.0 ml. with water. 
1.5 ml of 6/06 trichloroacetic acid was added and these 
solutions processed as described above. 
Glucose-6-phosphate dehydrogenase (G-6-PDH) - marker for 
soluble fraction. 
The assay system used here was baseýl on the method 
of I-lar. '^-. s (1956). The incubation system consisted of: 
ml. added to 
0.25M glycylglycine buffer pH7.6 
O''M Ma'2 
0.01M glucose-6-phosphate ............. 
ITADP (1 mg; ý, /ml) ........................ 
or KC1 (1-150) ....................... 
liver fraction (diluted 1: 1 with KC1).. 
Total Volume 
Test Blanic 
0.5 0.5 
0.5 0.5 
0.1 0.1 
1.0 - 
- 1.0 
0.2 0.2 
2.3 ml. 
Incubations were commenced by addition of substrate 
and the reaction (absorbance change) followed aGainst time 
at 340 nm using a recording spectrophotometer; quartz 
cuvettes were used. On addition to the cuvette the 
homogenate and nuclear fraction were too turbid to permit 
assay of this enzyme. 
Organic nitrate reductase 
The incubation system used here was essentially 
that of, Needleman and E'rantz (1965) as modified by Short 
et al. (1977) and consisted of: 
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added 
? 5m!,, potassium phosphate buffer, pH7.4 .... 1.3 
160 mM GSHI. IKCN in buffer .................. 0.1 
20TnI. I nitroglycerin in aqueous DIISO ........ 0.1 
undiluted tissue fraction ................. 0.5 
Total Volume 2.0 ml 
Incubations were commenced by addition of 
substrate and conducted for 10 minutes at 370C in a 
shaking water bath. Termination of the reaction was 
accomplished by protein precipitation using 0.5 ml of 
51c6; HgCl 2 solution. ýControl incubations contained 
homogenising medium instead of the tissue fraction and 
control assays were conducted in triplicate. After 
suitably diluting aliquots of the incubation mi. -Ictures, 
nitroglycerin content was determined by g. l. c. using, the 
procedure described in Chapter . 
3, 
Glutathione-S- transferases 
The procedure described by Jalcoby and co-workers 
(1974,1975) using 1-chloro-2,4-dinitrobenzene (CDIM) as 
substrate was used. The incubation system consisted of: 
ml. added 
lOrrS reduced slutathione (GSH) ............ 0.1 
0.114 potassium phosphate buffer, pH6.5 .... 0.8 
tissue fraction (diluted up to 200 times 
for liVer) .... 0.1 
Total Volume 1.0 ml 
Incubations were commenced by addition of 20/4cl 
,) and the absorbance increase of 50mM CD1TB, in ethanol (9615o 
at 340nm follot., ied with time in a recording spectrophoto- 
meter against a reference cuvette which contained buffer 
in place of GSH. T"he incubation temperature was maintained 
at 200C. Controls contained homogenising mediun rather 
'ract than tissue L L.. ion. 
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The extinction coefficient of the reaction product 
iý, ras determined by monitoring the total conversion of fixed 
amounts of CDITB at several concentrations (not exceeding 
the GSH concentration), and this oras used in calculation 
of the rate of reaction (product formation). 
Glutathione reductase 
The procedure of Racker (1955) was used. The 
incubation system consisted of: 
ml. added 
O. lM potassium phosphate buffer, pH7.6 .... 0.7 
0.0011A NADFH .............................. 0.1 
Zý oxidised glutathione (GSSG) ............ 0.1 
soluble fraction (undiluted or diluted 
two times) .... 0.1 
Total Volume 1.0 ml 
The reaction was initiated with GSSG and the 
absorbance change at, 340= lollowed in a recording 
spectrophotometer aSainst a reference which contained 
buffer in place of GSSG. Control incubations contained 
homogenising medium rather than soluble fraction. 
C77tochromes P-450 and b 
. 11 
The method employed was essentially that of 
Ullrich (1969). Equal volumes of microsomal suspension 
(2-5 ril containing approximately 2 mg protein/ml in 
H 0- 31-1 Na2l": 'O LL/KH2PO4 buffer, PH7-6) were added to two 
matched cuvettes. INADH (5 /419 10 mg/ml of buffer) was 
added to the test cuvette, mixed and the difference 
spectrum for cyt. b 5 recorded (390-430nm). A few granules 
of sodium'dithionite were added to both cuvettes to 
reduce cyt. P-450, and the test euvette gently gassed with 
carbon monoxide for about 30 seconds. The difference 
spectrum for cyt. P-450 was then recorded (430-500'. 1m). The 
amounts of cytochromes b5 and P-450 in the samples were 
calculated using extinction coefficients of 
'-lcm-l(E424-2409) and 9l-riM-lcm-l(E450 -E 500)' respectively. 170mlrL 
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Ethox7resorufin-0-de-ethylase 
The method used for this assay was that of Burke 
and Mayer (1974). The reaction mixture comprised, 
2ml of 0.1M sodium phosphate buffer (pH7.8), 20 . ki of 
microsomal suspension and 10 /, 41 of ethoxyresorufin 
(50 /, M in methanol). The reaction rate was measured at 
370C in a Perkin-Elmer MPF-3 spectrophotofluorimeter with 
an emission wavelength of 586nm and an excitation 
wavelength of-510nm. A baseline was initially drawn before 
addition of 50mM NADPH (10 , al) to commence the reaction 
which was then followed for two minutes. A standard was 
prepared in which ethoxyresorufin was replaced by O. lmM 
resorufin (10 /41) and this was used in calculating the 
amount of product formed. 
Determination of Protein Concentrations 
Protein content was determined by the method of 
Lowry et al. (1951). To O. lml of diluted tissue fraction 
(times 40 for homogenate, times 20 for other fractions) 
were added 0.4 ml of H20 and 0.5 ml of 1M NaOH, and the 
mixture incubated for 15 minutes at 370C in a shaking 
water bath. After allowing the mixture to cool, 5 ml of 
copper tartrate solution (lml of 2% Na 2CO, mixed with 
20 ml of 0-51o' CuS04-5H20 in 1056 Na-K tartrate) were added, 
the solution was thoroughly mixed and allowed to stand for 
10 minutes at room temperature. 0.5 ml of folin-ciocalteau 
reagent (diluted 1: 2 of H20) was then added, mixed 
immediately and allowed to stand for 30 minutes at room 
temperature, whereupon the absorbance was determined at 
? 00nm. The blank consisting of 0-5ml of H 2ý rather than 
tissueýfraction-j and a, series of standards containing 
0.1-0.5 ml of bovine serum albumin (0-5 mg/ml), were taken 
through the procedure described above. 
General Considerations 
All incubations were conducted in duplicate. 
Linearity of the assay with respect to enzyme concentration 
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Fig. 6.1. Rate of Metabolism as a Function of Enzyme 
Concentration for Hepatic Glutathione Reductase, 
Glucose-6-phosphate Dehydrogenase and 
Glutathione-S-transferase 
Rate of metabolism as a function of enzyme concentration 
E, mg protein) is shown for hepatic glutathione reductase (A), 
glucose-6-phosphate dehydrogenase (B) and glutathione-S- 
transferase (C). Linearity of these plots (v vs. :E) is 
demonstrated. Progress curves for these assay systems are not 
shown since the enzymes are monitored using a recording 
spectrophotometer which automatically generates such a curve; 
the linear portion of each curve is used for subsequent 
determinations. 
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and incubation time was investigated for GSH-S-transferase, 
GSSG reductase, G-6-PDH and organic nitrate reductase, and 
this is shoim in Fig. 6.1,6.2. Spectrophotometric 
determinations were carried out using a Pye-Unicam, S. P. 1800 
recording spectrophotometer fitted with variable 
temperature cell holder. 
The Effect of Phenobarbital and 3-Methylcholanthrene 
Pretreatment on Hepatic Organic Nitrate Reductase Activity 
Three groups of four rats (180 :ý 59) were used. 
One group was given sodium phenobarbital, 75 mg/kg/day for 
three'days (1 ml/kg, intraperitoneally), the second group 
was given. 3-methylcholanthrene (in corn oil), 20 mg/kg/day 
for three days (4 ml/kg, intraperitoneally), and the third 
group received saline (1 ml/k-, 2 rats) or corn oil 
(4 mi/kg, 2 rats) intraperitoneally each'day for three 
days; compounds were administered at 9 a. m. t1 hour each 
day. On the fourth day each rat was killed by cervical 
dislocation, their livers quickly removed into ice-cold 
1-15ioo' KC1, rinsed, blotted and then weighed. 59 Portions 
ofliver were homogenised in 0.25M sucrose - 5mm tris, pH7.4 
as described earlier. The totall homogenates were 
centrifuged at 12,000 r. p. m. in an M. S. E. High Speed 18 
cenurifuge for 15 minutes to remove cell debris, nuclear, 
mitochondrial and lysosomal fractions, leaving the 
postu-lysosomal supernatants which contained microsomes and 
soluble fraction. 10 nl. portions of these were centrifuged 
at 40,000 r. p. m. in an I. I. S. E. Super Speed 50 centrifuge 
(8 25 ml. angle rotor) for 60 minutes. Microsomal 
fractions-irrere re-suspended in 5 ml. of 1.15, %' KC1 solution 
using an homogeniser as described earlier. The following 
enzymes were assayed: organic nitrate reductase, G-6-PPH, 
GSH-S-transferase, GSSG reductase, cytochrome P-450, 
cytochrome b5 and ethoxyresorufin-0-de-ethylase. 
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Metabolism of Nitroglycerin by Plasma 
Blood samples were obtained by cardiac puncture 
from sagatal (60 mg/kg, intraperitoneally) anaesthetised 
rats, and were collected in cold 10 ml. heparinised tubes. 
Plasma was obtained by centrifuging the blood at full 
speed for five minutes in a bench centrifuge in the cold 
room. 
Two incubation systems were used. The first 
incubation system was that described by Di Carlo and Melgar 
(1970) and consisted of: 
2 ml., O-2M sodium phosphate buffer, pH7.4 
2 ml. plasma 
1 Ig of nitroglycerin in 100 K1 buffer. 
Reaction was commenced by addition of nitroglycerin and 
this incubation system was used to monitor the time course 
for the degradation of nitroglycerin at substrate 
concentrations found in plasma following an intravenous 
dose of 0.75 m,, r/kg. Controls consisted of buffer and 
nitroglycerin only. 200 ., 
A41 aliquots of the incubation 
mixture were removed at regular time intervals, and 
iodoacetamide solution (10/zLl, 0.214) added. This experi- 
ment was carried out four times, in each case using plasma 
from individual rats. 
The second incubation system was as described 
earlier, and was used in all subsequent experiments. 
Incubations were generally conducted without GSH although 
one experiment was performed with GSTIH, in order to check 
requirement for this cofactor by the plasma enzyme. 
Substrate concentrations ranging between O. lmM and 2. OmM 
were used. The reactions were initiated by addition of 
substrate and terminated after ten minutes at 37 0C by 
addition of 55o' HgC'2, as before. For construction of 
progress'curves, 0.1 ml aliquots o'L incubation mixtures 
were removed into 0.5 ml of 5c, o HgCl2 solution. Wherever 
necessary, control incubations (no plasma) were made. 
Nitroglycerin content , -ias determined by g. l. c. 
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Determination of Km and Vmax for Organic Nitrate Reductase 
of Plasma and Liver 
The incubation systems described earlier were used; 
plasma incubations were performed in the absence of GSH. 
Linearity of progress curves over the ten minutes incubation 
period was demonstrated at the highest and lowest substrate 
concentrations'used. Incubations were commenced by 
addition of substrate to give final concentrations of 
0.1 - 2.0 mM. After ten minutes at 37 
0C in a shaking water 
bath, the reactions were terminated with 5% HgC12 solution. 
Control incubations (no tissue) with equivalent substrate 
concentration were also carried out, and nitroglycerin 
content was determined by g. l. c. Enzyme parameters were 
determined from Lineweaver-Burke plots. 
Stability of Nitroglycerin under Acidic Conditions 
An experiment was performed to investigate the 
possible degradation of nitroglycerin, at pH values similar 
to those found in the gastro-intestinal tract in order to 
establish if degradation at gastro-intestinal pH 
contributed towards the "first-pass" metabolism'of 
nitroglycerin. 
Aqueous solutions of hydrochloric acid (volume'5ml) 
were prepared, having pH values of. 1-0,3.0,5.0 and 7.0. 
50 /, Al of 
20mM nitroglycerin (45.4 ,,, g/ml) were added and 
the mixture incubated at 37 0C for five hours. This 
concentration of substrate is of the same order of magnitude 
as that expected in the stomach, following an oral dose of 
0.? 5 mg/kg to rats. After five hours, 100 /ul of each was 
added to 1.9 ml of 0.01M NaHCO 3 solution to terminate the 
reaction, and a 50 1, al aliquot of 
this processed for g. l. c. 
analysis. 
Inhibition of GSH-S-transferase by Nitroglycerin 
The incubation system described earlier was used, 
with the exception that the volume of buffer was adjusted 
in order to retain a total volume of 1 mi. when 
nitroglycerin was added. Two concentrations of nitroglycerin 
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(0.4 and 0.8m11-1) and six substrate concentrations ranging 0Q 
between 0.02mM and 0-5MM, were used. Soluble fraction 
was diluted 200 times for these incubations. Incubations 
were conducted with or without nitroglycerin, and 
suitable controls and reference cuvettes prepared. The 
rate of reaction (with or without nitroglycerin) at each 
concentration was determined and Lineweaver-Burke plots 
constructed. 
Presentation of Results 
Subeellular Localisation of Enz7mes 
Histograms are constructed by plotting relative 
specific activity (R. S. A., as ordinate) against 01, L total 
protein in the fraction (abscissa), as described by 
De Duve et al. (1955) where., 
R. S. A. = specific activity in fraction 
specific activity in total 
i. e. R. S. A. = enzyme activity in fraction 11ý 
protein content of fraction 
enzyme activity in total 
total amount of protein 
in this case: 
1) the width of each bar represents OP protein in that 
fraction and the sum of the widths represents c,. 5 
protein recovery. 
2) the height of each bar reflects the enrichment factor 
3) the area of each bar denotes the rl)' activity in that 
fraction. 
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Statistical Analysis 
Statistically significant differences are 
determined by Students t-test. All linear plots are 
constructed'using linear regression analysis, 
I 
Determination of Ki 
for competitive inhibition, 
Vmax S 
Km(1+)+S 
whence , 
Ki KmI 
S( Vm"Lý: K' 
vm 
where , 
initial rate of reaction of substrate 
concentration S 
Vmax = maximum initial rate 
Km = Michaelis constant 
Ki inhibition constant 
concentration of inhibitor. 
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RESULTS 
Sites of Organic Nitrate Reductase Activit7 
Organic nitrate reductase activity has been 
demonstrated in each tissue examined, that is liver, kidney, 
intestine and heart, and appears to be localised in the 
cytosolic fraction. Subeellular fractionation of liver 
indicated that organic nitrate reductase activity occurs 
in the soluble fraction only (Fig. 6.3, Table 6.1), 
activity in the nuclear fraction can be attributed to 
contamination with intact hepatocytes; the marker enzymes 
distributed as expected and the advantage of including 
fluoride io n in the glucose-6-phosphatase incubation 
system is demonstrated. The organic nitrate reductase 
activity of mitochondrial and lysosomal fractions (Fig. 6-3) 
is insignificant when compared with controls if 
"uncorrected" data are used ("uncorrected" data, refers to 
results for which the non-enzymic degradation due to 
GSH -control value - has not been subtracted, Table 6.2), 
and probably does not occur. Tissue activity is greatest 
in liver, which is far more active than the other tissues 
examined (Table 6-3); considering the whole organ 
(Table 6.4), organic nitrate reductase activity of liver 
is 14 times greater than activity of intestine (2g of 
mucosal cells), 16 times greater than kidney and 150 times 
greater than 
heart. There is some correlation between the 
activities (per gram of tissue) for organic nitrate 
reductase and GSH-S-transferase in the various tissues since 
the activities decrease: liver>kidney> intestine> heart 
in both cases. Total in vivo gut activity may be even 
greater since only a 60 cm portion was considered in these 
experiments. Activity of heart, although small, is 
significantly different from controls when "uncorrected" 
data are compared (Table 6.3. ), however activity in the 
M, L, Mic pellet is probably not significant. Control 
activity appeared to vary two fold over this series of 
experiments. 
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Table 6.1 Activities of Marker Enz7mes and Organic Nitrate 
Reductase in the Various Subfractions of Liver* 
Table 6.1 shows the distribution of organic nitrate 
reductase and various marker enzymes in liver. The 
livers from three rats were homogenised and fractionated 
by differential centrifUGation. Each fraction %ras 
tested for the presence of organic nitrate reductase and 
the various mar'-: er enzymes indicated. Results are 
e: -. pressed as the mean t S. D. 15, total activity is 
e. -c-pressed as the mean value, and recoveries for the 
enzymes were: 
acid phosphatase 
succinic dehydrogenase 
Slucose-6-phosphatase 
glucose-5-phosphatase 
orSanic nitrate reductase 
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Organic nitrate reductase activity also occurs in 
plasma (Fig. 6.4), but no degradation of nitroglycerin 
occurred in aqueous acidic solution at any of the pH values 
used. 1, --letabol-ism by plasma is characterised by a quite 
slow half-life (48-50 minutes) and is an activity which 
does not require GSH as cofactor, whereas hepatic organic 
nitrate reductase activity does. For the plasma enzyme, 
a Lineweaver-BurIte plot (Fig. 6-5) produced values of 
15.3m, q for KM and 0.045/tmol/min/mg protein for Vmax; 
when compared with the hepatic enzyme (Fig. 6-5), which 
shows values of 4.4m14 for Km and 0.090, /xmol/min/mg protein 
for Vmaxj this confirms the higher activity of the liver. 
However, total plasma activity in vivo cannot be discounted 
as insignificant when one considers the large plasma 
volume of the animal. 
Correlation between the Activities of Organic Nitrate 
Reductase and GSH-S-transferase 
As described above, there is correlation between 
organic nitrate reductase activity and GSH-S-transferase 
activity in various tissues. Pretreatment of rats with 
phenobarbital and 3-methylcholanthrene produced a 
significant increase in: the liver weight to body weight 
ratio, the activities of all the drug metabolisinS enzymes 
studied (these were used as markers for induction and both 
cyt. P-450 and cyt-P-448 activities were monitored), the 
activities of the three soluble fraction enzymes, 
GSH-S-transferase, GSSG-reductase and G-10-PDH and also in 
orcy, anic nitrate reductase activity (Table 6-5A, B). 
However, the degree of induction of organic nitrate 
reductase (15-22, ', j' for both pretreatments) did not correlate 
with that of GS'-H-S-transferase (increased 76-82ý'., by 
phenobarbital and 46/ao' by 3-methyTcholanthrene), G-6-PDH 
(increased 60-83ý'o by phenobarbital and 53-67ý, ý by 
3-methylcholanthrene) or with that of GSSSG reductase 
(increased 40-48, ýj' by ph--nobarb-ital). 
ý155- 
HIg. 0.6 shows competitive inhibition by 
nitroglycerin of GSH-S 0 -transferase activity and this 
provides good evidence for nitroglycerin being a 
substrate for GSH-S-transferase. Vmax and Km for 
GSH-S-transferase are 0.9 /, cmol/min/mg protein and 
49/xM respectively and Km changes to 77/xM and l2`;.,. zM C) Iýe- 
in the presence of 0.4mM and O. Smll nitroglycerin 
respectively. Ki was 0-56mM (for 0.4mM nitroglycerin) 
and 0.68mM (for 0.8mM nitroglycerin). 
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Table 6.4 Comparison of the Cotml Activity of Or7 sanic 
Nitrate Reductase in Various Tissues 
Results are expressed as total /Amoles of nitroglycerin 
consumed per minute for each tissue, and as a ratio of 
the total activity of each tissue to the total activity 
of liver. 
Tissue Activity 'Ratio, Liver/Tissue 
/xmol/min/t, issue 
Liver 9.2 
lHeart 0.06 153 
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Fig. 6.4 Metabolism of Nitroglycerin b7 Plasma 
A. Metabolism of nitroglycerin (O. lmM) by plasma in 
the presence and absence of GSH (incubation 
system of Short et al., 19?? ). 
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B. Time course for the degradation of nitroglycerin 
by plasma at in vivo substrate concentrations (incubation s7s-t=mof Di Carlo and Melgar., 19? 0). 
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Fig. 6.5 Lineweaver-Burke Plots for Organic Nitrate 
Reductase 
r1 
'-4 
0 
"rI E 
1/s (MM-1 ) 
0-% 
0 
El. 
43 %. ool 
k, 
r-I 
1 
(MM-1 ) 
DISCUSSION 
Metabolism of Nitroglycerin in vitro 
Nitroglycerin appears to be metabolised by several 
tissues, and this activity is mediated by enzymes of the 
cytosolic fraction. Liver is by far the most active 
tissue (total activity = 9.2/zmol/min) and this finding 
confirms the studies of others (Maier et al., 1980) who 
obtained a value of 10.6 t 1.9 /Umol/ýin for' the total 
liver activity of 250-3009 rats. These workers used the 
assay system of Neddleman and Krantz (1965), which follows 
the disappearance of NADPH, rather than nitroglycerin as 
used here; there is thus good agreement between the two 
types of methodology used to determine organic nitrate 
reductase (ONR). 
Experiments designed to determine the subeellular 
location of ONR clearly showed this activity to be present 
in the soluble fraction only of each tissue tested and it 
is unlikely that significant nitroglycerin metabolism 
occurs in the mitochondrial, lysosomal or microsomal 
fractions of heart as claimed by Di Carlo et al. (1967). 
Total ONR activity of-the tissues varies: 
liver>intestine; ýkidney>heartj where liver activity is 
, --'15 times that of intestine and kidney, and kidney 
activity is -4, '10 times that of heart. If one considers 
specific activity, then the liver enzyme has 1v 3 times the 
specific activity of the enzymes of intestine and kidney 
which haveq in turn, /, -, 10 times greater specific activity 
than the enzyme in heart. On the contrary, the work of 
Posadas del Rio (1973) showed a specific activity for ONR 
of intestinal mucosa higher than that of the liver enzyme 
when, partially purified enzyme preparations were used, but 
a similar total activity to ours for intestine relative 
to liver; but, these workers used the partially purified 
enzymes isolated from a different strain of rats (Sprague- 
Dawley) - 
Previous studies (see Chapter 1) have left some 
confusion as to the tissue sites and subeellular site of 
oNR. Maier et al. (1980) showed no activity in intestine 
-157- 
and heart, but these workers chose a value of 
<0.6 /cmol/min/tissue as a negligible activity; if this 
value is applied to our results then a similar 
conclusion can be drawn, i. e. negligible activity for 
all tissues, other than liver and plasma. Organic 
nitrate reductase has, however, been demonstrated in the 
heart (Di Carlo et al., 1967), in the gut mucosa 
(Posadas del Rib, 1973), in the kidney (Maier et al*, 1980), 
in er3ithrocytes (Armstrong et al., 1980b) and in serum 
(Di Carlo and Melgar, 1970). Lack of intestinal OITR 
activity in the experiments of Maier et al. (1980) is 
perhaps not surprising since these workers used only 
15-20 cm. of small intestine, from a region distal to the 
pyloric sphincter, and homogenised this; in these studies, 
isolated intestinal mucosal cells were not used. 
In the present studies, only slight activity was 
observed Lor heart homogenates and soluble fraction and 
this correlates well idth the studies of Di Carlo et'al. 
(1ý70). These workers showed ONR activity in heartt but 
used several organic nitrates in the study; nitroglycerin 
produced the lowest 0174R activity of the compounds tested. 
Consideration o'L the metabolism of organic nitrates by the 
heart is interesting since these compounds are coronary 
vasodilators and cardiac. stimulants (Parratt, 1979). It 
appears that metabolism of nitroglycerin and other organic 
nitrates does occur in the heart but it is unlikely that 
a significant contribution is made by this tissue to their 
overall in vivo elimination. 
The contribution of intestinal metabolism to the 
overall in, vivo elimination of nitroglycerin is difficult 
to estimate since only a small section of gut was used. 
Significant metabolism of, nitroglycerin, occurred in 
homogenates of intestinal mucosa and it is liI. Cely that Sut V to 
enzymes-are., at least partlyýresponsible, for the "first-pass" 
e-'L'-L'ect undersone by this dr ug. As only 60 cm. of gut was 
used7 and the recovery of mucosal cells from this section 
is unknown, the possibility exists that the observed 
-0 0ý21 in " pctjvity oL this tissue has been underestimated. V 
-158- 
Undoubtedly, there are more than 2S of mucosal cells 
per 60 cm intestine. Organic nitrate reductase activity 
may also be resent in cells from other parts of the pI 
gastro-intestinal tract. The studies of Maier et al. 
(1980) however do not show activity in small intestine 
and it is possible that ONR is limited to mucosal cells 
of the duodenum. A contribution from intestinal smooth 
muscle cannot be ruled out however as these structures 
contain receptors for organic nitrates at which 
denitration may occur. 
In the present studies, the total capacity of 
kidney L 'or nitroglycerin metabolism appears to be 
approximately 716 of that of liver. Previous studies 
(Maier et- al 
'. 
1980) reported a kidney 01-TR activity of 
, --'12-5, ýý of that of liver, and this provides excellent 
correlation considering the different methodologies 
used. Since the hidney is highly perfused, a significant 
contribution must be nade by this or-gan to the overall 
in vivo elimination of administered nitroglycerin. 
Denitration of nitroglycerin by sulphhydryl groups 
of its receptors has been demonstrated (Needleman and 
Johnson, 19? 5) and these structures undoubtedly exist in 
many tissues including smooth muscle. Therefore many 
tissues may have the potential for degrading nitroglycerin, 
albeit at a fairly slow rate. The slight activity 
observed in heart may be the result of denitration by 
such means rather than by an enzyme similar to the 
hepatic enzyme. Perhaps these receptors are membrane 
bound forms of OIT11. Formation of G, 3170 2 (see later) may 
occur here which is then transported into mitochondria 
where NOE* is released and the pharmacological activity of 2- 
the 'organic nitrates is realised. It is interesting to U0 
note that only compounds which are capable of denitration 
by GSH-dependent OHR are potent vasodilators (ITeedleman, 
1969), which lends support for this hypothesis. 
Degradation of nitroglycerin-did not occur in 
aqueous hydrochloric acid solutions up to a pH of 1.0 and 
-159- 
therefore gastro-intuestinal pH plays no role in the 
elimination of orally administered nitroglycerin. 
-r' 
Hol,. 7ever, plasma metabolism did occur, and this exhibited 
an in vitro hal-L"-life OIL. ' /A--'50 minutes at nitroglycerin 
concentrations in the range observed following an intra- 
venous dose of 0.75 mg/l: g to rats. This is slower than 
the metabolism due to rat, serum described by Di Carlo and 
,, Ielr,,:, ar ' 
(1970) who estimated a half-life of /--20 minutes; 
however, these workers used far higher nitroglycerin 
concentrations and rather insensitive -methodology. Blood 
appears to contain two independent types oL' organic 
nit-rate reductase, one which is GSH-dependent (erythrocytes) 
lihe the hepatic enzyme, and the other, the plasma enzyme 
which does not require GSH. Such multiplicity of enzymes 
may occur in other tissues but has gone undetected due to 
Uhe high activity of the GSH-requiring enzyme. The t 
presence of 01, TIR activity in isolated human blood cells was 
demonstrated by Armstrong et al. (1980b) who reported a 
half-li. 1'e of the order of six minutes for nitroglycerin. 
This is, however, a controversial point since Heedleman 
and co-workers (Johnson et al., 1972; Lang et al., 1972 
Needleman, et al.,. 1972) have reported a very slow 
disappearance of nitroglycerin in blood in vitro. The 
only GSH-S-transferase reported for the - 
erythrocyte (human, 
GSII-S- transferasetc ) has been claimed not to act on 
nitro-Glycerin (Marcus et al., 1978), which sheds some doubt 
upon the claims of Armstrong et al. since GSIH-S-trans. 11erase 
is believed to be responsible for 011T., activity; the 
e:, c, planation for these discrepancies may involve a species 
variation in the metabolism of nitroglycerin by blood. 
Nel'Mbolism of nitroglycerin by blood is undoubtedly 
significant Ln vivo; although the contribution from 
erythrocytes, (human) Greatly exceeds that from plasma, the 
combination of these enZymes and the large blood volume in 
the animal must ensure an active role for blood in the 
overall in vivo metabolism of nitro-1-7cerin. Z) V 
Considering that a 955ý "firslt, --pass" effect occurs 
ollowinS oral administratfon of nitroSlý-cerin, one may ýD V 
-160- 
'I assusie that 1-11055 of b., he dose is metabolised by the gut. 
Intravenous and sublingual administration avoid the 
"first-pass" effect and the dose is probably metabolised 
_primarily 
by the liver, kidne7 and blood and 
to a lesser extent by heart and perhaps arterial - smooth 
muscle - cells (nitroglycerin receptors). 
Characteristics of Organic Nitrate Reductase from Plasma 
and Liver 
The present studies have shoi-, m that liver contains 
the most active form of this enzyme possessing a lower 0 
Iým (4.4m2,1) and greater Vmax (0.09 /xmol/min/mg protein) 
than the plasma enzyme, the latter is GSH independent and 
therefore probably more versatile, and has a Km of 15.3mM 
and Vmax oL ' 0.045 . zcmol/min/mg protein. Previous studies 
have indicated similar properties for hepatic OITR 
(Km --lmM; Stein et al., 1930) although for the plasma 
(serum) enzyme, Di Carlo and Melgar (1970) reported a Km ca 
oJ_ 0.23m1,1 and Vmax of 0.92 /amol/r. in/mg protein. The low 
., m 
for the hepatic enzyme suggests that OYR has a high 
'or nitroglycerin (which is thus a good substrate), affinity L 
and this is supported in vivo by its short half-life. The 
plasma enzyme has a higher Km, lower specific activity and 
consequently produces a slower half-life. 
Or7anic Nitrate Reductase as an Activity of GSH-G-transferase 
There is mountinS evidence that MIME, activity is 
possessed by the multi-functional enzymes, the 
GSII-S-transferases. These enzymes catalyse several 
reactions in which the sulphhydryl moiety of GSH attacks 
some electrophilic centrej either displacing a leaving group 
or adding to alkenes or epoxides. In addition, these 
proteins bind a variety oL chemically diverse comDounds and 
have been implicated as being important in the transport of 
bilirubin in liver (Levi, et al. 1969; lKirsh, et al., 1975) 
and of organic acids in kidney (ýLrias et al. 1976). 
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Habig et al. (1975) isolated and partially purified 01TR 
and showed it to be indistinguishable -from the 
GSH-or'-transferase enzymes; five distinct protein bands 
with GSH-S-transf erase activity (labelled LY- to F- ) 
have been isolated from human liver. The predominant 
metabolic activity for nitroglycerin has been localised 
in the 6 species with a specific activity of 72.6 mg 
nitroglycerin/min/mg protein (Habig et al., 1976). More 
recently (Armstrong et al 1980b) indicated ONR activity 
'n human blood and this activity has been attributed to 
GSH-S-tra-nsferase e of er-ythrocytes. 
Support for this hypothesis is presented here, 
since there is correlation between total tissue OUR 
activity and GS-E-S-transferase activity. There is a 
trend for activities to lielliver> intestine> kidney>heart 
for both enzymes, although liver total ONIR activity is 
somewhat greater than expected for this trend. Some 
Jnvestigations into the GSTH-S-transferase content of 
different tissues, has been conducted. Quantitative 
estimates of the concentration of transferase B (ligandin) 
have been made for normal rat liver (45 , &g per mg of 
soluble protein) , 7-, -i-CLney 
(22 "g/mg) and small intestinal 
mucosa (17 /4cg/r, 1z) 
(Fleischner et al. 1976). In rat 
intestine all the transferases for vrhich antibody is 
available have been observed vdth very high activity in 
the duodenum and jejenum, and decreasinG-in the lower gut', 
(1.0inhus et- al. 1979). In the jejenum, the enzymes are 
highest inthe tip cells of the intestinal villi and lowest 
in the crypt cells. These findings correlate very well 
j., -ith the present findings discussed earlier, and provide 
Sood support for OITR activity due to GSH-S-transferase. 
However, in the pretreatment studies using 
phenobarbital and 3-methylcholanthrene there is poor 
correlation-between, the degree of induction of 
GSH-S-transferase and the degree of induction of 01,7,,. An 
e:. -Pla-nation for this discrepancy may lie with the 
s1fostrate used for GSILIL-S-transf li 
'erase assay. This was 
1-chloro-2,4-dinitrobenzene which is by far the most readily 
-162- 
metabolised of the transferase substrates. Considering 
the varying substrate specificities of the different 
transferases, it would be more sensible to conduct this 
induction study by using several substrates with at leas-t'. o 
one good substrate for each transferase. In the original 
studies of Habig et al., however, OITR activity was 
demonstrated for each of the transferases and therefore 
one would e. -T-ect the increase in OITR activity by such 
pretreatments to be at least equal to the increase in 
GSH-S-transferase activity, since only one substrate, 
reflecting accurately the induction of perhaps one or two 
than all, was used. Consider o. xL kOhe transferases rather ' 
two transferases, differing by 10-Lold in activity towards 
a given substrate (e. g. CDITB) and both induced 20ý'o 
induction of the transferase having lower activity would 
be negligible in the overall situation i. e. 2ý5. The 
transferases less active towards CDITB may well be those 
having greater activity towards nitroglycerin (see 
Table 6.6). 1-Chloro-2,4-dinitrobenzene (CDNB) was chosen 
for these studies since it is the only substrate metabolised 
ef. -if'iciently b-., r all the transferases and is easy to determine 
spectrophotome-li-rically. 
Induction of the GSH-S-transferases has been 
reported previously (Chasseaud, 19? 9); it would appear that 
transferase B is the most easily inducible but all the 
trans-ferases can be induced; phenobarbital appears 1. -o be a 
C rat liver ligandin than is 'ective inducer oL more eff 
3-metphy1cholanthrene. 
Investigation into the effects of phenobarbital on 
the metabolism of nitroglycerin have also been conducted 
by Lee and Belpaire (1972). These viorl-rlers observed an 
increase in 01M, activity of 201,., in the presence of GSH a-nd 
an increase o. -, ' 43,13' in the absence of GSH (which compares 
favourably with the present studies, 15-221, r. 4 increase in the 
presence of GSH), a 5335ý5 increase in G-0-PDH' activity 
(presently 60-3.3; 'j) and a 30, '. ') increase in GSSG-reductase 
activit, '/r (presently 40-48, cVý). These worhers ex'-plained the 
more pronounced effect on their preparation in the *absence 
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of added GS'-. i- (CF 1., rith added GSH), on the basis that 
phenobarbital pretreatment provokes, as well as an 
increase in overall 01M.. activity, an increase in the 
activity of the GSH regenerating system. However, this 
may also be evidence for the existence of a GSH independent 
form. of OITIR in liver with a much lower activity than the 
GSH-requiring form. 
1-1ore convincing evidence comes from the effect 
of nitroglycerin on GSH-S-transferase activity in vitro. 
Clearly, competitive inhibition was demonstrated, which 
suggests that nitroglycerin is a substrate for this V 
enzyme. It is possible, however, that interpretation of 
k, he data may be complicated by consideration of the 
substrate (CD1TB) used and the multiplicity of enzymes 
involved. In a similar series of ex. periments, Stein 
et al. (1980), using partially purified GSH-S-transferase 
C from 6uinea-pig liver as OITIR, indicated competitive 
inhibition by probenecid, a compound 1-: noim to be 
netabolised by this enzyme (transferase); nitroglycerin 
was used as the substrate. Er7thrityl tetranitrate (ETN) 
produced a mixed type of inhibition of GSH-S-tr sferases S an 
a and c when employed in a similar e-,, -periment to that 
described here, but using 112-dichloro-4-nitrobenzene as 
substrate (Ki for =-N was --'0.3m!, I; presently 0-56-0.68mM 
for nitroglycerin) on 'Uh6 contrar,,, no inhibition was 
observed when CD1TB was used as the stibstrate. 
ConsiderinG all the available data: similar sites 
of activit. -ml similar species variation (Chapter 5), 
similar tissue variation, GSH-S-transiferase activity in 
purified OITMI OTTR activity by all partially-purified 
GSH-6-tr=-sferasesj competitive inhibition of GSH-S-trans- 
ferase with organic nitrates and induction of both enzymes 
, 
by phenobarbital and 3-meth, 71cholanthrene (which is 
uncommon - usually onl-,, - microsomal enzymes are inducible), 
it is very li. ely that OITR is an activity of V 
GSTH-SS-transferase. Nevertheless, there is still the 
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possibility that more than one form Of ONR is present in 
tissues other than blood; e. g. two species, one GSH 
dependent, the other GSH independent. Support for this 
idea comes from the pretreatment study of Lee and 
Belpaire (1972), from the GSH depletion experiments of 
Chapter 4 (where a rapid metabolism of nitroglycerin still 
occurs even though GSH is depleted to very low levels) and 
from the work of Tsuruta and Hazegawa (1970) which 
demonstrated GSH independent-ONR-activity in both liver 
and plasma. As two forms of ONR are present in blood, the 
possibility that both these forms may be present in other 
tissues cannot be excluded. 
Assuming that ONR is an activity of GSH-S-transferase 
then the mechanism is probably as follows: 
2GSH CH 2- CH - CH 2 CH 2- CH - CH 2 
00000 OR 
IIIII 
N02 N02 N02 N02 NO 2 
ONO H 
121 +10 
0 
CH 2- CH C- 0 -N II 
H Q- ON02 
GS- 
(H+) 
GSH-S- 
transferase 
GSSG + HN02 
01T02 
CH 2-C CE2 10H II 
OITO 2H 
0 
GS IT 
+0 
non- +GS-(+H+) enzymic 
GSSG + El"'02 
-165- 
The formation of nitrite is interpreted on the 
basis of GSH, probably as the glutathione thiolate ion, 
reacting at an electrophilic nitrogen to form GSITO 0 2; the 
-oroduct is attac. '-. ed non-enzymically by a second molecule 
of GSH to release nitrite and GSSG (Keen et al., 1976). 
For the enzymic reaction of GSH with nitroglycerin, the 
e:. "istence of such an intermediate has been assessed by 
examining the effect of a second thiol in the reaction 
mixture. The stoichiometry of the reaction is that of 
the f ormaljion of equivalent amounts o. L Qjý C nitrite and GSS)G. 
On inclusion of 2-mercaptoethylamine in concentrations 
equal to that of GSHý GSSG formation was markedly 
reduced without affecting the production of nitrite. 
These findings are in accord iii-th the formation of the 
predicted gluuathione-sulphenyl nitrite (Keen et al., 
1976); this compound has, however, never been isolated. 
There is thus reasonable evidence for OITR activity to be 
a propertly of GSH-S-trans'i'erase. 
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CHAPTER 7 
EFFECTS OF'DEUTERATION ON THE METABOLISM 
AND PHARMACOLOGICAL ACTIVITY OP IMIPRAMINE 
INTRODUCTION 
Imipramine has been widely used for many years in 
the treatment of endogenous depression; it is very 
effective in the treatment of this illness and was one of 
the first in the tricyclic antidepressant series of drugs to be 
prescribed clinically. As described in Chapter 1, 
imipramine is believed to possess tranquillising properties 
which are masked by its rapid conversion, by N-demethylation, 
to desmethylimipramine (DMI), the major metabolite; this 
compound appears to be largely responsible for the 
therapeutic effects of imipramine. It is hoped that 
deuteration of imipramine, both in the aromatic rings and 
in one of the N-methyl groups of the side chain, will slow 
metabolic transformation by one or both of its two major 
metabolic roVtes$ aromatic hydroxylation and N-demethyla- 
tion, leading to a prolonged half-life and increased tissue 
levels of imipramine which does not normally occur in man 
or the rat (Dingell et al., 1964). The inhibition of 
imipramine metabolism is expected to accentuate its 
tranquillising properties and lead to the development of 
an antidepressant which would initially sedate the patient 
and later exhibit antidepressant effects. 
The animal model chosen for studying the effects of 
deuteration of imipramine is the rat since this is the 
species which most closely relates to man in its pattern 
of metabolism (Dingell et al., 1964), that is, rapid 
N-demethylation to desmethylimipramine and then slower 
metabolism of the latter compound to didesmethylimipramine, 
giving rise to desmethylimipramine accumulation. 
A large number of analytical procedures are 
available for the determination of tricylclic 
antidepressants; methods involving g. l. c. (Hammer and 
Brodie, 1967; Frigerio et al., 1972; Belvedere et al., 
1975; Cooper et al., 1975; Gifford et al., 1975; Reite, 1975; 
Bailey and Jatlow, 1976; Dubois et al,., 1976; Bertrand et al., 
1978; Jenkins and Freidel, 1978), h. p. l. c. (Kraak and 
Bijster, 1977; Van den Berg et al., 1977; Watson and 
Stewart, 1977; Lohman et al., 1978; Vandemark et al., 1978) 
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and t. l. c. (Nagy and Treiber, 1973; Fenimore et al., 1977; 
Kaul et al., 1978) have been published. However, few have 
been applied to imipramine and desmethylimipramine 
determination in biological specimens and none dealt with 
further metabolites. These procedures have been 
criticised on the grounds that they require either 
sophisticated instrumentation not readily available to 
clinical laboratories, or multistep extraction and/or 
derivatisation. Normal phase - h. p. l. c. (Sutfin and 
Jusko, 1979) proved to be most efficient in separating all 
the major metabolites of imipramine found in rat urine 
and plasma and, when coupled with fluorimetric detection, 
sensitive enough to permit serial blood samples to be 
obtained from individual animals for pharmacokinetic 
determinations. 
The effects of deuteration on the pharmacokinetic 
properties of this drug are compared by both the oral and 
intravenous routes of administration, and the urinary 
excretion profile of the metabolites formed following oral 
doses of imipramine and deuterated imipramine are compared. 
Three deuterated analogues of imipramine have been used; 
imipramine-d 3 (N-deuteromethylimipramine), imipramine-d 4 
(4 aromatic ring deuterons) and the combination, 
imipramine-d,? (both regions deuterated). Imipramine-d. 
was to be the analogue involved in the main study and 
imipramine-d 3 and imipramine-d4 were to be used as Probes 
to indicate the locus and relative magnitudes of any 
isotope effect observed for the highly deuterated form. 
The pharmacokinetic studies are supported by a series of 
pharmacological experiments related to the effects of the 
drug on gastro-intestinal motility. 
The pharmacokinetics of imipramine have been widely 
studied clinically (Gram, 1974,1977; Nagy, 1980) but in 
animals few studies have been conducted and these have used 
methodology which is far less sensitive and specific than 
is available today (Dingell et al., 1964). Therefore it 
was advisable to re-examine the pharmacokinetics of 
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imipramine metabolism in the rat, and studies involving 
comparison of routes of administration, effect of dose 
and studies on absorption and elimination following an 
oral dose are conducted. 
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EXPERIMENTAL 
MATERIALS 
Solvents for h. p. l. c. were from the following 
sources; acetonitrile - h. p. l. c. grade, hexane - glass 
distilled grade, from Rathburn Chemicals Ltd., 
(Walkerburn, Peebleshire), methanol (A. R. ) from James 
Burroughs Ltd. (London), ammonium hydroxide (35% w /v) 
from the B. D. H. Ltd. (Poole, 
' 
Dorset). Ketodase for 
hydrolysis of glucuronides was obtained from William R. 
Warner & Co. Ltd. (Eastleigh, Hampshire). Atropine 
sulphate was a gift from Biorex Laboratories Ltd. 
(London). Protriptyline-hydrochloride was kindly 
donated by Merck, Sharp and Dohme Research Laboratories 
(Hoddesdon, Hertfordshire), and the following metabolites 
bf imipramine were kindly donated by Dr. V. A. John of 
Ciba-Geigy Ltd. (Macclesfield, Cheshire): 
desmethylimipramine (hydrochloride) 
didesmethylimipramine (hydrochloride) 
2-hydroxyimipramine (hydrochloride) 
2-hydroxydesmethylimipramine (oxalate) 
imipramine-N-oxide 
10-hydroxyimipramine (hydrochloride) 
Deuterated analogues of imipramine were synthesised 
as described in Chapter 2. All other solvents and 
chemicals (including anaesthetics and nor-adrenaline) were 
A. R. grade from the B. D. H. Ltd. Screw-cap vials (3.5ml) 
used for extractions were supplied by Phase Separations 
Ltd. (Queensferry, Clwyd). 
Abbreviations 
imipramine - I 
desmethylimipramine - DMI 
didesmethylimipramine - DDMI 
2-hydroxyimipramine - 2-OH I 
2-hydroxydesmethylimipramine - 2-OH DMI 
imipramine-N-oxide - IPNO 
2-hydroxyimipramine glucuronic acid - 2-OH I GA 
2-hydroxydesmethylimipramine glucuronic acid 
- 2-OH DMI GA 
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METHODS 
Determination of Imipramine and Metabolites in Plasma and 
Urine 
Chromatography 
H. p. l. c. was carried out using a Waters Associates 
model 440 liquid chromatograph connected from 'collect 
outlet' (pump) to the flow cell (20/41, double mirrored) 
of a Perkin Elmer model 3000 spectrofluorimeter. 
The h. p. l. c. procedure used was essentially that 
of Sutfin and Jusko (19? 9). Protriptyline was used as 
internal standard, and the solvent flow-rate increased in 
order to decrease run time to 20 minutes. Optimum 
conditions for both h. p. l. c. (with respect to solvent 
system composition) and fluorimetry were confirmed and 
were as stated below: 
Column 25cm x 0.46cm stainless steel, packed 
with Lichrosorb Si 60-5 (Chrompak U. K. London). 
Solvent system acetonitrile-methanol (5: 1 by volume) 
containing 4ml of 35% w/v NH40H per 
litre. 
Flow-rate 3.5 ml/min 
Pressure 1600 p. s. i. 
Fluorimeter excitation. 240nm (15= slit width ý 
emission. 370nm (20= slit width 
time constant 4.8 sec. 
expansion scales X5, X102 X20. 
Prior to use the colilron was equilibrated by running 
solvent through at 0.1 ml/min for 12 hours and then at 
3.5 ml/min for 3 hours in order to obtain reproducible 
retention volumes. 
All reference compounds were shown to be pure by 
h. p. l. c- (single peaks) and t. l. c. (single spots - for 
solvent systems see Chapter 2). 
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Extraction from plasma and urine 
_I: To 
250 A-cZ of plasma or urine in 3-5ml screw-cap 
septum vials (teflon coated. septa) were added; 250,, al of 
water, 50, &1 of internal standard solution (containing 
50ng of protriptyline hydrochloride in water) and 1.0 ml 
of acetate buffer, p. H. 5-0.50^1 of 35% (w/v)-NH,, PH 
were then added followed by 1.0 ml of 20% n-butanol in 
hexane and the mixture shaken (reciprocating shaker) for 
20 minutes. The phases were separated by centrifugation 
for five minutes (at full speed) in an M. S. E. minor bench 
centrifuge, and the organic phase decanted and evaporated 
to dryness at 400C, in a stream of nitrogen. The residue 
was re-dissolved in 100^1 of methanol prior to 
chromatography when up to 90/41 were injected. 
Reproducibility of the analytical procedure 
This was determined by adding known quantities of 
each reference compound to 250,41 of plasma and taking 
these through the extraction and chromatography 
procedures. Each compound was prepared in methanolic 
solution such that 10, *l of these solutions contained 
200ng of reference compound (calculated as the free base). 
Five concentrations of each compound were used: 
I-d 3, -d4, -d? 
/I/DMI 20,200,400,800 and 2,000 
ng/ml plasma 
DDMI/2-OH I/2-OH DMI/IPNO 20,100,200,400 and 800 
ng/ml plasma 
At each level, four determinations were made. 
Recoveries by the extraction Procedure 
Recoveries were determined by adding known quantities 
of each compound (50 or 200 ng i. e. 200 or 800 ng/ml) to 
plasma or urine, in duplicate. These were taken through 
the extraction procedure but internal standard (50ng in 
methanolic solution) added after extraction rather than 
before. The extracts were compared chromatographically 
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with a series of pure solution standards prepared using 
the same quantities of methanolic solutions, evaporated 
to dryness after internal standard had been added, then 
re-dissolved in 1001kl of methanol. 
Stability of imipramine-N-oxide 
Since IPNO may not be stable under the conditions 
used for extraction and storage, an experiment was 
conducted to test this possibility: 
200ng quantities of IPNO were added to four sets 
of plasma (250, zf. 1-, in duplicate), containing internal 
standard, and the following alternative processing 
procedures used: 
a) no NHOH added before extraction 
b) NHOH added and extracted, evaporated and 
i=ediately chromatographed 
c) NHOH added, extracted, stored as residue (-200C) 
d) NH,, PH added, extracted, stored as extract (-20 0 C) 
usual procedure 
Each was chromatographed and the index of IPNO 
stability was the production of imipramine; if no imipramine 
was produced then IPNO must be stable under the conditions 
used. 
As a result of this investigation, the complete 
stability of IPNO under the conditions used was demonstrated. 
Characteristics of the analytical procedure 
Retention data for the analytical procedure are 
shown in Table 7.1, and calibration curves for all the 
reference compounds are shown in Fig. 7.1. Linearity of 
detector response was demonstrated over the required range, 
and chromatograms obtained from extracts of urine and plasma 
containing the majority of these compounds are shown (Fig. 7.2). 
As indicated in Table 7.1, isotopic fractionation occurs; 
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Table 7.1 Retention Data for All the Compounds 
Chromatographed 
ý, Compound 
Retention 
Time 
tR (min) 
Retention 
Volume 
VR (ml) 
imipramine 3.6 12.6 
imipramine-d4 3.6 12.6 
imipramine-d 3 4.0 14.0 
imipramine-d? 4.0 14.0 
2-hydroxyimipranine 4.4 15.4 
" 2-hydroxyimipramine-d4 4*4, 
ý 
15.4 
2-hydroxyimipramine-d3 5.0 17.5 
" 2-hydroxyimipramine-d? 5.0 17.5 
didesmethylimipramine 5.3 18.6 
didesmethylimipramine-d4 5.3 18.6" 
desmethylimipramine 11.5 40.3 
desmethylimipramine-d4 11.5 40.3 
desmethylimipramine-d 3 13.0 45.5 
desmethylimipramine-'ý7 13.0 45.5 
2-hydroxydesmethylimipramine 14.0 49.0 
" 2-hydroxydesmethylimipramine-d4 14.0 49.0 
2-hydroxydesmethylimipramine-d 3 16.8 58.8 
" 2-hydroxydesmethylimipramine-d. 16*8 58.8 
imipramine-N-oxide 17.5 61.3 
imipramine-N-oxide-d4 17.5 61.3 
imipramine-N-oxide-d 3 18.5 64.8 
imipramine-N-oxide-d,? 18.5 64.8 
protriptyline 16.0 56.0 
10-hydroxyimipramine 4.4 15.4 
In fact, these hydroxylated metabolites are d n-l - one 
deuterium has been replaced by the hydroxy group. 
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in other words, replacement of hydrogen by deuterium 
caused a shift in retention time to a longer period. 
This effect was only observed for the N-deuteromethyl 
analogues, if a fractionation effect was caused by 
aromatic deuteration (d4) this was too small to be 
observed. No standards were'available for a number of 
the deuterated analoguesq and the only means of 
quantifying these was to use the non-deuterated standards 
and apply a correction factor in order to obtain 
accurate measurement. '' 
The correction factor was-calculated by comparison 
of the peak areas for deuterated and non-deuterated 
analogues. A number of assumptions had'to be made: 
a) the fluorescence intensity of equal amounts of 
deuterated and non-deuterated ahalogue is equal 
b) for equivalent amounts of deuterated and non-deuterated 
analogue the peak areas are equal 
c) the identity of the peaks is as indicated in Table 7.1 
d) the area of the peaks =J base x height 7 
=jb. h 
e) the length of the base of the peak is independent of 
the amount of compound. 
Thus, for the correction factor: 
consider two peaks Al and A2 containing equal 
amounts of compound but peak Al (non-deuterated) 
ch. romatographs before peak A2 (deuterated) 
Area Al Area A2 
b1h 1 b2h 2 
22 
bh '2 1, 
b, h2' 
if b2 
b1 
then, h, = h2x where x is the correction factor. 
-1? 4- 
magnitude of x, 
x b2 base of deuterated p2. aý 
b base of non-deuterated peak 
By comparison of a large number of peaks it was 
possible to obtain a correction factor of L33, which 
applied to isotopic fractionations observed for all the 
affected compounds. 
Assumption(a) was validated by an experiment in 
which response factors for imipramine were compared with 
those for imipramine-d 3' imipramine-d4 and imipramine-d?. 
In this experiment peak areas were virtually equivalent 
for each analogue in the same concentration; peak areas 
for imipramine-d? were never <90% of the peak areas of 
imipramine. Thus fluorescence intensity can be assumed 
to be equal. 
Assumption(c) is'harder to validate. By comparison 
of chromatograms obtained from urine extracts of 
imipramine-treated and imipramine-cL7-treated rats one can 
see that the extra peaks were due to deuteration; no 
peaks were observed from blank urine and it is unlikely 
that a radically different pattern of metabolism of 
imipramine would be produced. In the unlikely event of 
variation in the site of aromatic hydroxylation, no 
change in the chromatogram recorded would occur since all 
these isomers would co-chromatograph. Few other sites 
for metabolism are available which would produce the large 
quantities of these extra metabolites observed (i. e. as 
a result of a small isotope effect). Also, based on 
previous knowledge of fractionation between imipramine, 
and imipramine-d 3 and imipramine-d7 this is the pattern 
of metabolites and chromatogram to be expected. 
The internal standard protriptyline and 2-OH DMI-d 3 
partially co-chromatographed (see Fig. 7.2). However, it 
was still possible to quantify all the peaks by introducing 
a form of external standardisation. Fixed volumes of 
identically treated extracts were injected and these 
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compared with extracts containing internal standard only, 
carried through the same procedure. Analytical accuracy 
could be increased in this way by demonstration of, and 
calculation of, reproducible peak heights for the 
quantity of internal standard produced by injection of a 
fixed volume of extract. 
Reproducibility and recoveries for the analytical 
procedure are shown in Tables 7.2 and 7.3 respectively, 
for all the available reference compounds. The assay 
was reproducible and deuteration appears to have no effect 
on recovery from either urine or plasma; recovery of all 
compounds was identical from both these matrices. 
Reproducibility was poor at levels below the approximate 
minimum detectable concentrations indicated: 
I/2-OH I/I-d4 5-10 nE; /ml 
I-d? /I-d 3 10-20 ng/ml 
DDMI/DMI 20-40 ng/ml 
2-OH DMI/IPNO 50-100 ng/ml 
Pharmacokinetic Studies 
In all experiments, male Wistar-albino rats 
(235-320g) were used; for experiments involving the oral 
route of administration, the animals were fasted for 12 
hours - 
intravenous administration 
Pentobarbitone could not be used as the anaesthetic 
for this-experiment since this compound interacts with 
imipramine to extend its half-life,. (Bickel and Gigon,, 1969; 
Nakazawaj 1970). The procedure adopted for induction *. '- 
and maintenance of anaesthesia was as follows; the rats 
were initially anaesthetised with chloral hydrate 
(300 mg/kgg 2 ml/kgj intraperitoneally) followed one hour 
after imipramine administration, by a maintenance dose of 
urethane (800 mg/kg, 2 ml/kg, intraperitoneally). 
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Maintenance thereafter was by further doses of urethane. 
In this way, administration of imipramine intravenously 
did not result in animal death as had occurred previously 
when anaesthesia was achieved using urethane (2.8g/kg, 
7ml/kg, intraperitoneally) or chloral hydrate (300 mg/kg, 
2 ml/kg) individually. With urethane anaesthesia, death 
immediately followed imipramine administration whereas 
with chloral hydrate anaesthesia, death occ urr ed 2-2j hours 
later. 
Imipramine had to be administered over five minutes 
and into a peripheral vein, since administration via the 
jugular vein resulted in death, probably due to respiratory 
shock. Rapid administration via a peripheral vein had a 
similar effect. These problems are probably the result of 
a synergistic effect of the anaesthetic and imipramine on 
the central nervous system causing respiratory shock and 
subsequent death. 
Imipramine-hydrochloride at two dose levels (10 mg/kg 
and 20 mg/kg, 20 mg/ml) and imipramine-cL7-hydrochloride 
(10 mg/kg, 20 mg/ml) were administered intravenously via 
a femoral vein; four rats were used per group. 
, 
Skin overlying the left femoral vein was pared to 
reveal the vein, superficial connective tissue was cut away 
and the vein entered by means of a 25 gauge, 16 mm needle 
(bent to an angle of --1200) connected to a 1.0ml syringe. 
The drugs were administered slowly over fa. Ve minutes, the 
needle was then removed and bleeding prevented by applying 
pressure to the wound for several seconds. Zero-time was 
taken as the time when all the drug had been administered, 
and blood samples (0.6 ml) were removed by serial cardiac 
puncture, or in the case of rat A (20 mg/kg) by tail 
bleeding, into heparinised tubes at regular time intervals. 
Plasma was obtained by centrifugation of the blood 
samples at full speed in a bench centrifuge for five 
minutes. 
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oral administration 
The drugs were administered orally to four or five 
rats by gastric intubation, in doses of 50 mg/kg 
(12.5 mg/ml, 4 ml/kg). Animals were not allowed food 
until three hours after drug administration. Blood 
samples (0.6ml) were obtained, at regular time intervals, 
by tail bleeding. 
Three experiments were conducted; one compared 
absorption of imipramine and imipramine-d? (hydrochlorides), 
the second compared elimination of imipramine and 
imipramine-d3l -d4 and -d? (hydrochlorides) and the third 
compared the urinary excretion profile following imipramine 
and imipramine-d? (hydrochlorides). 
For the experiment involving collection of urine 
samples, animals were housed individually in metabolic 
cages and allowed free access to food and water. Volumes 
of the pooled urines were noted at each collection time. 
Urine samples were processqd-by two means; the first 
involved direct extraction of diluted urine, the second 
involved hydrolysis of glucuronides prior to extraction. 
This enabled the proportion of phenolic metabolites in the 
form of glucuronides to be quantified. 
All plasma samples were hydrolysed (ketodase), 
except those obtained in the experiment designed to compare 
drug absorption. 
Anal7sis of samples. 
Plasma and urine samples, if not processed 
immediately, were stored frozen at -200C. 
-Hydrolysis of glucuronides was achieved as follows: 
To 250 `f. 1 of urine or plasma in LP3 tubes were added, 
50 al of internal standard solution, 250 /41 of water, 
500 oAl of O. lM acetate 
buffer, pH 5.0, and 500 Al of 
ketodase solution (5, OOOU of jS-glucuronidase per ml of 
acetate buffer). This mixture was incubated for 24 hours 
at 370C in a shaking water bath. After incubation, 50, -Xl 
of NH40H were added and the mixture extracted with 1.0 ml 
of 20% n-butanol/hexane as described earlier. 
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For plasma extracts, 90 /Al of the reconstituted extract 
were injected. 
For urine extracts, 10-25/41 of the reconstituted extracts 
were injected. 
Peak height ratios were calculated and compared with 
a series of standards processed in identical fashion. 
Statistical analysis. 
Plots of log-concentration against time were 
constructed utilising linear regression analysis, and 
statistical analysis of the data was carried out by use 
of Students t-test. 
Pharmacological Studies 
Two experiments were conducted, one in vivo and 
one in vitro. 
Intestinal motility (charcoal meal) test (in vivo) 
This experiment was carried out in both mice 
(male Ult 25 t lg) and rats (male Wistar-albino, 100 t log). 
In each case, five groups of ten, 12 hour fasted animals 
were used. Each group was pretreated with the following 
compounds one hour prior to administration of the charcoal 
suspension by gastric intubation; a dosing volume of 
3 mi/kg was used for the drug solutions, and for the 
charcoal suspensiont O-lml was administered to mice and 
0.2ml to rats. (Sacra and. McColl, 1960). 
Group Oral Pretreatment 
(1 hour) 
Dose (mg/kg) 
Mice Rats 
A imipramine-c % 
hydrochlorid 50.0 30.0 
B imipramine 
hydrochloride 50.0 30.0 
C desmethylimipramine 
hydrochloride 50.0 50.0 
D saline - - 
E atropine sulphate 0.6 0.6 
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The charcoal suspension consisted of: 10 mi. 
distilled water, 1.0g powdered charcoal (5-6Ac) and 
0.5g gum acacia. 
20 minutes (mice) or 30 minutes (rats) following 
administration of the charcoal suspension, the animals were 
killed by a sharp blow on the head and cervical dislocation. 
The small intestine of each was dissected out from the 
pyloric sphincter to the appendix (care being taken to avoid 
undue stretching of the intesti'ne) and the intestine laid 
out as straight as possible. The length of the intestine 
was measured, as was the distance the charcoal had 
travelled. The passage of charcoal was calculated as a 
percentage inhibition, or enhancement, of movement of 
charcoal along the intestine (relative to saline controls). 
Isolated rabbit jejenum (in vitro) 
One female rabbit (3-5 kg) was killed by a blow on 
the head and exsanguination. The abdomen was opened and 
the intestine cut at a point 5-10cm below the stomach and 
a length taken from here downwards and placed in a dish 
containing Tyrodes solution (see Appendix 2). The 
mesenteric membrane was trimmed away and the jejenum out 
into strips 2-3cm long; threads were passed, from'inside 
the gut outwards, using a needle through either end of 
the gut taking care that the lumen was not closed off. 
One thread was tied to a fixed pin in the organ bath 
(volume 20ml) and the other to a lever attached to a 
tension transducer (Fig. 7-3), the gut was bathed in 
Tyrodes solution at 3? OC and gassed with oxygen/carbon 
dioxide (95: 5). Tension (/, Ilg) was adjusted until good 
pendular movement was obtained; the preparation was then 
allowed to stand for 30 minutes to stabilise before any 
additions to the organ bath were made. Concentrations of 
the drug solutions used, ranged from O. JmM to lOmM, and 
5 , zAM nor-adrenaline solution 
(+ve control) was used; the 
volume of addition of each varied from 0.1ml to 0.4ml. 
(Livingstone, 1970a). 
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Fis. 7.3 The Isolated Rabbit Jejenum Preparation. 
ExDerimental Set-uD 
. ias e 
Two types of experiment were conducted: 
a) Effect of the drugs directly on pendular movement 
- simple addition of the test compound, at several 
concentrations, to the organ bath for 30 seconds and the 
effect on pendular motion was continuously monitored using 
a physiograph. After 30 seconds the preparation was 
washed with fresh Tyrodes solution by emptying and filling 
the organ bath three times. Further additions were not 
made until the preparation had restabilised. 
b) Potentiation of the effect of nor-adrenaline 
- the effects of the test compounds, at several 
concentrations, on the response of the tissue to a fixed 
amount of nor-adrenaline, was monitored. This was achieved 
by pretreatment of the tissue, for 30 seconds with the test 
compound, then addition of nor-adrenaline (5 x 10-6M) for 
30 seconds. The effects of these combinations were 
monitored and'the preparation then washed three times as 
described above. 
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RESULTS 
Pharmacokinetics - Interpretation and Presentation of 
Results 
Results are presented for individual rats (A-Z) 
as plasma concentration (c) - time (t) curves (plotted 
on log-linear axes) for imipramine and its deuterated 
analogues following administration by various routes 
(Fig. 7.4-?. 61 7.8). Levels of the demethylated 
metabolites desmethylimipramine and didesmethylimipramine 
are shown as plasma concentration - time curves for 
groups of rats (mean values with standard deviation - 
bars) (Fig. ?.?, ?. 9). Pharmacokinetic data are 
obtained from the plasma concentration - time curves 
which demonstrate that imipramine is eliminated by 
first-order kinetics for a one-compartment model 
(Fig. 7.4, ?. 5), and this model is used for interpreta- 
tion of the data obtained following oral administration. 
Brief experimental details are given with the tables 
rather than with the figures, and tables are placed 
opposite the appropriate figures. The pharmacokinetic 
parameters were calculated as follows: (see Appendix 1) 
for intravenous administration, 0= Co e -kelt 
Biological half-life (t and initial concentration (Co, 
by extrapolation) were obtained directly from the plots. 
Total area under the curve (AUCtot) was calculated by 
addition of the factor C/k el 
to the area under the curve 
to the last sampling point (determined by the Trapezoidal 
Rule). C is the plasma concentration at the last sampling 
time. The other parameters were calculated as follows: 
volume of distribution, V=x D -0 
Co 
where Xo is the administered drug 
elimination rate constant, kel 0-693 
t 
total systemic clearance, C1 
X0 
AUCtot 
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for oral administration, C kaFXO e -k elt e -k at 
vD (k 
a-kel) 
Absorption rate constant (ka) was obtained using the method 
of residuals. The terminal-linear portion of the 
concentration - time curve generates elimination parameters 
(t iIk el); 
I (intercept on concentration axis, by 
extrapolation), and AUCtot (Trapezoidal Rule + C/k el) can 
also be obtained from these plots. The remaining 
parameters were calculated as follows: 
VD kaFXO 
(k 
a7 
k 
el), 
time to peak plasma level, tp 2.303 log ka/k 
el (k 
a -k el) 
maximum plasma concentration, Cmax FXo e-k el 
tp 
VD 
fraction of the dose entering the systemic circulation, 
FM = AUctot-oral .1x 100 
AUC tot-iv 
2.5 
The factor 2.5 is the dose correction factor (oral dose/ 
intravenous dose) 
cl FX 0 
AUC tot 
The urinary excretion profiles of drug and 
metabolites are expressed as the cumulative total of each 
compound excreted per rat as a function of time following 
oral administration of both deuterated and non-deuterated 
drugs (Fig. 7.10) 
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KEY I imipramine 
2-OH I 2-hydroxyimipramine 
2-OH DMI 2-hydroxydesmethylimipramine 
DMI - desmethylimipramine 
DDMI - didesmethylimipramine 
IPNO - imipramine-N-oxide 
GA - Slucuronic acid 
Effects of Route of Administration and Dose on Imipramine 
Pharmacokinetics 
The effect of route of administration and dose on 
the pharmacokinetics of imipramine and its deuterated 
analogues is shown in Table 7.8 (from Tables 7.4-?.? ); a 
direct comparison is possible for the two routes even 
though different methods of blood sampling were used. 
There appears to be no difference in plasma levels 
determined by different methods of blood sampling 
(compare Fig. ?. 4, rat A with B, C and D). All parameters 
monitoredt except initial concentration and bioavailability 
(area under the curve, which is dose related) appear to be 
independent of either route or dose (Table 7.8). 
Comparison of the oral and intravenous routes of 
administration shows a markedly lower bioavailability for 
the oral route, much lower plasma levels of parent 
compound but higher plasma levels of the demethylated 
metabolites. The fraction of the oral dose reaching the 
systemic circulation appears to be less than 5%, and 
demethylated metabolite levels reach 200-300 ng/ml of 
plasma very quickly (within one hour). 
The half-life of imipramine was 2.5-3 hours 
(Table'7.41 7.59 ?.? ) with a total systemic clearance of 
A, 90ml kg-lmin-1 and the most striking feature of its 
pharmacokinetic properties was the low plasma levels 
(large volumes of distribution, ?- 20 lkg-') produced by 
either route (i. e. -100 ng/ml following oral administra- 
tion of 50 mg/kg), the very small fraction of the dose 
entering the circulation unchanged (< 5%), and the high 
levels of metabolites produced after only a few minutes 
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following oral administration (Fig. 7.7,7-9). Levels of 
the phenolic metabolites in plasma were too low to be 
determined even following treatment of the plasma with 
ketodase; plasma levels of 2-OH I were therefore below 
5 ng/ml-and levels of 2-OH DMI below 50 ng/mi, following 
either oral or intravenous administration of imipramine. 
Only demethylated metabolites were observed in plasma 
although all the major metabolites of imipramine were 
observed in urine (Fig. 7.10), which indicated that by 
far the greatest proportion of these metabolites formed 
as the hydroxylated compounds 2-OH I and 2-OH DMI, either 
as free phenolic compounds or as glucuronides. The 
amounts of metabolite formed, in largest proportion first 
were: 
2-OH DMI GA> 2-OH DMI C'- 2-OH I GA> 2-OH I> DMI IPNO> DDMI 
-A slight variation in the traction of the dose 
reaching the circulation intact (F) was observed between 
the two oral experiments but this was quite small with a 
range of 2.3 - 4.3% (Table 7.8). This effect was mirrored 
in values for the maximum plasma concentration (Cmax) for 
the same experiments, however, quite large standard 
deviations for these parameters were apparent and 
individual animal variation may explain this discrepancy. 
Effect-of Deuteration on the Pharmacokinetics Of Imipramine 
The pharmacokinetic comparison of imipramine and 
its deuterated analogues was divided into an absorption 
comparison (using the oral route of administration) and 
an elimination comparison (using both the oral and intra- 
venous routes of administration). 
Effects of deuteration on the absorPtion of imipramine 
The effects of deuteration of both an N-methyl 
group and the aromatic rings of imipramine on its 
pharmacokinetic properties are shown in Table ?. 6 and 
Fig. ?. 6 and ?.?. No statistically significant differences 
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were apparent for any of the parameters calculated 
although peak plasma levels were achieved earlier with 
the non-deuterated compound; however, the fraction 
absorbed (F) was the same. Low plasma levels of the drugs 
were obtained and a very small fraction of the administered 
dose (< 3%) was absorbed unchanged. 
Effects of deuteration on the elimination of imipramine 
Each of the deuterated analogues were used in 
these studies. Tables 7.5 and 7.7 and Fig. 7.8 and 7.9 
show the effect of deuteration on the elimination of 
imipramine. Clearly, deuteration of one of the N-methyl 
groups of imipramine caused an isotope effect, but there 
was no isotope effect observed as a result of aromatic 
deuteration. A similar magnitude for the isotope effect 
is observed for imipramine-d7 (following intravenous 
administration) and imipramine-d 3 (following oral 
administration). The isotope effect calculated by ratio 
of tj or kel (or clearance) for deuterated to non-deuterated 
alogues (or vice-versa) was 1.32 (intravenous) and 
1.33 (oral). Table 7.7 shows an effect of N-methyl 
deuteration to slow t.,, increase peak plasma levels and 
area under the curve 
7 (Table 7.5), decrease k 
el and 
total 
systemic clearance and increase the fraction of the oral 
dose reaching the circulation (0.01<P. < 0.05). 
Support for an isotope effect on N-demethylation 
comes from the plasma metabolite patterns observed following 
oral administration of imipramine-d 3 (or _d7) (Fig. 7.7,7-9). 
For example, the amount of DMI-d 3 was in excess of DMI-do, 
by a factor of., - 2, which indicates an isotope effect of 
,, --2 on N-demethylation of 
the -CD 3 group. In fact, an 
isotope effect of 2 on N-demethylation of one methyl group 
only, with demethylation of the second methyl group 
remaining unaffectedý would produce an overall isotope 
effect of , -1.33. 
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Fig. 7.7 Plasma Concentrations of Metabolites as a 
Function of Time After Oral Administration 
of ImiDramine and ImiDramine to Rats 
Blood samples were obtained from the tail 
vein following oral administration of the 
two drugs (50 mg/ks) to two groups of four 
male rats. Mean plasma levels and standard 
deviation (bars) are presented for the 
demethylated metabolites., DMI (-dn) and 
DDMI (-<In)s for each group of rats. 
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Table 7.7 Pharmacokinetics of Imipramine, Imipramine-d 
and Imipramine-d 3 Following Oral Administration 
to Rats. Elimination Comparison. 
Weight 
of rat 
Drug Correlation 
coefficient 
t 
(ng ml-i 
kel 
(min) (min: 
A- 265 1 -0-999 150 200 0.0046 
B- 265 1 -0-976 150 101 0.0046 
C- 255 1 -0-999 159 135 0.0044 
D- 245 1 -0.993 204 64 0-0034 
E- 260 1 -0-985 132 74 0-0053 
Mean t S. D. (n 5) 159 1 27 t 115 : 55 0-0045 
0.000'? 
F- 265 I-d 4 -0.989 206 123 0-0034 
G- 250 I-d4 -0.990 155 108 0.0045 
H- 255 I-d4 -0.980 155 110 0.0045 
I- 250 
1 
I-d4 -0.985 154 120 0.0045 
Mean t S. D. (n 4) 168 1 26 115 t7 0.0042 
+ 0-0006 
K- 265 I-d3 -0.940 249 ill 0.0028 
L- 230 I-d 3 -0.988 212 86 0-0033 
M, - 225 I-d3 -0.988 193 138 0-0036- 
N- 240 I-d 3 -0-987 150 290 0.0046 
0- 270 I-d3 -0.98v 252 ill 0.0028 
Mean I S. D. (n 5) 211 t 42 147 "± 82 0-00-34- L 
00 :t0 0- 000"77 
AUCtot-intravenous - 197 , 
Ag min ml-1 after a dose of 20 me; /kg 
assuming Ka n 0.054 min-' (from Table 7-6) 
0.01 4<0-05, t P, <0.05 
Blood samples were obtained from the tail vein following 
oral administration of the drugs (50 mg/kg as hydrochlorides 
or 44.3 mg/kg as free bases) to male rats. Blood samples 
were taken over a longer period (up to 7 hours) in order to 
compare the elimination characteristics of the drugs. 
AUCtot ci tp Cmax 
v D (/199 min F(%) (ml kg-' (min) (ng ml-1) 
(1) (lkg-1) mi-i ) min-') 
3.4 13 31 6.3 90 50 175 
5.2 20 20 4.1 91 50 73 
4.5 18 24 4.9 90 51 99 
6.3 26 17 3.5 91 55 50 
4.4 17 13 2.6 89 48 53 
4.8 :ý1.1 19 :ý5 21 t ?t +43 1: -411 
90 :ý1 50 :ý3 90 t 51 
7.3 28 32 6.5 90 55 86 
4.6 18 20 4.1 91 50 79 
4.7 18 20 4.1 91 50 79 
4.5 is 22 4.5 91 50 88 
5.3 i; 1.4 21 :ý5 24 t6 4.8 91 t1 51 f2 83 5 t 1.1 1 
8.8 33 39 7.9 90 58 89 
6.2 27 2Lý 4.9 90 55 67 
5.3 24 34 6.9 90 54 106 
3.8 16 47 9.5 90 50 210 
8.3 31 36 7.3 90 58 90 
6o5 2.1 26 :ý7 36 :t8t +73 : 90 55 :ý3 112 :ý 56 -1 7t 
Fig. 7.8A Plasma Concentration of Imipramine as a 
Function of Time After Oral Administration 
to Rats 
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Table 7.8 Effect of Route of Administration on the 
Route Drug Dose 
(mg/kg) n 
ti 
(min) 
I/cO 
(ng/ml) 
k 
el 
(min7l) 
i. v. 1 20 4 183±26 ? 88: t24 0.0039±0.0006 
i. v. 1 10 4 1 155t24 533t194 0.0046+-0.0006 
i. v. I-d? 10 4 205±31 564+194 0-0035±0-0006 
P. O. 1 50 4 139t25 59±33 0.005ltO. 0009 
P. O. I-d? 50 4 150±58 69: t23 0.0053: tO. 0026 
P. O. 1 50 5 159: t2? 115: t55 0.0045t0-000? 
P. O. I-d4 50 4 168t26 115ý;? 0.0042tO. OOO6 
P. O. I-d 3 50 5 211: 
42 14?: t82 0-0034±0-000? 
All the pharmacokinetic parameters obtained in Tables ?. 4-?.,? 
are collated here. 
Table 7.8 (contd) 
Pharmacokinetics of Imipramine and Deuterated Analogues 
Fk 
.a (lnjn_1) 
a _, 
v 
(1) lkg 
AUC tot 
min 
m1-1 
F(%) 
ci (mi 
kE-1 
min-1) 
tý 
(Min) 
Cmax 
(ng 
m1-1 
5.9: ý0.4 23t1 19742 92t16 - 
5.1±1.4 18f5 109±28 85: t20 - 
4.3: ý0.7 16Z2 15844 59k7 - - 
o. 066±0.062 5. Otl. 0 20t5 11.24.4 2-3k-7 90k 54-22 3742 
0.042t0.020 5- Ok -8 204 12.3: 
ý3.8 2.5±0.8 90t1 6446 41t12 
4.8±1.1 19t5 21: t7 4.3: ý1.4 90k 51: ý3 90ý51 
5.3k -4 21: 
ý5 246 4.8±1.1 gitl 51t2 83: ý 5 
6.5±2.1 26t7 36: t8 7.3: ý1.7 90 55: ý3 112t56 
Fig. 7.9 Plasma Concentrations of Metabolites as a 
Iýmction of Time After Oral Administration 
of Imipramine, Imipramine-d,, and lmipramineýd 
to Rats 
Blood samples were obtained from the tail 
vein following oral administration of the 
three drugs (50 mg/kg) to three groups of 
male rats. Mean plasma levels and standard 
deviation (bars) are presented for the 
demethylated metabolites,, DMI (-dn) and 
DDMI (-dn), for each group of rats (4 -5 
per group - see Table 7.7). 
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A. Administration of Imipramine 
Effect of deuteration on the urinary excretion pattern 
of imipramine and metabolites. 
The urinary excretion profile of imipramine and metabolites 
(Fig. 7.10) appears to be similar for the deuterated and 
non-deuterated analogues. Nevertheless, there is 
evidence for an isotope effect on N-demethylation since 
the quantity of IPNO-d? excreted was greater than that 
of JPNO and, with isotopic fractionation, it was possible 
to observe that the N-deuteromethyl analogues of DMI and 
2-OH DMI (total including glucuronides) were in excess, 
by a factor of /--, 2, of their N-methyl (do) counterparts. 
There also appeared to be a greater proportion of 
2-OH I-d.? (including glucuronides) formed than 2-OH I 
formedg lending support to the idea that the first 
N-demethylation step was slowed. 
Effeots of Deuteration on the Pharmacology of Imipramine 
The results obtained for the charcoal meal test, 
in both rats and mice, are shown in Tables ? -9 and 7.10. 
A lower dose of imipramine and analogues was used for 
rats since only a small quantity of imipramine-cL? had been 
synthesised; it was thus a necessary economy to use a 
lower dose. All the compounds tested produced statistically 
significant differences to control response, imipramine 
and imipramine-d? produced similar effects but atropine 
sulphate (the positive control) produced the most 
pronounced effects. Obviously deuteration showed no effect 
on the inhibition of gastro-intestinal motility by 
imipramine. 
The in vitro test system used confirmed these 
findings: 
a) direct effects of the test compounds - no differences 
between imipramine and its deuterated analogues were 
observed here. Results from Table 7.11 are Plotted in 
Fig. 7.11 and the close similarity of effects due to 
imipramine and all its deuterated analogues can easily be 
-187- 
Fig. 7.10 Urinary Excretion Profile of Drug and 
Metabolites Following Oral Administration 
of Imi2ramine and Imipramine-d to Rats 
--`7 
Pooled urine samples from five male rats 
(per group) were collected at regular 
times following oral administration of the 
drug hydrochlorides (50 mg/kg). Results 
are presented as the cumulative amount of 
drug or metabolite excreted (per rat) as a 
function of time after administration. 
Glucuronides are calculated as /4g of 
unconjugated compound present following 
hydrolysis with ketodase (total amount) 
minus the free compound already present 
(unconjugated compound). 
: pig. 7.10A UrinarY Excretion Profile Following 
Administration of Imipramine 
600 
4-00 
200 
141 GA 
OH DMI 
I GA 
-OH I 
)MI 
? NO 
DKI 
1,, - 10 2ý 3ý 2; b Cý() 60- 70 80 
Time After Administration. (hours) 
Fig. 7.10B Urinary Excretion Profile Following 
Administration of Imipramine- 
I 
Id7 
DMI-d4 
d7 
-d4 
I-d 
-d4 
10 20 30 40 50 60 ?o 80 
Time After Administration (min) 
I 
a% 
Cý 
4) 
r-4 
12 
E-1 
C, 
C) 
43 
a, 
r-I 
z 
0 
C) 
C) 
0 
-r-1 0 p 02 r-i 0 rl 0 
r-i a) 
Ici P., Ici C) m0 
r-1 
cri 
iz 40 %- o cl 
cl 
1 4-4 0 
00V 
9 $4 
-r4 0 co 04 
-H 0 p 4-ý 
P4 Cd 0 
-r-i p4 S 4--) 4-3 
. ri (D 0.0 o 
s co co 
0 
P4 P 
-ri 0 4-) 
*H 
4-4 A 
0 914 
00 a) 
Id r-I 
r-f 
Cd 
p 
0 
.0 4-3 
-r4 Cd -r-4 
4) 0 10 t 
a) 
4-) 
(D -P to p Cd 0 
4-) .0 -P 
P4 
(D 
9: C\j 
P4 P 
(1) 0 0) 
0P 4-ý 
-ri 4-) 2: cd 
4-ý 
Cd 
cs 
Cd 
(D 
0 
.H 4-ý 
0 
. rq 
4-) 
i 
r-I 
H 
D- 
+1 
co 
+1 
C\j 
C\j 
+1 
rc\ 
U'\ Lr\ co 0 
r-i M , ýR r-I C\j NN -: d- zt 
+1 +1 +1 +1 
ý? C\j Lfl\ KN Oj C\j r-q 
4) 
4-1 
cd 
4 ho 
bo 
-H 4) b) 114, El 9: M 
0 
p f-A 0) 0, o 
0 rq so 
(D 
0 
0 - P 
Lr\ 
P 
UN 
P -H A 
t 1:: ý P, 0 
. rj $4 0 El 4.3 
ri co 
4-) 
0 
$4 
4-) P4 
0 
0 944 
0 
4-) 
> 
Id 
to 
(D CO 
pq 
0 
0 
0t 
ý 
ý4 
0 
H P4 
0 
P 
¶1 
I 
. rq 
r-i 
0 
rg 
0 
. rf 4.3 
m 
(D 
4J 
V) 
Cd 
c 
r. 
0 
4-4 
0 
0 
0 
cd 
4.3 
0 
0 
-P e. ) 
(1) 
4-4 
4-4 
0 
H 
CZ 
a) 
r-q 
10 Cd 
E-4 
02 
-P 
02 
du 
E-1 
H 
Z: 
H 
Cd 
0 
c) 
P 
ri 
Id 4) 
0 r-4 4 -r-I 
ly 0 
V4 a) 
0 FA 
0 
4-3 
02 4) 
co 
Cd 4-3 
cd 
p El Id 
0 0) 
0t 
H 
Id 4.3 
4.4 
cd 
V0 
. r-I 0 Cd 
Id 9: ý: 00 
-ri rq 0) Ea 0 
02 0 -rq 
'd Q 4-3 
P4 0) 
9) (D 
004.3 
0 ri 
f. ) cd 4) 
0 .0 o 4J 
43 
00 
4J, 
rl cd 
4-1 
0 4) 
0 0) 
$4 Cc 
43 Ff 
0 4. ) 
P 4.3 
rn 
$4 
V2 
Cd 
0 
4-) 
a) 0 
r-i -rl 
Cd 94 
2: " 
0 
rq 
KIN 
Cj 
0 
C\j 
Lr\ 
Cv 
C\j 
Nl\ 
KN 
N 
Lf'\ 
If, \ 
e-% C) ON co 01-S CN 
O-N 
olý #11% 0 
r-I %.., o %-, o %1-01 % ., H 
Id 
0 
,H 
ON tD ON r-q 
H 
0 
r-I 
co 
:> + +1 +1 +1 +1 +1 Cd co . 
2: 43+1 NN 0 r-I C7\ 0 Lr\ 4- C\j 
to to 
, 
tD 4.3 hO s 4 
5,4 
m 
p 11 
P4 Z b 
Cd 1ý4 
PI"O R El ,t 0 
I f-q 
0 
S r-I 0 
0 00 0o 
93 K, \ r4 
0 m 
0 
r-I 
p 
4-) 
a) 
.,. q 
P4 
4. ) 0 P4 
r-I 
P4. 
H 
S 
C13 
0 
P 
0 a) 
C\j 
8 
C; 
(D 
4-) 
A 
r-q H 
r-I r-q 
o cd cd 
. r4 bo 00 
4-4 4-4 
to 
-H r-i r-I 0 
0 
0 
Ryy $: 4 P4 0 
94 4-: 0 -P a) 
P4 
-P +1 +1 
Cd 
$4 0 
0 11 11 
p r-i r-I Q00 $4 $4 
43 
0 
00 
U0 
CO-4 4-4 
E-4 F-I H 
4-4 
0 
CD 
0 
r-4 
:1 
Id 
P4 
rA 4 
4-2 
Cd 
lid 9 
. r4 El 
1-4 
4-4 
0 
4-3 
4-1 
44 
P 
r-4 
r-I 
E-1 
4-3 
m 
H 
4-) 0 
4-ý 
V) Cd 
(D p 
P4 4a 
90 
Ea 
00 (D 
10 W co Id 0) 
(D 10 (1) 4-3 4-ý 
Cd 04 
0 4) P4 
. f. 4 10 
-P 4-3 91 Cd 
t 
(D 
(D 43 
P0H 
P4 CD ko 
H (D 4) 
0o 
0 
0) El 
T13 m 
4) ý rl 
. r, z 0 
r-I *rl Id :3 
(D Id 
4-3 0 
H P4 0 
0 $4 
w 93 0 
-rl -ri 4-) 
a) 
(D (D Id 
El 
Cd 4-1 
a) 0 
P 
00p 
0) (D 
to 'd 'D 
0 
R 0 E-4 
W 
:19 18 0 
0 > 0, 
00 
0 Id V 
a) m 4, ) 
4-) 
t 
Ea 
0 a) (D 
4) M 4-3 
co-4 4) 
4-1 $4 0) 
4) pq 4 
43 
4-4 
E-1 0 
4a 
H 
:31 J- -: d* -4- r-I cm co WN co to (D 4) %-. # %-. * r-I %... o %-0 %-. # -. -. o (D 91-10 
C\j ri tr\ r-I tc% KN N 
H P4 P4 +1 +1 +1 +1 +1 +1 +1 
0 -rl r4 ý 00 El lt: P i qI r-I C\l UIN C\j 
Lr\ cl- 
K 
ý -Zj- UN 2 -1 r r \ 
0 tD ko 
F4 -H 
i P4 +I +I +I 
0 -r-I t 
0m ti 
P iI 
110 
q -r 
m 
43 K\ 
H Id 
:31 e-% 
it tc\ 
t 
(D 94 1 +1 +1 +1 
r-i Pq 0 -ri 'd C- LA C\J 0 os 
P., rl 
Lr\ 
a) C\j C\l N rq N r-4 N 93 %-. 10 %-. 4 %_o %-. * %-00 %,. d 
-H 
PC% C\j t-41, PC\ 
+1 +1 +1 +1 
0 Lr\ _: I- 0 tc\ cl- H C\j C%j K% Lr\ 0 
CD 
0 
J-1% 
0-% 
C\j 
e-% 
Lrl% r-4 CQ 
e-% 
H 
e-% 
C\j 
.H C\J %-, o %-. o %-. # --. o '-p %-. * 9 
0-% r-i Lr\ KN r-i 94 
$24 +1 +1 +1 +1 
C\j 0 WN co tC\ Cý- ON N C\l tc\ K\ 4 V\ 0 
0 
. rj 
4-3 
cd 0 Lr\ 0 
1 
LA Cý UN 0 Lr\ 0 
0 r. -i r-I C\j C\j Lr\ 
0 
0 
0 
4-2 
0 
P4 
4) 
0 
Cd 
I 
P 
0 
0 
0 
n 
H 
ci 
0 H 
-0 Cid E-4 
4-1 
:> 
0 
4.3 
cd 
Pý 
oI P-1 
cl 
f-i 
S-11 
(D 
Ea 4-ý 0 
co ul 0 
pq 
'd 0 
ý?, s '. c0 
01 
-rf 0 43, H 
Cd 
0m0 
Co rj P4 
0 +1 ý,, 00 
4-) -ri -P 
m0iA 
Cd 4-3 P: (1) 
a) 4 
4-1 
C, 
m Cd P, 
mI 
a) P-a P0 
PP0 -P 
0) 
4mW 
P :j 4) 
a) VH $4 
Cd A 
4-) r-i 0U 94 
-rq 0 
(1) 0 
Pi P4 0 
(1) 
Ea 
Cd 
ED 
'd 
v" 
H 
> rg 
(D 0 9,41 
co Cid 
Id P 
(1) 0 
(n 04 
Ea -r-I 0) 4-4 
0 
4.3 
0 
(D -r-I 
co 
4131, 
0 
0 P4 
Ea 
00 
g\ zt (M (M 4.4 4 Co %-. 0 %... - %-. - %-., %-, e %-. # 
04-f 
to 0 +1 
ri 0 KN KN Kl% r-i Cl- Lr\ 
+I +I +I +I +I +I +I 
0 gi 00 
0) (D ri 0 r-i 0 C CY% CYN (D CO Z Ici Ei Ici Cd CM cm r-i hl% CM r-1 
e-% 
e*-% 0-% 
zt -4- 
el% e% 
_ze NN 
e-% eN 
N 
0-% 
CU 0 ý-o %-10 %. 10 %-lýp NI-ýO %.. d %-f 
Cd (M Lr\ w ce KIN -t- cm 
0 +1 +1 +1 +1 +1 +1 +1 
(D CD 00 C% (M 
KN KN CM UN cm N 
0 
. ri 
1 
4-11 
cö Lr\ Lr\ 
p Lr\ LN cm (M 
4-N LN (M cu lý Ilý 
R 
lý 12 93 1 G) 0 6 r-i 0 r-i r-i CM . CM (D 0 0 r-i g3 %-. # 
0 
cý Ul 0- Co -p 
Kl\ -p KIN 4-3 KN 
ri 1 ri 
1 
0 0 to 0 0 to 0 (D m (D 
r. Z: G) %Z 9: 0 %Z 1 r. 0 Pi ;4H 
*f-l ;4H . ý4 
0 P p 
e 
ci 
9 
11 
9 
0; 1P 
d 
A pl 
4 
H PA A r-i A A r-i A -H -H 0 -r-1 Ici ri 0 ri ri 0 r4 d 
ri i H p i H 
0 P 1 
Ei 
i 
0 E3 c: P cd 
1 
r 
1 
lr f ri r 4H 
1 
Cd 
Q CM C\j N C\j r-I P %.. 0 %. 01 %-. * %_0 %-. o V 
Lr\ CV H Cm 
+I +I +I +I 
C) U-\ --ý s U-\ ' z +1 
0 
p CC) U, \ 0 Ull 0 Lr\ 4-3 1 0 9 0 0 0 0 0 CM Lr\ C- 0 CM 
(D 
0 
0 
0 ri P 
pi-ri 
.H0 
c1p 
94 ;40 
00 p4 
0 
0 :1 
C) 0. (1) 
0 fcj 4.3 
4912) 
4-1 
Q) 0 Ci 
Pd 4.3 
0a 
4 04-1 
4-1 00 
M -P u2 
-ri M4 
0 ei 
m 4-3 0 
. ri f4-4 
x44 4-1 4-4 
E-4 00 
* 
. t-I 
4-1 
C. ) cd 
0 
4-4 
0 
P-4 
0 
4-1 
C V2 
cd 
cd 
C%j 
r-4 
C: 
ýo 
. rq P4 
4 
C 
. 1. 
C 
C 
C 
C. 
cl 
02 0 IC5, *- 0 
P4 
C. ) 
0 
P4 
44 
0 
V] 
ci 
0 
Ir4 
9 
41) 
P4 
V 
-6 
0 
Cý 
6 
. r4 OR 
I- 
LrN 00 
Ll- NN 
s4TAT40V U-F as-eaaoa(r 
() 4TAT. ov utes 
a) 
cL, 
C, 
.i 
CD 
0 
9 
lid 
0 
0 
4-3 
Cd 
$4 
0 
z 
4-4 
0 
0 
$4 
4-1 
u 
4-ý 
EA 
CH 
0 
9.1 
0 
.H 4.3 
0 
0 
0 
Cd 
0 
-P 
NN 
r-i 
Cý 0) 
rq 
10 co 
E-1 
00 Cd 
r--f Ea 4J Cd 0 Cd 
0 1: $ 
0 P., 
m Id 
4a) CD 
K-N 
Cd 
Q 
H 
Cd Cd 
1 :: 3. P q r 00 
Z 
4-f co Cd 
09 1 t 
r. 
0 
0 F4 
-H 0 Id 
4-1 0) 
4--) C\j rc\ H ON r-i co co P Id f. ) 0 0 
t (D a) _: t _: t C6 Cý Mý Ký P P 
P 
o 
0Q 
0 
0 -H 
.,. 4 r-I 
4-5 Cd : E: 
Cd 9.4 co 
p 
4) 1 
tý c l Lr\ UN Lr\ UN Lr\ ts\ Ul\ 4) co r- i Cý Cý Cý Cý Cý Cý Cý 
() I 
9.1 P 
00 
4-1 
0 
r. 
09 
. r-I 0 Lfl\ LIN Lr\ 0 0 
Lr\ 
C\j 
Lr\ 
C\j pq 
gq El 
0-% 
ý 
cli N C\j LN Lrl\ t. 0 týo 
Lr F 0 01 4 Cý Cý 0 
-P H 
00 
tC\ 
0 (D 
0 
0 
rd l 
ý 
I P $4 x: 0) PI k 
d 
(D k Id 4. ) 
W 
pq P4 H P4 P4 HA P4 rq P4 
a) 
E-i 
r-I Eý rq Eý 0 -r-I 4 M rj L. 0 -r4 ws 4 s 'd H 5 o rq 0g 
. ri r-I . r-I I . ri C2. H 
0 P 
co 
0 
ýH 
C9 
ri 
E-i 
cri 
* 
seen. From this plot it is possible to calculate the 
concentration of test compound required to produce half 
maximum inhibition of pendular movement, and the mean 
values are 22.5 cLM and 24.0, gM for imipramine and 
imipramine-d? respectively. 
b) potentiation effects of the test compounds - imipramine 
and its deuterated analogues were all capable of 
potentiating the effect of nor-adrenaline when both 
compounds were present together. Once again, no differences 
between the test compounds were apparent. Table 7.12A and 
Fig. 7.12 show the effect of nor-adrenaline (alone) in 
varying concentrations on pendular activity, and Table 7-12B 
the effect of varying concentrations of test compound in 
the presence of nor-adrenaline. It is clear that 
potentiation does occur. The results are presented in two 
ways, the first form demonstrates the total effect of test 
compound plus nor-adrenaline on pendular motion, and allows 
calculation of the equivalent amount of nor-adrenaline 
required to produce an equal response. The second way was 
to subtract, from the overall response, the effect due to 
test compound alone (this was possible since additions 
were stepwise and the effects were continuously monitored); 
this shows the apparent effect of nor-adrenaline in the 
presence of test compound. Table 7.13 indicates the 
equivalent concentrations of nor-adrenaline required to 
produce the response observed for test compound plus 
nor-adrenaline in fixed concentrations. It was possible 
to calculate the degree of potentiation from this table 
as; for 'uncorrected data, 300% and 600516, and for 
'corrected' data, 150% and 200%, for concentrations of test 
compound of 12.5 le,, 
M and 25.0/zM respectively. 
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DISCUSSION 
The Analytical Procedure 
The analytical procedure has been shown to be 
very versatile, not only was it capable of resolving a 
large number of compounds but these all chromatographed 
within 20 minutes. Few published chromatographic 
procedures have been designed to determine all the 
metabolites of imipramine, and those that do, such as 
t. l. c, are rather insensitive or inaccurate. The h. p. l. c. 
procedure of Sutfin and Jusko (1979), used in the present 
studies, was originally designed to monitor I, DMI, 
2-OH I and 2-OH DMI. Presently, we have extended this 
procedure to quantify DDMI and IPNO which now provides 
a sensitive and reproducible means of determining 
imipramine and all its major metabolites produced in the 
rat (with the exception of iminodibenzyl and further 
metabolites). 10-Hydroxyimipramine co-chromatographed 
with 2-OH I but, the former compound is not produced to an 
appreciable extent in, the rat (Bickel and Weder, 19658). " '... 
With fluorescence detection, h. p. l. c. provides the 
only simple method capable of determining these 
metabolites at the very low levels observed; other 
procedures (t. l. c. and g. l. c. ) are far less sensitive or 
require laborious sample processing. This h. p. l. c. 
procedure entails a very simple processing stage and quick 
run time; it is sensitivel reproducible and recoveries 
are good (60-80%) from both plasma and urine. The present 
method is not, however, as sensitive as the published 
procedure of Sutfin and Jusko (19? 9); although very high 
purity solvents were used, a significant background 
fluorescence-was apparent, and this accounts for the 
decreased sensitivity. 
Isotopic Fractionation 
Isotopic fractionation provided a means of observing 
the different rates of cleavage from imipramine of the -CD 3 
and-CH 3 groups. Numerous examples of isotopic fractionation 
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in gas and liquid chromatographies have been reported 
(Klein, 1966; de Ridder and van Hal, 1976; Shepard et al. 
1976, Tanaka and Thornton, 1976) and more recently 
Heck, Simon and Anbar-(1977) reported that imipramine 
undergoes isotopic fractionation on t. l. c. when both 
N-methyl groups are deuteratedt. but not when four aromatic 
protons are substituted. These are similar to our 
findings although only one N-methyl group needed to be 
deuterated for isotopic fractionation to occur. These 
authors explained isotopic fractionation of imipramine by 
a stronger basicity of deuterated imipramine relative to 
its unlabelled analogue, Isotopic fractionation of 
imipramine can be explained by a stronger interaction of 
deuterated, more basic, imipramine with the weakly acidic 
Si-OH groups of silica (Heck et al., 1977) leading to 
longer retention of these compounds. This is based on 
studies with deuterated imipramine in a large number of 
solvent systems using t. l. c. as the chromatographic 
technique; isotopic fractionation occurred only in neutral 
or basic solvents, never in acidic solvents. 
. 
As indicated in the results section, several new 
peaks were evident on chromatograms of urine extracts 
from rats dosed with imipramine-d,?. These are assumed to 
be due to isotopic fractionation rather than as. the 
result of a novel metabolic pathway induced by deuteration. 
The case for this assumption has been argued in the results 
section and it is reasonable to suppose that these peaks 
are due to the compounds indicated, and that accurate 
quantitation can be achieved using non-deuterated standards 
and a, correction factor. 
Pharmacokinetics of Imipramine 
Only recently have analytical procedures been made 
available which are sensitive and specific enough to allow 
pharmacokinetic determinations on the small blood samples 
one can obtain from an experimental animal. Determination 
of the pharmacokinetics of imipramine, in a number of 
species, was originally carried out by Dingell, Sulser and 
Gillette (1964), who obtained a biological half-life for 
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imipramine in rats of 4., 2.5 hours, in an experiment 
where imipramine was administered intravenously (20 mg/kg) 
and two rats were killed per time point; determination was 
accomplished by spectrofluorimetry after selective 
extraction of imipramine from homogenates of whole rats, 
however the specificity of this assay must be quite low. 
As only three time points were used to obtain this 
half-life it is surprising to see such good correlation 
between their results and ours, since we also obtained a 
half-life of /. -2.5 hours following both oral and intra- 
venous administration. 
It is unclear which anaesthetic was used in their 
experiments but it is now generally recognised that drugs 
of the barbiturate class interact with the tricyclic 
antidepressant group of compounds to alter their 
pharmacokinetic properties. Barbiturates are known to 
lower the plasma levels of imipramine, protriptyline 
', 
DMI 
and nortriptyline (Sjoquistj et al., 1968; Burrows and 
Davies, 19? 1)7 and in vitro studies show a stimulatory 
effect of phenobarbital on hydroxylation and demethylation 
of imipramine (Bickel and Gigon, 1969; Hakazawa, 
19? 0). In the light of these findings, urethane and 
chloral hydrate were used in our studies, since there 
have been no reports of a kinetic interaction of imipramine 
with either of these anaesthetics. Using these compounds 
anaesthesia had to be carefully controlled to prevent 
death of the animals upon administration of imipramine. 
This synergistic effect is probably quite common for drugs 
which act on the central nervous system and the danger is 
undoubtedly due to respiratory shock. The similarity 
between half-lives obtained for the oral and intravenous 
routes of administration indicates the lack of an effect 
of the anaesthetic on*elimination of imipramine. It is 
unlikely that the plasma levels of imipramine were affected 
by the presence of anaesthetic, since the plasma levels we 
found show good agreement with those obtained by Dingell 
. 
et al,., (1964), by Bickel and Weder (1968) and by 
Nagy (19?? ). 
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The metabolite profile of imipramine in urine was 
extensively investigated by Bickel and Weder (1968); our 
findings closely relate to theirs. 2-OH DMI GA appears 
to be the major urinary metabolite, but phenolic 
metabolites in general (2-OH It 2-OH I GAI 2-OH DMI9 
2-OH DMI GA) are the major metabolites (200-500 
excreted after 3 days) and are far in excess of 
imipramine (16 /Ag after 3 days) and other metabolites 
(DMI, IPNO9 DDMI - 35-70 /. zg after 3 days). Comparing 
the present results with those of Bickel and Weder, 
similar proportions of each type of metabolite were 
observed, although we have evidence for a larger fraction 
of 2-OH I (GA) relative to 2-OH DMI (GA), and higher 
levels of DDMI formed. 
The plasma profile of metabolites following 
intravenous and oral administration was quite different 
from the urinary profile; only the demethylated metabolites 
DMI and DDMI could be detected, and levels of these were 
quite high (*> 100 ng/ml within one hour of an oral dose 
of 50 mg/kg), however there was no sign of phenolic 
metabolites, either free or as glucuronides, or IPNO. This 
is surprising since Bickel and Weder (1968) reported these 
metabolites to be present in quantities exceeding 100 ng/ml 
fort in the case of 2-OH DMI, up to six hours following 
intraperitoneal administration of imipramine (50 mg/kg). 
However, these workers used a qualitative/semi-quantitative 
approach in which large errors are to be expected, and this 
may explain the discrepancy. 
In the light of the present experiments, imipramine 
follows first-order kinetics for a one-'compartment model, 
does not exhibit saturation kinetics up to a dose of 
20 mg/kg (intravenously) and undergoes an extensive 'first- 
pass' effect. On the contrary, Gram et al '. 
(1974) showed 
that-in rats apparent saturation kinetics operate at 
imipramine and nortriptyline doses of 10 mg/kg. We 
found no evidence for saturation kinetics, area under the 
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curve (bioavailability) following 20 mg/kg (intravenously) 
was approximately twice that following 10 mg/kg, and 
half-life was independent of dose. 
The results indicate that imipramine is rapidly 
absorbed following oral administration, it is eliminated 
with a half-life of -ý2-5 hours and has a total systemic 
clearance of /., 90 ml kg-lmin-1. The fraction of the oral 
dose entering the system unchanged is very low, < 5%, 
which must be due to a ! first-pass' effect. There is good 
evidence in the literature that orally administered 
imipramine is completely absorbed; in studies with 
140-labelled imipramine and nortriptyline (Gram and 
Christiansen, 1975; Gram and Fredericson Overo, 1975), 
the total urinary excretion of radioactivity and the 
metabolite excretion showed that absorption was /-,, 100%6. 
If this is the case the parameter F (fraction reaching 
the circulation) is an indication of the amount of 
conversion of imipramine as a result of a lfirst-pasýl 
effect; results presented here suggest a 'first-passl- 
effect of > 95icol. The magnitude of the Ifirst-pass' effect 
suggests that imipramine should have a Very short half-life 
of the order of several minutes. This, however, was not 
the case; systemic clearance was similar to hepatic blood 
flow (see Chapter 5) and imipramine exhibited a large 
volume of distribution. This suggests that the metabolism 
of imipramine is predominantly hepatic and is limited by 
the supply of drug to this organ. The drug is extensively 
distributed, probably bound to tissue proteins and 
localised in various tissues (e. g. erythrocytes), and the 
rate of its clearance is dependent on the supply of drug 
to the metabolising enzyme from its distribution sites. 
On its 'first-pasd through the liver the drug may not be 
protein bound to a significant extent, and therefore 
available for metabolism by a very active enzyme which does 
not exhibit saturation kinetics at these drug concentrations. 
Much support for a 'first-pass' effect on tricyclic- 
antidepressants has been published. Bickel and Weder (1967) 
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showed that appearance of DMI in rat brain was much 
faster after intraperitoneal and oral administration than 
after subcutaeneous administration of imipramine. In 
clinical studies with 
14 C-labelled imipramine, 
amitriptyline and clomipramine, the urinary excretion 
(^-, 96-98% metabolit es) was considerably faster after 
oral than intravenous administration of the test dose 
(Gram et al., 1971). Studies comparing plasma 
concentration - time curves after oral and intramuscular 
administration of nortriptyline indicated that 33-50% of 
the oral dose was removed by metabolism before reaching 
systemic distribution (Alexanderson et al., 1973). In 
isolated perfused rat liver, an almost completeý extraction 
of nortriptyline was found (von Bahr et al, 1973) and, in 
a similar experiment, imipramine was extracted to the 
extent. of 1v 99% after an exposure period of only two 
minutes (Stegmann and Bickel, 1977). 29-77% of an orally 
administered dose of imipramine to humans is removed by 
a 'first-pass' effect (Gram and Christiansen, 1975), and 
it-is believed that this may be partly responsible for 
wide variations in the plasma levels in humans, although 
the major cause is thought to be due to individual 
differences in the rate of elimination by hepatic 
metabolism, and this results in individual variations in 
therapeutic effect. 
The complete picture of this 'first-pass' 
metabolism remains to be elucidated, but there is good 
evidence that in humans, liver is the main site of 
biotransformation of imipramine. This has been widely 
studied in vivo on hepatectomised rats and in vitro on 
homogenates from different tissues by Minder et al. (19? 3); 
imipramine is metabolised mainly in liver and only to a 
minor extent in other tissues. Studies with portal vein 
catheter have strongly indicated that there is no 
intestinal metabolism of imipramine in man (Dencker et al. 
19? 6), but demethylation of imipramine has been shown in 
many organs including the gastro-intestinal tract (Minder 
et al., 19? 1). In vitro studies indicated that 
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demethylation was mediated by the intestinal contents. 
Urinary excretion data provided by Gram and Christiansen 
(1975) indicates that 65-85ýL of the 'first-pass' effect 
on imipramine was mediated by demethylation. Our studies, 
comparing levels of demethylated metabolites formed 
following intravenous and oral administration support 
this since far higher levels are produced after oral 
administration; also consider the ratio of metabolites to 
parent compound-excreted in the urine, metabolite levels 
exceed the parent compound by a factor of > 50 after 
three days. Thus it appears that imipramine undergoes an 
extensive 'first-pass' effect which is mediated to a minor 
extent by gut metabolism but primarily by hepatic 
metabolism. 
Another striking feature of imipramine pharmaco- 
kinetics is its large volume of distribution (VD)I 
--20 1/kg in the rat. A large VD has also been observed 
in humans and thorough studies on the pharmacokinetics of 
tricyclic antidepressants, both clinically and 
experimentally (Alexanderson, 1972a, b; von Bahr, 1972; 
Gram, 19? 4 and 19? 7; Nagy, 1980) have shown extensive 
binding to tissue proteins and an apparent VD in the range 
10-20'l/kg (humans). Plasma protein binding of tricyclic 
antidepressants ranges from 75-97% in humans (Borga et al 
1969; Campbell and Todrick, 1970, Glassman et al 
, -ý 
1973; 
Burrows, et al., 1974; Kragh-Sýrensen et al., 1976). The 
overall picture for imipramine in humanst as well as the 
rat, is shovm in Fig. 7.13. CD 
Effects of Deuteration on the Metabolism and Activity of 
Imipramine 
Evidence for an-isotope effect on N-demethylation, 
but not on aromatic hydroxylation of imipramine is 
presented. Demethylation, 2-hydroxylation, N-oxidation 
and glucuronide conjugation are all quantitatively 
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Fig. 7.13 Fate of Administered Imipramine 
Following oral administration of imipramine, the. dose is rapidly 
and completely absorbed and undergoes an extensive 'first-pass' 
effect which is mediated primarily by the liver. Following 
absorption, the drug is extensively bound to plasma and tissue 
proteins producing low plasma levels and, in humans, wide 
inter-individual variations. It is then rapidly and efficiently 
eliminated (facilitated by its high extraction into liver), and 
a wide range of metabolites are excreted. 
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important routes of imipramine metabolism in both man 
and the rat (Bickel and Weder, 1968; Christiansen et ale) 
1967; Crammer et al., 1969), and the rat more closely 
resembles man in the relative rates of these metabolic 
transformation steps than any other species studied 
(Dingell et al., 1964). On these grounds, the rat was 
chosen as the model to compare the effects of deuteration 
of imipramine on its kinetics and pharmacology and 
imipramine was deuterated at its main sites of metabolism 
(the N-methyl group and aromatic rings). Although only 
four deuterons could be inserted into the aromatic rings 
this would occur at the chemically most active positions, 
which are also the metabolically most active positions. 
Since deuteration can have an effect on lipid solubility 
as well as on the basicity of certain compounds, an 
experiment designed to study the absorption properties of 
imipramine and its deuterated analogues was conducted to 
complement the elimination studies. As sufficient blood 
samples could not be obtained from one animal in order to 
combine these studies, it was necessary to separate the 
oral experiment into two parts; the first part considered 
absorption and the second, elimination. 
No major effect of deuteration on the absorption 
characteristics of imipramine was observed; small changes 
in the time to peak plasma level (tp) and the maximum 
plasma concentration (Cmaxi were apparent but these were 
not statistically significant. The lack of a pronounced 
effect is perhaps surprising when one considers isotopic 
fractionation and the theoretical explanation for this 
i. e. increased basicity. Although pk b was not determined 
it is reasonable to assume that deuteration did produce an 
altered pkb and, since absorption of drugs of the imipramine 
type is governed by the pH partition hypothesis whereby 
the rate and site of drug absorption is determined by its 
pka/pkb and gastro-intestinal pH, one would expect an 
effect on absorption. If this occurred it appears to have 
been too small to detect. 
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A small kinetic isotope effect of magnitude --, 1.33 
was observed and located at the N-methyl position. This 
resulted in an extended half-life and decreased total 
systemic clearance(and subsequently smaller 'first-pass' 
effect) but not in a significant degree of metabolic 
switching. A small change in metabolite pattern, an 
increased proportion of metabolites not dependent upon 
removal of the -CD 3 group, was apparent and an increased 
excretion of mong-demethylated metabolites containing a 
-CD, group rather than a -CH 3 group was observed. Since 
the potential for demethylation of imipramine should be 
equivalent to each N-methyl group, the-observation that 
deuteration causes removal of the -CH 3 group preferably 
to the -CD 3 group suggests that the effect on half-life 
is a real kinetic effect. Since demethylated metabolites 
-CD 3 exceed demethylated metabolites -CH 3 by a factor of 
,, j2, this suggests an isotope effect of magnitude 2 is 
occurring. Considering that two methyl groups are present 
in imipramine and only one is deuterated, then a kinetic 
isotope effect of magnitude 2 on demethylation of the 
-CD 3 group only, would lead to an overall isotope effect 
of magnitude 1.33, as was observed. This, therefore, 
suggests that no other properties of imipramine (transport, 
tissue distribution etc. ) were affected (i. e. this was 
purely an effect on the enzyme), and since enhanced 
aromatic hydroxylation (metabolic switching) would 
decrease the observed isotope effect, there is good 
evidence for the existence of the pathway 2-OH I --ý 2-OH DMI 
(the amount of 2-OH I-d? formed is in excess of 2-OH I 
formed). 
The mechanism by which imipramine is believed to 
be demethylated is as follows: 
CH MFO- CH 2 OH /H 
RN3- 
NADPH 
,RNe --- 
)R -N+ HCHO 
CH 3 
1W. 
\CH 
3ý 
\C 
.H3 
R1 
lý 5; o01 
1 
L2CH2CH 
2 
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One would expect to see a primary isotope effect 
for this transformation if initial C-H bond cleavage 
occurs during the rate determining step and, since an 
isotope effect was observed this is likely. The majority 
of deuteration effects on N-demethylation previously 
studied in biological systems have usually shown no 
isotope effect or a small magnitude for this effect 
(kH/kD < 2.0). Nelson, Pohl and Trager (1975) 
specifically labelled lidocaine-in the 04-methylene 
position (d4) and /S-methyl position (d 6) in order to 
elucidate the nature of the transition step in the 
N-dealkylation reaction. These workers measured the rate 
of reaction in rat liver microsomes and found isotope 
effects of 1.49 for the primary isotope effect due to d4 
replacement and a4 -secondary isotope effect of ---l-52 
for d6 replacement. Abdel-Monem (1975), using rat and 
mouse liver homogenates compared N-demethylation of 
1-(N-methyl-N-trideuteromethylamino)-3-phenylpropane with 
its non-deuterated analogue and found isotope effects of 
1.31 and 1.45 in the rat and mouse respectively. These 
workers explained this as a primary kinetic isotope effect 
on cleavage of aC-H bond of the N-methyl group which 
appeared to be the rate limiting step of N-demethylation 
reactions of tertiary amines. This conclusion has been 
questioned recently by Miwa et al. (1980), who claim that 
observation of an intramolecular isotope effect is 
insufficient evidence for a rate limiting carbon-hydrogen 
bond cleavage step in an enzymic reaction. 
N-Deuteromethylnormorphine was found to be less 
potent pharmacologically by Elýson et'al., (1962) although 
its duration of action was unaffected; N-demethylation was 
slower and Km increased which suggests the drug had lower 
affinity for the enzyme. The significant reduction in 
potency and lethality of morphine in mice observed in this 
case indicates how a small isotope effect (found to be 
,, 1.4 in an in vitro rat liver microsomal system) can alter 
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the pharmacological properties of certain compounds. Thus 
the magnitude of the observed isotope effect, -"-'1.33 for 
demethylation of imipramine, is in accord with the majority 
of isotope effects observed for N-demethylations; however 
the mechanism remains controversial. Recent studies by 
Miwa et al. (1980) suggest that for N-demethylation 
reactions, the observed isotope effect is a balance 
between a forward commitment to catalysis (binding affinity 
of drug for enzyme) and a reverse commitment to catalysis 
(intramolecular isotope effect), and this is undoubtedly 
the case for imipramine. 
On theoretical grounds, increased basicity and 
increased van der Waals forces which occur on deuteration 
should increase the affinity of the d-rug for proteins 
(e. g. the metabolising enzyme) and lead to a quicker 
metabolism and stronger binding (forward commitment to 
catalysis). Thus the observed isotope effect is a balance 
between a kinetic effect (reverse commitment to catalysis) 
and these phenomena. For this reason, in the'ease of 
imipramine, it was necessary to synthesise the hybrid form 
(one methyl group only deuterated) so that the increased 
affinity on deuteration (intermolecular isotope effect) 
was minimised but a kinetic isotope effect (intramolecular) 
still possible. This maximisation in the hybrid form has 
been demonstrated (Foster et al., 19? 4; Miwa et al*, 1980). 
Miwa et al. (1980) observed no overall isotope effect on 
the total production of metabolites by N-demethylation of 
N, N-di(trideuteromethyl)-phentermine, but an isotope effect 
of 1.6 - 2.0 for demethylation of the hybrid form, using a 
rat and rabbit liver microsomal/cytochrome P-450/cytochrome 
P-450-reductase system. 
Aromatic hydroxylations', are only usually associated 
with kinetic isotope effects if an epoxide intermediate is 
not formed. For mono-substituted benzenes, hydroxylations 
ortho and para are not associated with isotope effects 
whereas for hydroxylations meta, an epoxide is probably not 
the intermediate and an isotope effect is observed. In the 
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case of imipramine, hydroxylation is para to the nitrogen 
bridge group and meta to one of the carbon atoms of the 
ethylene bridge; both these groups are chemically directing 
towards this position. Although unlikely, it was hoped 
that an epoxide intermediate would not be formed and an 
isotope effect observed; this appears not to have been 
the case and suggests that aromatic hydroxylation in 
imipramine does occur via an epoxide. An isotope effect 
on 2-hydroxylation may have occ urr ed but gone undetected 
because of a shift in the site of aromatic hydroxylation; 
it was demonstrated earlier that all, the hydroxylated 
isomers of the iminodibenzyl ring would co-chromatograph 
with 2-OH I or 2-OH DMI. Such a shift is unlikely 
however, since the new site of hydroxylation would 
probably be the 4-position (the other chemically activated 
position) and there are no reports of hydroxylation at 
this position. Perhaps none of the analytical procedures 
used for quantitation of 2-hydroxy metabolites have been 
capable of separating and selectively quantitating 
2-hydroxy and 4-hydroxy metabolites. The original studies 
by Schindler (1960) which indicated 2-hydroxylation as a 
metabolic pathway involved comparison (by paper chromato- 
graphy) of chemically oxidised imipramine (shown to be 
oxidised in the 2-position) with a metabolite of 
imipramine isolated from urine. It is possible, however, 
that since isomers of hydroxy-imipramine, other than 
10-OH 1, have not been compared, the true picture of 
aromatic hydroxylation may be a combination of both 
2-hydroxylation and 4-hydroxylation. This may account for 
unidentified hydroxylated metabolites which are known to 
exist (Gram, 1974 and 1977); these may be twice 
hydroxylated analogues of imipramine. 
Pharmacological experiments were conducted to 
determine whether deuteration caused a change in the 
pharmacological activity of imipramine. Possible causes 
of an altered pharmacological potency could be effects of 
deuteration on interaction with receptors, alterations in 
plasma levels of drugs or metabolites leading to changes 
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in pharmacological properties, slowed elimination leading 
to a longer duration of action and, in the case of 
imipramine, possibly a change in the relative rates of 
metabolism so that the parent compound would build up 
rather than the active metabolite, DMI. Effects on 
drug-receptor affinity as a cause of pharmacological 
changes were tested in the in vitro isolated jejenum 
preparation (Livingstone, 1970a) and no apparent difference 
between imipramine and its deuterated analogues occurred. 
A change in the plasma levels had not been shown by the 
kinetic experiments and so altered pharmacology from this 
cause could not be expected. However, N-demethylation 
was slowed and there was thus the possibility of an effect 
on pharmacology in an in vivo system. The charcoal meal 
test (Sacra and McCollq 1960; Vischer et al., 1964) 
showed no difference between the effects of imipramine 
and imipramine-d? on gastro-intestinal motility, although 
the effects of imipramine and DMI were shown to be 
quantitatively different. It is probable, when one 
considers the 'first-pass' effect undergone by imipramine, 
that inhibition of gastroz-intestinal motility is largely 
mediated by DMI. Therefore an effect on the charcoal meal 
test could be expected when demethylation is slowed (less 
inhibition); however, the isotope effect was small and 
the kinetic experiments indicate similar levels of both 
parent compound and monodemethylated metabolites following 
administration of deuterated and non-deuterated drugs. 
The lack of a pharmacological change is undoubtedly due to 
the small magnitude of the isotope effect, which caused 
minor, if any, changes in the relative plasma levels of 
imipramine and metabolites. 
The major difficulty in this type of study is to 
design an experiment capable of detecting pharmacological 
changes due to small kinetic effects. The gastro-intestinal 
motility tests provide a means of observing only a small 
part of the wide range of physiological effects due to 
imipramine and it is possible that pharmacological changes 
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as a result of deuteration may be detected in another type 
of screening test such as the cat nictitating membrane 
preparation (Sigg et al., 1963). This is another 
nor-adrenaline potentiation test, which is very sensitive 
to imipramine and in particular DMI. Experiments 
utilising potentiation of the pressor response due to 
nor-adrenaline (as in gastro-intestinal motility) are a 
good means of distinguishing the tranquillising and 
antidepressant properties of a drug and have been used as 
screening procedures to differentiate between tranquillisers, 
such as the phenothiazines, and antidepressants, such as 
the tricyclics (Halliwell, et al., 1964). Nor-adrenaline 
potentiation should be a good measure of the antidepressant 
effect of a drug since it is believed that the mode of 
action of the antidepressants - the amine uptake hypothesis 
(Byck, 1975; Spencer, 1977; Hollister, 1978; Sulser et al., 
1978) - is the blockade of the re-uptake of nor-adrenaline 
and 5-hydroxytryptamine into neurones resulting in an 
increased availability of these transmitter substances at 
their post synaptic receptor sites (Sulser et al., 1978), 
and thus potentiation of their effects. However, changes 
in potentiation of nor-adrenaline as a result of deuteration 
were not observed although it would be advisable to conduct 
a series of experiments investigating the effects of 
deuteration on the other physiological effects of imipramine 
before a definite conclusion is drawn in this respect. A 
number of potential test systems include; prolongation of 
sleep due to alcohol, antagonism of acetylcholine, 
inhibition of vagal stimulation, antagonism of tremorine 
and effects on the toxicity of yohimbine (Halliwell et al., 
1964). 
Summary. Deuteration of one of the N-methyl 
groups of imipramine, but not of the aromatic rings, 
produces an in vivo isotope effect (, 4-'1.33); this, however, 
has no effect on imipramine pharmacology. The only 
pharmacokinetic parameters significantly affected are those 
concerning elimination; absorption and distribution 
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parameters remain unchanged. The pharmacokinetics of 
imipramine are characterised by rapid elimination 
(t I ,v2.5hours and C1 e4. r90ml kg-lmin-1), extensive 
distribution (VD ,. - 20 1/kg) and a large 'first-pass' 
effect Ov95%) following oral administration. 
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CHAPTER 8 
FINAL DISCUSSION 
There is increasing evidence that significant 
kinetic isotope effects due to deuterium substitution may 
occur on pathways of drug metabolism in biological systems. 
Application of the kinetic isotope effect to drug metabolism 
can have a number of advantages, such as extending the 
duration of a drug's therapeutic effect, potentiating or 
modifying a drug's'pharmacological properties and minimising 
a drug's toxic effects by slowing the metabolic pathways 
which lead to toxic metabolites. In the present studies, 
the deuterium kinetic isotope effect has been utilised in 
an attempt to a) slow the elimination of nitroglycerin and 
so extend the duration of its therapeutic effects, and 
b) slow the biological demethylation of imipramine to its 
active metabolite desmethylimipramine in the hope of 
enhancing the tranquillising properties associated with the 
parent compound. 
In order to achieve these aims it was necessary to 
set up suitably sensitive and accurate analytical 
methodology for the determinaton of the drugs pharmaco- 
kinetics in experimental animals; this required highly 
sensitive techniques (electron capture - g. l. c. and h. p. l. c. 
fluorimetry) due to the small blood samples one can obtain 
from these animals and the resulting low plasma levels of 
the drugs administered. Because of the lack of such 
methodology there have been few pharmacokinetic studies 
previously accomplished with these drugs in laboratory 
animals. Therefore extensive pharmacokinetic investigations 
in a number of species were undertaken. This type of study 
is important to further our knowledge of the safety of drugs 
and-to further our understanding of drug metabolism in 
general. 
0 
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Hitroglycerin 
Nitroglycerin is the drug of choice for rapid 
alleviation of the symptoms associated with angina 
pectoris and for the prophylaxis of this affliction. 
Nitroglycerin has been available for more than 100 years 
but, due to the lack of sensitive analytical methodology 
for determination of the drug in plasma, very little is 
known about its pharmacokinetic properties. Available 
information concerning the clinical pharmacokinetics of 
nitroglycerin suggests that the main disadvantage of this 
drug is its rapid biotransformation from the pharmaco- 
logically active parent compound to far less active 
metabolites (glycerol dinitrate and glycerol mononitrate) 
with a half-life in man of 1.9 - 4.4 min. (Armstrong 
et al., 1979., 1980a). The present studies describe our 
attempts to extend the duration of action of nitroglycerin, 
by per-deuteration, use of enzyme inhibitors or 
co-substrate depletion, and, by detailed pharmacokinetic 
investigation, to expand the knowledge of the pharmaco- 
kinetics of nitroglycerin. These studies include 
comparison of routes of administration, dosage level, the 
effects of sex difference and species variation, and an 
investigation into the kinetics of nitroglycerin in the 
presence of other drugs. Complementing these studies is 
an in vitro investigation concerning the tissue sites, 
subeellular sites and nature of the enzyme(s) responsible 
for nitroglycerin metabolism. 
Gas Liquid Chromatography of Nitroglycerin. The initial 
problem-involved the development of a sensitive, specific 
and reproducible analytical method for determination of 
nitroglycerin in plasma. Available procedures were not 
reproducible due to the presence of active sites within 
the chromatography columns which resulted in retention of 
sub-nanogram amounts of nitroglycerin. Since for a 
pharmacokinetic study one needs to determine <50 pg of 
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nitroglycerin injected-into such columns, these methods 
were useless. A number of modifications were made to an 
existing method (Yap et al, 19? 8) in order to achieve a 
sensitive system. These included elimination of all metal 
surfaces within the g. l. c. columng inactivation of the 
column by treatment with carbowax 20M degradation products, 
and the use of a thicker coating of liquid phase. In this 
way it was possible to rniniTnise the effects of active sites,, 
and a specific, reproducible and sensitive method was 
achieved which was capable of determining concentrations 
of nitroglycerin as low as 100pg/plasma sample. A reliable 
system seems to require an inactive glass column packed 
with a support which is fairly thickly coated with a 
moderately polar liquid phase (such as a trifluoropropyl- 
silicone). 
Also developed was an efficient means of protecting 
nitroglycerin from degradation in blood samples. By the 
addition of iodoacetamide, to a final concentration of 4mM, 
complete stability of nitroglycerin in rat plasma or blood 
for up to 5 hours at room temperature was ensured; in the 
absence of iodoacetamide, nitroglycerin is rapidly degraded 
by a glutathione-independent form of organic nitrate 
reductase, with a half-life of 20-60 minutes . 
(DiCarlo and 
Melgar, 19? 0; Yap et al., 1978; presently, Chapter 3). 
Approaches to Slowing the Elimination of Nitroglycerin. 
Pentadeutero-nitroglycerin was synthesised and compared 
with its non-deuterated analogue. These compounds were 
pharmacokinetically similar and elicited the same 
response on the isolated heart preparation and on rat 
blood pressure (in Livo). Only a secondary isotope 
effect (KH/KD <1.25) is possible for the type of 
metabolism undergone by nitroglycerin but it was hoped 
that this, in combination with changes in the lipid 
solubility of nitroglycerin may have caused significant 
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changes in its pharmacokinetic and pharmacological 
properties; this was not the case. A more successful 
approach was to use sustained-release forms of the. drug, 
and these appear capable of maintaining therapeutic 
concentrations of nitroglycerin for up to 12 hours 
following dosage. 
Of the approaches employed, pre-administration of 
a compound that interferes with the availability of 
hepatic glutathione (GSH) is the most effective. Both 
paracetamol and diethylmaleate dramatically lowered 
hepatic GSH levels (to 20-50% of control values) and 
caused an extention in the half-life of nitroglycerin 
(from 4.8 to 7.8 min and 5.7 to 9.0 min. respectively). 
Even so the elimination remained rapid and this may be 
explained by the contribution made by extra-hepatic sites 
to overall nitroglycerin metabolism in vivo. Although it 
would be useful to determine the effect of therapeutic 
concentrations of paracetamol on nitroglycerin elimination, 
it is unlikely that this approach could be applied to 
human therapy, since the low GSH levels required for 
slower nitroglycerin elimination may lead to toxic side 
effects in the human. 
None of the compounds employed as inhibitors 
(edrophonium, physostigmine, aspirin or dichloroacetate) 
in an in vitro buffered plasma system significantly 
perturbed the metabolism of nitroglycerin. Nitroglycerin 
metabolism catalysed by the GSH-S-transferases, occurs 
predominatly in liver, kidney and blood, and concerted 
effort to find a non-toxic compound which will compete., 
with nitroglycerin for these enzymes may bring about the 
development of a, more effective anti-anginal preparation, 
one which can be administered orally without suffering 
an extensive 'first-pass' effect. 
Pharmacokinetics of Nitroglycerin. The present studies 
provide a'clearer picture of the fate of administered 
nitroglycerin which to a great extent is governed by its 
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route of administration. The oral route proved to be the 
least efficient route whereas the sublingual route was 
virtually equivalent to the intravenous route with 
respect to ýioavailability (, --195% bioavailability). The 
same conclusions have been drawn previously, based on 
such factors as clinical effectiveness and observed 
physiological effects rather than on pharmacokinetic data. 
Until recently, the method of choice for estimating 
nitroglycerin bioavailability was digital (finger) 
plethysmography, obviously not a very precise technique. 
In the rat, an oral dose of nitroglycerin avoids 
degradation catalysed by stomach acidity, but is 
metabolised to a significant degree (^-, 10%) by intestinal 
mucosal cells, during the process of absorption from the 
gut into the portal circulation. Since the rate of 
absorption of nitroglycerin (tj absorption = 30 min., 
ka = 0.027 min is somewhat slower than.,, its rate of 
elimination (tj 5 min., k el = 
0.14 min7l), 'flip-flop' 
pharmacokinetics are in operation. The nitroglycerin 
escaping intestinal metabolism enters the portal circulation 
and is immediately transported to the liver. Here, 
virtually all the absorbed drug is metabolised so that the 
combination of intestinal metabolism and hepatic 
metabolism, leads to a very large 'first-pass' effect (> 955o), 
and dramatically reduces the effectiveness of oral 
preparations. However2 by the use of a sustained-release 
formulation, and by administering sufficiently large doses, 
this route may be clinically effective. The sustained- 
release formulation - sustac (at a dose level of 7.5 mg/kg 
to rats) - is capable of maintaining plasma levels of 
nitroglycerin above 1 ng/ml for up to 12 hours following 
oral-administration, whereas for a standard oral prepara- 
tion nitroglycerin plasma levels fall below 1 ng/ml within 
one hour. Although controversy has existed about the 
usefulness of these preparations (Chapter 5), there is 
growing evidence for their effectiveness in the prophylaxis 
of angina pectoris. Perhaps the prophylaxis of angina 
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requires only low plasma levels of the drug, whereas 
rapid alleviation of anginal pain requires far higher 
concentrations (obtainable by sublingual administration). 
With the-advent of sensitive and reproducible analytical 
methodology, it should be possible to correlate the 
plasma (and tissue) levels of nitroglycerin with its 
pharmacological effect, and to resolve the requirements 
(drug concentration) for a given therapeutic response. 
Sublingual administration shows a bioavailability 
very similar to the intravenous route (95% reaching the 
circulation). Again, the absorption rate (t 4 absorption 
. 14.3 mint ka = 0.05 min-') is slower than the elimination 
rate and 'flip-flop' pharmacokinetics may operate. Since 
total systemic clearance (1-6 lkg-lmin-1), greatly exceeds 
hepatic blood flow in the rat (&70 ml kg-lmin7l), nitro- 
glycerin elimination following sublingual. and intravenous 
administration cannot be explained by hepatic metabolism 
alone. Instead, the drug is metabolised at several sites 
including liver2 kidney and blood (metabolism originating 
from both erythrocytes and plasma), with minor contributions 
from other tissues such as the heart. 
Nitroglycerin shows a large volume of distribution, 
elimination is rapid and follows first-order kinetics for 
a one-compartment model in all species investigated, and 
the trend observed is for the larger species to metabolise 
more slowly. However, total systemic clearance is similar 
for each species. 
Species Half-life 
(min) 
Volume of , distribution 
(Ikg-') 
Total systemic 
clearance 
(lkg-lmin-1) 
Hamster 3.? t 0.4 11.4 t 3.2 2.2 t 0.7 
R at o--* 4.4 t 0.7 9.5 t 7.4 1.59 t 1.49 
Rat 7.7 t 1.2 18.9 t 6.5 1.71 t 0.47 
Guinea-pig 8.0 2.3 34 15 2.9 0.4 
Ferret 9.5 2.8 9.2 2.1 0.72 0.31 
Rabbit o- 12.2 2.5 44 19 2.4 0.8 
Rabbit Or 11.5 1.3 55 10 3.4 1.0 
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Total systemic clearance is constant, and the volume of 
distribution increases with increasing size of the species; 
since the elimination half-life is dependent on the volume 
of distribution, elimination is slower for larger sized 
species. The ferret is anomalous and has a smaller 
volume of distribution and slower clearance rate. A sex 
difference in half-life is apparent in the rat but not the 
rabbit, but there appears to be a larger volume of 
distribution in the females of both species. This variation 
in volume of distribution may reflect fundamental differ- 
ences in the proportion of fatty tissues in these animals; 
females have more fatty tissue as a percentage body 
weight and the ferret is a more muscular species compared 
with the others, there is thus less fat for this highly 
lipophylic drug to distribute into. If a variation in 
plasma concentration of nitroglycerin does occur as a 
function of the proportion of body fat, then this may be 
of importance in the design of dosage regimens for patients 
of differing sex and weight. 
Following the observed trend in elimination half- 
life, one would expect an elimination half-life in man of 
the order of 60 minutes. This is not the case since the 
human exhibits a half-life for nitroglycerin of less than 
5 minutes (Armstrong et al, 1979,1980a). The GSH-S- 
transferases, which account for the predominant metabolism 
of nitroglycerin, occur in many tissues and in the human 
are particularly active in liver and blood. In 
contrast, the activity of rat blood appears not to be 
GSH-S-transferase dependent and is associated with a 
glutathione independent organic nitrate reductase of rat 
plasma (Johnson ' 
et al, 1972; Yap, 1977). Thus, the 
unexpectedly rapid elimination of nitroglycerin in the 
human may be the direct result of a very active GSH-S- 
transferase in human blood, which is not present, or is 
much less active in the other species. Considering the 
large blood volume and the availability of drug to this 
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enzyme (100% available), this enzyme may account for the 
majority of nitroglycerin biotransformation in the human. 
However, the value for elimination half-life in man is 
questionables considering the quality of the available 
analytical procedures, and may be subject to change once 
accurate methodology becomes available (Chapter 3). The 
determinations of Armstrong et al, (1979 , 1980a) were 
made at blood concentrations (1-2 ng/ml) similar to the 
coefficient of variation of their method (t 14% at 
7 ng/ml i. e. t1 ng/ml) and only one half-life decrease 
was monitored (2 --- ý1 ng/ml). A useful experiment would 
be to compare the activity of organic nitrate reductase 
(of blood and other tissues), in a variety of species 
including man, and to correlate these with the overall 
in vivo elimination of the drug. 
Co-administration of other drugs (propranolol, 
theophylline, quinidine sulphate and digitoxin) produced 
no change in the pharmacokinetic properties of nitro- 
glycerin. A control group was required for each of these 
comparisons since wide animal variations are apparent both 
within and between groups of rats. This is a common finding 
in nitroglycerin pharmacokinetic studies and is thought 
to reflect variation in the activity of the hepatic 
enzyme (Maier et al, 1980). 
It is not clear in the literature where the site 
of nitroglycerin metabolism in the hepatocyte is, or 
indeed which tissues possess organic nitrate reductase 
activity. In the present studies using rats, all the 
tissues examined were capable of metabolising nitroglycerin 
(total activities are liver,; ýkidneyzn: gut >heart), although 
the significance of metabolism by the heart must be very 
slight. Nitroglycerin metabolism appears to be a 
cytosolic. activity and is due to organic nitrate reductase, 
although the true nature of this enzyme is inconclusive. 
The possibility remains that nitroglycerin metabolism may 
be both glutathione dependent and glutathione independent, 
although the former is by far the most active. No 
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conclusive evidence is presented here for the hypothesis 
that organic nitrate reductase activity reflects 
GSH-S-tran ferase activity, although competitive inhibition 
of this enzyme by nitroglycerin was demonstrated, however, 
if the studies of other workers are considered (Habig et al, 
19? 5; Zeen et al, 19? 6) this appears likely. 
Much rema, in to be achieved concerning the metabolism 
and pharmacokinetics of nitroglycerin. The availability 
of. good analytical methodology should lead to many 
advances in this field, and of prime importance must be 
investigations into the pharmacokinetics of nitroglycerin 
in other species, particularly primates, and further more 
conclusive studies with the human. In the case of the 
human, it would be of great interest to determine the main 
sites of biotransformation and to correlate these with 
other species, to determine the causes of the extensive 
inter-individual differences in the pharmacokinetics of 
nitroglycerin (also seen in the rat), to observe the effect 
of sex and obesity on the kinetics of nitroglycerin in the 
human and to correlate the observed plasma levels with the 
clinical response. The identification, isolation and 
characterisation of all the enzymes possessing organic 
nitrate reductase activity, and the elucidation of the 
mechanism of action of this drug are both areas in which 
little progress has been made. Although one of the oldest 
drugs, it still remains one of the drugs about which very 
little is known; perhaps this deficiency will soon be 
resolved. 
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Imipramine 
Imipramine has been widely used for more than 
20 years for the treatment of endogenous depression and 
is one of the best drugs available for this application. 
Pharmacokinetic studies, primarily in man but also in 
experimental animalsq have indicated that the 
antidepressant activity of imipramine is associated with 
its metabolite desmethylimipramine (DMI), and it is 
widely believed that the parent compound may possess 
tranquillising properties. By deuteration it was 
proposed to slow the metabolic transformation of 
imipramine to DMI and so enhance the tranquillising 
properties of the former compound. By this means a very 
useful drug may have been obtained, one which would 
initially sedate the patient and later exhibit 
antidepressant effects. 
I Knowledge of the pharmacokinetics of imipramine 
in experimental animals is minimal and restricted to a 
few studies which have used rather inaccurate or 
non-specific methodology. Thus the present investigations 
compare the effects of deuteration on the pharmacokinetics 
and pharmacology of imipramine and include some basic 
pharmacokinetic studies comparing routes of administration 
and effects of dosage level in the rat. 
Deuteration of Imipramine. Imipramine was specifically 
deuterated in its aromatic rings (4 deuterons) and in 
one-N-methyl group of the side chain (3 deuterons), both 
individually and combined. Imipramine-d7 was the main 
analogue of interest and imipramine-d 3 and imipramine-d4 
were used-as probes to indicate the origin of the 
observed isotope, effect. 
The, metabolism of deutero-imipramine did-exhibit 
a. kinetic isotope effect (of magnitude 1.33) and this was 
traced to demethylation of the N-deuteromethyl group, and 
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probably results from a combination of a direct effect 
of deuterium substitution on bond cleavage (bond strength) 
and effects resulting from changes in lipid solubility, 
basicity and van der Waals attractive forces. Biological 
half-life and total systemic clearance were slowed 
(ti, from 183 min to 205 min and Cl, from 92 ml kg-lmin7l 
to 59 ml kg-lmin-1 respectively) but the volume of 
distribution was unaffected. 
There is ample evidence in the literature for 
metabolism involving N-demethylation to be associated with 
small isotope effects (Chapter 1), however, significant 
pharmacological changes can occur as a result of an isotope 
effect of this order of magnitude. Pharmacological 
comparison of the deuterium labelled and unlabelled forms 
of imipramine involved the use of gastro-intestinal 
motility tests, both in vivo (charcoal meal test) and in 
vitro (isolated rabbit jejewim preparation); no 
differences were observed between the analogues of 
imipramine, but since imipramine causes a wide range of 
physiological effects further investigations should be 
conducted before a definite conclusion can be drawn in 
this respect. 
Of interest in these studies was the useful 
consequence of isotopic fractionation to permit observation 
of. the different rates of cleavage of the -CH 3 and -CD 3 
groups from imipramine (i. e. chromatographic separation 
between compounds containing -CH 3 and -CD 3 groups was 
achieved). Comparison of the rates of cleavage of these 
groups allows an estimate for the actual kinetic isotope 
effect on demethylation, of /-2.0. This correlates well 
with, the overall in vivo isotope effect determined from 
pharmacokinetic parameters (tiv kell C" since an 
isotope effect on the cleavage of only one of the two 
N-methyl groups would result in an overall isotope effect 
of this magnitude (, -1.3). 
A similar series of experiments has been conducted 
by Horning et al (1978), using methsuximide. This compound 
is metabolised by N-demethylation and aromatic hydroxylation 
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(as for imipramine) and the urinary excretion profiles 
of N-CD 3 -methsuximide and unlabelled methsuximide were 
compared. An isotope effect on N-demethylation was 
apparent, which led to a significant increase in the 
proportion of metabolites formed by aromatic 
hydroxylation, ' and a reduction in the N-demethylated 
metabolites. This is a, very similar situation to the 
present studies; 'the urinary. excretion profiles following 
oral administration of imipramine and imipramine-d., 
showed greater amounts of phenolic m6tabolites 
(including glucuronides) of the parent compound for 
labelled imipramines IPNO-, d? was excreted in greater 
amounts than IPNO-do and the amount of DDMI-d4 excreted 
was less than DDMI-do excreted. This suggests that 
pathways other than N-demethylation (N-oxidation and 
aromatic hydroxylation) are enhanced whilst 
N-demethylation is lowered. 
The isotope effect monitored by pharmacokinetic 
studies is an apparent isotope effect rather than a pure 
kinetic isotope effect. In a biological system, many 
factors may be influenced by deuteration (e. g. plasma 
levels, transport, binding affinities and many more) and 
a far better estimate of the kinetic isotope effect can 
be obtained using an in vitro system and determining, by 
the use of mass spectrometry, the relative rates of 
reaction of a mixture of the deuterated and non-deuterated 
compounds; comparison of V max 
data generates a value for 
the kinetic isotope effect. Nevertheless this would still 
indicate a combination of an intramolecular isotope 
effect (kinetic isotope effect due to variation in bond 
strength) with an intermolecular isotope effect 
(influence of deuteration on binding of the drug to the 
enzyme). Determination of the pure kinetic effects on the 
reaction rate in a biological system is thus quite 
difficult. 
Although there must remain many applications in 
pharmacology of deuterium labelling, to extend the 
duration of action of a drug or to alter the pharmacological 
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properties of a drug (as used here), the future for 
specific deuteration undoubtedly lies in alteration of the 
route of metabolism of d drug from, via a pathway leading 
to a toxic metabolite to via a safer pathway (metabolic 
switching); this may be particularly applicable if the 
drug is metabolised by multiple alternative pathways. In 
previous studies, deuterated amphetamines have been shown 
to be less hepatotoxic in mice than protio-amphetamines 
(Foreman et al, 1969; Benoit and Lu, 1978) and phenacetin-d2 
causes less hepatic necrosis than protio-phenacetin in 
3-methyleholanthrene treated hamsters (Nelson et al, 1978)., 
both as the result of isotope effects of ^, 1.9. As the 
safety of a drug is an important factor in its development, 
this application of deuterium labelling may find widespread 
use in the future. 
Pharmacokinetics of Imipramine in the Rat. Imipramine 
exhibits rapid absorption following oral administration 
(t 4 absorption - 10.5 min, ka = 0.066 min7l) but it also 
undergoes an extensive 'first-pass' effect (>95%) of 
similar magnitude to that of nitroglycerin. However, 
imipramine exhibits its antidepressant properties through 
one of its metabolites, DMI, and thus the 'first-pass' 
effect potentiates the therapeutic effects of the drug. 
In the rat, an elimination half-life of 2.5-3.0 
hours was observed for imipramine, and this was independent 
of route of administration and size of the dose. The total 
systemic clearance (t-w90 ml kg-lmin-1) was similar to 
hepatic blood flow in the rat (,, -, 70 ml kg-lmin7l) which 
suggests that the elimination of imipramine is dependent 
upon, hepatic blood flow, and that this organ is the main 
site of imipramine biotransformation. Also, the pattern 
of metabolites formed supports the observed 'first-pass' 
effect, since high levels of demethylated, metabolites are 
observed very soon after administration of an oral dose, 
and the plasma levels of these compounds are greater, at 
this stage, than the plasma levels of the parent compound. 
By far the major metabolites are the glucuronides of 
2-hydroxyimipramine and 2-hydroxydesmethylimipramine with 
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large amounts of the free phenolic compounds and 
imipramine-N-oxide also being excreted. Perhaps the most 
striking feature of the pharmacokinetics of imipramine is 
its large volume of distribution (, *451.1-20 lkg-1) and this 
has also been observed in the human. There appears to be 
some similarity in the metabolism of imipramine by man and 
the rat, since the pattern of metabolites is similar, as 
are the, relative rates of the individual metabolic steps; 
other species which have been investigated (e. g. mouse and 
rabbit) differ markedly in this respect from both man and 
the rat (Dingell et al, 1964). 
General pharmacokinetic data concerning the 
metabolism of imipramine in different species and sexes is 
quite limitedt but the development of sensitive and 
specific methodology for determination of imipramine and 
its metabolitest now permits such studies to be accomplished. 
The main clinical problem associated with the use of 
tricyclic antidepressants is the wide inter-individual 
differences observed, for which the cause has not yet been 
elucidated. There is therefore scope for the solution of 
this problem, using both experimental animals and man, and 
for the study of general pharmacokinetic properties and 
ultimately for the improvement of imipramine therapy. 
Concluding Remarks. The present studies have investigated 
the pharmacokinetics of two important drugs, nitroglycerin 
and imipramine, about which very little is known due to 
the previous lack of sensitive analytical methodology. 
Previous studies have been few and have used radiolabels, 
very high drug concentrations (notably in vitro) or 
determined related compounds which may be consumed or 
produced as a consequence of metabolism of the drug 
(e. g. formaldehyde, NADPH, NO 2- or glycerol dinitrate). 
Thus the present studies have the advantage of using 
accurate methodology to directly monitor the drug itself 
and so for the first time to reliably determine the 
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pharmacokinetics of the two drugs in experimental animals, 
and to study the effects of deuteration on these 
pharmacokinetic properties, and also on their pharmaco- 
logical properties. 
The two drugs contrast markedly in metabolism and 
pharmacokinetics; both display rapid absorption and a very 
large volume of distribution, and undergo an extensive 
'first-pass' effect, but the rate of their elimination is 
quite different. In the rats nitroglycerin is eliminated 
, -36 times faster than imipramine; their sites of 
biotransformation are very different, with hepatic 
metabolism accounting for virtually all the administered 
imipramine, but metabolism by extrahepatic sites (blood, 
kidney etc) accounting for a large proportion of 
administered nitroglycerin. Application of deuterium 
labelling did not produce an improved drug in either case, 
and, although an isotope effect was observed for 
demethylation of imipramine, there was no change in its 
pharmacological properties. 
%, MEN THE DUST IS CLEAR, ONE KNOWS IF HE 11AS BEEN RIDING A 
HORSE OR AN ASS. 
(A Chinese legend$ cited in Glutathione: Metabolism and 
Function, 1975. Arias and Jakoby. ) 
I RODE ACROSS THE DESERT ON A HORSE 
UITH NO NAME 
(Lyrics of a song by the group America) 
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APPENDIX 1 
BASIC PHA'RMCOKINETICS 
One-Compartment Model 
The most commonly employed approach to the 
pharmacokinetic characterisation of a drug is to 
represent the body as a system of compartments, even 
though these compartments often have no apparent 
physiological or anatomical reality. The one-compartment 
model, the most'simple model, depicts the body as a 
single homogeneous unit and is particularly 4pplicable to 
drugs-which rapidly distribute between plasma and other 
body fluids and tissues upon entry into the systemic 
circulation. The one-compartment model assumes that any 
changes that occur in the plasma quantitatively reflect 
changes occurring in tissue drug levels. A second 
criterion for utilisin, a one-compartment model is that 
drug elimination occurs in a first-order fashion 
(i. e. the rate of elimination at any time is proportional 
to the amount of drug in the body at that time). 
Intravenous injection 
Following rapid intravenous injection of 
'a 
drug 
that distributes in the body according to a one-compartment 
model and is eliminated by apparent first-order kinetics, 
the rate of loss of drug from the body is given by: 
dX 
-kelX 
dt 
where X is the amount of drug in the body 
injection, k 
el 
is the apparent first-orde: 
constant for the drug. The negative 6ign 
drug is being lost from the body. 
To describe the time course of the 
in the body after injection, Eq. (1) must 
give: 
-kol t 
at time (t) after 
r elimination rate 
indicates that 
amount of drug 
be integrated to 
xxe 
0 
where Xo is the amount of drug injected. 
Conversion to common logarithms gives: 
(2) 
log X= log X0 -k el 
t 
2.303 
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If the relative binding of a drug to tissue 
components is essentially independent of drug concentra- 
tion, then the ratio of drug concentrations in the various 
tissues and fluids is constant. Consequently, there will 
exist a constant relationsip between drug concentration in 
the plasma, C. and the amount of drug in the body: 
X ý" VDC (4) 
The proportionality constant VD has the units of volume and 
is known as the apparent volume of distribution; however, 
it does not refer to a real volume. 
Use of Eq. (4) allows the conversion of Eq. (3) 
from an amount-time to a concentration-time relationship, 
which can be expressed as: 
log C= log Co -k elt 
2.303 
where Co is the plasma drug concentration immediately after 
injection. Equation (5) shows that a plot of log C versus 
t will be linear under the stated conditions. Co may be 
obtained by extrapolation of the log C versus t plot to 
time zero. This intercept, Co, may be used in the 
calculation of the apparent volume of distribution. Since 
Xo equals the intravenous dose: 
VD xo 
Co 
(6) 
The apparent first-order elimination rate constant, k ell 
can be determined from the slope of the line that equals 
-k el/2.3039 or 
by use of the relationship: 
k 
el 
0.693 i. e. ln2 
tj t 
71) 
where tS is the biological half-life of the drug, determined 
from a semilogarithmic plot of plasma drug concentration 
(log. scale) versus time (linear scale), and is the time 
required for the drug concentration at any point on the 0 
straight line to decrease by one-half of this value. 
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One further useful parameter, is the total area 
under the plasma concentration - time curve (AUC tot), 
which can be obtained by converting Eq. (5) to natural 
logarithms and integrating over the time interval zero 
to infinity, thus: 
- Ob 
-k t Co el Co AUCtot Cdt e 
C. c" fo 
kel 0 el 
i. e. AUCtot Co (8) 
and can easily be calculated as both Co and kel can readily 
be obtained from the plasma concentration-time curves. 
First-order absorption 
For a drug that enters the body by an apparent 
first-order absorption process, is eliminated also by a 
first-order process, and distributes in the body according 
to a one-compartment model, the following differential 
equation applies: 
dX ka Xa -k el 
X (9) 
dt 
where X and k el are as 
defined Previously, ka is the 
apparent first-order absorption rate constant, and Xa is 
the amount of drug at the absorption site. The Laplace 
transform of Ejq- (9) is: 
sZ k7 lk eý a el 
(10) 
(s - Laplace operator) 
The rate of loss of drug from the absorption site is: 
dX 
a -k a 
Xa 
dt 
(11) 
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the Laplace transform of which is: 
FX -k `Za s 2a 0a 
where F is the fraction of the administered dose Xo that 
is absorbed following oral administration. Solving 
Eq. (12) for '7a' substituting this value for .7a in 
Eq. (10) and solving for 2 yields: 
ka F Xo 
(s + kel)(s + ka) - 
(13) 
By employing a table of Laplace transforms, the following 
biexponential. relationship between the amount of drug in 
the body and time results: 
XkaF X0 e 
-1c elt -e _-ka 
t 
ka el 
which in concentration terms is: 
C=kaF X0 
(e- 
-k el't -e -k at 
V(ka-k 
el) 
For most drugs administered in readily available dosage 
forms the absorption rate constant is significantly larger 
than the elimination rate constant. As a result, at some 
time after administration the term e -k at approaches zero, 
and reduces to: 
kaFX0e -k el 
t 
v D(ka -k el) 
which describes the postabsorptive phase of a plasma 
concentration-time curve., 
(16) 
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Written in common logarithms, 
ka FX0 kel t 
log C log (17) 
vD (ka -k el) 2.303 
A plot of the logarithm of the plasma concentration 
versus time yields a biexponential curve, the terminal 
portion of which is linear and described by Eq. (17). 
Therefore an estimate of the elimination rate constant 
can be obtained from the slope -k el/2-303 
in this terminal 
linear segment. 
If ka is not greater than k e17 exactly the same type 
of curve is observed; however, the rate constant obtained 
from the slope -ka/2.303 of the terminal linear portion of 
the curve is now the absorption rate constant, not the 
elimination rate constant. Such allflip-flop" model 
(i. e. when kel >ka) may be observed for drugs that are 
very rapidly eliminated, or for dosage forms that slowly 
release drug in an apparent first-order fashion. The 
equation describing the "flip-flop" model is: 
ka FXD 
(e 
-k at-. e- 
-k el 
t) 
VD(k 
el - 
"'ca)' 
As discussed previously, the apparent volume of 
distribution of a drug can be estimated following 
intravenous administration by the relationship V= Xo/Co, 
where Co, is the zero-time intercept. However, when a drug 
enters the body by an apparent first-order process, an 
estimate of VD cannot be made by simply extrapolating the 
log-linear portion of the curve to t=o, since the 
intercept is equal to log Uca Fx o/VD 
(k 
a-kel)] and not 
log Co. If k 
a, 
kell -and an estimate of the fraction of the 
dose administered which is absorbed are known, the 
apparent volume of distribution may be estimated since: 
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VD kaFx0 
(k 
a-k el) 
I 
where I is the zero-time intercept. A more satisfactory 
method for determining VD following first-order absorption 
is available. Integration of Eq. (15) from time zero to 
infinity yields: 
C dt kaFX011 (20) 
v -k kk a D("a el) el 
I 
where ka F XOIVD (ka -k el 
) equals I, the zero-time intercept. 
Equation (20) readily permits an estimate of. the area under 
the plasma concentration-time curve since all that is 
required are estimates of ka, ke, and I. Further 
simplification of Eq. (20) yields: 
AUCtot F X0 
VDkel 
or 111 (22) ll: 
el ka 
I 
Area under the concentration-time curve, for both oral and 
intravenous administration, may also be determined over 
any period of time by use of the Trapezoidal Rule, provided 
sufficient time points are available. 
Determination of tp and Cmax. Mathematical relationships 
may be developed to estimate the time at which a peak 
plasma concentration of drug (tp) should be observed, and 
the maximum plasma concentration at this time following 
first-order input into the body. 
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Expanding Eq. (15) yields: 
-k C ka FX0e -k el 
tkaF Xo e_ at 
VD (k 
a-k el) vD 
(k 
a-kel) 
(23) 
which when differentiated with respect to tinie is: 
dC ka 2p Xo e 
-k at_k ake, FXo e 
-kel t 
dt VD(k 
a-"el) VD(ka-kel) (24) 
When the plasma concentration reaches a maximum (C max) 
at time tp, dC/dt = 0. Therefore, 
ka 2 FXo e 
-k a 
tP 
kake, FXO e -k eltP 
vD (k 
a7 
k 
el) VD(k a -k el) 
(25) 
which reduces to: 
ka e 
-k eltP 
k 
el e 
-k atP 
(26) 
or. tp 2.303 log ka 
(k -k 
(27) 
a el) 
Fe 
1 
The maximum plasma concentration is described by 
substituting tp for t in Eq. (15): 
kFX 
(e. 
el ea -k- 
tp -k 0) 
(28) 
Cmax a0 
VD(ka-kel) 
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From Eq. (26): 
-k a 
tP k 
el e -k el 
tP (29) 
7a 
substituting for e -Ic a 
tp 
into Eq. (28) yields: 
Cmax = 
ka F Xo ka-k 
el e -k eltP (30) 
VD(ka7lcel) ka 
Or Cmax F XO e -kel 
tP 
VD 
Determination of F. The fraction of the oral dose 
entering the bod, 7 (bio-available dose, F) can be determined 
by compabison of the areas under the plasma concentration- 
time curves for intravenous (100566 bio-available dose) and 
oral routes of administration if the same dose is 
administered, or if a dose correction is made. Thus, 
AUC-oral 
x oral 
dose 
x 100 
AUC-intravenous ravenous dose 
(32) 
Method of Residuals. The method of residuals can be 
applied to determining ka (or k el 
for the "flip-flop" model) 
following first-order oral absorption. 
Assuming ka>k 
ell 
the term e _IC at (Eq. 15) will 
approach zero while the term e -k el 
t 
retains a finite 
value. 
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At this time Eq. (15) will reduce to 
C ka F Xo e. -k el 
t 
VD (ka-kel) 
or log C log ka F Xo 
k 
el 
t 
VD (k 
a7kel) 
2.303 
A plot of log C versus t produces a biexponential 
curve with a terminal linear portion of slope, -kel/2.303, 
and extrapolation of this line to to yields an 
intercept, log (ka F XO/V (k 
a -k el) 
Subtraction of the 
true plasma drug concentration-time values in the 
absorptive phase from the corresponding concentration-time 
values on the extrapolated line yields a series of 
residual concentration values. These residual values are 
described by the following equation which is obtained by 
substracting Eq. (15) from Eq. (16): 
cr ka Fx0e -k at 
(33) VDý"a-kel-) 
where-C r 
is the residual "plasma" concentration. In terms 
of common logarithms (Eq. (33) becomes: 
log cr log ka F Xo ka t 
(34) 
VD(ka - kel) 2.303 
Hence a plot of log C. versus t yields a straight line with 
slope -k a 
/2.303 and zero-time intercept of 
log ['ýa F )KO/V (ka-k el)]. 
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Multicompartment Models 
Most drugs entering the systemic circulation require 
a finite time to distribute fully throughout the available 
body space. If drug distribution is related to blood flow, 
highly perfused organs and tissues such as the liver and 
kidney should be in rapid distribution equilibrium with the 
blood. The blood and all readily accessible fluids and 
tissues may often be treated kinetically as a common 
heterogeneous unit referred to as the central compartment. 
Since it is assumed that any change in the plasma level of 
a drug reflects a change in the central compartment tissue 
levels, then following the intravenous injection of a drug 
that exhibits multicompartment pharmacokinetics, the levels 
of drug in all tissues and fluids associated with the 
central compartment should decline more rapidly during the 
distributive phase than during the post-distributive phase. 
In contrastq drug levels in poorly perfused tissues 
(e. g. muscle, lean tissue, and fat) will first increase, 
reach a maximum, and then begin to decline during the 
distributive phase. At some point in time-a pseudo- 
distribution equilibrium is attained between the tissues 
and fluids of the central compartment, and the poorly 
perfused or less readily accessible tissues. Once this 
has been established, loss of drug from the plasma will be 
described by a monoexponential process indicating kinetic 
homogeneity with respect to drug levels in all fluids and 
tissues of the body. Again drug elimination is assumed to 
occur in a first-order fashion. 
Total Systemic Clearance 
This pharmacokinetic parameter is model independent 
and represents elimination of a drug from the systemic 
circulation: 
Cl XO 
AUC tot 
for the intravenous route 
Cl Fxo 
AUC 
ý tot 
for the oral route 
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APPENDIX 2 
PHYSIOLOGICAL MEDIA 
The following table shows the constituents of 
Ringer-Tiocke solution and Tyrodes solution, which were 
used in the isolated-perfused rat heart (Chapter 4) and 
isolated rabbit jejenim (Chapter 7) preparations 
respectively. 
Compound Ringer-Locke Tyrodes 
HaCl 9.0 8.0 
KC1 0.42 0.2 
CaCl2 (anhydrous) 0.24 0.2 
MgCl2 (anhydrous) - 0.1 
NaHCO 3 0.15 1.0 
NaH2PO4 - 0.05 
Glucose 1.0 1.0 
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APPENDIX 
INTERPRETATION OP MASS SPECTRA 
Glyce: ýoltrinitrate and Pentadeuterogl7cerol trinitrate 
The mass spectra of glycerol trinitrate and 
glycerol trinitrate-d 5 are shown in Chapter 2 (Fig. 2.2). 
A molecular ion is not evident due to the breakdown of 
these compounds within the mass spectrometer (thermal 
decomposition). The base peak for both spectra is 
m/e 46 (due to NO+), the highest m/e is ?6 (CH20NO+) or 22 
78 (CD20NO+) for glycerol-trinitrate and glycerol 2 
trinitrate-d 5 respectively. A simple mass spectrum, with 
very few fragments is observed for these compounds, and 
the identity of the major fragments is indicated below: 
Table 1. 
m/e 
Relative Abundance 
Glycerol Glycerol 
trinitrate trinitrate-d 5 
Fragment 
78 - 14 CD ONO+ 2 2ý 
76ý 9 - CH ONO+ 22 
46 100 100 NO+ 2 
45 1 - 
44 3 6 
43 5 - 
42 1 
33 5 CD2 ' OH+ 
32 22 CD2 =0 
31 5 - CD2 = OH+ 
30 24 15 CD = O/CH2 ý 0+ 
29 15 - CH =0 
28 6 6 
27 1 1 
26 1 - 
16 - 1 
15 2 1 
(Fragments of relative abundance of <1% of the base 
peak are not included). 
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The mechanisms by which these fragments are formed is as 
follows: 
MH 2 ONO 2tA R* + CH 2 ON 2+ 
RCH ONO + RCHP + NO + 222 
RCHJ+ R* + CH 20 
+ 
where R is CHON02 
I 
CHýONO 2 
(from Fraser and Paul, 1968). 
Imipramine and Deuterated Analogues 
The mass spectra of these compounds were viewed in 
two ways. Using an ionisation potential of ? OeV the 
fragmentation patterns of the compounds were recorded, 
and by repeated scanning of the molecular ion region 
(using an ionisation potential of lOeV), in each case it 
was possible to determine the percentage incorporation of 
deuterium at specific sites. 
1. Mass spectr_a_of_imipramine and deuterated analogues 
The mass spectra 
deuterated analogues are 
In each case a molecular 
relative abundance <4, % 
included. Table 2 shows 
abundance of ions in the 
for imipramine and all its 
shown in Chapter 2 (Fig. 2.6). 
ion was observed, fragments of 
of the base peak are not 
the distribution and relative 
mass spectra. 
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Table 2. 
Relative Abundance of Fragments 
m/e 
I 
imipramine imipramine-d 3 imipramine-d4 imipramine-d? 
288 8 
287 41 
236 - - 30 
285 - - 10 11 
234 - 14 46 - 
283 - 58 19 - 
282 - - - - 
281 10 - 
280 43 - - - 
240 - - 15 15 
239 - - 100 100 
238 - - 73 81 
23? - - 32 63 
236 27 19 10 19 
235 100 100 - 5 
234 81 73 - 
233 13 - - 
226 - - 5 5 
225 - 10 4 6 
224 - - 10 10 
223 - - 6 8 
222 5 6 - 4 
221 7 4 - 
220 7 14 
218 - - - 
213 - - 5 
212 - - 20 19 
211 - - 10 18 
210 - - 9 14 
209 10 6 6 9 
208 29 26 4 5 
207 5 4 - - 
206 13 10 
205 
Table, 2 (cont'd). 
m/e 
204 
200 
199 
198 
197 
196 
195 
194 
193 
192 
191 
183 
182 
181 
180 
179 
l? s 
169 
168 
167 
165 
140 
132 
131 
130 
129 
128 
121-, 
120 
119 
118 
117 
108 
106 
I-d 3 I-d4 I-d 7 
GO 
4 5 
28 13 
23 32 
- - 29 29 
6 6 13 22 
50 28 8 11 
28 23 - 5 
40 22 
10 8 
6 4 
6 
6 7 
5 
7 4 
11 7 
8 4 
4 
4 
5 
6 
4 
- 14 15 
- 6 10 
12 - 
4 
11 
4 
41 6 
6 4 
4-4 
5 5 
6 
Table 2 (cont'd). 
m/e 
II I-d I-d4 Id7 
94 6 
93 6 
91 8 
89 4 4 8 
88 36 57 
87 - 4 - 7 
86 8 - 9 - 
85 58 - 51 - 
84 8 - 8 - 
82 8 - - - 
70 9 8 - 
62 - 5 
61 55 91 
60 - - - 5 
59 6 - 5 - 
58 94 - 71 
57 - - 4 - 
44 8 7 6 6 
42 8 - 7 - 
Imipramine fragmentation pattern. The fragment of highest 
m/e (235) represents the elimination of a molecule of 
dimethylamine from imipramine as the result of a 1,4 
rearrangement. The ion formed, further fragments by the 
loss of a hydrogen radical to m/e 234; this transition is 
supported by a metastable ion at m/e 233.00. The ion at 
m/e 85 results from a similar 1,4 rearrangement with 
formation of iminodibenzyl as a neutral fragment, which 
further fragments. The ion at m/e 179 indicates a transition 
from the ion at m/e 208 by the elimination of a methyl 
radical from the 7 membered ring of the heterocyclic iminium 
ion (m/e 208) to yield a radical ion with a six membered 
middle ring. The ion at m/e 208 arises from fragmentation 
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of the molecular ion by fission of the C-C bond U- to 
the heterocyclic nitrogen, after initial ionisation of 
the ring nitrogen. 
Determination of the deuterium content of labelled 
analogues. 
By repetitive scanning (>5 times) of the molecular ion 
region (see Fig. 1), for each compound an indication of the' 
deuterium content may be obtained. The relative 
intensities of the molecular ion (M) for imipramine (Fig. 1) 
and the 14+1 and M+2 peaks due to natural abundance 
isotopes (C13 and N15) were 1.000,0.240 and 0.024 
respectively. Using these values it was possible to 
determine the distribution of labelled species in all the 
deuterated analogues by stepwise computation of, and 
subtraction ofq the contributions made to the various ions 
of the spectra (molecular ion region) by these naturally 
occurring isotopes. For example, the molecular ion region 
of imipramine-d4 shows 5 peaks (m/e 282,283,284,285 and 
286 with a relative distribution of 1.6 : 8.1 : 20.4 : 
4.2 : 1.0, from 5 determinations) (Fig. 1), by correcting 
for natural abundance, this leaves only 3 peaks now with 
relative distributions of 1.6 : 7.7 : 18.5 (for m/e 282 
283 : 284) which leads to the distributionýof labelled 
species in mole percent as 5.3% d2 , 27.7% d3 and 66-51/'p' d4. 
For imipramine-d 3 the distribution of labelled species 
is 9?. Sýo' d3 and 2.2116' d2, and for imipramine-d? the 
distribution is 1.8% d4l 11.3% d5j 38% d6 and 48.8% d?. 
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